

Curriculum Vitae and Bibliography

Mark R Litzow, MD

Personal Information

Place of Birth: Rochester, MN
Citizenship: United States of America
Work Address: Mayo Clinic Rochester
200 First St SW
Rochester, MN 55905-0001
507-284-2511
Email Address: litzow.mark@mayo.edu

Present Academic Rank and Position

Consultant - Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 11/01/1993 - Present
Master's Faculty Privileges in Clinical & Translational Science - Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic College of Medicine and Science 06/11/2007 - Present
Professor of Medicine - Mayo Clinic College of Medicine and Science 12/01/2010 - Present
Consultant (Joint Appointment) - Section of Palliative Care, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 01/05/2022 - Present

Education

Carleton College - BA 1976
University Of Chicago Pritzker School Of Medicine - MD 1976 - 1980
Department of Internal Medicine - Resident 1980 - 1983
Division of General Internal Medicine, Department of Internal Medicine - Fellow 1983 - 1984
Division of Hematology, Department of Internal Medicine - Fellow 1986 - 1988
Hematology/Oncology, Programs in Rochester, Mayo School of Graduate Medical Education, Mayo Clinic College of Medicine, Rochester, Minnesota - Resident 01/01/1986 - 06/30/1989
Department of Oncology - Fellow 1988 - 1989
Fred Hutchinson Cancer Research Center, Seattle, Washington - Research Fellowship, Mayo Foundation Scholar 1989 - 1990

Certification

Board Certifications

American Board of Hematology

Hematology - 091976 1988 - Present

American Board of Hospice and Palliative Medicine

Hospice and Palliative Medicine 2012 - Present

American Board of Internal Medicine (ABIM)

Internal Medicine - 091976 1983 - Present

American Board of Medical Oncology

Medical Oncology - 091976 1989 - Present

Licensure

Minnesota 26419 (Medical) 1981 - Present
Montana MED-PHYS-LIC-28175 (Medical) 2013 - Present
Colorado DR.0053169 (Medical) 2013 - Present

Georgia	070981 (Medical)	2013 - Present
Iowa	MD-41449 (Medical)	2013 - Present
Arizona	48518 (Medical)	2013 - Present
Michigan	4301104371 (Medical)	2013 - Present
Florida	ME118286 (Medical)	2013 - Present
Wisconsin	61758 (Medical)	2014 - Present
North Dakota	13057 (Medical)	2014 - Present

Honors and Awards

Phi Beta Kappa Freshman Prize - Carleton College	1973
Noyes Prize - Carleton College	1975
Magna Cum laude - Carleton College	1976
Phi Beta Kappa - Carleton College	1976
AMA Scholarship (Clinical Nutrition) - University Of Chicago Pritzker School Of Medicine	1980
Graduate Travel Award - Mayo Clinic	1983
Scholar - Mayo Foundation	08/1989 - 11/1990
Travel Award - American Society of Hematology	12/1998
America's Top Doctors - Castle Connolly Medical Ltd.	2001 - 2011
Henry S. Plummer Distinguished Physician Department of Internal Medicine - Mayo Clinic	2004
America's Top Doctors for Cancer - Castle Connolly Medical Ltd.	2005 - 2012
Distinguished Mayo Clinicians - Mayo Clinic in Rochester, Mayo Clinic	2010
Best Doctors in America - Best Doctors in America	2011
2020 Provider Recognition Award - Mayo Clinic, Rochester, Minnesota	05/22/2020 - Present

Previous Professional Positions and Major Appointments

Senior Associate Consultant - Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota	08/01/1989 - 10/31/1993
Director - Blood and Marrow Transplant Program, Mayo Clinic, Rochester, Minnesota	1992 - 2005
Assistant Professor of Medicine - Mayo Clinic College of Medicine and Science	10/01/1992 - 01/01/2004
Section Head - Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota	1997 - 2002
Chair - Myeloid Disease Oriented Group, Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota	2002 - 05/26/2016
Associate Professor of Medicine - Mayo Clinic College of Medicine and Science	01/01/2004 - 11/30/2010
Master's Faculty Privileges of Clinical Research - Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic College of Medicine and Science	07/14/2004 - 06/10/2007
Director - Blood and Marrow Transplant Program, Mayo Clinic, Rochester, Minnesota	01/2007 - 01/2009

Service

Community Memberships and Services

Gift of Life Transplant House Board of Directors	2008 - 2017
---	-------------

President	2014 - 2015
Strategic Planning Task Force	2016 - 2017
Development Committee Member	2008 - 2017
Zumbro Valley Medicine, Religion and Bioethics Committee Member	01/1995 - 01/1997

Professional Memberships and Societies

Professional Memberships and Services

American College of Physicians Fellow	01/1989 - Present
Member	01/1989 - Present
American Medical Association Member	01/1980 - 01/1995
American Society for Blood and Marrow Transplantation Committee on Education Chair	02/2013 - Present
Subcommittee on Web-Based Learning Chair	2013 - 2019
Task Force on Generic Immunosuppressants Committee Member	2010 - Present
American Society for Transplantation and Cellular Therapy Member	1991 - Present
American Society of Clinical Oncology Member	01/1992 - Present
American Society of Hematology Member	01/1992 - Present
Abstracts on Acute Myelogenous Leukemia Therapy Coordinating Reviewer	09/2005
Reviewer	09/2005
Hematology Web Focus - ALL Editor	01/2010 - 12/2011
Test Material Development Committee Member	01/2009 - 2013
Autologous Bone Marrow Transplant Registry Chair-Elect	01/2004 - 01/2005
Member	01/2004 - 01/2005
Center for International Blood and Marrow Transplant Research Member	01/2006 - Present
Vice Chair, North America	03/2006 - 01/2011
Abstract Reviewer	01/2008
Co-Chair Organizing Committee Tandem BMT Meeting 2005 Member	01/2005
Co-Chair Organizing Committee Tandem BMT Meeting 2009 Member	01/2009
RCI BMT Clinical Trials Advisory Committee Member	03/2012
Eastern Cooperative Oncology Group Member	01/1992 - Present
Bone Marrow Transplant Committee	

Member	01/1993 - Present
Leukemia Committee	
Member	01/1992 - Present
Co-Chair	01/2001 - 09/2013
Chair	09/2013 - Present
Foundation for the Accreditation of Cellular Therapy	
Member	01/1998 - Present
Inspector	01/1998 - Present
Board of Directors	2011 - Present
Clinical Standards Subcommittee	
Member	11/2007 - Present
FACTWEB Oversight Committee	
Chair	09/2009 - Present
Standards Committee	
Member	09/2007 - Present
Hematology Vision	
Advisory Board Member	09/2013 - Present
International Blood and Marrow Transplant Registry	
Member	02/2002 - Present
Executive Committee	
Member	02/2002 - Present
International Bone Marrow Transplant Registry & Autologous Blood and Marrow Transplant Registry	
Member	01/1998 - Present
Acute Leukemia Working Committee	
Member	01/1998 - Present
Chronic Leukemia Working Committee	
Member	01/1998 - Present
GVHD/Immune Reconstitution Working Committee	
Member	01/1998 - Present
Solid Tumor Working Committee	
Member	01/1998 - Present
International Society for Hematotherapy and Graft Engineering	
Member	01/1995 - 01/1999
International Society of Hematology	
Member	01/1992 - Present
Lambda Association	
Member	01/1985 - 11/1985
Volunteer Medical Director	06/1985 - 11/1985
National Marrow Donor Program - NMDP	
Member	01/1998 - Present
Curriculum Subcommittee	
Chair	2011 - Present
Donor and Patient Safety Monitoring Committee	
Member	01/1998 - 2002
Physician Workforce Working Group	
Member	2010 - Present
Co-Chair	10/2012 - Present
Review panel for Amy Strelzer Manasevit Research Program	
Member	11/2012 - Present

Strategic Planning Committee Member	2007
System Capacity Initiative Physician Workforce Working Group Member	09/2009 - Present
Phi Beta Kappa Honor Society Member	01/1976 - Present
Royal Society of Medicine Overseas Affiliate Member	02/2015 - Present
Sigma Xi, The Scientific Research Society Member	01/1991 - Present
Tandem BMT 2009 Annual Meeting Organizing Committee Co-Chair	01/2008 - 01/2009
Worldwide Network for Blood and Marrow Transplantation Member	02/2011 - Present

Journal Responsibilities

Journal Editorial Responsibilities

Advances in Hematology Editorial Board Member	2008 - 2013
BMC Palliative Care Reviewer	07/06/2021
Bone Marrow Transplantation Member	2015 - Present
Journal of Palliative Medicine Reviewer	05/10/2021
Leukemia Editorial Board Member	2009 - Present
Leukemia & Lymphoma Editorial Board Member	01/01/2017 - Present

Journal Other Responsibilities

American Journal of Hematology Scientific Reviewer Advisory Board Member	2009 - Present
Biology of Blood and Marrow Transplantation Scientific Reviewer	
Blood Scientific Reviewer	
Blood and Lymphatic Cancer: Targets and Therapy Peer Reviewer Reviewer	12/2013 - Present
Blood Cancer Journal Scientific Reviewer	2011 - Present
Bone Marrow Transplantation Scientific Reviewer Member	2015
British Journal of Medicine and Medical Research Reviewer	03/2014 - Present
Cancer Scientific Reviewer	
Cancer Research UK	

International Advisor	2009 - 2011
Clinical Medicine Insights: Oncology Reviewer	11/2011
Haematologica Scientific Reviewer	
International Blood Research and Reviews Reviewer	10/2014 - Present
Journal of Clinical Apheresis Scientific Reviewer	
Journal of Clinical Oncology Reviewer	05/17/2021 - Present
Journal of Palliative Medicine Reviewer	05/17/2021 - Present
Leukemia Scientific Reviewer	
Leukemia and Lymphoma Scientific Reviewer	
Leukemia Research Scientific Reviewer	
Mayo Clinic Proceedings Scientific Reviewer	
Molecular Cancer Therapeutics Reviewer	12/2013 - Present

Education Interests and Accomplishments

Teaching

Friday Noon Hematology Fellow Journal Club Rochester, Minnesota	1991 - Present
Presentations Monday noon 2-4 times per year Hematology Clinical Pathologic Conference, Mayo Clinic Rochester, Minnesota	01/1991 - Present
Acute Leukemia Quarterly core Lecture to internal medicine residents rotating on hematology service Mayo Clinic Rochester, Minnesota	1992 - 2000
Bone Marrow Transplantation in the Hematologic Malignancies Department of Oncology Core Curriculum Lecture Series Mayo Clinic Rochester, Minnesota	01/1993
Lectures on acute and chronic leukemia and bone marrow transplantation Hematology course, 1st year medical students Mayo Medical School Rochester, Minnesota	01/1994 - 01/2000
Bone Marrow Transplantation in the Hematologic Malignancies Department of Oncology Core Curriculum Lecture Series Mayo Clinic Rochester, Minnesota	01/1995
Bone Marrow Transplantation in the Hematologic Malignancies Department of Oncology Core Curriculum Lecture Series Mayo Clinic Rochester, Minnesota	01/1997
3rd and 4th Year Palliative Medicine Courses Instructor	01/1997 - 01/2004

Mayo Medical School Rochester, Minnesota	
Overview of Bone Marrow Transplantation Transfusion Medicine Blood Donor Center staff, Mayo Clinic Blood Bank Rochester, Minnesota	04/1997
Bone Marrow Transplantation in the Hematologic Malignancies Department of Oncology Core Curriculum Lecture Series Mayo Clinic Rochester, Minnesota	01/1999
Overview of Blood and Marrow Transplantation Hematology desk and secretarial staff Mayo Clinic Rochester, Minnesota	01/1999
Bone Marrow Transplant for Acute Myelogenous Leukemia Hematology Conference Mayo Clinic Rochester, Minnesota	04/1999
Biology of Blood and Marrow Transplant Fellows Hematology Conference, Mayo Clinic Rochester, Minnesota	11/1999
Complications of Blood and Marrow Transplantation Fellows Hematology Conference, Mayo Clinic Rochester, Minnesota	07/2000
Acute Lymphoblastic Leukemia Fellows Hematology Conference, Mayo Clinic Rochester, Minnesota	07/2000
Acute Myelogenous Leukemia Fellows Hematology Conference, Mayo Clinic Rochester, Minnesota	07/2000
Management of Adult Acute Lymphocytic Leukemia Fellows Hematology Conference, Mayo Clinic Rochester, Minnesota	05/2002
Chronic Myelomonocytic Leukemia Internal Medicine Resident Morbidity and Mortality Conference, Mayo Clinic Rochester, Minnesota	07/2002
Aplastic Anemia: An Update and the Role of BMT Transplant Center Grand Rounds	04/2003
Introduction to Blood and Marrow Transplantation Mayo Clinic Billing and Insurance Collections Technical meeting	04/2003
ASH update: Acute Leukemia Hematology Conference	02/2004
Acute Lymphoblastic Leukemia in Adults Hematology Conference	05/2004
Update on Allogeneic BMT from the 2004 ASH meeting Hematology Conference	01/2005
Gleevec Resistance: Obstacles and Opportunities Hematology Conference	02/2005
Chronic Myelogenous Leukemia Hematology Conference	04/2005
ALL in Adults Hematology Conference	05/2006
Introduction to Hematopoietic Stem Cell Transplantation Hematology Conference	10/2006
CML Hematology Conference	03/2007

ALL in Adults Hematology Conference	04/2008
Introduction to Hematopoietic Stem Cell Transplantation Hematology Conference	10/2008
Overview of Blood and Marrow Transplantation Hematology desk and secretarial staff Rochester, Minnesota	06/2010
Nilotinib Before or After Imatinib for Newly Diagnosed CML Hematology Conference Rochester, Minnesota	03/2011
Blast Crisis of Acute Leukemia Morbidity and Mortality Conference Rochester, Minnesota	12/2011
Acute Lymphoblastic Leukemia in Adults: Progress and Challenges in 2012 Hematology Conference Rochester, Minnesota	10/2012

Mentorship

Markovic, Svetomir (Hematology/Oncology Fellow) Description: Hematology/Oncology Fellow Current Status: Staff Member, Mayo Clinic in Rochester Outcome:	01/1996 - 01/1999
Hogan, William (Hematology/Oncology Fellow) Description: Hematology/Oncology Fellow Current Status: Staff Member, Mayo Clinic in Rochester Outcome:	01/1998 - 01/2001
Kumar, Shaji (Hematology/Oncology Fellow) Description: Hematology/Oncology Fellow Current Status: Staff Member, Mayo Clinic in Rochester Outcome:	01/1999 - 01/2003
Behl, Deepti (Hematology/Oncology Fellow) Description: Current Status: Private practice Outcome:	01/2006 - 01/2009
Patnaik, Mrinal (Hematology/Oncology Fellow) Description: Current Status: Outcome:	07/2008 - 06/2011
Badar, talha Description: Current Status: Outcome:	01/2021 - Present
saliba, Antoine Description: Current Status: Outcome:	01/2022 - Present

Institutional/Departmental Administrative Responsibilities, Committee Memberships and Other Activities

Mayo Clinic

Department of Education Administration Mayo Clinic Center for Humanities in Medicine Rochester Center for Humanities in Medicine Humanities in Medicine Committee Member	01/1999 - Present
Theater Task Force	

Chair	2004 - Present
Mayo Clinic College of Medicine	
Mayo Graduate School of Medicine	
Education Committee	
Internal Medicine	
Member	01/1980 - 01/1983
Mayo Clinic in Rochester	
Department of Internal Medicine	
Continuing Medical Education Committee	
Grand Rounds	
Coordinator	01/1991 - 01/1996
Member	01/1991 - 01/1996
Division of Hematology	
Education Committee	
Member	01/1992 - 01/1999
Hematology Executive Committee	
Member	01/1997 - 01/2005
Mayo Clinic Rochester Committees	
Hematology Society	
Monthly Dinners	
Coordinator	01/1994 - 01/1995
Member	01/1994 - 01/1995
William J von Liebig Transplant Center	
Executive Committee	
Member	01/1999 - 06/2005
Member	01/2007 - 01/2009
Practice Committee	
Member	01/1999 - 01/2005
Member	01/2007 - 01/2009
Activities at Other Institutions	
Blood and Marrow Transplant Clinical Trials Network	
Chair	01/01/2018 - 01/18/2020
Presentations Extramural	
National or International	
What is new about the management of Acute Lymphoblastic Leukemia (ALL) 26th Annual Hematology/Oncology Reviews Amelia Island, Florida	07/27/2016 - 07/30/2016
E1910: A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR- ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults ECOG-ACRIN Fall Meeting Rochester, Minnesota	10/27/2022
Invited	
Acute Myeloid Leukemia: Progress and Challenges in 2014 24th Annual Hematology/Oncology Reviews Amelia Island, Florida	
Bone Marrow Transplantation for Breast Cancer International College of Surgeons CME Day Mason City, Iowa	10/1993
An Overview of Anemias Upper Iowa District Dietetic Association	05/1997

New Hampton, Iowa	
Acute Leukemia: Diagnosis and Management NCCTG Clinical Research Associates Symposium Rochester, Minnesota	10/1997
Bone Marrow Transplantation KROC Healthline Radio Show Rochester, Minnesota	01/2000
Overview of Blood and Marrow Transplantation Winona State University Winona, Minnesota	04/2000
CML: Update on Management Continuing Challenges in Hematology/Oncology and Hematopathology Snowmass, Colorado	02/2001
New Developments in Blood and Marrow Transplants Continuing Challenges in Hematology/Oncology and Hematopathology Snowmass, Colorado	02/2001
What's New in Iron Deficiency? Continuing Challenges in Hematology/Oncology and Hematopathology Snowmass, Colorado	02/2001
Imatinib Resistance: Opportunities and Obstacles 13th Annual Symposium on Molecular Pathology: DNA Technology in the Clinical Laboratory Troy, Michigan	10/2004
Chronic Myelogenous Leukemia 3rd Mayo Clinic State of the Art Symposium on Hematologic Malignancies Scottsdale, Arizona	01/2006
Myeloid Session 3rd Mayo Clinic State of the Art Symposium on Hematologic Malignancies Scottsdale, Arizona	01/2006
Supportive Care - Growth Factor 3rd Mayo Clinic State of the Art Symposium on Hematologic Malignancies Scottsdale, Arizona	01/2006
Myelodysplastic Syndromes: New Developments Asociacion de Hematologia Y Oncologia Medica de Puerto Rico 2009 Convention Fajardo, Puerto Rico	10/2009
Treatment of Acute Leukemia in Adults Asociacion de Hematologia Y Oncologia Medica de Puerto Rico 2009 Convention Fajardo, Puerto Rico	10/2009
Leukemias Best of ASCO Panama 2010 Panama City, Panama	07/2010
Acute Myeloid Leukemia Learn BMT Program, Fenwal Corporation Chicago, Illinois	10/2010
Blood and Marrow Transplantation Learn BMT Program, Fenwal Corporation Chicago, Illinois	10/2010
The Evolving Therapy of Acute Lymphoblastic Leukemia in Adults First Emirates Hematology Conference Dubai, United Arab Emirates	03/2011
Acute Lymphoblastic Leukemia: Applications of Pediatric Chemotherapies in Adults III National Hematology Congress of the Panamanian Society of Hematology Panama City, Panama	04/2011
Update in stem cell transplant SAMS 12th Annual International Convention Istanbul, Turkey	07/2012

Acute Lymphoblastic Leukemia in Adults: Progress and challenges in 2012 Cleveland Clinic Cleveland, Ohio	09/2012
ECOG Trial Comparing Three Different chemotherapy Combination Regimens in Patients with Relapsed or Refractory Acute Leukemia NCI CTEP Spring 2013 EDD Bethesda, Maryland	04/2013
E1910 Information Session 2013 ECOG-ACRIN Spring Group Meeting Atlanta, Georgia	05/2013
E1910, A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL Negative B Acute Lymphoblastic Leukemia in Adults 2013 ECOG-ACRIN Spring Group Meeting Atlanta, Georgia	05/2013
New and Targeted Therapies (and Their Rationale) in Development for Acute Lymphoblastic Leukemia Annual Meeting of American Society of Clinical Oncology Chicago, Illinois	05/2013
Indications and Applications of Blood and Marrow Transplantation in the Developing World Syrian American Medical Association 13th Annual International Conference Amman, Jordan	06/2013
Acute Lymphoblastic Leukemia in Adults: Progress and Challenges in 2013 23rd Annual Hematology/Oncology Reviews Amelia Island, Florida	08/2013
Selected Non-Pain Symptom Management Topics in Palliative Care 14th Annual Oncology Symposium Sioux Falls, South Dakota	09/2013
Stem Cell Transplantation and Palliative Care: An Oxymoron 14th Annual Oncology Symposium Sioux Falls, South Dakota	09/2013
Old and Novel Monoclonal Antibodies in ALL Acute Lymphoblastic Leukemia: It's Not Just a Pediatric Disease New Orleans, Louisiana	12/2013
Acute Leukemia and Stem Cell Transplantation 11th Annual Mayo Clinic Hematology Review Minneapolis, Minnesota	01/2014
New approaches for improving transplant outcomes in ALL patients with MRD Current Status of Stem Cell Transplant for Acute Lymphoblastic Leukemia during 2014 BMT Tandem Meetings Grapevine, Texas	02/2014
Who should be transplanted for ALL in first remission? What is the role of minimal residual disease assessment? 18th Annual International Congress on Hematologic Malignancies New York, New York	02/2014
BMT elective rotation for learners 2014 Tandem BMT Meetings Grapevine, Texas	03/2014
Arsenic Trioxide and Acute Promyelocytic Leukemia Peruvian Society of Medical Oncology IX Congress Lima, Peru	07/2014
Myelodysplastic Syndromes: Biology and Therapy Peruvian Society of Medical Oncology IX Congress Lima, Peru	07/2014
Course Co-Director 24th Annual Hematology/Oncology Reviews	08/2014

Amelia Island, Florida	
ALL in Adults: Perspectives from ECOG-ACRIN and the Intergroup Second Annual Conference of the Society for Adolescent and Young Adult Oncology: Breaking Barriers in Acute Lymphoblastic Leukemia Irvine, California	10/2014
Which ALL Patients, Young or Older Adults, Should be Transplanted? Spanning our Life Cycle: Novel Therapies, Targets, and Transplant Strategies in ALL San Francisco, California	12/2014
New Treatment Approaches and Targeted Therapy The Important Role of Clinical Trials CancerCare Teleconference - Treatment Update for Adults Living with Acute Lymphocytic/Lymphoblastic Leukemia United States of America	02/2015
Acute Lymphoblastic Leukemia in Adults: Progress After All These Years Hematologic Malignancies: New Therapies and the Evolving Role of Transplant Chicago, Illinois	04/2015
Course Co-Director Hematologic Malignancies: New Therapies and the Evolving Role of Transplant Chicago, Illinois	04/2015
Bi-specific T Cell Engaging Antibodies in the Treatment of Acute Lymphoblastic Leukemia Emerging Approaches to Cancer Immunotherapy New York, New York	05/2015
Practical Information on recently Approved Agents: Blinatumomab New Drugs in Oncology Seminar, Pre-Annual ASCO Meeting Chicago, Illinois	05/2015
Co-Director 25th Annual Hematology/Oncology Reviews Amelia Island, Florida	07/2015
Update - Adult NIH Cooperative Group Studies in ALL Society for Adolescent and Young Adult Oncology Irvine, California	10/2015
Update on T-ALL Spotlight on Lymphoid Leukemias New York, New York	10/2015
Meeting Chair Putting It ALL Together in Adult ALL: Clinical Insights into the Latest Developments Orlando, Florida	12/2015
Patients with Acute Myeloid Leukemia Unfit for Intensive Therapy How I Treat: Bringing Science to Clinical Dilemmas Orlando, Florida	12/2015
What's next in adult ALL: Can we make any progress in the forgotten T-cell ALL? Putting it ALL Together in Adult ALL: Clinical Insights into the Latest Developments Orlando, Florida	12/2015
Update on BMT UC Health Annual ASH Update Colorado Springs, Colorado	02/06/2016
NCTN Collaboration Updates Blood and Marrow Transplant Clinical Trials Network Honolulu, Hawaii	02/17/2016
Reducing Cancer's BiTE with T-Cell Engaging Antibodies BMT Tandem Meetings 2016 Honolulu, Hawaii	02/18/2016 - 02/22/2016
Should anyone with Ph+ ALL who is MRD-negative receive a transplant in first remission?	03/18/2016

Acute Leukemia Forum 2016 Newport Beach, California	
Palliative Care: Putting Quality into Life after Transplant Celebrating a Second Chance at Life Chicago, Illinois	04/30/2016 - 05/01/2016
Planning for the Best, preparing for the Worst: How to Have the Conversation Celebrating a Second Chance at Life Chicago, Illinois	04/30/2016 - 05/01/2016
Acute Lymphoblastic Leukemia in Adults: Progress After All These years 4th Lu Daopei Hematology Forum Beijing, China	07/01/2016
Advances in Leukemia 3rd Annual ASBMT Regional Conference for NPs, PAs, and Fellows featuring "Best of Tandem" Minneapolis, MN, Minnesota	10/13/2016
ECOG Leukemia Group The Society for Adolescent and Young Adult Oncology (SAYAO) Newport Beach, California	11/15/2016
End-of-Life Discussions in Hematologic Malignancies (Adult Perspective) American Society of Hematology San Diego, California	12/05/2016
Acute lymphoblastic leukemia 2017 Highlights of ASH in North America Seattle, Washington	01/27/2017
ALL in adults: The emerging role of immunotherapy Scripps' 37th Annual Conference: Clinical Hematology & Oncology 2017 La Jolla, California	02/19/2017
Acute lymphoblastic leukemia in adults: The emerging role of immunotherapy Hematologic Malignancies: New Therapies and the Evolving Role of Transplant Chicago, Illinois	03/18/2017
Prognosis, Palliative Care, and Hospice for Advanced Heart Failure Patients 22nd Annual Success with Failure, Strategies for the Evaluation and Treatment of Heart Failure Kohala Coast, Hawaii	07/28/2017
Symptom management in advanced heart failure 22nd Annual Success with Failure, Strategies for the Evaluation and Treatment of Heart Failure Kohala Coast, Hawaii	07/28/2017
What is new about the management of acute lymphoblastic leukemia (ALL) Hematology & Oncology Reviews Amelia Island, Florida	08/17/2017
Update on Transplant in ALL Society of Hematologic Oncology 5th Annual Meeting Houston, Texas	09/13/2017
Acute Myeloid Leukemia: An Interactive Case Presentation Acute and Chronic Leukemia 2017 Las Vegas, Nevada	10/06/2017
Chronic Myeloid Leukemia: An Interactive Case Presentation Acute and Chronic Leukemias 2017 Las Vegas, Nevada	10/06/2017
Myeloproliferative Case: An Interactive Case Presentation Acute and Chronic Leukemias 2017 Las Vegas, Nevada	10/06/2017
Graft versus host disease: The state of the art 7th National Congress for Bone Marrow Transplantation Guadalajara, Mexico	11/11/2017

Which is the best time for HSCT in ALL? 7th National Congress for Bone Marrow Transplantation Guadalajara, Mexico	11/11/2017
Is transplant still an imperative in Ph+ ALL? Acute Leukemia Forum 2018 Newport Beach, California	04/12/2018
What is new on the management of acute lymphoblastic leukemia (ALL)? 28th Annual Hematology/Oncology Reviews Amelia Island, Florida	08/01/2018 - 08/04/2018
What is New on the Management of Acute Lymphoblastic Leukemia(ALL) 28th Annual Hematology/Oncology Reviews Amelia Island, Florida	08/02/2018
Acute lymphoblastic leukemia in adults: Progress after all these years Acute and Chronic Leukemias 2017 Las Vegas, Nevada	10/07/2018
Current and planned trials from ECOG-ACRIN SAYAO/CHOC Children's 5th Leukemia Symposium Orange, California	11/05/2018 - 11/06/2018
Acute Lymphoblastic Leukemia Oshsner Hematology And Medical Oncology Fellowship Program New Orleans, Louisiana	01/25/2019
Acute lymphoblastic leukemia in adults: progress after all these years 30th Annual Conference of the Egyptian Society of Laboratory Medicine Cairo, Egypt	04/07/2019
Updates in blood and marrow transplantation 30th Annual Conference of the Egyptian Society of Laboratory Medicine	04/07/2019
Indications for allogeneic HSCT in adult Acute Lymphoblastic Leukemia International Conference Acute Lymphoblastic Leukaemia Berlin, Germany	05/18/2019
Acute Lymphoblastic Leukemia in Adults: Standard Induction Regimens and Treatment for Relapsed Disease Acute and Chronic Leukemias 2019 Coronado, California	10/12/2019
Acute Myeloid Leukemia: Increasing Complexity and Increasing Treatment Opportunities BMTInfoNet Webinar	10/14/2021
Annual Saudi Hematology Congress 2022-Virtual Meeting Talk about "How I treat AYA-ALL in first relapse: novel agents/CART vs pediatric salvage regimen vs conventional Virtual meeting	03/05/2022
United States National Clinical Trials Network Studies in AML and MDS Estey Leukemia Conference, Division of Hematology, University of Washington, Seattle Seattle, Washington	03/25/2022
Selection of Initial Therapy (risk stratification in adult ALL/selection of initial therapy) NCCN 2022 Annual Congress: Hematologic Malignancies New York City, New York	10/17/2022
Progress in Acute Lymphoblastic Leukemia and Highlights of the 2022 ASH meeting University of Kansas Cancer Center 2022 ASH Review Conference Rochester, Minnesota	01/21/2023
Acute Lymphoblastic Leukemia in Adults: New Multimodality Treatment Approaches Bring Ever Improving Outcomes The 10th International Conference of the Jordanian Society of Hematology Rochester, Minnesota	02/23/2023
When to transplant in ALL: Mark Litzow, Mayo Clinic Comprehensive Cancer Center"	07/08/2023

AML-ALL US Focus Meeting
Rochester, Minnesota

Oral

Course Co-Director, Hematology/Oncology Update: Current Issues and Controversies Annual Mayo Clinic Hematology/Oncology Review Amelia Island, Florida	09/1994
Overview of Blood and Marrow Transplantation American Association for Medical Transcription Minneapolis, Minnesota	08/1996
Acute Myelogenous Leukemia: New Data, New Drugs, New Decisions Mayo Clinic Jacksonville 9th Annual State of the Art Hematology/Oncology Reviews Amelia Island, Florida	07/1999
Comparison of Allogeneic Bone Marrow Transplantation with Cyclophosphamide-Total Body Irradiation versus Busulfan-Cyclophosphamide Conditioning Regimens for Acute Myelogenous Leukemia in First Remission Annual Meeting, American Society of Hematology San Francisco, California	12/2000
Acute Leukemias Update 14th Annual Mayo Clinic Jacksonville Hematology/Oncology Reviews Amelia Island, Florida	07/2004
Course Co-Director 14th Annual Mayo Clinic Jacksonville Hematology/Oncology Review Amelia Island, Florida	07/2004
Moderator - Leukemia/BMT session 14th Annual Mayo Clinic Jacksonville Hematology/Oncology Reviews Amelia Island, Florida	07/2004
Imatinib Resistance: Opportunities and Obstacles 13th Annual Symposium on Molecular Pathology, DNA Technology in the Clinical Laboratory Royal Oak, Michigan	10/2004
Blood or Marrow Transplantation for Hematologic Malignancies in Solid Tumors Continuing Medical Education, Parrish Medical Center Titusville, Florida	04/2005
An Update on the Treatment of AML 15th Annual Mayo Clinic Jacksonville Hematology/Oncology Reviews, Amelia Island Plantation Amelia Island, Florida	07/2005
Course Co-Director 15th Annual Mayo Clinic Jacksonville Hematology/Oncology Reviews Amelia Island, Florida	07/2005
Moderator - Leukemia and Chronic Myeloid Disorders Session 15th Annual Mayo Clinic Jacksonville Hematology/Oncology Reviews Amelia Island, Florida	07/2005
Imatinib Resistance: Obstacles and Opportunities 3rd Annual Therapeutic Advances in the Treatment of Hematologic Malignancies Santa Monica, California	08/2005
Moderator for Oral Session - Acute Myeloid Leukemia - Adult and Pediatric Therapy 47th Annual Meeting of American Society of Hematology Atlanta, Georgia	12/2005
Chronic Myelogenous Leukemia 3rd Mayo Clinic State of the Art Symposium on Hematologic Malignancies Scottsdale, Arizona	01/2006
Chronic Myelogenous Leukemia 3rd Mayo Clinic State of the Art Symposium on Hematologic Malignancies Phoenix, Arizona	01/2006

Myeloid Session 3rd Mayo Clinic State of the Art Symposium on Hematologic Malignancies Scottsdale, Arizona	01/2006
Supportive Care - Growth Factors 3rd Mayo Clinic State of the Art Symposium on Hematologic Malignancies Scottsdale, Arizona	01/2006
Supportive Care Growth Factors 3rd Mayo Clinic State of the Art Symposium on Hematologic Malignancies Phoenix, Arizona	01/2006
Course Co-Director 16th Annual Mayo Clinic Jacksonville Hematology/Oncology Review Amelia Island, Florida	08/2006
Leukemia and Chronic Myeloid Disorders Session 16th Annual Mayo Clinic Jacksonville Hematology/Oncology Review Amelia Island, Florida	08/2006
Update on the Management of CML 16th Annual Mayo Clinic Jacksonville Hematology/Oncology Review Amelia Island, Florida	08/2006
Moderator for Oral Session - Acute Promyelocytic Leukemia and Novel Approaches to AML 48th Annual Meeting of the American Society of Hematology Orlando, Florida	12/2006
Acute Leukemia 4th Mayo Clinic State of the Art Symposium on Hematologic Malignancies Wellington, New Zealand	01/2007
Molecular Cytogenetics and Myeloid Diseases 4th Mayo Clinic State of the Art Symposium on Hematologic Malignancies Wellington, New Zealand	01/2007
Inspector - Hematopoietic Progenitor Transplant Program Mock Survey Westchester Medical Center New York, New York	02/2007
Targeted Therapy for Chronic Myelogenous Leukemia 9th Annual Evolving Science of Cancer Treatments and Blood/Marrow Transplantation United Resource Network Medical Management Conference New Orleans, Louisiana	02/2007
Reviewer - Acute Leukemia Forum 2007 Advances and Controversies in the Biology and Therapy of Acute Myelogenous Leukemia and Myelodysplasia San Francisco, California	03/2007
Course Director Indications for Blood and Marrow Transplantation in the Era of Targeted Therapies St. Paul, Minnesota	04/2007
Course Co-Director 17th Annual Mayo Clinic Jacksonville Hematology/Oncology Review Amelia Island, Florida	07/2007
Indications for Allogeneic Stem Cell Transplantation and the Management of its Complications 17th Annual Mayo Clinic Jacksonville Hematology/Oncology Review Amelia Island, Florida	07/2007
The Latest and Greatest of Acute Myeloid Leukemia 5th Mayo Clinic State of the Art Symposium on Hematologic Malignancies Phoenix, Arizona	01/2008
Moderator for Oral Session - Pediatric Disorders, Histocompatibility and Alternative Stem Cell Sources 2008 Tandem BMT meetings San Diego, California	02/2008

The outcome of allogeneic stem cell transplantation for the treatment of therapy-related myelodysplastic syndrome and acute myeloid leukemia varies considerably by risk factor: an observational study from the CIBMTR. 2008 BMT Tandem Meetings San Diego, California	02/2008
Chronic Myeloid Leukemia: A Practical Approach to Current Management Imedex Regional Meeting Chicago, Illinois	04/2008
Chronic Myeloid Leukemia: On the Cusp of Cure Management of Chronic Myeloid Disorders and Lymphocytic Leukemia Jackson, Mississippi	04/2008
Reviewer Acute Leukemia Forum San Francisco, California	04/2008
Acute Leukemia Living with a Blood Cancer - A Comprehensive Patient Centered Symposium Chicago, Illinois	05/2008
Acute Myelogenous Leukemia: The Latest and Greatest 18th Annual Mayo Clinic Jacksonville Hematology/Oncology Review Amelia Island, Florida	08/2008
Course Co-Director 18th Annual Mayo Clinic Jacksonville Hematology/Oncology Review Amelia Island, Florida	08/2008
Acute Myeloid Leukemia ECOG Training Sesion fo CRAs and Oncology Nurses Fort Lauderdale, Florida	11/2008
Therapy of Acute Lymphoblastic Leukemia in Adults: New Paradigms Sixth Annual Mayo Clinic Hematology 2009 and Practical Update for Clinicians - Transplanting Today's Clinical Excellence and Tomorrow's Cures Phoenix, Arizona	01/2009
Course Director Indications for Blood and Marrow Transplantation in the Era of Targeted Therapies St. Paul, Minnesota	04/2009
Reviewer Acute Leukemia Forum San Francisco, California	04/2009
Myelodysplastic Syndromes: New Developments Asociacion de Hematologia Y Oncologia Medica de Puerto Rico Fajardo	10/2009
Treatment of Acute Leukemia in Adults Asociacion de Hematologia Y Oncologia Medica de Puerto Rico Fajardo	10/2009
Acute Lymphoblastic Leukemia in Adults Seventh Annual Mayo Clinic Hematology for the Practicing Hematologist-Oncologist Phoenix, Arizona	01/2010
Case Studies in Transplant for Myeloid Disorders Seventh Annual Mayo Clinic Hematology for the Practicing Hematologist-Oncologist Phoenix, Arizona	01/2010
Reviewer Acute Leukemia Forum San Francisco, California	04/2010
Chair, Disease Specific Mini Symposiums on Myeloid Disease Living with a Blood Disease Symposium Rochester, Minnesota	05/2010
Acute Myeloid Leukemia: New Developments 20th Annual Mayo Clinic Jacksonville Hematology/Oncology Review	07/2010

Amelia Island, Florida	
Course Co-Director 20th Annual Mayo Clinic Jacksonville Hematology/Oncology Review Amelia Island, Florida	07/2010
ABIM Maintenance of Certification Learning Session American Society of Hematology Orlando, Florida	12/2010
Outcome of 1,229 adult Philadelphia chromosome negative B acute lymphoblastic Leukemia (B-ALL) patients from the International UKALLXII/E2993 trial: no different in results between B cell immunophenotypic subgroups Oral presentation at Annual ASH meeting Orlando, Florida	12/2010
The Evolving Therapy of Acute Lymphoblastic Leukemia in Adults Clinical Hematology and Oncology 2011: The 8th Annual Mayo Review Scottsdale, Arizona	01/2011
Monoclonal Antibody Therapy of Acute Lymphoblastic Leukemia Eastern Cooperative Oncology Group - Leukemia BMT Committee Boston, Massachusetts	06/2011
Course Co-Director 21st Annual Mayo Clinic Hematology/Oncology Reviews Amelia Island, Florida	08/2011
Indications, Types and Outcomes of Allogeneic Stem Cell Transplants: What Every Hematologist/Oncologist Should Know 21st Annual Mayo Clinic Hematology/Oncology Reviews Amelia Island, Florida	08/2011
MDS: Current Thinking on the Disease, Diagnosis and Treatment (Lower Risk) Living with Aplastic Anemia, MDS or PNH Minneapolis, Minnesota	09/2011
Acute Lymphoblastic Leukemia Hematologic Malignancies: New Therapies and the Evolving Role of Transplant Chicago, Illinois	10/2011
Course Director Hematologic Malignancies: New Therapies and the Evolving Role of Transplant Chicago, Illinois	10/2011
Solid Tumors Hematologic Malignancies: New therapies and the Evolving Role of Transplant Chicago, Illinois	10/2011
Acute Lymphoblastic Leukemia: Promises, Challenges and Opportunities Clinical Hematology and Oncology 2012: The 9th Annual Mayo Review Scottsdale, Arizona	01/2012
Compliance Application Review FACT Cellular Therapy Inspection and Accreditation Workshop San Diego, California	01/2012
Inspection and Accreditation Reports FACT Cellular Therapy Inspection and Accreditation Workshop San Diego, California	01/2012
Inspecting with FACTWeb Cord Blood Inspection and Accreditation Workshop San Francisco, California	06/2012
Myeloid Malignancies 22nd Annual Mayo Clinic Hematology/Oncology Reviews Amelia Island, Florida	08/2012
Should targeting MRD in adult ALL be a primary therapeutic goal prior to transplant? 2013 BMT Tandem Meeting Salt Lake City, Utah	02/2013
Course Co-Director	10/2013

Hematologic Malignancies: New Therapies and the Evolving Role of Transplant
Chicago, Illinois

E2905: Randomized Ph III trial comparing the frequency of major erythroid response (MER) to treatment with lenalidomide alone and in combination with epopetin alfa in subjects with low- or intermediate-1 risk MDS and symptomatic anemia
ECOG-ACRIN Group Meeting
Boston, Massachusetts 05/13/2016

CNS involvement prophylaxis and therapy
International Conference Acute Lymphoblastic Leukaemia
Berlin, Germany 05/18/2019

Poster

In Vitro Culture and Recombinant Gamma Interferon Increase the Percentage of Cytogenetically Normal Bone Marrow Cells in Patients with Myelodysplastic Syndromes
Annual Meeting of American Society of Hematology
San Antonio, Texas 12/1988

Autologous versus allogeneic bone marrow transplantation for Hodgkin's disease
Annual meeting of the American Society of Hematology 12/1990

CD34+, CD33- 7B9- marrow cells have high proliferative potential and can be distinguished from CD34+, CD33+ 7B9+ marrow cells on the basis of their proliferative responses to IL-3 and G-CSF
Annual meeting of the American Society of Hematology 12/1990

Importance of Streptococcal Viridans Bacteremia and Morbidity and Mortality Post Stem Cell Transplantation
Annual Meeting, American Society of Blood and Marrow Transplantation
Miami, Florida 10/1996

Importance of Streptococcal Viridans Bacteremia and Morbidity and Mortality Post Stem Cell Transplantation
Fifth International Blood Cell Transplantation Symposium
Omaha, Nebraska 10/1997

Veno-occlusive Disease of the Liver Following Bone Marrow Transplantation: Analysis of Risk Factors and Results of Therapy with Tissue Plasminogen Activator
Annual Meeting, American Society of Hematology
San Diego, California 12/1997

Phenotypic Differences in Dendritic Cells Derived from CD14+ Peripheral Blood Cells of Chronic Myelogenous Leukemia Patients and Normal Donors
Annual Meeting, American Society of Hematology
Miami, Florida 12/1998

A randomized phase II trial of gemtuzumab ozogamacin vs liposomal daunorubicin vs cyclophosphamide plus topotecan, each combined with intermediate dose Ara-C for the treatment of patients with relapsed or refractory acute myelogenous leukemia
American Society of Clinical Oncology Annual Meeting
Chicago, Illinois 06/2003

Regional

Acute Leukemia and Stem Cell Transplantation
17th Annual Hematology Review
Minneapolis, Minnesota 01/18/2020

Invited

Blood and Marrow Transplantation: An Update
CME Oncology Grand Rounds Program
Sioux Falls, South Dakota 11/2003

Acute Leukemia
Mayo Clinic Hematology Review
Minneapolis, Minnesota 01/24/2004

Blood and Marrow Transplantation for Hematologic Malignancies
Visiting Faculty Program Mayo Medical Laboratories 04/2005

Titusville, Florida

Acute Leukemia/CML Mayo Clinic 3rd Annual Hematology Review Minneapolis, Minnesota	01/2006
Blood and Marrow Transplantation: An Overview Mayo Medical Laboratories Lincoln, Nebraska	04/2009
AML in the Elderly St. Marys Duluth Cancer Center Duluth, Minnesota	12/2009
The Evolving Therapy of Ph-Negative Acute Lymphoblastic Leukemia in Adults: Change You Can Believe In Hematology-Oncology Grand Rounds, Northwestern University Chicago, Illinois	03/2010
An Overview of Allogeneic Blood and Marrow Transplantation and Its ICU Complications Critical Care Grand Rounds Rochester, Minnesota	07/2013
Acute Lymphoblastic Leukemia Hematologic Malignancies: New Therapies and the Evolving Role of Transplant Chicago, Illinois	11/2013
Impaired Cognition Post Hematopoietic Stem Cell Transplant: The Challenge of Finding the Right Balance Transplant Center Grand Rounds Rochester, Minnesota	07/2014
Adult Acute Lymphoblastic Leukemia (ALL): Update on diagnosis and Treatment Cancer Connections Meeting Rochester, Minnesota	09/2015
Acute Leukemia and Stem Cell Transplantation 13th Annual Hematology Review Minneapolis, Minnesota	01/23/2016
Acute Leukemia and Stem Cell Transplantation 15th Annual Mayo Clinic Hematology Review Minneapolis, Minnesota	01/20/2018

Oral

Hematology/Oncology Update Practice of Internal Medicine Rochester, Minnesota	05/1993
Bone Marrow Transplantation for Solid Tumors Symposium on Bone Marrow Transplantation Rochester, Minnesota	11/1993
Bone Marrow Transplantation for Breast Cancer Dental Reviews Rochester, Minnesota	04/1994
Hematology/Oncology Update Practice of Internal Medicine Rochester, Minnesota	05/1994
Institutional Ethics: On the Preservation of Certain Values Medical Grand Rounds Rochester, Minnesota	11/1995
Hematology/Oncology Update Practice of Internal Medicine Rochester, Minnesota	05/1996
Cancer Connection: A Multidisciplinary Update Panel Presentation on Bone Marrow Transplantation Rochester, Minnesota	03/1997

Chronic Myelogenous Leukemia: Advances in Diagnosis and Treatment Mayo Grand Rounds Rochester, Minnesota	07/1997
Veno-Occlusive Disease of the Liver Following Marrow Transplantation: The Mayo Experience Mayo Alumni Association Annual Meeting Rochester, Minnesota	09/1997
Unrelated Donor Bone Marrow Transplantation Hematology/Oncology Professional Development Seminar, Department of Nursing Rochester, Minnesota	10/1997
Unrelated Donor Bone Marrow Transplantation Hematology/Oncology Professional Development Seminar, Department of Nursing Rochester, Minnesota	11/1997
An Overview of the Anemias Dietetic Staff Rochester, Minnesota	03/1998
Autologous Stem Cell Transplant for Treatment of Rheumatoid Arthritis Medical Grand Rounds Rochester, Minnesota	09/1998
Guinan, et al, Transplantation of Anergic Histoincompatible Bone Marrow Allografts, NEJM 340:1704, 1999 Transplant Center Grand Rounds Journal Club Rochester, Minnesota	01/1999
Stem Cell Transplantation for Solid Tumors: Concepts, Controversies, and Clinical Trials Nursing Symposium: Current Issues in Cancer Care Rochester, Minnesota	11/1999
1000th BMT Celebration Rochester, Minnesota	07/2000
Blood and Marrow Transplantation for Solid Tumors: An Update Transplant Center Grand Rounds Rochester, Minnesota	08/2002
The Evolution of Cancer Treatment: A Look Back Cancer Connections: A Multidisciplinary Update Rochester, Minnesota	08/2002
Aplastic Anemia: An Update and the Role of BMT Transplant Center Grand Rounds Rochester, Minnesota	04/2003
Acute Leukemia First Annual Mayo Clinic Hematology Review Minneapolis, Minnesota	01/2004
Acute and Chronic Leukemia Trends in Hematologic Disorders: Implications for 2005 Cincinnati, Ohio	01/2005
Meditation Inservice for station 73/93 Rochester Methodist Hospital Nursing Staff Rochester, Minnesota	01/2005
Acute Leukemia/Chronic Myeloid Leukemia Third Annual Mayo Clinic Hematology Review Minneapolis, Minnesota	01/2006
Acute Leukemia and Chronic Myeloid Leukemia Fourth Annual Mayo Clinic Hematology Review Minneapolis, Minnesota	01/2007
Acute Leukemia/Chronic Myeloid Leukemia Fourth Annual Mayo Clinic Hematology Review Minneapolis, Minnesota	01/2007

Acute Leukemia/Chronic Myeloid Leukemia Fifth Annual Mayo Clinic Hematology Review Minneapolis, Minnesota	01/2008
Acute Lymphoblastic and Chronic Myeloid Leukemia 6th Annual Mayo Clinic Hematology Review Minneapolis, Minnesota	01/2009
An Overview of Allogeneic Blood and Marrow Transplantation and Its ICU Complications Rochester, Minnesota	10/2009
Acute Leukemia and Stem Cell Transplantation Seventh Annual Mayo Clinic Hematology Review Minneapolis, Minnesota	01/2010
Blood and Marrow Transplantation or How to Be More Therapeutic Fourth Annual Mayo Transplant Nursing Symposium Rochester, Minnesota	11/2010
Acute Leukemia and Stem Cell Transplantation 8th Annual Mayo Clinic Hematology Review Minneapolis, Minnesota	01/2011
BMT - Blood & Marrow Transplantation or How to Be More Therapeutic Mayo BMT Nurses Professional Education Days Rochester, Minnesota	02/2011
Acute Leukemia and Stem Cell Transplantation 9th Annual Mayo Clinic Hematology Review Minneapolis, Minnesota	01/2012
Acute Leukemia and Stem Cell Transplantation 10th Annual Mayo Clinic Hematology Review Minneapolis, Minnesota	01/2013
Unclassified	
Practical Management Pearls for Immunotherapy for the Treatment of Acute Leukemia - SITC CPG Webinar Webinar Rochester, Minnesota	10/14/2021
Acute leukemia and Stem Cell Transplantation 20th Annual Mayo Clinic Hematology Review 2023	01/28/2023
Acute Lymphoblastic Leukemia ESH 3rd Translational Research Conference	05/19/2023 - 05/21/2023

Clinical Practice, Interests, and Accomplishments

Interests:

Diagnosis and treatment of patients with myeloid disorders including myelodysplastic syndrome, myeloproliferative disorders, chronic myelogenous leukemia, and acute myelogenous leukemia.

Diagnosis and treatment of acute lymphoblastic leukemia.

Modality of blood and marrow transplantation in improving the care of these patients, and lessening morbidity to improve their clinical outcomes.

Accomplishments:

Key role in reorganizing the Hematology hospital services to develop a dedicated leukemia service (1998).

Key role in reorganizing the myeloproliferative, myelodysplastic, and acute leukemia groups within the Division of Hematology into one myeloid disease oriented group (2001-2002).

Research Interests and Accomplishments

Development of new therapies for patients with myelodysplastic syndrome, acute myelogenous leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, use of blood and marrow transplantation for the treatment of solid tumors, immunotherapy of myeloid hematologic malignancies, and treatment of complications of blood and marrow transplantation.

Research Grants Awarded

Active Grants**Federal sub award**

Program Director / Principal Investigator	ECOG-ACRIN Operations Center - Clinical Trials. Funded by National Cancer Institute. (CA 180820)	03/2019 - 08/2024
Program Director / Principal Investigator	MCW PAVE AML (IRB 20-006448): A Multisite Phase Ib Study of Pevonedistat, Azacitidine, and Venetoclax (PAVE) for the Treatment of Patients With Acute Myelogenous Leukemia (AML). Funded by Takeda Pharmaceuticals International Co. . (MCW PAVE AML)	01/2021 - 12/2021
Program Director / Principal Investigator	The Role of HIF1A-DNMT3A axis in AML1/ETO-Driven Acute Myelogenous Leukemia. Funded by National Cancer Institute. (CA 248019)	12/2022 - 11/2025
Co-Investigator	Specialty Compared to Oncology Delivered Palliative Care for Patients with Acute Myeloid Leukemia – SCOPE-Leukemia . Funded by Patient-Centered Outcomes Research Institute. (PLACER-2020C3-21247)	03/2022 - 06/2027
Co-Investigator	Targeting CD103 with engineered cell therapy for the treatment of GVHD. Funded by Minnesota Partnership for Biotechnology and Medical Genomics. ()	05/2023 - 04/2025

Industry

Program Director / Principal Investigator	Replacement Budget #1- MCR 16-001301 Iomab-01 A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation versus Conventional Care in Older Subjects with Active, Relapsed or Refractory Acute Myeloid Leukemia. Funded by Actinium Pharmaceuticals, Inc.. (Iomab-01 IOM301 004)	05/2017 - 05/2022
Program Director / Principal Investigator	Amd 1: AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients with Recurrent or Refractory Active cGVHD who have Received at least 2 Lines of Therapy. Funded by Syndax. (SNDX2504 SITE: 840-042)	10/2021 - 09/2024

Mayo Clinic

Program Director / Principal Investigator	EA9181: A Phase III Randomized Trial of Steroids +Tyrosine Kinase Inhibitor Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-positive Acute Lymphoblastic Leukemia in Adults. Funded by Hybrid Intramural Proposal for Cancer Center	04/2022 - 03/2028
Program Director / Principal Investigator	EA9213, A Phase II Trial of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T cell Acute Lymphoblastic Leukemia (T-ALL). Funded by Hybrid Intramural Proposal for Cancer Center	03/2023 - 02/2028

Completed Grants**Federal**

Principal Investigator	Dendritic Cell Therapy of Chronic Myelogenous Leukemia. Funded by National Cancer Institute. (R01 CA 84368)	05/2001 - 04/2006
Co-Investigator	Eastern Cooperative Oncology Group. Funded by National Cancer Institute. (U10 CA 13650)	05/1999 - 04/2004
Co-Principal Investigator	A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell with Marrow Transplantation from HLA Compatible Unrelated Donors. BMT CTN trial 0201 BMT Budget - Roll-up of costs. Funded by National Institutes of Health. (U01 HL 69294)	11/2003 - 11/2009

Federal sub award

Program Director / Principal Investigator	Reliable Biomarkers for Prediction of Transplant-Related-Mortality. Funded by University of Minnesota/Mayo/IBM Collaboration Seed Grant Program. (H0000557601)	09/2008 - 02/2010
Program Director / Principal Investigator	RDSafe: A Multicenter Study of Hematopoietic Stem Cell Donor Safety and Quality of Life. Funded by National Heart, Lung, and Blood Institute. (HL 85707)	10/2009 - 09/2014
Program Director / Principal Investigator	A Phase II/III Randomized, Multicenter Trial Comparing Sirolimus plus Prednisone, Sirolimus/Extracorporeal Photopheresis plus Prednisone, and Sirolimus/Calcineurin Inhibitor plus Prednisone for the Treatment of Chronic Graft-versus-Host Disease. Funded by National Institutes of Health. (NMDP-#0801)	01/2011 - 06/2017
Program Director / Principal Investigator	Pilot Study to Assess the Feasibility of Collecting Quality of Life Data in Collaboration with the Stem Cell Therapeutic Outcomes Database. Funded by National Marrow Donor Program. (20015)	05/2011 - 01/2012
Program Director / Principal Investigator	BMT CTN 0901- A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia. Funded by National Heart, Lung, and Blood Institute. (NMDP-0901)	01/2012 - 12/2016
Program Director / Principal Investigator	Myelodysplastic syndrome: Bench to Bedside. Funded by Minnesota Partnership for Biotechnology and Medical Genomics. (P003084001)	02/2012 - 09/2015
Program Director / Principal Investigator	CIBMTR 09-PLEX: A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients with Hematological Malignancies. Funded by Genzyme Corporation. (CIBMTR PROTOCOL 09- PLEX / Genzyme Protocol #MAMO0109-2)	04/2013 - 03/2016
Program Director / Principal Investigator	ECOG Leukemia Chair (subaward contract LKCO39ML-00). Funded by National Cancer Institute. (CA021115)	08/2013 - 05/2015
Program Director / Principal Investigator	BMT CTN 0903: Allogenic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic Syndromes in HIV- Infected Individuals. Funded by National Heart, Lung, and Blood Institute. (#0903)	09/2013 - 09/2016
Program Director / Principal Investigator	PrE0901: Phase I Dose Finding/Phase II Placebo-Controlled Trial of Eltrombopag During Consolidation Therapy in Adults with Acute Myeloid Leukemia (AML) in Complete Remission. Funded by GlaxoSmithKline. (Protocol Number: PrE0901)	10/2013 - 10/2015
Program Director / Principal Investigator	BMT CTN 1205: Easy-to-Read Informed Consent (ETRIC) for Hematopoietic Cell Transplantation Clinical Trials . Funded by National Marrow Donor Program. (NMDP-#1205)	03/2014 - 06/2017
Program Director / Principal Investigator	ECOG-ACRIN Operations Center grant - Leukemia Committee Chair. Funded by National Cancer Institute. (CA 180820)	04/2014 - 02/2019
Program Director / Principal Investigator	Repl Am. 2: A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus Host-Disease . Funded by Miltenyi Biotec Inc. (BMT CTN 1301)	08/2015 - 07/2020

Program Director / Principal Investigator	Selection of Allogeneic Hematopoietic Cell Donor Based on KIR and HLA Genotypes. Funded by National Heart, Lung, and Blood Institute. (HL 129472)	05/2017 - 04/2020
Program Director / Principal Investigator	Beat AML Master Clinical Trial: A Clinical Trial for Acute Myeloid Leukemia Patients (Umbrella Trial). Funded by Leukemia & Lymphoma Society. (Beat Aml)	03/2018 - 03/2021
Program Director / Principal Investigator	BMT CTN 1506: A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML . Funded by National Institutes of Health. (BMT CTN 1506)	04/2018 - 04/2020
Program Director / Principal Investigator	ECOG-ACRIN Operations Center - MyeloMATCH. Funded by National Cancer Institute	03/2021 - 02/2022
Program Director / Principal Investigator	MAIN MAGENTA/NMDP FP: A Phase II Study Evaluating the Safety and Efficacy of MGTA-145 in Combination with Plerixafor for the Mobilization and Transplantation of HLA-Matched Donor Hematopoietic Stem Cells in Recipients with Hematological Malignancies. Funded by NMDP/Be The Match. (MGTA-145-ADS-202)	06/2021 - 06/2024
Co-Investigator	U of Michigan Core Clinical Center for BMT Research Network. Funded by National Heart, Lung, and Blood Institute. (HL 69330 / SUBK00000862)	01/2013 - 06/2016
Co-Investigator	The Role of HIF1A-DNMT3A axis in AML1/ETO-Driven Acute Myelogenous Leukemia. Funded by National Cancer Institute. (CA 248019)	12/2020 - 08/2022

Foundation

Program Director / Principal Investigator	A Randomized Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: BMT CTN Protocol 0403. Funded by National Marrow Donor Program	07/2006 - 02/2010
---	---	-------------------

Industry

Principal Investigator	The Effect of Subcutaneous r-HuEPO Combined with Subcutaneous rhGM-CSF in the Treatment of Patients with Myelodysplastic Syndrome (91-80-03). Funded by R. W. Johnson Pharmaceutical Research Institute. (PRI #3)	01/1992 - 12/1992
Principal Investigator	A Phase III Study Comparing FK506 with Cyclosporine for GVHD Prophylaxis after Allogeneic Bone Marrow Transplantation. Funded by Fujisawa Pharmaceutical Company	01/1993 - 01/1994
Principal Investigator	A Phase III Study Comparing FK506 with Cyclosporine for Graft Versus Host Disease Prophylaxis After Allogeneic Bone Marrow Transplantation. Funded by Fujisawa USA, Incorporated. (Fujisawa #5)	07/1993 - 07/1996
Principal Investigator	WP1018-A Phase II Randomized, Double Blind, Placebo Controlled Trial of Lisofylline(LSF) in Patients with Hematologic Malignancies Undergoing HLA-Identical Related Allogeneic Bone Marrow Transplantation. Funded by Cell Therapeutics, Inc.. (Cell #2)	07/1995 - 06/1996
Principal Investigator	A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Lisofylline in Patients with Hematologic Malignancies Undergoing Bone Marrow Transplantation from HLA-Identical Sibling Donors. Funded by Cell Therapeutics, Inc.. (Cell 3)	11/1996 - 10/2005
Principal Investigator	A Phase II Study of Flt3 Ligand in Combination With GM-CSF or G-CSF for Mobilization of Peripheral Blood Progenitor Cells in	12/1997 - 06/2004

	Patients With Breast Cancer. Funded by Immunex Research and Development Corporation. (Immunex 3)	
Principal Investigator	A Phase I Trial of Toptecan Combined With High Dose Cyclophosphamide and Carboplatin with Peripheral Blood Stem Cell Transplant for the Treatment of Relapsed Ovarian Cancer and Primary Peritoneal Cancer. Funded by SmithKline Beecham. (SmithKline 10)	05/1998 - 12/2006
Program Director / Principal Investigator	C-701a/204A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence with Standard Chemotherapy to Patients with Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations. Funded by Cephalon, Incorporated. (MC1552/R0701 / Protocol C0701a/204)	02/2004 - 10/2009
Program Director / Principal Investigator	C0701a/501 - An Open-Label Extended-Use Study of Oral CEP-701 in Patients with Hematologic and Non-Hematologic Malignancies Who Have Completed a Clinical Study of CEP-701. Funded by Cephalon, Incorporated. (C0701a/501)	06/2004 - 12/2009
Program Director / Principal Investigator	CAMN107A2101 -Ph IA/II Mlticntr, Dose-Escalation Stdy of Oral AN107 on a Continuous Daily Dosing Schedule in Adult Pts w/ Gleevec-Resistant CML in Accelerated Ph or Blast Crisis, Relapsed/Refractory Ph+ ALL, & Other Hematologic Malignancies. Funded by Novartis. (CAMN107A2101)	10/2005 - 03/2009
Principal Investigator	CAMN107A2109 - An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients with Imatinib (Glivic/Gleevec) - Resistan or -Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase. Funded by Novartis. (NOVARTIS #95; 1A5989)	05/2006 - 04/2009
Program Director / Principal Investigator	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF PROPHYLACTIC USE OF MARIBAVIR FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN RECIPIENTS OF ALLOGENEIC STEM CELL TRANSPLANTS",. Funded by Viropharma. (1263-300)	12/2006 - 11/2009
Principal Investigator	CLBH589B2202, "A Phase II, Multicentre Study of Oral LBH589 in Patients with Chronic Phase Chronic Myeloid Leukemia with Resistant Disease Following Treatment with at Least Two BCR-ABL Tyrosine Kinase Inhibitors". Funded by Novartis. (NOVARTIS #106, 1A6428)	04/2007 - 03/2009
Principal Investigator	CLBH589B2211, "A Phase II, Multicentre Study of Oral LBH589 in Patients with Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia with Resistant Disease Following Treatment with at Least Two BCR-ABL Tyrosine Kinase Inhi. Funded by Novartis. (NOVARTIS #107, 1A6452)	07/2007 - 06/2009
Program Director / Principal Investigator	AC220-002, "A Phase 2 Open-Label, AC220 Monotherapy Efficacy (ACE) Study In Patients With Acute Myeloid Leukemia (AML) With FLT3-ITD Activating Mutations". Funded by Ambit Biosciences Corp.. (Procotol AC220-002)	01/2010 - 01/2013
Program Director / Principal Investigator	E7373-A001-101, A Phase 1 Open-Label, Dose Escalation Study to Determine the Absolute Bioavailability of a Single Oral Dose Administration of Decitabine in Patients with Myelodysplastic Syndrome (MDS). Funded by Eisai Medical Research, Inc.. (Protocol E7373-A001-101)	03/2010 - 08/2011
Program Director / Principal Investigator	2689-CL-2004: A Phase II, Randomized, Open label study of the safety and efficacy of two doses of Quizartinib in subjects w/ FLT3 -ITD Positive relapsed or refractory AML. Funded by Ambit Biosciences Corp.. (Protocol # 2689-CL-2004 / Work Order #1APGD-1)	06/2012 - 05/2014
Program Director /	MT103-211: An open label, multicenter, phase II study to evaluate efficacy and safety of the BiTE® antibody blinatumomab in adult	06/2012 - 05/2016

Principal Investigator	patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). Funded by Amgen. (Protocol #MT103-211)	
Program Director / Principal Investigator	20120216 A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE Antibody Blinatumomab in Adult Subjects with Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia (Alcantara Study). Funded by Amgen. (Protocol No. 20120216)	02/2014 - 01/2016
Program Director / Principal Investigator	00103311 A Phase 3, Randomized, Open Label Study Investigating the Efficacy of the BiTE Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (TOWER Study). Funded by Amgen. (Amgen Protocol No. 00103311 / TOWER Study)	03/2014 - 02/2018
Program Director / Principal Investigator	Amend 2 (Repl) MCR 2215-CL-0101 14-000354 A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia . Funded by Astellas Pharma Global Development, Inc. (APGD). (Protocol 2215-CL-0101)	06/2014 - 05/2016
Program Director / Principal Investigator	MCR 2215-CL-0101 14-000354 A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia . Funded by Astellas Pharma Global Development, Inc. (APGD). (Protocol 2215-CL-0101)	06/2014 - 05/2016
Program Director / Principal Investigator	AM#1-(PA 4,5) M16-802: A Multicenter, Open-Label Phase 1b Study to Assess Safety and Efficacy of Venetoclax in Combination with Gilteritinib in Subjects with Relapsed/Refractory Acute Myeloid Leukemia. Funded by AbbVie Inc.. (M16-802 4201281012)	03/2015 - 03/2018
Program Director / Principal Investigator	Amendment #2_Replacement-CPKC412AUS56X: An open-label, multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in adult patients with newly diagnosed Fms-like tyrosine kinase receptor (FLT3) mutated Acute Myeloid Leukemia (AML). Funded by Novartis. (CPKC412AUS56X)	06/2016 - 12/2018
Program Director / Principal Investigator	MCR: TPI-ALV-201, A Phase 2, Randomized, Biomarker-driven, Clinical Study in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with an Exploratory Arm in Patients with Newly Diagnosed High-Risk AML. Funded by Tolero Pharmaceuticals. (TPI-ALV-201)	06/2018 - 06/2021
Program Director / Principal Investigator	A Phase 1 Open-Label Dose-Escalation Study to Evaluate the Safety of Intra-Muscular Injections of PLX-R18 in Subjects with Incomplete Hematopoietic Recovery following Hematopoietic Cell Transplantation. Funded by Pluristem Ltd. . (PLX-R18-HCT-01)	10/2018 - 10/2020
Co-Investigator	Determination of the Therapeutic Efficiency of Photochemically Treated Platelets in Thrombocytopenic Patients. Funded by Baxter Healthcare Corporation. (Baxter 26)	07/1999 - 12/2005
Co-Investigator	CG53135-CLN-12 - Phase II randomized double blind placebo controlled trial to assess safety and efficacy of velafermin for prevention of oral mucositis in hematologic cancer patients receiving autologous stem cell transplant. Funded by CuraGen Corporation. (CG53135-CLN-12)	10/2006 - 03/2009
Co-Investigator	INCY-001, "Assessment of Functional Exercise Capacity in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PVMF) and Post-Essential Thrombocythemia Myelofibrosis (Post-ETMF) Using the Six Minute Walk Test". Funded by Incyte. (INCY-001)	07/2007 - 07/2008
Co-Investigator	A Phase III, Randomized, Double-Blind, Placebo-Controlled Study	12/2007 - 11/2008

	to Evaluate Prochymal (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion in Combination with Corticosteroids for Treatment of diagnosed Acute GVHD (Protocol 265). Funded by Osiris Therapeutics, Inc.. (Protocol 265)	
Co-Investigator	MF-TG101348-001, "A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability, PK and Pharmacodynamics of Oral TG101348 in Pts With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis". Funded by TargeGen Corporation. (MF-TG101348-001)	01/2008 - 01/2010
Co-Investigator	CLOMDS01206, "A Phase I, Open-Label, Dose-Finding and Food Effect Study of Oral Clofarabine in Previously Treated Adult Patients with Myelodysplastic Syndromes (MDS). Funded by Genzyme Corporation. (CLOMDS01206)	03/2008 - 03/2010
Co-Investigator	MF-TG101348-002, "An Open-Label Study Evaluating the Long-Term Effects of Orally Administered TG101348 in Patients With Primary or Secondary Myelofibrosis" . Funded by TargeGen Corporation. (MF-TG101348-002)	10/2008 - 10/2009
Co-Investigator	A Phase I/IIa randomized, observer-blind, placebo controlled, multicenter study to evaluate the safety and immunogenicity of the GSK Biologicals? herpes zoster vaccine . Funded by GlaxoSmithKline. (110258/ETR (Zoster-001 PRI))	05/2009 - 04/2011
Co-Investigator	CCL09101, A Phase I/II, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability Pk and PD of Orally-Administered CYT387 in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis. Funded by Gilead Sciences. (CCL09101)	10/2009 - 10/2012
Co-Investigator	CLBH589BUS58, "Phase II trial of Oral Panobinostat (LBH589), a Novel deacetylase Inhibitor (DACi) in Patients with Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis". Funded by Novartis. (CLBH589BUS58)	10/2009 - 10/2011
Co-Investigator	INCB18424-351, "A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Admin Orally to Subjects with PMF, PPV-MF or PET-MF". Funded by Incyte. (INCB18424-351)	11/2009 - 11/2012
Co-Investigator	APL-B-020-10, Open-label, Phase II Clinical Trial of Aplidin® (Plitidepsin) in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia (Post-PV/ET) Myelofibrosis . Funded by PharmaMar USA Inc.. (APL-B-020-10)	06/2010 - 05/2012
Co-Investigator	Amend 3 Repl CC-4047-MF-002, A Phase-3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Compare Efficacy and Safety of Pomalidomide in subjects With Myeloproliferative Neoplasm-Asso. Funded by Celgene. (CC-4047-MF-002)	08/2010 - 08/2012
Co-Investigator	CCL09101E Phase II, Open-Label Extension Study Evaluating the Long Term Safety, Tolerability & Efficacy of Orally-Administered CYT387 in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis. Funded by Gilead Sciences. (Protocol CCL09101E)	01/2011 - 01/2014
Co-Investigator	Amend #4 (Replacement) CA215001: A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of BMS-911543 in Subjects with Myelofibrosis. Funded by Bristol Meyers Squibb. (Protocol CA215-001)	02/2011 - 01/2013
Co-Investigator	A randomized, prospective, double blind, placebo-controlled, phase 3 study of US-ATG-F prophylaxis as a supplement to SOC prophylaxis to prevent moderate to severe chronic GVHD in adult	05/2012 - 05/2016

AML, ALL, and MDS patients after allogeneic SCT from unrelated donors. Funded by Fresenius Biotech. (IV-ATG-SCT-01)

Mayo Clinic

Principal Investigator	A Phase I Trial of Recombinant Human Interleukin-3 and Granulocyte Macrophage-Colony Stimulating Factor in Autologous Bone Marrow Transplantation for Non-Hodgkin's Lymphoma and Hodgkin's Disease (91-78-01). Funded by Mayo Clinic CR10 Award. (NO1-CM-07309)	01/1992 - 01/1995
Principal Investigator	Phase II Randomized Double-Blind Placebo Controlled Trial of Lisofylline in Patients with Hematologic Malignancies Undergoing Bone Marrow Transplant from HLA-Identical Sibling Donors.. Funded by Mayo Clinic. (CTI 1029)	10/1996 - 04/2001
Principal Investigator	Dendritic Cell Therapy for Chronic Myelogenous Leukemia. Funded by Mayo Clinic Cancer Center	01/1997 - 01/1999
Principal Investigator	A Phase II Study of Flt3 Ligand in Combination with GM-CSF or G-CSF for Mobilization of Peripheral Blood Progenitor Cells in Patients with Breast Cancer.. Funded by Mayo Clinic. (Protocol 97-32-01)	12/1997 - 08/2001
Program Director / Principal Investigator	MCR J1319: Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside (ara-C) with and without the Checkpoint Kinase 1 (CHK1) Inhibitor MK-8776 in Adults with Relapsed Acute Myelogenous Leukemia (AML) . Funded by Hematology Research	01/2014 - 12/2015
Program Director / Principal Investigator	S1612 A Randomized Phase II/III Trial of Novel Therapeutics Versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older (LEAP: Intergroup Less Intense AML Platform Trial) . Funded by Hybrid Intramural Proposal for Cancer Center	06/2018 - 05/2021
Co-Investigator	Mobilizing bone-marrow derived stem cells and progenitors by hyperbaric oxygen. A clinical study in healthy subjects (Novel Methodology Development Award). Funded by Other Mayo	07/2007 - 07/2008
Co-Investigator	A Randomized, Placebo-Controlled, Pilot Study of Colesevelam and Serum Bovine Immunoglobulin to prevent Diarrhea in Patients with Multiple Myeloma Receiving Conditioning Chemotherapy for Autologous Stem Cell Transplantation (SCT). Funded by Development - Gifts from benefactors	08/2015 - 07/2016

Other

Effect of gamma interferon on cytogenetically abnormal bone marrow progenitors in myelodysplastic syndromes in the laboratory of L.A. Solberg, Jr., M.D., Ph.D., Mayo Clinic, Rochester, Minnesota Research Project Rochester, Minnesota	01/1988
Hematopoietic stem cell research in the laboratory of Irwin D. Bernstein, M.D., at the Fred Hutchinson Cancer Research Center Research Project Seattle, Washington	01/1989 - 01/1990
Highlights in Acute Lymphoblastic Leukemia Webinar MedScape TV	12/2020
Approach to Ph+ and Ph-Like ALL Webinar "Great Debates & Updates in Hematologic Malignancies"	04/2021
Acute Myeloid Leukemia: Increasing Complexity and Increasing Treatment Opportunities Webinar	10/2021

Bibliography

Peer-reviewed Articles

1. **Litzow MR**, Kyle RA. Multiple responses of aplastic anemia to low-dose cyclosporine therapy despite development of a myelodysplastic syndrome. *Am J Hematol*. 1989 Nov; 32 (3):226-9 PMID: 2816916 DOI: 10.1002/ajh.2830320313
2. **Litzow MR**, Brashem-Stein C, Andrews RG, Bernstein ID. Proliferative responses to interleukin-3 and granulocyte colony stimulating factor distinguish a minor subpopulation of CD34-positive marrow progenitors that do not express CD33 and a novel antigen, 7B9. *Blood*. 1991 Jun 1; 77:2354-2359. PMID: 1710150
3. Letendre L, Hoagland HC, Moore SB, Chen MG, Gastineau DA, Gertz MA, Habermann TM, **Litzow MR**, Noel P, Noel P, Solberg LA Jr. Mayo Clinic experience with allogeneic and syngeneic bone marrow transplantation, 1982 through 1990. *Mayo Clin Proc*. 1992 Feb; 67 (2):109-16 PMID: 1312187 DOI: 10.1016/s0025-6196(12)61309-3
4. **Litzow MR**. Hematology/oncology update. *The Practice of Internal Medicine-1992*. 1992 May 11-15; 185-90.
5. **Litzow MR**. Advances in bone marrow transplantation. *Mayo Clinic Update*. 1993; 9(1):5-7.
6. Anderson JE, **Litzow MR**, Appelbaum FR, Schoch G, Fisher LD, Buckner CD, Petersen FB, Crawford SW, Press OW, Sanders JE. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. *J Clin Oncol*. 1993 Dec; 11(12):2342-50. PMID: 8246023
7. Ho TC, Tefferi A, Su JQ, **Litzow MR**, Hoagland HC, Noel P, Noel P. Acute lymphocytic leukemia in adults: a retrospective study and analysis of current management options. *Mayo Clin Proc*. 1994 Oct; 69 (10):937-48 PMID: 7934190 DOI: 10.1016/s0025-6196(12)61817-5
8. Gertz MA, Pineda AA, Chen MG, Letendre L, Greipp PR, Solberg LA Jr, Witzig TE, Garton JP, Inwards DJ, **Litzow MR**. Refractory and relapsing multiple myeloma treated by blood stem cell transplantation. *Am J Med Sci*. 1995 Mar; 309 (3):152-61 PMID: 7879820 DOI: 10.1097/00000441-199503000-00006
9. Gertz MA, Witzig TE, Pineda AA, Greipp PR, Kyle RA, **Litzow MR**. Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation. *Bone Marrow Transplant*. 1997 Feb; 19 (4):337-42 PMID: 9051243 DOI: 10.1038/sj.bmt.1700670
10. Tefferi A, **Litzow MR**, Noel P, Noel P, Dewald GW. Chronic granulocytic leukemia: recent information on pathogenesis, diagnosis, and disease monitoring. *Mayo Clin Proc*. 1997 May; 72 (5):445-52 PMID: 9146688 DOI: 10.4065/72.5.445
11. Kuffel DG, Lindor NM, **Litzow MR**, Zinsmeister AR, Dewald GW. Mitomycin C chromosome stress test to identify hypersensitivity to bifunctional alkylating agents in patients with Fanconi anemia or aplastic anemia. *Mayo Clin Proc*. 1997 Jun; 72 (6):579-80 PMID: 9179145 DOI: 10.4065/72.6.579
12. Gertz MA, Lacy MQ, Inwards DJ, Pineda AA, Chen MG, Gastineau DA, Tefferi A, Kyle RA, **Litzow MR**. Factors influencing platelet recovery after blood cell transplantation in multiple myeloma. *Bone Marrow Transplant*. 1997 Sep; 20 (5):375-80 PMID: 9339752 DOI: 10.1038/sj.bmt.1700897
13. Galanis E, **Litzow MR**, Tefferi A, Scott JP. Spontaneous pneumomediastinum in a patient with bronchiolitis obliterans after bone marrow transplantation. *Bone Marrow Transplant*. 1997 Oct; 20(8):695-6. PMID: 9383235 DOI: 10.1038/sj.bmt.1700939
14. Winkelmann RK, **Litzow MR**, Umbert IJ, Lie JT. Giant cell granulomatous pulmonary and myocardial lesions in necrobiotic xanthogranuloma with paraproteinemia. *Mayo Clin Proc*. 1997 Nov; 72 (11):1028-33 PMID: 9374976 DOI: 10.4065/72.11.1028
15. Palmas A, Tefferi A, Myers JL, Scott JP, Swensen SJ, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, **Litzow MR**. Late-onset noninfectious pulmonary complications after allogeneic bone marrow transplantation. *Br J Haematol*. 1998 Mar; 100 (4):680-7 PMID: 9531334 DOI: 10.1046/j.1365-2141.1998.00617.x
16. Letendre L, Noel P, Noel P, **Litzow MR**, Hoagland HC, Tefferi A. Treatment of acute myelogenous leukemia in the older patient with attenuated high-dose ara-C. *Am J Clin Oncol*. 1998 Apr; 21 (2):142-4 PMID: 9537199 DOI: 10.1097/00000421-199804000-00009
17. Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, Fay JW, Nademanee A, Antin JH, Christiansen NP, van der Jagt R, Herzig RH, **Litzow MR**, Wolff SN, Longo WL, Petersen FB, Karanes C, Avalos B, Storb R, Buell DN, Maher RM, Fitzsimmons WE, Wingard JR. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. *Blood*. 1998 Oct 1; 92(7):2303-14. PMID: 9746768
18. Gertz MA, Lacy MQ, **Litzow MR**. Blood stem cell transplantation as therapy for primary systemic amyloidosis. *Department of Internal Medicine Intramural Newsletter Mayo Clinic*. 1999; 21(11):6-8.

19. **Litzow MR.** High-dose chemotherapy and autologous stem cell transplantation for breast cancer: results of recent randomized trials. Department of Internal Medicine Intramural Newsletter Mayo Clinic. 1999; 21(11):1-4.
20. Gertz MA, Lacy MQ, Inwards DJ, Chen MG, Pineda AA, Gastineau DA, Greipp PR, Lust JA, Tefferi A, Witzig TE, Kyle RA, **Litzow MR.** Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma. Bone Marrow Transplant. 1999 Feb; 23(3):221-6. PMID: 10084252 DOI: 10.1038/sj.bmt.1701559
21. Rajkumar SV, Fonseca R, Lacy MQ, Witzig TE, Therneau TM, Kyle RA, **Litzow MR,** Gertz MA, Greipp PR. Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma. J Clin Oncol. 1999 May; 17: (5)1551-7. PMID: 10334543 DOI: 10.1200/JCO.1999.17.5.1551
22. Rajkumar SV, Fonseca R, Lacy MQ, Witzig TE, Lust JA, Greipp PR, Therneau TM, Kyle RA, **Litzow MR,** Gertz MA. Autologous stem cell transplantation for relapsed and primary refractory myeloma. Bone Marrow Transplant. 1999 Jun; 23(12):1267-72. PMID: 10414914 DOI: 10.1038/sj.bmt.1701805
23. Rajkumar SV, Fonseca R, Lacy MQ, Witzig TE, Lust JA, Greipp PR, Therneau TM, Kyle RA, **Litzow MR,** Gertz MA. Beta(2)-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma. Bone Marrow Transplant. 1999 Jun; 23(12):1261-1266. PMID: 10414913
24. Rajkumar S, Fonseca R, Lacy M, Witzig T, Lust J, Greipp P, Therneau T, Kyle R, **Litzow M,** Gertz M. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma. Bone Marrow Transplant. 1999 Sep; 24(5):497-503. PMID: 10482933 DOI: 10.1038/sj.bmt.1701943
25. Letendre L, Noel P, Noel P, White WL, Tefferi A, **Litzow MR,** Li CY, Schroeder G. Treatment of unfavorable myelodysplastic syndrome with all-trans-retinoic acid and subcutaneous Ara C. Leuk Res. 1999 Sep; 23(9):811-5 PMID: 10475620 DOI: 10.1016/s0145-2126(99)00095-8
26. **Litzow MR.** Arsenic trioxide for acute lymphoblastic leukemia. ECOG Update. 2000 Spring; 5(1):5-7.
27. List AF, Maziarz R, Stiff P, Jansen J, Liesveld J, Andrews F, Schuster M, Wolff S, **Litzow M,** Karanes C, Dahlberg S, Kirkhart B, Bianco JA, Singer JW. A randomized placebo-controlled trial of lisofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients. Bone Marrow Transplant. 2000 Feb; 25(3):283-291. PMID: 10673700
28. Dietz AB, Bulur PA, Erickson MR, Wettstein PJ, **Litzow MR,** Wyatt WA, Dewald GW, Tefferi A, Pankratz VS, Vuk-Pavlovic S. Optimizing preparation of normal dendritic cells and bcr-abl+ mature dendritic cells derived from immunomagnetically purified CD14+ cells. J Hematother Stem Cell Res. 2000 Feb; 9(1):95-101 PMID: 10738977 DOI: 10.1089/152581600319676
29. **Litzow MR.** Acute lymphoblastic leukemia in adults. Curr Treat Options Oncol. 2000 Apr; 1(1):19-29 PMID: 12057058 DOI: 10.1007/s11864-000-0012-2
30. Gertz MA, Lacy MQ, Inwards DJ, Gastineau DA, Tefferi A, Chen MG, Witzig TE, Greipp PR, **Litzow MR.** Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma. Bone Marrow Transplant. 2000 Jul; 26(1):45-50. PMID: 10918404 DOI: 10.1038/sj.bmt.1702445
31. Gertz MA, Lacy MQ, Bjornsson J, **Litzow MR.** Fatal pulmonary toxicity related to the administration of granulocyte colony-stimulating factor in amyloidosis: a report and review of growth factor-induced pulmonary toxicity. J Hematother Stem Cell Res. 2000 Oct; 9: (5)635-43. PMID: 11091487 DOI: 10.1089/15258160050196678
32. Gertz MA, Lacy MQ, Gastineau DA, Inwards DJ, Chen MG, Tefferi A, Kyle RA, **Litzow MR.** Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL). Bone Marrow Transplant. 2000 Nov; 26(9):963-9. PMID: 11100275 DOI: 10.1038/sj.bmt.1702643
33. Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Witzig TE, Lust JA, Larson D, Therneau TM, Kyle RA, **Litzow MR,** Greipp PR, Gertz MA. Effect of complete response on outcome following autologous stem cell transplantation for myeloma. Bone Marrow Transplant. 2000 Nov; 26(9):979-83. PMID: 11100277 DOI: 10.1038/sj.bmt.1702640
34. **Litzow MR.** Acute myelogenous leukemia: new drug, new data, new decisions. Cancer Res Therapy and Control. 2001; 11:99-105.
35. Porrata LF, **Litzow MR,** Tefferi A, Kumar S, Geyer SM, Markovic SN. Early lymphocyte recovery post-autologous hemtopoietic stem cell transplantation is associated with better survival in Hodgkin's disease. J Clin Oncol. 2001; 98: (3)579-85.
36. Porrata LF, **Litzow MR,** Markovic SN. Immune reconstitution after autologous hematopoietic stem cell transplantation. Mayo Clin Proc. 2001; 76(4):407-12.
37. Dietz AB, **Litzow MR,** Bulur PA, Vuk-Pavlovic S. Transgenic interleukin 2 secreted by CML dendritic cells

- stimulates autologous T(H)1 T cells. *Cytotherapy*. 2001; 3 (2):97-105 PMID: 12028832 DOI: 10.1080/14653240152584505
38. Porrata LF, **Litzow MR**, Markovic SN. Immune reconstitution after autologous hematopoietic stem cell transplantation. *Mayo Clin Proc*. 2001 Apr; 76(4):407-12. PMID: 11322356
 39. Razonable RR, Patel R, Wilhelm MP, Gertz MA, **Litzow MR**, Inwards DJ, Dearani JA, Edwards BS, McGregor CG. Fatal disseminated aspergillosis following sequential heart and stem cell transplantation for systemic amyloidosis. *Am J Transplant*. 2001 May; 1 (1):93-5 PMID: 12095046 DOI: 10.1034/j.1600-6143.2001.010117.x
 40. Capizzi SA, Kumar S, Huneke NE, Gertz MA, Inwards DJ, **Litzow MR**, Lacy MQ, Gastineau DA, Prakash UB, Tefferi A. Peri-engraftment respiratory distress syndrome during autologous hematopoietic stem cell transplantation. *Bone Marrow Transplant*. 2001 Jun; 27 (12):1299-303 PMID: 11548849 DOI: 10.1038/sj.bmt.1703075
 41. Kumar S, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, Harmsen WS, **Litzow MR**. Prophylaxis of graft-versus-host disease with cyclosporine-prednisone is associated with increased risk of chronic graft-versus-host disease. *Bone Marrow Transplant*. 2001 Jun; 27(11):1133-40. PMID: 11551023 DOI: 10.1038/sj.bmt.1703053
 42. Porrata LF, Gertz MA, Inwards DJ, **Litzow MR**, Lacy MQ, Tefferi A, Gastineau DA, Dispenzieri A, Ansell SM, Micallef IN, Geyer SM, Markovic SN. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. *Blood*. 2001 Aug 1; 98 (3):579-85 PMID: 11468153 DOI: 10.1182/blood.v98.3.579
 43. Dietz AB, **Litzow MR**, Gastineau DA, Vuk-Pavlovic S. Engineering dendritic cell grafts for clinical trials in cellular immunotherapy of cancer: example of chronic myelogenous leukemia. *Croat Med J*. 2001 Aug; 42 (4):428-35. PMID: 11471194
 44. Kumar S, Dispenzieri A, Lacy MQ, **Litzow MR**, Gertz MA. High incidence of gastrointestinal tract bleeding after autologous stem cell transplant for primary systemic amyloidosis. *Bone Marrow Transplant*. 2001 Aug; 28 (4):381-5. PMID: 11571511 DOI: 10.1038/sj.bmt.1703155
 45. Afessa B, **Litzow MR**, Tefferi A. Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation. *Bone Marrow Transplant*. 2001 Sep; 28(5):425-34. PMID: 11593314 DOI: 10.1038/sj.bmt.1703142
 46. Tefferi A, Kumar S, Wolf RC, Lacy MQ, Inwards DJ, Gloor JM, Albright RC, Kamath PS, **Litzow MR**. Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantation. *Bone Marrow Transplant*. 2001 Nov; 28(10):997-9. PMID: 11753559 DOI: 10.1038/sj.bmt.1703267
 47. Kumar S, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, **Litzow MR**. Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow transplantation for acute myelogenous leukemia. *Bone Marrow Transplant*. 2001 Nov; 28 (10):951-6 PMID: 11753550 DOI: 10.1038/sj.bmt.1703262
 48. Porrata LF, Ingle JN, **Litzow MR**, Geyer S, Markovic SN. Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. *Bone Marrow Transplant*. 2001 Nov; 28(9):865-71. PMID: 11781647 DOI: 10.1038/sj.bmt.1703236
 49. Lee SJ, Klein JP, Anasetti C, Antin JH, Loberiza FR, Bolwell BJ, LeMaistre CF, **Litzow MR**, Marks D, Waller EK, Matlack M, Giralt S, Horowitz MM. The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase. *Blood*. 2001 Dec 1; 98(12):3205-11. PMID: 11719355
 50. Weisdorf D, Bishop M, Dharan B, Bolwell B, Cahn JY, Cairo M, Giralt S, Klein J, Lazarus H, **Litzow M**, Marks D, McCarthy P, Miller C, Milone G, Russell J, Schultz KR, Sierra J, Wiernik P, Keating A, Loberiza F, Kollman C, Horowitz M. Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: comparative toxicity and outcomes. *Biol Blood Marrow Transplant*. 2002; 8(4):213-20. PMID: 12014810
 51. Mow BM, Chandra J, Svigen PA, Hallgren CG, Weisberg E, Kottke TJ, Narayanan VL, **Litzow MR**, Griffin JD, Sausville EA, Tefferi A, Kaufmann SH. Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. *Blood*. 2002 Jan 15; 99 (2):664-71 PMID: 11781252 DOI: 10.1182/blood.v99.2.664
 52. Razonable RR, **Litzow MR**, Khaliq Y, Piper KE, Rouse MS, Patel R. Bacteremia due to viridans group Streptococci with diminished susceptibility to Levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. *Clin Infect Dis*. 2002 Jun 1; 34 (11):1469-74 Epub 2002 May 07 PMID: 12015693 DOI: 10.1086/340352
 53. Porrata LF, **Litzow MR**, Tefferi A, Letendre L, Kumar S, Geyer SM, Markovic SN. Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute

54. Hogan WJ, Letendre L, **Litzow MR**, Tefferi A, Hoagland HC, Pruthi RK, Kaufmann SH. Neutropenic colitis after treatment of acute myelogenous leukemia with idarubicin and cytosine arabinoside. *Mayo Clin Proc.* 2002 Aug; 77(8):760-2. PMID: 12173711 DOI: 10.4065/77.8.760
55. Kumar S, Wolf RC, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, **Litzow MR**. Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease. *Bone Marrow Transplant.* 2002 Aug; 30(3):161-5. PMID: 12189534 DOI: 10.1038/sj.bmt.1703616
56. Afessa B, Tefferi A, **Litzow MR**, Krowka MJ, Wylam ME, Peters SG. Diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients. *Am J Respir Crit Care Med.* 2002 Sep 1; 166 (5):641-5 PMID: 12204858 DOI: 10.1164/rccm.200112-141cc
57. Gertz MA, Lacy MQ, Dispenzieri A, Gastineau DA, Chen MG, Ansell SM, Inwards DJ, Micallef IN, Tefferi A, **Litzow MR**. Stem cell transplantation for the management of primary systemic amyloidosis. *Am J Med.* 2002 Nov; 113 (7):549-55 PMID: 12459400 DOI: 10.1016/s0002-9343(02)01208-1
58. **Litzow MR**, Repoussis PD, Schroeder G, Schembri-Wismayer D, Batts KP, Anderson PM, Arndt CA, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, Noel P, Solberg LA Jr, Letendre L, Hoagland HC. Veno-occlusive disease of the liver after blood and marrow transplantation: analysis of pre- and post-transplant risk factors associated with severity and results of therapy with tissue plasminogen activator. *Leuk Lymphoma.* 2002 Nov; 43 (11):2099-107 PMID: 12533034 DOI: 10.1080/1042819021000032962
59. Afessa B, Tefferi A, **Litzow MR**, Peters SG. Outcome of diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients. *American Journal of Respiratory & Critical Care Medicine.* 2002 Nov 15; 166 (10):1364-8. PMID: 12406834
60. **Litzow MR**, Perez WS, Klein JP, Bolwell BJ, Camitta B, Copelan EA, Gale RP, Giral SA, Keating A, Lazarus HM, Marks DI, McCarthy PL, Miller CB, Milone G, Prentice HG, Russell JA, Schultz KR, Trigg ME, Weisdorf DJ, Horowitz MM. Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission. *Br J Haematol.* 2002 Dec; 119 (4):1115-24 PMID: 12472596 DOI: 10.1046/j.1365-2141.2002.03973.x
61. Elliott MA, Nichols WL Jr, Plumhoff EA, Ansell SM, Dispenzieri A, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Micallef IN, Tefferi A, **Litzow M**. Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review. *Mayo Clin Proc.* 2003 Apr; 78 (4):421-30 PMID: 12683694 DOI: 10.4065/78.4.421
62. Caplice NM, Bunch TJ, Stalboerger PG, Wang S, Simper D, Miller DV, Russell SJ, **Litzow MR**, Edwards WD. Smooth muscle cells in human coronary atherosclerosis can originate from cells administered at marrow transplantation. *Proc Natl Acad Sci U S A.* 2003 Apr 15; 100 (8):4754-9 Epub 2003 Mar 28 PMID: 12665618 PMID: 153628 DOI: 10.1073/pnas.0730743100
63. Ringden O, Barrett AJ, Zhang MJ, Loberiza FR, Bolwell BJ, Cairo MS, Gale RP, Hale GA, **Litzow MR**, Martino R, Russell JA, Tiberghien P, Urbano-Ispizua A, Horowitz MM. Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses. *Br J Haematol.* 2003 Jun; 121(6):874-85. PMID: 12786798
64. Afessa B, Tefferi A, Dunn WF, **Litzow MR**, Peters SG. Intensive care unit support and Acute Physiology and Chronic Health Evaluation III performance in hematopoietic stem cell transplant recipients. *Crit Care Med.* 2003 Jun; 31(6):1715-21. PMID: 12794410 DOI: 10.1097/01.CCM.0000065761.51367.2D
65. Howe R, Micallef INM, Inwards DJ, Ansell SM, Dewald GW, Dispenzieri A, Gastineau DA, Gertz MA, Geyer SM, Hanson CA, Lacy MQ, Tefferi A, **Litzow MR**. Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma. *Bone Marrow Transplant.* 2003 Aug; 32(3):317-24. PMID: 12858205
66. Ghobrial IM, Dispenzieri A, Bundy KL, Gastineau DA, Rajkumar SV, Therneau TM, Lacy MQ, Witzig TE, **Litzow MR**, Christensen BR, Hayman S, Pribula CG, Gertz MA. Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma. *Bone Marrow Transplant.* 2003 Sep; 32(6):587-92. PMID: 12953131 DOI: 10.1038/sj.bmt.1704173
67. Kumar S, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, **Litzow MR**. Lymphocyte recovery after allogeneic bone marrow transplantation predicts risk of relapse in acute lymphoblastic leukemia. *Leukemia.* 2003 Sep; 17(9):1865-70. PMID: 12970788 DOI: 10.1038/sj.leu.2403055
68. Rabinstein AA, Dispenzieri A, Micallef IN, Inwards DJ, **Litzow MR**, Wijdicks EFM. Acute neuropathies after peripheral blood stem cell and bone marrow transplantation. *Muscle & Nerve.* 2003 Dec; 28(6):733-6. PMID: 14639588
69. Kumar S, **Litzow MR**, Rajkumar SV. Effect of allogeneic stem cell transplantation on bone marrow

- angiogenesis in chronic myelogenous leukemia. *Bone Marrow Transplant.* 2003 Dec; 32(11):1065-9. PMID:
70. Porrata LF, **Litzow MR**, Inwards DJ, Gastineau DA, Moore SB, Pineda AA, Bundy KL, Padley DJ, Persky D, Ansell SM, Micallef IN, Markovic SN. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma. *Bone Marrow Transplant.* 2004 Feb; 33 (3):291-8 PMID: 14676784 DOI: 10.1038/sj.bmt.1704355
 71. Ghobrial IM, Bunch TJ, Caplice NM, Edwards WD, Miller DV, **Litzow MR**. Fatal coronary artery disease after unrelated donor bone marrow transplantation. *Mayo Clin Proc.* 2004 Mar; 79(3):403-6. PMID: 15008613 DOI: 10.4065/79.3.403
 72. Ogle BM, Butters KA, Plummer TB, Ring KR, Knudsen BE, **Litzow MR**, Cascalho M, Platt JL. Spontaneous fusion of cells between species yields transdifferentiation and retroviral transfer in vivo. *FASEB J.* 2004 Mar; 18(3):548-50. Epub 2004 Jan 08. PMID: 14715691 DOI: 10.1096/fj.03-0962fje
 73. **Litzow MR**. The therapy of relapsed acute leukaemia in adults. *Blood Rev.* 2004 Mar; 18 (1):39-63 PMID: 14684148 DOI: 10.1016/s0268-960x(03)00036-5
 74. Dispenzieri A, Kyle RA, Lacy MQ, Therneau TM, Larson DR, Plevak MF, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA, Zeldenrust SR, Snow DS, Hayman SR, **Litzow MR**, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata LF, Elliott MA, Gertz MA. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. *Blood.* 2004 May 15; 103 (10):3960-3 Epub 2004 Jan 22 PMID: 14739213 DOI: 10.1182/blood-2003-12-4192
 75. Porrata LF, Gertz MA, Geyer SM, **Litzow MR**, Gastineau DA, Moore SB, Pineda AA, Bundy KL, Padley DJ, Persky D, Lacy MQ, Dispenzieri A, Snow DS, Markovic SN. The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma. *Leukemia.* 2004 Jun; 18 (6):1085-92 PMID: 15042106 DOI: 10.1038/sj.leu.2403341
 76. Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S, Allmer C, Witzig TE, Lust JA, Greipp PR, Kyle RA, **Litzow MR**, Gertz MA. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. *Bone Marrow Transplant.* 2004 Jul; 34(2):161-7. PMID: 15133489
 77. Elliott MA, Wolf RC, Hook CC, Pruthi RK, Heit JA, Letendre LL, Tefferi A, Kaufmann SH, Mesa RA, **Litzow MR**. Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin. *Leuk Lymphoma.* 2004 Aug; 45 (8):1545-9 PMID: 15370205 DOI: 10.1080/10428190410001693588
 78. Dietz AB, Souan L, Knutson GJ, Bulur PA, **Litzow MR**, Vuk-Pavlovic S. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. *Blood.* 2004 Aug 15; 104 (4):1094-9 Epub 2004 Apr 20 PMID: 15100154 DOI: 10.1182/blood-2003-12-4266
 79. Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S, Allmer C, Witzig TE, Lust JA, Greipp PR, Kyle RA, **Litzow MR**, Gertz MA. Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. *Bone Marrow Transplant.* 2004 Sep; 34(6):485-90. PMID: 15286691 DOI: 10.1038/sj.bmt.1704633
 80. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, McConnell JP, **Litzow MR**, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata LF, Elliott MA, Hogan WJ, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA, Zeldenrust SR, Snow DS, Hayman SR, McGregor CG, Jaffe AS. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. *Blood.* 2004 Sep 15; 104 (6):1881-7 Epub 2004 Mar 25 PMID: 15044258 DOI: 10.1182/blood-2004-01-0390
 81. Eapen M, Giralt SA, Horowitz MM, Klein JP, Wagner JE, Zhang MJ, Tallman MS, Marks DI, Camitta BM, Champlin RE, Ringden O, Bredeson CN, Martino R, Gale RP, Cairo MS, **Litzow MR**, deLima M. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. *Bone Marrow Transplant.* 2004 Oct; 34(8):721-7. PMID: 15322568
 82. Dispenzieri A, Moreno-Aspitia A, Suarez GA, Lacy MQ, Colon-Otero G, Tefferi A, **Litzow MR**, Roy V, Hogan WJ, Kyle RA, Gertz MA. Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature. *Blood.* 2004 Nov 15; 104 (10):3400-7 Epub 2004 July 27 PMID: 15280195 DOI: 10.1182/blood-2004-05-2046
 83. Gertz MA, Lacy MQ, Dispenzieri A, Ansell SM, Elliott MA, Gastineau DA, Inwards DJ, Micallef IN, Porrata LF, Tefferi A, **Litzow MR**. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. *Bone Marrow Transplant.* 2004 Dec; 34 (12):1025-31. PMID: 15516945 DOI: 10.1038/sj.bmt.1704691
 84. Dispenzieri A, Wiseman GA, Lacy MQ, **Litzow MR**, Anderson PM, Gastineau DA, Tefferi A, Inwards DJ,

- Micallef IN, Ansell SM, Porrata L, Elliott MA, Lust JA, Greipp PR, Rajkumar SV, Fonseca R, Witzig TE, Erlichman C, Sloan JA, Gertz MA. A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. *Leukemia*. 2005 Jan; 19: (11)118-25 PMID: 15526021 DOI: 10.1038/sj.leu.2403575
85. Cassileth PA, Lee SJ, **Litzow MR**, Miller KB, Stadtmauer EA, Tallman MS, Lazarus HM, Bennett JM, Paietta E, Dewald GW, Rowe JM. Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation: an Eastern Cooperative Oncology Group trial (E4995). *Leuk Lymphoma*. 2005 Jan; 46(1):55-61. PMID: 15621781
 86. Porrata LF, Gertz MA, **Litzow MR**, Lacy MQ, Dispenzieri A, Inwards DJ, Ansell SM, Micallef INM, Gastineau DA, Elliott M, Hogan WJ, Hayman SR, Tefferi A, Markovic SN. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis. *Clin Cancer Res*. 2005 Feb 1; 11 (3):1210-8 PMID: 15709191
 87. Oh H, Loberiza FR, Zhang MJ, Ringden O, Akiyama H, Asai T, Miyawaki S, Okamoto S, Horowitz MM, Antin JH, Bashey A, Bird JM, Carabasi MH, Fay JW, Gale RP, Giller RH, Goldman JM, Hale GA, Harris RE, Henslee-Downey J, Kolb HJ, **Litzow MR**, McCarthy PL, Neudorf SM, Serna DS, et al. Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. *Blood*. 2005 Feb 15; 105(4):1408-16. PMID: 15486071
 88. Tefferi A, Dewald GW, **Litzow ML**, Cortes J, Mauro MJ, Talpaz M, Kantarjian HM. Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment. *Mayo Clin Proc*. 2005 Mar; 80(3):390-402. PMID: 15757021 DOI: 10.4065/80.3.390
 89. Leung N, Griffin MD, Dispenzieri A, Haugen EN, Gloor JM, Schwab TR, Textor SC, Lacy MQ, **Litzow MR**, Cosio FG, Larson TS, Gertz MA, Stegall MD. Living donor kidney and autologous stem cell transplantation for primary systemic amyloidosis (AL) with predominant renal involvement. *Am J Transplant*. 2005 Jul; 5 (7):1660-70 PMID: 15943624 DOI: 10.1111/j.1600-6143.2005.00920.x
 90. Sharma S, Nadrous HF, Peters SG, Tefferi A, **Litzow MR**, Aubry MC, Afessa B. Pulmonary complications in adult blood and marrow transplant recipients - Autopsy findings. *Chest*. 2005 Sep; 128(3):1385-92. PMID: 16162733
 91. Yoong Y, Porrata LF, Inwards DJ, Ansell SM, Micallef IN, **Litzow MR**, Gertz MA, Lacy MQ, Dispenzieri A, Gastineau DA, Tefferi A, Elliott M, Snow DS, Hogan WJ, Markovic SN. The effect of absolute lymphocyte count recovery kinetics on survival after autologous stem cell transplantation for non-Hodgkin's lymphoma. *Leuk Lymphoma*. 2005 Sep; 46 (9):1287-94 PMID: 16109605 DOI: 10.1080/10428190500126380
 92. Kaufmann SH, Karp JE, Letendre L, Kottke TJ, Safgren S, Greer J, Gojo I, Atherton P, Svingen PA, Loegering DA, **Litzow MR**, Sloan JA, Reid JM, Ames MM, Adjei AA, Erlichman C. Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia. *Clin Cancer Res*. 2005 Sep 15; 11 (18):6641-9 PMID: 16166443 DOI: 10.1158/1078-0432.CCR-05-0817
 93. Lacy MQ, Hogan WJ, Gertz MA, Dispenzieri A, Rajkumar SV, Hayman S, Kumar S, **Litzow MR**, Schroeter AL. Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantation. *Arch Dermatol*. 2005 Oct; 141(10):1277-82. PMID: 16230566 DOI: 10.1001/archderm.141.10.1277
 94. Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, **Litzow MR**, Henderson KJ, Van Wier SA, Ahmann GJ, Fonseca R. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. *Blood*. 2005 Oct 15; 106 (8):2837-40 Epub 2005 June 23 PMID: 15976175 PMCID: 1895302 DOI: 10.1182/blood-2005-04-1411
 95. Prabhu RM, Piper KE, **Litzow MR**, Steckelberg JM, Patel R. Emergence of quinolone resistance among viridans group streptococci isolated from the oropharynx of neutropenic peripheral blood stem cell transplant patients receiving quinolone antimicrobial prophylaxis. *Eur J Clin Microbiol Infect Dis*. 2005 Dec; 24 (12):832-8 PMID: 16331335 DOI: 10.1007/s10096-005-0037-3
 96. Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM, Lazarus HM, Franklin IM, **Litzow MR**, Ciobanu N, Prentice HG, Durrant J, Tallman MS, Goldstone AH. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. *Blood*. 2005 Dec 1; 106(12):3760-7. PMID: 16105981
 97. Behl D, Porrata LF, Markovic SN, Letendre L, Pruthi RK, Hook CC, Tefferi A, Elliot MA, Kaufmann SH, Mesa RA, **Litzow MR**. Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. *Leukemia*. 2006 Jan; 20(1):29-34. PMID: 16281063 DOI: 10.1038/sj.leu.2404032
 98. **Litzow MR**, Dietz AB, Bulur PA, Butler GW, Gastineau DA, Hoering A, Fink SR, Letendre L, Padley DJ, Paternoster SF, Tefferi A, Vuk-Pavlovic S. Testing the safety of clinical-grade mature autologous myeloid DC in a phase I clinical immunotherapy trial of CML. *Cytotherapy*. 2006; 8 (3):290-8 PMID: 16793737 DOI: 10.1080/14653240600735743
 99. Tallman MS, Perez WS, Lazarus HM, Gale RP, Maziarz RT, Rowe JM, Marks DI, Cahn JY, Bashey A, Bishop

- MR, Christiansen N, Frankel SR, Garcia JJ, Ilhan O, Laughlin MJ, Liesveld J, Linker C, **Litzow MR**, Luger S, McCarthy PL, Milone GA, Pavlovsky S, Phillips GL, Russell JA, Saez RA, Schiller G, Sierra J, Weiner RS, Zander AR, Zhang MJ, Keating A, Weisdorf DJ, Horowitz MM. Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission. *Biol Blood Marrow Transplant*. 2006 Feb; 12(2):204-16. PMID: 16443518 DOI: 10.1016/j.bbmt.2005.10.013
100. Lazarus HM, Perez WS, Klein JP, Kollman C, Bate-Boyle B, Bredeson CN, Gale RP, Geller RB, Keating A, **Litzow MR**, Marks DI, Miller CB, Douglas Rizzo J, Spitzer TR, Weisdorf DJ, Zhang MJ, Horowitz MM. Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloid leukaemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research. *Br J Haematol*. 2006 Mar; 132(6):755-69. PMID: 16487177 DOI: 10.1111/j.1365-2141.2005.05947.x
 101. Dingli D, Nowakowski GS, Dispenzieri A, Lacy MQ, Hayman S, **Litzow MR**, Gastineau DA, Gertz MA. Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma. *Clin Lymphoma Myeloma*. 2006 Mar; 6: (5)384-8. PMID: 16640814 DOI: 10.3816/CLM.2006.n.014
 102. Marks DI, Forman SJ, Blume KG, Perez WS, Weisdorf DJ, Keating A, Gale RP, Cairo MS, Copelan EA, Horan JT, Lazarus HM, **Litzow MR**, McCarthy PL, Schultz KR, Smith DD, Trigg ME, Zhang MJ, Horowitz MM. A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. *Biol Blood Marrow Transplant*. 2006 Apr; 12(4):438-53. PMID: 16545728 DOI: 10.1016/j.bbmt.2005.12.029
 103. Dispenzieri A, Lacy MQ, Katzmann JA, Rajkumar SV, Abraham RS, Hayman SR, Kumar SK, Clark R, Kyle RA, **Litzow MR**, Inwards DJ, Ansell SM, Micallef IM, Porrata LF, Elliott MA, Johnston PB, Greipp PR, Witzig TE, Zeldenrust SR, Russell SJ, Gastineau D, Gertz MA. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. *Blood*. 2006 Apr 15; 107 (8):3378-83 Epub 2006 Jan 05 PMID: 16397135 PMCID: 1895763 DOI: 10.1182/blood-2005-07-2922
 104. Dingli D, Nowakowski GS, Dispenzieri A, Lacy MQ, Hayman SR, Rajkumar SV, Greipp PR, **Litzow MR**, Gastineau DA, Witzig TE, Gertz MA. Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system. *Blood*. 2006 Apr 15; 107 (8):3384-8 Epub 2005 Dec 08 PMID: 16339399 PMCID: 1895764 DOI: 10.1182/blood-2005-08-3398
 105. **Litzow MR**. Imatinib resistance: obstacles and opportunities. *Arch Pathol Lab Med*. 2006 May; 130 (5):669-79 PMID: 16683885 PMCID: 0 DOI: 10.5858/2006-130-669-IROAO
 106. Elliott MA, Tefferi A, Hogan WJ, Letendre L, Gastineau DA, Ansell SM, Dispenzieri A, Gertz MA, Hayman SR, Inwards DJ, Lacy MQ, Micallef IN, Porrata LF, **Litzow MR**. Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia. *Bone Marrow Transplant*. 2006 Jun; 37(11):1003-8. PMID: 16604096 PMCID: 0 DOI: 10.1038/sj.bmt.1705369
 107. Buadi FK, Micallef IN, Ansell SM, Porrata LF, Dispenzieri A, Elliot MA, Gastineau DA, Gertz MA, Lacy MQ, **Litzow MR**, Tefferi A, Inwards DJ. Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma. *Bone Marrow Transplant*. 2006 Jun; 37(11):1017-22. PMID: 16633361 PMCID: 0 DOI: 10.1038/sj.bmt.1705371
 108. Holtan SG, Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, **Litzow MR**, Gastineau DA, Markovic SN. Timing of autologous stem cell transplantation from last chemotherapy affects lymphocyte collection and survival in non-Hodgkin lymphoma. *Br J Haematol*. 2006 Jun; 133 (6):628-33 PMID: 16704437 PMCID: 1472657 DOI: 10.1111/j.1365-2141.2006.06088.x
 109. Cripe LD, Rader K, Tallman MS, Gordon MS, Paietta E, Bennett J, Neuberg D, **Litzow MR**, O'brien TE, Rowe JM. Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997. *Leuk Res*. 2006 Jul; 30(7):823-7. Epub 2006 Jan 18. PMID: 16413056 PMCID: 0 DOI: 10.1016/j.leukres.2005.11.006
 110. Lazarus HM, Richards SM, Chopra R, **Litzow MR**, Burnett AK, Wiernik PH, Franklin IM, Tallman MS, Cook L, Buck G, Durrant IJ, Rowe JM, Goldstone AH, Medical Research Council (MRC)/National Cancer Research Institute (NCRI) Adult Leukaemia Working Party of the United Kingdom and the Eastern Cooperative Oncology Group. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. *Blood*. 2006 Jul 15; 108(2):465-72. Epub 2006 Mar 23. PMID: 16556888 PMCID: 1895498 DOI: 10.1182/blood-2005-11-4666
 111. **Litzow MR**, Lee S, Bennett JM, Dewald GW, Gallagher RE, Jain V, Paietta EM, Racevskis J, Rousey SR, Mazza JJ, Tallman MS. A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia. *Haematologica*. 2006 Aug; 91 (8):1105-8 Epub 2006 July 25 PMID: 16870552
 112. Rodriguez V, Anderson PM, **Litzow MR**, Erlandson L, Trotz BA, Arndt CA, Khan SP, Wiseman GA. Marrow

irradiation with high-dose ¹⁵³Samarium-EDTMP followed by chemotherapy and hematopoietic stem cell infusion for acute myelogenous leukemia. *Leuk Lymphoma*. 2006 Aug; 47 (8):1583-92 PMID: 16966270 DOI: 10.1080/10428100600580847

113. Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL, Hogan WJ, **Litzow MR**, Allred JB, Jones D, Byrne C, Zeldis JB, Ketterling RP, McClure RF, Giles F, Kantarjian HM. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. *Blood*. 2006 Aug 15; 108 (4):1158-64 Epub 2006 Apr 11 PMID: 16609064 DOI: 10.1182/blood-2006-02-004572
114. Fonseca R, Van Wier SA, Chng WJ, Ketterling R, Lacy MQ, Dispenzieri A, Bergsagel PL, Rajkumar SV, Greipp PR, **Litzow MR**, Price-Troska T, Henderson KJ, Ahmann GJ, Gertz MA. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. *Leukemia*. 2006 Nov; 20(11):2034-40. Epub 2006 Oct 05. PMID: 17024118 DOI: 10.1038/sj.leu.2404403
115. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, Steensma DP, Elliott MA, Wolanskyj AP, Hogan WJ, McClure RF, **Litzow MR**, Gilliland DG, Tefferi A. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. *Blood*. 2006 Nov 15; 108 (10):3472-6 Epub 2006 July 25 PMID: 16868251 DOI: 10.1182/blood-2006-04-018879
116. Halfdanarson TR, **Litzow MR**, Murray JA. Hematologic manifestations of celiac disease. *Blood*. 2007 Jan 15; 109 (2):412-21 Epub 2006 Sept 14 PMID: 16973955 PMID: 1785098 DOI: 10.1182/blood-2006-07-031104
117. Hogan WJ, **Litzow MR**, Tefferi A. Allogeneic hematopoietic cell transplantation in myelofibrosis with myeloid metaplasia. *Curr Hematol Malig Rep*. 2007 Feb; 2 (1):34-42 PMID: 20425386 DOI: 10.1007/s11899-007-0005-3
118. Fielding AK, Richards SM, Chopra R, Lazarus HM, **Litzow MR**, Buck G, Durrant IJ, Luger SM, Marks DI, Franklin IM, McMillan AK, Tallman MS, Rowe JM, Goldstone AH, Medical Research Council of the United Kingdom Adult ALL Working Party, Eastern Cooperative Oncology Group. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. *Blood*. 2007 Feb 1; 109 (3):944-50. Epub 2006 Oct 10. PMID: 17032921 DOI: 10.1182/blood-2006-05-018192
119. **Litzow MR**. Progress and strategies for patients with relapsed and refractory acute myeloid leukemia. *Curr Opin Hematol*. 2007 Mar; 14(2):130-7. PMID: 17255790 DOI: 10.1097/MOH.0b013e32801684ef
120. Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M, Vance GH, Cherry AM, Higgins RR, Fielding AK, Foroni L, Paietta E, Tallman MS, **Litzow MR**, Wiernik PH, Rowe JM, Goldstone AH, Dewald GW, Adult Leukaemia Working Party Medical Research Council/National Cancer Research Institute. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. *Blood*. 2007 Apr 15; 109(8):3189-97. PMID: 17170120
121. Tallman MS, Dewald GW, Gandham S, Logan BR, Keating A, Lazarus HM, **Litzow MR**, Mehta J, Pedersen T, Perez WS, Rowe JM, Wetzler M, Weisdorf DJ. Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission. *Blood*. 2007 Jul 1; 110(1):409-17. Epub 2007 Mar 20. PMID: 17374741 PMID: 1896123 DOI: 10.1182/blood-2006-10-043299
122. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Gastineau DA, **Litzow MR**, Fonseca R, Roy V, Rajkumar SV, Gertz MA. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. *Leukemia*. 2007 Sep; 21 (9):2035-42 Epub 2007 June 21 PMID: 17581613 DOI: 10.1038/sj.leu.2404801
123. Kantarjian HM, Giles F, Gattermann N, Bhatta K, Alimena G, Palandri F, Ossenkoppele GJ, Nicolini FE, O'Brien SG, **Litzow M**, Bhatia R, Cervantes F, Haque A, Shou Y, Resta DJ, Weitzman A, Hochhaus A, le Coutre P. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. *Blood*. 2007 Nov 15; 110(10):3540-6. Epub 2007 Aug 22. PMID: 17715389 DOI: 10.1182/blood-2007-03-080689
124. Elliott MA, **Litzow MR**, Letendre LL, Wolf RC, Hanson CA, Tefferi A, Tallman MS. Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival. *Blood*. 2007 Dec 15; 110 (13):4172-4 Epub 2007 Oct 01 PMID: 17909077 DOI: 10.1182/blood-2007-07-104091
125. Gertz M, Lacy M, Dispenzieri A, Hayman S, Kumar S, Buadi F, Leung N, **Litzow M**. Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. *Leuk Lymphoma*. 2008 Jan; 49 (1):36-41 PMID: 18203009 DOI: 10.1080/10428190701684518
126. Schlenk RF, Pasquini MC, Perez WS, Zhang MJ, Krauter J, Antin JH, Bashey A, Bolwell BJ, Buchner T, Cahn JY, Cairo MS, Copelan EA, Cutler CS, Dohner H, Gale RP, Ilhan O, Lazarus HM, Liesveld JL, **Litzow MR**, Marks DI, Maziarz RT, McCarthy PL, Nimer SD, Sierra J, Tallman MS, Weisdorf DJ, Horowitz MM, Ganser A, CIBMTR Acute Leukemia Working Committee. HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR. *Biol Blood Marrow Transplant*. 2008 Feb; 14(2):187-96.

Epub 2007 Dec 20 PMID: 18215779 PMCID: 2531160 DOI: 10.1016/j.bbmt.2007.10.006

127. Chahal P, Levy C, **Litzow MR**, Lindor KD. Utility of liver biopsy in bone marrow transplant patients. *J Gastroenterol Hepatol*. 2008 Feb; 23(2):222-5. PMID: 18289356 DOI: 10.1111/j.1440-1746.2006.04742.x
128. Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK, Burnett AK, Chopra R, Wiernik PH, Foroni L, Paietta E, **Litzow MR**, Marks DI, Durrant J, McMillan A, Franklin IM, Luger S, Ciobanu N, Rowe JM. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). *Blood*. 2008 Feb 15; 111(4):1827-33. Epub 2007 Nov 29. PMID: 18048644 DOI: 10.1182/blood-2007-10-116582
129. Bishop MR, Logan BR, Gandham S, Bolwell BJ, Cahn JY, Lazarus HM, **Litzow MR**, Marks DI, Wiernik PH, McCarthy PL, Russell JA, Miller CB, Sierra J, Milone G, Keating A, Loberiza FR, Giralto S, Horowitz MM, Weisdorf DJ. Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research. *Bone Marrow Transplant*. 2008 Apr; 41(7):635-42. Epub 2007 Dec 17. PMID: 18084335 PMCID: 2587442 DOI: 10.1038/sj.bmt.1705952
130. Kumar SK, Dingli D, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, Rajkumar SV, **Litzow MR**, Gertz MA. Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders. *Br J Haematol*. 2008 Apr; 141(2):205-11. Epub 2008 Mar 03. PMID: 18318761 DOI: 10.1111/j.1365-2141.2008.07069.x
131. Gill P, **Litzow M**, Buckner J, Arndt C, Moynihan T, Christianson T, Ansell S, Galanis E. High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system. *Cancer*. 2008 Apr 15; 112(8):1805-11. PMID: 18300237 DOI: 10.1002/cncr.23362
132. Dispenzieri A, Lacy MQ, Hayman SR, Kumar SK, Buadi F, Dingli D, **Litzow MR**, Gastineau DA, Inwards DJ, Elliott MA, Micallef IN, Ansell SM, Hogan WJ, Porrata LF, Johnston PA, Afessa B, Bryce A, Kyle RA, Gertz MA. Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome. *Eur J Haematol*. 2008 May; 80(5):397-406 Epub 2008 Jan 23 PMID: 18221391 PMCID: 2327207 DOI: 10.1111/j.1600-0609.2008.01037.x
133. Halfdanarson TR, Walker JA, **Litzow MR**, Hanson CA. Severe vitamin B12 deficiency resulting in pancytopenia, splenomegaly and leukoerythroblastosis. *Eur J Haematol*. 2008 May; 80(5):448-51. Epub 2008 Jan 23. PMID: 18221385 DOI: 10.1111/j.1600-0609.2008.01043.x
134. Kumar SK, Dingli D, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Rajkumar SV, **Litzow MR**, Gertz MA. Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT. *Bone Marrow Transplant*. 2008 Jun; 41(12):1013-9 Epub 2008 Mar 10 PMID: 18332915 DOI: 10.1038/bmt.2008.24
135. **Litzow MR**. Arsenic trioxide. *Expert Opin Pharmacother*. 2008 Jul; 9(10):1773-85 PMID: 18570609 DOI: 10.1517/14656566.9.10.1773
136. Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Gastineau DA, **Litzow MR**, Winters JL, Markovic SN. Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study. *Biol Blood Marrow Transplant*. 2008 Jul; 14(7):807-16 PMID: 18541201 PMCID: 4494659 DOI: 10.1016/j.bbmt.2008.04.013
137. Lacy MQ, Dispenzieri A, Hayman SR, Kumar S, Kyle RA, Rajkumar SV, Edwards BS, Rodeheffer RJ, Frantz RP, Kushwaha SS, Clavell AL, Dearani JA, Sundt TM, Daly RC, McGregor CG, Gastineau DA, **Litzow MR**, Gertz MA. Autologous stem cell transplant after heart transplant for light chain (AL) amyloid cardiomyopathy. *J Heart Lung Transplant*. 2008 Aug; 27(8):823-9 Epub 2008 July 03 PMID: 18656793 DOI: 10.1016/j.healun.2008.05.016
138. Kumar SK, Dingli D, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, Rajkumar SV, **Litzow MR**, Gertz MA. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis. *Am J Hematol*. 2008 Aug; 83(8):614-7. PMID: 18429054 DOI: 10.1002/ajh.21191
139. Kumar S, Dingli D, Dispenzieri A, Lacy M, Hayman SR, Buadi F, Rajkumar S, **Litzow M**, Gertz M. Impact of additional cytoreduction following autologous SCT in multiple myeloma. *Bone Marrow Transplant*. 2008 Aug; 42(4):259-64 Epub 2008 June 16 PMID: 18560409 PMCID: 3904360 DOI: 10.1038/bmt.2008.166
140. Kumar S, Mahmood ST, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, Dingli D, Rajkumar SV, **Litzow MR**, Gertz MA. Impact of early relapse after auto-SCT for multiple myeloma. *Bone Marrow Transplant*. 2008 Sep; 42(6):413-20. Epub 2008 Jun 30. PMID: 18587435 DOI: 10.1038/bmt.2008.180
141. Malhotra P, Hogan WJ, **Litzow MR**, Elliott MA, Gastineau DA, Ansell SM, Dispenzieri A, Gertz MA, Hayman SR, Inwards DJ, Lacy MQ, Micallef IN, Porrata LF, Tefferi A. Long-term outcome of allogeneic stem cell transplantation in chronic lymphocytic leukemia: analysis after a minimum follow-up of 5 years. *Leuk Lymphoma*. 2008 Sep; 49(9):1724-30 PMID: 18798106 DOI: 10.1080/10428190802263535

142. Gertz MA, Ansell SM, Dingli D, Dispenzieri A, Buadi FK, Elliott MA, Gastineau DA, Hayman SR, Hogan WJ, Inwards DJ, Johnston PB, Kumar S, Lacy MQ, Leung N, Micallef IN, Porrata LF, Schafer BA, Wolf RC, **Litzow MR**. Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. *Mayo Clin Proc*. 2008 Oct; 83(10):1131-8. PMID: 18828972 DOI: 10.4065/83.10.1131
143. Costa LJ, Micallef IN, Inwards DJ, Johnston PB, Porrata LF, **Litzow MR**, Ansell SM. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma. *Br J Haematol*. 2008 Oct; 143(2):268-73. Epub 2008 Aug 10. PMID: 18699848 DOI: 10.1111/j.1365-2141.2008.07342.x
144. Lee SJ, Kukreja M, Wang T, Giralto SA, Szer J, Arora M, Woolfrey AE, Cervantes F, Champlin RE, Gale RP, Halter J, Keating A, Marks DI, McCarthy PL, Olavarria E, Stadtmauer EA, Abecasis M, Gupta V, Khoury HJ, George B, Hale GA, Liesveld JL, Rizzieri DA, Antin JH, Bolwell BJ, Carabasi MH, Copelan E, Ilhan O, **Litzow MR**, Schouten HC, Zander AR, Horowitz MM, Maziarz RT. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. *Blood*. 2008 Oct 15; 112(8):3500-7. Epub 2008 Jul 29. PMID: 18664621 PMID: 2954751 DOI: 10.1182/blood-2008-02-141689
145. **Litzow MR**. Evolving paradigms in the therapy of Philadelphia-chromosome-negative acute lymphoblastic leukemia in adults. *Hematology Am Soc Hematol Educ Program*. 2009; 362-70. PMID: 20008222 DOI: 10.1182/asheducation-2009.1.362
146. Gertz MA, Kumar SK, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, Dingli D, Gastineau DA, Winters JL, **Litzow MR**. Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. *Bone Marrow Transplant*. 2009 Apr; 43 (8):619-25 Epub 2008 Nov 10 PMID: 18997825 PMID: 2914501 DOI: 10.1038/bmt.2008.369
147. Costa LJ, Kumar S, Dispenzieri A, Hayman SE, Buadi FK, Dingli D, **Litzow MR**, Gertz MA, Lacy MQ. Factors associated with favorable outcome after allogeneic hematopoietic stem cell transplantation for multiple myeloma. *Leuk Lymphoma*. 2009 May; 50(5):781-7. PMID: 19330657 DOI: 10.1080/10428190902803644
148. Fielding AK, Rowe JM, Richards SM, Buck G, Moorman AV, Durrant IJ, Marks DI, McMillan AK, **Litzow MR**, Lazarus HM, Foroni L, Dewald G, Franklin IM, Luger SM, Paietta E, Wiernik PH, Tallman MS, Goldstone AH. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. *Blood*. 2009 May 7; 113 (19):4489-96. Epub 2009 Feb 24. PMID: 19244158 PMID: 4188540 DOI: 10.1182/blood-2009-01-199380
149. Mesa RA, Schwager S, Radia D, Cheville A, Hussein K, Niblack J, Pardanani AD, Steensma DP, **Litzow MR**, Rivera CE, Camoriano J, Verstovsek S, Sloan J, Harrison C, Kantarjian H, Tefferi A. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. *Leuk Res*. 2009 Sep; 33 (9):1199-203 Epub 2009 Feb 27 PMID: 19250674 PMID: 4419687 DOI: 10.1016/j.leukres.2009.01.035
150. **Litzow MR**. Therapy of Philadelphia chromosome-negative acute lymphoblastic leukemia in adults: new paradigms. *Future Oncol*. 2009 Sep; 5(7):1039-50. PMID: 19792972 DOI: 10.2217/fon.09.74
151. Fernandez HF, Sun Z, Yao X, **Litzow MR**, Luger SM, Paietta EM, Racevskis J, Dewald GW, Ketterling RP, Bennett JM, Rowe JM, Lazarus HM, Tallman MS. Anthracycline dose intensification in acute myeloid leukemia. *N Engl J Med*. 2009 Sep 24; 361(13):1249-59. PMID: 19776406 PMID: 4480917 DOI: 10.1056/NEJMoa0904544
152. Sinha Shirshendu, Kumar SK, Gastineau DA, Hogan WJ, Buadi F, Dingli D, Dispenzieri A, Gertz MA, Greiner Carl, Hayman SR, Inwards DJ, Johnston PB, Lacy MQ, **Litzow MR**, Porrata LF, Winters JL, Micallef IN. Predicting Poor Peripheral Blood Stem Cell Mobilization Using Initial Peripheral CD34 Counts in Patients with Lymphoma Blood. November 2009; 114(22):4228.
153. Lacy MQ, Mandrekar S, Dispenzieri A, Hayman S, Kumar S, Buadi F, Dingli D, **Litzow M**, Wettstein P, Padley D, Kabat B, Gastineau D, Rajkumar SV, Gertz MA. Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival. *Am J Hematol*. 2009 Dec; 84 (12):799-802 PMID: 19899131 PMID: 2908015 DOI: 10.1002/ajh.21560
154. Eid AJ, Brown RA, Hogan WJ, Lahr BD, Eckel-Passow JE, **Litzow MR**, Razonable RR. Kinetics of interferon-gamma producing cytomegalovirus (CMV)-specific CD4+ and CD8+ T lymphocytes and the risk of subsequent CMV viremia after allogeneic hematopoietic stem cell transplantation. *Transpl Infect Dis*. 2009 Dec; 11(6):519-28. Epub 2009 Sep 09. PMID: 19744286 DOI: 10.1111/j.1399-3062.2009.00446.x
155. Marks DI, Paietta EM, Moorman AV, Richards SM, Buck G, DeWald G, Ferrando A, Fielding AK, Goldstone AH, Ketterling RP, **Litzow MR**, Luger SM, McMillan AK, Mansour MR, Rowe JM, Tallman MS, Lazarus HM. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). *Blood*. 2009 Dec 10; 114(25):5136-45.

156. **Litzow MR**, Othus M, Cripe LD, Gore SD, Lazarus HM, Lee SJ, Lee SJ, Bennett JM, Paietta EM, Dewald GW, Rowe JM, Tallman MS, Eastern Cooperative Oncology Group Leukemia Committee. Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group. *Br J Haematol*. 2010 Jan; 148 (2):217-25 Epub 2009 Oct 05 PMID: 19804455 PMCID: 2809127 DOI: 10.1111/j.1365-2141.2009.07917.x
157. Tefferi A, Lasho TL, Patnaik MM, Finke CM, Hussein K, Hogan WJ, Elliott MA, **Litzow MR**, Hanson CA, Pardanani A. JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygotosity for the JAK2 46/1 haplotype is associated with inferior survival. *Leukemia*. 2010 Jan; 24(1):105-9. Epub 2009 Oct 22. PMID: 19847199 DOI: 10.1038/leu.2009.225
158. Ballen KK, Shrestha S, Sobocinski KA, Zhang MJ, Bashey A, Bolwell BJ, Cervantes F, Devine SM, Gale RP, Gupta V, Hahn TE, Hogan WJ, Kroger N, **Litzow MR**, Marks DI, Maziarz RT, McCarthy PL, Schiller G, Schouten HC, Roy V, Wiernik PH, Horowitz MM, Giral SA, Arora M. Outcome of transplantation for myelofibrosis. *Biol Blood Marrow Transplant*. 2010 Mar; 16(3):358-67. Epub 2009 Oct 30. PMID: 19879949 PMCID: 2908949 DOI: 10.1016/j.bbmt.2009.10.025
159. **Litzow MR**, Peethambaram PP, Safgren SL, Keeney GL, Ansell SM, Dispenzieri A, Elliott MA, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Micallef IN, Porrata LF, Lingle WL, Hartmann LC, Frost MH, Barrette BA, Long HJ, Suman VJ, Reid JM, Ames MM, Kaufmann SH. Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma. *Bone Marrow Transplant*. 2010 Mar; 45 (3):490-7 Epub 2009 Aug 03 PMID: 19648970 PMCID: 2836387 DOI: 10.1038/bmt.2009.181
160. **Litzow MR**, Tarima S, Perez WS, Bolwell BJ, Cairo MS, Camitta BM, Cutler CS, de Lima M, Dipersio JF, Gale RP, Keating A, Lazarus HM, Luger S, Marks DI, Maziarz RT, McCarthy PL, Pasquini MC, Phillips GL, Rizzo JD, Sierra J, Tallman MS, Weisdorf DJ. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. *Blood*. 2010 Mar 4; 115 (9):1850-7 Epub 2009 Dec 23 PMID: 20032503 PMCID: 2832815 DOI: 10.1182/blood-2009-10-249128
161. Dispenzieri A, Wiseman GA, Lacy MQ, Hayman SR, Kumar SK, Buadi F, Dingli D, Laumann KM, Allred J, Geyer SM, **Litzow MR**, Gastineau DA, Inwards DJ, Micallef IN, Ansell SM, Porrata L, Elliott MA, Johnston PB, Hogan WJ, Gertz MA. A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. *Am J Hematol*. 2010 Jun; 85 (6):409-13 PMID: 20513117 PMCID: 3900492 DOI: 10.1002/ajh.21696
162. Schriber J, Agovi MA, Ho V, Ballen KK, Bacigalupo A, Lazarus HM, Bredeson CN, Gupta V, Maziarz RT, Hale GA, **Litzow MR**, Logan B, Bornhauser M, Giller RH, Isola L, Marks DI, Rizzo JD, Pasquini MC. Second unrelated donor hematopoietic cell transplantation for primary graft failure. *Biol Blood Marrow Transplant*. 2010 Aug; 16(8):1099-106. Epub 2010 Feb 19. PMID: 20172038 PMCID: 2897953 DOI: 10.1016/j.bbmt.2010.02.013
163. Duval M, Klein JP, He W, Cahn JY, Cairo M, Camitta BM, Kamble R, Copelan E, de Lima, Gupta V, Keating A, Lazarus HM, **Litzow MR**, Marks DI, Maziarz RT, Rizzieri DA, Schiller G, Schultz KR, Tallman MS, Weisdorf D. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. *J Clin Oncol*. 2010 Aug 10; 28(23):3730-8. Epub 2010 Jul 12. PMID: 20625136 PMCID: 2917308 DOI: 10.1200/JCO.2010.28.8852
164. Navarro WH, Agovi MA, Logan BR, Ballen K, Bolwell BJ, Frangoul H, Gupta V, Hahn T, Ho VT, Juckett M, Lazarus HM, **Litzow MR**, Liesveld JL, Moreb JS, Marks DI, McCarthy PL, Pasquini MC, Rizzo JD. Obesity does not preclude safe and effective myeloablative hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML) in adults. *Biol Blood Marrow Transplant*. 2010 Oct; 16(10):1442-50. Epub 2010 Apr 20. PMID: 20412867 PMCID: 2933950 DOI: 10.1016/j.bbmt.2010.04.009
165. Rowe JM, Kim HT, Cassileth PA, Lazarus HM, **Litzow MR**, Wiernik PH, Tallman MS. Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group. *Cancer*. 2010 Nov 1; 116(21):5012-21. PMID: 20629023 PMCID: 3566633 DOI: 10.1002/ncr.25263
166. Cripe LD, Uno H, Paietta EM, **Litzow MR**, Ketterling RP, Bennett JM, Rowe JM, Lazarus HM, Luger S, Tallman MS. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. *Blood*. 2010 Nov 18; 116(20):4077-85. Epub 2010 Aug 17. PMID: 20716770 PMCID: 2993615 DOI: 10.1182/blood-2010-04-277269
167. Mesa RA, Yao X, Cripe LD, Li CY, **Litzow M**, Paietta E, Rowe JM, Tefferi A, Tallman MS. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. *Blood*. 2010 Nov 25; 116 (22):4436-8 Epub 2010 July 22 PMID: 20651074 PMCID: 2996111 DOI: 10.1182/blood-2010-05-287417
168. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK, Dingli D, Ansell SM, Gastineau DA, Inwards DJ, Johnston PB, **Litzow MR**, Micallef IN, Porrata LF, Leung N, Hogan WJ, Buadi FK. Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. *Leuk Lymphoma*. 2010 Dec; 51

(12):2181-7 Epub 2010 Oct 20 PMID: 20958232 DOI: 10.3109/10428194.2010.524329

169. Holtan SG, Hogan WJ, Elliott MA, Ansell SM, Inwards DJ, Porrata LF, Johnston PB, Micallef IN, Lacy MQ, Gastineau DA, **Litzow MR**. CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies. *Bone Marrow Transplant*. 2010 Dec; 45(12):1699-703 Epub 2010 Mar 08 PMID: 20208572 PMCID: 7091776 DOI: 10.1038/bmt.2010.49
170. Begna KH, Mesa RA, Pardanani A, Hogan WJ, **Litzow MR**, McClure RF, Tefferi A. A phase-2 trial of low-dose pomalidomide in myelofibrosis. *Leukemia*. 2011 Feb; 25(2):301-4. Epub 2010 Nov 05. PMID: 21052089 DOI: 10.1038/leu.2010.254
171. Naina HV, Pruthi RK, Inwards DJ, Dingli D, **Litzow MR**, Ansell SM, William HJ, Dispenzieri A, Buadi FK, Elliott MA, Gastineau DA, Gertz MA, Hayman SR, Johnston PB, Lacy MQ, Micallef IN, Porrata LF, Kumar S. Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilization. *Bone Marrow Transplant*. 2011 Feb; 46(2):291-3. Epub 2010 May 03. PMID: 20436522 DOI: 10.1038/bmt.2010.106
172. Cutler C, Kesselheim A, Gabardi S, Andersson BS, Carpenter P, Khoury HJ, **Litzow M**, Rowley SD, Lanum S, Leather H, Tina Shih YC, Gale RP, Wingard JR, Appelbaum FR, Anasetti C, American Society of Blood and Marrow Transplantation. Generic immunosuppressants in hematopoietic cell transplantation. *Biol Blood Marrow Transplant*. 2011 Mar; 17(3):285-90. Epub 2010 Nov 16. PMID: 21087678 DOI: 10.1016/j.bbmt.2010.11.006
173. Hebart H, Lengerke C, Ljungman P, Paya CV, Klingebiel T, Loeffler J, Pfaffenrath S, Lewensohn-Fuchs I, Barkholt L, Tomiuk J, Meisner C, Lunenberg J, Top B, Razonable RR, Patel R, **Litzow MR**, Jahn G, Einsele H. Prospective comparison of PCR-based vs late mRNA-based preemptive antiviral therapy for HCMV infection in patients after allo-SCT. *Bone Marrow Transplant*. 2011 Mar; 46(3):408-15. Epub 2010 Jun 28. PMID: 20581879 DOI: 10.1038/bmt.2010.136
174. Horan JT, Logan BR, Agovi-Johnson MA, Lazarus HM, Bacigalupo AA, Ballen KK, Bredeson CN, Carabasi MH, Gupta V, Hale GA, Khoury HJ, Juckett MB, **Litzow MR**, Martino R, McCarthy PL, Smith FO, Rizzo JD, Pasquini MC. Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made? *J Clin Oncol*. 2011 Mar 1; 29(7):805-13. Epub 2011 Jan 10. PMID: 21220593 PMCID: 3068057 DOI: 10.1200/JCO.2010.32.5001
175. **Litzow MR**. Pharmacotherapeutic advances in the treatment of acute lymphoblastic leukaemia in adults. *Drugs*. 2011 Mar 5; 71(4):415-42 PMID: 21395356 DOI: 10.2165/11588950-000000000-00000
176. Levis M, Ravandi F, Wang ES, Baer MR, Perl A, Coutre S, Erba H, Stuart RK, Baccarani M, Cripe LD, Tallman MS, Meloni G, Godley LA, Langston AA, Amadori S, Lewis ID, Nagler A, Stone R, Yee K, Advani A, Douer D, Wiktor-Jedrzejczak W, Juliusson G, **Litzow MR**, Petersdorf S, Sanz M, Kantarjian HM, Sato T, Tremmel L, Bensen-Kennedy DM, Small D, Smith BD. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. *Blood*. 2011 Mar 24; 117(12):3294-301. Epub 2011 Jan 26. PMID: 21270442 PMCID: 3069671 DOI: 10.1182/blood-2010-08-301796
177. Fernandez HF, Sun Z, **Litzow MR**, Luger SM, Paietta EM, Racevskis J, Dewald G, Ketterling RP, Rowe JM, Lazarus HM, Tallman MS. Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin. *Blood*. 2011 May 19; 117(20):5306-13. Epub 2011 Mar 17. PMID: 21415269 PMCID: 3109705 DOI: 10.1182/blood-2010-09-309229
178. Carlson AM, Lindor NM, **Litzow MR**. Therapy-related myelodysplasia in a patient with Rothmund-Thomson syndrome. *Eur J Haematol*. 2011 Jun; 86(6):536-40. PMID: 21418107 DOI: 10.1111/j.1600-0609.2011.01609.x
179. Sinha S, Gastineau D, Micallef I, Hogan W, Ansell S, Buadi F, Dingli D, Dispenzieri A, Gertz M, Greiner C, Hayman S, Inwards D, Johnston P, Lacy M, **Litzow M**, Porrata L, Winters JL, Kumar S. Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention. *Bone Marrow Transplant*. 2011 Jul; 46(7):943-9 Epub 2010 Oct 11 PMID: 20935680 PMCID: 3021104 DOI: 10.1038/bmt.2010.236
180. Smith MR, Neuberger D, Flinn IW, Grever MR, Lazarus HM, Rowe JM, Dewald G, Bennett JM, Paietta EM, Byrd JC, Hussein MA, Appelbaum FR, Larson RA, **Litzow MR**, Tallman MS. Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997. *Blood*. 2011 Sep 29; 118(13):3525-7. Epub 2011 Jul 29. PMID: 21803850 PMCID: 3186330 DOI: 10.1182/blood-2011-03-342485
181. Kaufmann SH, Karp JE, **Litzow MR**, Mesa RA, Hogan W, Steensma DP, Flatten KS, Loegering DA, Schneider PA, Peterson KL, Maurer MJ, Smith BD, Greer J, Chen Y, Reid JM, Ivy SP, Ames MM, Adjei AA, Erlichman C, Karnitz LM. Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia. *Haematologica*. 2011 Nov; 96(11):1619-26 Epub 2011 July 26 PMID: 21791475 PMCID: 3208679 DOI: 10.3324/haematol.2011.049551
182. Farag SS, Maharry K, Zhang MJ, Perez WS, George SL, Mrozek K, DiPersio J, Bunjes DW, Marcucci G, Baer MR, Cairo M, Copelan E, Cutler CS, Isola L, Lazarus HM, **Litzow MR**, Marks DI, Ringden O, Rizzieri DA,

- Soiffer R, Larson RA, Tallman MS, Bloomfield CD, Weisdorf DJ, Acute Leukemia Committee of the Center for International Blood and Marrow Transplant Research and Cancer and Leukemia Group B. Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. *Biol Blood Marrow Transplant.* 2011 Dec; 17(12):1796-803. Epub 2011 Jun 24. PMID: 21699370 PMCID: 2817559 DOI: 10.1016/j.bbmt.2011.06.005
183. **Litzow MR.** Novel therapeutic approaches for acute lymphoblastic leukemia. *Hematol Oncol Clin North Am.* 2011 Dec; 25(6):1303-17. PMID: 22093588 DOI: 10.1016/j.hoc.2011.09.019
 184. Stock W, Douer D, DeAngelo DJ, Arellano M, Advani A, Damon L, Kovacs T, **Litzow M**, Rytting M, Borthakur G, Bleyer A. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. *Leuk Lymphoma.* 2011 Dec; 52(12):2237-53. Epub 2011 Aug 10. PMID: 21827361 DOI: 10.3109/10428194.2011.596963
 185. Black JL, **Litzow MR**, Hogan WJ, O'Kane DJ, Walker DL, Lesnick TG, Kremers WK, Avula R, Ketterling RP. Correlation of CYP2B6, CYP2C19, ABCC4 and SOD2 genotype with outcomes in allogeneic blood and marrow transplant patients. *Leuk Res.* 2012 Jan; 36 (1):59-66 Epub 2011 July 08 PMID: 21741706 DOI: 10.1016/j.leukres.2011.06.020
 186. Cesano A, Rosen DB, O'Meara P, Putta S, Gayko U, Spellmeyer DC, Cripe LD, Sun Z, Uno H, **Litzow MR**, Tallman MS, Paietta E. Functional pathway analysis in acute myeloid leukemia using single cell network profiling assay: Effect of specimen source (bone marrow or peripheral blood) on assay readouts. *Cytometry Part B - Clinical Cytometry.* 2012; 82 B(3):158-72.
 187. Begna KH, Pardani A, Mesa R, **Litzow MR**, Hogan WJ, Hanson CA, Tefferi A. Long-term outcome of pomalidomide therapy in myelofibrosis. *Am J Hematol.* 2012 Jan; 87(1):66-8. Epub 2011 Nov 12. PMID: 22081489 DOI: 10.1002/ajh.22233
 188. Cashen A, Juckett M, Jumonville A, **Litzow M**, Flynn PJ, Eckardt J, LaPlant B, Laumann K, Erlichman C, DiPersio J. Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS). *Ann Hematol.* 2012 Jan; 91(1):33-8. Epub 2011 May 03. PMID: 21538061 PMCID: 3557843 DOI: 10.1007/s00277-011-1240-1
 189. Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL, Cutler CS, Urbano-Ispizua A, Pavletic SZ, Haagenson MD, Zhang MJ, Antin JH, Bolwell BJ, Bredeson C, Cahn JY, Cairo M, Gale RP, Gupta V, Lee SJ, **Litzow M**, Weisdorf DJ, Horowitz MM, Hahn T. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. *Blood.* 2012 Jan 5; 119(1):296-307. Epub 2011 Oct 18. PMID: 22010102 PMCID: 3251233 DOI: 10.1182/blood-2011-06-364265
 190. Armand P, Kim HT, Zhang MJ, Perez WS, Dal Cin, Klumpp TR, Waller EK, **Litzow MR**, Liesveld JL, Lazarus HM, Artz AS, Gupta V, Savani BN, McCarthy PL, Cahn JY, Schouten HC, Finke J, Ball ED, Aljurf MD, Cutler CS, Rowe JM, Antin JH, Isola LM, Di Bartolomeo, Camitta BM, Miller AM, Cairo MS, Stockerl-Goldstein K, Sierra J, Savoie ML, Halter J, Stiff PJ, Nabhan C, Jakubowski AA, Bunjes DW, Petersdorf EW, Devine SM, Maziarz RT, Bornhauser M, Lewis VA, Marks DI, Bredeson CN, Soiffer RJ, Weisdorf DJ. Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study. *Biol Blood Marrow Transplant.* 2012 Feb; 18(2):280-8. Epub 2011 Jul 31. PMID: 21810400 PMCID: 3224672 DOI: 10.1016/j.bbmt.2011.07.024
 191. Afessa B, Abdulai RM, Kremers WK, Hogan WJ, **Litzow MR**, Peters SG. Risk factors and outcome of pulmonary complications after autologous hematopoietic stem cell transplant. *Chest.* 2012 Feb; 141: (2)442-450. PMID: 21778261 DOI: 10.1378/chest.10-2889
 192. Jiang L, Malik S, **Litzow M**, Gastineau D, Micallef I, Roy V, Solberg L, Zubair AC. Hematopoietic stem cells from poor and good mobilizers are qualitatively equivalent. *Transfusion.* 2012 Mar; 52 (3):542-8 Epub 2011 Aug 09 PMID: 21827503 PMCID: 3214250 DOI: 10.1111/j.1537-2995.2011.03286.x
 193. Elliott MA, Letendre L, Tefferi A, Hogan WJ, Hook C, Kaufmann SH, Pruthi RK, Pardani A, Begna KH, Ashrani AA, Wolanskyj AP, Al-Kali A, **Litzow MR.** Therapy-related acute promyelocytic leukemia: observations relating to APL pathogenesis and therapy. *Eur J Haematol.* 2012 Mar; 88(3):237-43. Epub 2011 Nov 17. PMID: 22023492 DOI: 10.1111/j.1600-0609.2011.01727.x
 194. Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci ND, Heguy A, Cherry A, Vance G, Higgins RR, Ketterling RP, Gallagher RE, **Litzow M**, van den Brink MR, Lazarus HM, Rowe JM, Luger S, Ferrando A, Paietta E, Tallman MS, Melnick A, Abdel-Wahab O, Levine RL. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. *N Engl J Med.* 2012 Mar 22; 366(12):1079-89. Epub 2012 Mar 14. PMID: 22417203 PMCID: 3545649 DOI: 10.1056/NEJMoa1112304
 195. Thoma MD, Huneke TJ, DeCook LJ, Johnson ND, Wiegand RA, **Litzow MR**, Hogan WJ, Porrata LF, Holtan SG. Peripheral blood lymphocyte and monocyte recovery and survival in acute leukemia postmyeloablative allogeneic hematopoietic stem cell transplant. *Biol Blood Marrow Transplant.* 2012 Apr; 18(4):600-7. Epub

- 2014 Aug 16; PMID: 24910167 DOI: 10.1182/blood-2014-08-6237
196. Sive JI, Buck G, Fielding A, Lazarus HM, **Litzow MR**, Luger S, Marks DI, McMillan A, Moorman AV, Richards SM, Rowe JM, Tallman MS, Goldstone AH. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. *Br J Haematol*. 2012 May; 157(4):463-71. Epub 2012 Mar 13. PMID: 22409379 PMCID: 4188419 DOI: 10.1111/j.1365-2141.2012.09095.x
 197. D'Souza A, Lacy M, Gertz M, Kumar S, Buadi F, Hayman S, Dingli D, Zeldenrust S, Kyle R, Ansell S, Inwards D, Johnston P, Micallef I, Porrata L, **Litzow M**, Gastineau D, Hogan W, Dispenzieri A. Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience. *Blood*. 2012 Jul 5; 120 (1):56-62 Epub 2012 May 18 PMID: 22611150 DOI: 10.1182/blood-2012-04-423178
 198. Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C, **Litzow MR**, Nieto Y, Savani BN, Schriber JR, Shaughnessy PJ, Wall DA, Carpenter PA. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2012 Aug; 18(8):1150-63. Epub 2012 Apr 14. PMID: 22510384 PMCID: 3404151 DOI: 10.1016/j.bbmt.2012.04.005
 199. Battiwalla M, Ellis K, Li P, Pavletic SZ, Akpek G, Hematti P, Klumpp TR, Maziarz RT, Savani BN, Aljurf MD, Cairo MS, Drobyski WR, George B, Hahn T, Khera N, **Litzow MR**, Loren AW, Saber W, Arora M, Urbano-Ispizua A, Cutler C, Flowers ME, Spellman SR. HLA DR15 antigen status does not impact graft-versus-host disease or survival in HLA-matched sibling transplantation for hematologic malignancies. *Biol Blood Marrow Transplant*. 2012 Aug; 18(8):1302-8. Epub 2012 Mar 10. PMID: 22414493 PMCID: 3580851 DOI: 10.1016/j.bbmt.2012.02.011
 200. Romanowicz M, Ehlers S, Walker D, Decker P, Rundell J, Shinozaki G, **Litzow M**, Hogan W, Mrazek D, Black JL. Testing a diathesis-stress model: potential genetic risk factors for development of distress in context of acute leukemia diagnosis and transplant. *Psychosomatics*. 2012 Sep-Oct; 53: (5)456-62. PMID: 22652301 DOI: 10.1016/j.psym.2012.01.004
 201. Geng H, Brennan S, Milne TA, Chen WY, Li Y, Hurtz C, Kweon SM, Zickl L, Shojaee S, Neuberg D, Huang C, Biswas D, Xin Y, Racevskis J, Ketterling RP, Luger SM, Lazarus H, Tallman MS, Rowe JM, **Litzow MR**, Guzman ML, Allis CD, Roeder RG, Muschen M, Paietta E, Elemento O, Melnick AM. Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. *Cancer Discov*. 2012 Nov; 2(11):1004-23. Epub 2012 Oct 29. PMID: 23107779 PMCID: 3516186 DOI: 10.1158/2159-8290.CD-12-0208
 202. Diab A, Zickl L, Abdel-Wahab O, Jhanwar S, Gulam MA, Panageas KS, Patel JP, Jurcic J, Maslak P, Paietta E, Mangan JK, Carroll M, Fernandez HF, Teruya-Feldstein J, Luger SM, Douer D, **Litzow MR**, Lazarus HM, Rowe JM, Levine RL, Tallman MS. Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis. *Leuk Res*. 2013 Jan; 37 (1):32-6. Epub 2012 Oct 24. PMID: 23102703 PMCID: 5382928 DOI: 10.1016/j.leukres.2012.08.025
 203. Micallef IN, Sinha S, Gastineau DA, Wolf R, Inwards DJ, Gertz MA, Hayman SR, Hogan WJ, Johnston PB, Lacy MQ, Ansell SM, Buadi F, Dingli D, Dispenzieri A, **Litzow MR**, Porrata LF, Winters JL, Kumar S. Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization. *Biol Blood Marrow Transplant*. 2013 Jan; 19 (1):87-93 Epub 2012 Aug 23 PMID: 22922211 DOI: 10.1016/j.bbmt.2012.08.010
 204. **Litzow MR**. Monoclonal antibody-based therapies in the treatment of acute lymphoblastic leukemia. *Am Soc Clin Oncol Educ Book*. 2013; 294-9 PMID: 23714527 DOI: 10.14694/EdBook_AM.2013.33.294
 205. Barreto JN, Beach CL, Wolf RC, Merten JA, Tosh PK, Wilson JW, Hogan WJ, **Litzow MR**. The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole. *Am J Hematol*. 2013 Apr; 88(4):283-8. Epub 2013 Mar 05. PMID: 23460251 DOI: 10.1002/ajh.23388
 206. DeCook LJ, Thoma M, Huneke T, Johnson ND, Wiegand RA, Patnaik MM, **Litzow MR**, Hogan WJ, Porrata LF, Holtan SG. Impact of lymphocyte and monocyte recovery on the outcomes of allogeneic hematopoietic SCT with fludarabine and melphalan conditioning. *Bone Marrow Transplant*. 2013 May; 48(5):708-14. Epub 2012 Oct 29. PMID: 23103674 DOI: 10.1038/bmt.2012.211
 207. Lim MY, Al-Kali A, Ashrani AA, Begna KH, Elliott MA, Hogan WJ, Hook CC, Kaufmann SH, Letendre L, **Litzow MR**, Patnaik MS, Pardanani A, Tefferi A, Wolanskyj AP, Grill DE, Pruthi RK. Comparison of complication rates of Hickman((R)) catheters versus peripherally inserted central catheters in patients with acute myeloid leukemia undergoing induction chemotherapy. *Leuk Lymphoma*. 2013 Jun; 54 (6):1263-7 Epub 2012 Nov 19 PMID: 23088670 DOI: 10.3109/10428194.2012.742520
 208. Pardanani A, Laborde RR, Lasho TL, Finke C, Begna K, Al-Kali A, Hogan WJ, **Litzow MR**, Leontovich A, Kowalski M, Tefferi A. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. *Leukemia*. 2013 Jun; 27 (6):1322-7 Epub 2013 Mar 05 PMID: 23459451 PMCID: 3677140 DOI: 10.1038/leu.2013.71
 209. Marks DI, Moorman AV, Chilton L, Paietta E, Enshaie A, DeWald G, Harrison CJ, Fielding AK, Foroni L,

- Goldstone AH, **Litzow MR**, Luger SM, McMillan AK, Racevskis J, Rowe JM, Tallman MS, Wiernik P, Lazarus HM. The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t (4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial. *Haematologica*. 2013 Jun; 98(6):945-52 Epub 2013 Jan 24 PMID: 23349309 PMCID: 3669452 DOI: 10.3324/haematol.2012.081877
210. DiNardo CD, Propert KJ, Loren AW, Paietta E, Sun Z, Levine RL, Straley KS, Yen K, Patel JP, Agresta S, Abdel-Wahab O, Perl AE, **Litzow MR**, Rowe JM, Lazarus HM, Fernandez HF, Margolis DJ, Tallman MS, Luger SM, Carroll M. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. *Blood*. 2013 Jun 13; 121(24):4917-24. Epub 2013 May 02. PMID: 23641016 PMCID: 3682342 DOI: 10.1182/blood-2013-03-493197
 211. Foran JM, Pavletic SZ, Logan BR, Agovi-Johnson MA, Perez WS, Bolwell BJ, Bornhauser M, Bredeson CN, Cairo MS, Camitta BM, Copelan EA, Dehn J, Gale RP, George B, Gupta V, Hale GA, Lazarus HM, **Litzow MR**, Maharaj D, Marks DI, Martino R, Maziarz RT, Rowe JM, Rowlings PA, Savani BN, Savoie ML, Szer J, Waller EK, Wiernik PH, Weisdorf DJ. Unrelated donor allogeneic transplantation after failure of autologous transplantation for acute myelogenous leukemia: a study from the center for international blood and marrow transplantation research. *Biol Blood Marrow Transplant*. 2013 Jul; 19 (7):1102-8 Epub 2013 Apr 28 PMID: 23632091 PMCID: 3691352 DOI: 10.1016/j.bbmt.2013.04.022
 212. Kenderian SS, Al-Kali A, Gangat N, Letendre L, Hogan WJ, **Litzow MR**, Patnaik MM. Monosomal karyotype in Philadelphia chromosome-negative acute lymphoblastic leukemia. *Blood Cancer J*. 2013 Jul 5; 3:e122 Epub 2013 July 05 PMID: 23832069 PMCID: 3730199 DOI: 10.1038/bcj.2013.21
 213. Larsen JT, Hogan WJ, Micallef IN, Dispenzieri A, Gertz MA, Inwards DJ, Tun HW, Roy V, Geyer SM, Allred JB, Wu W, Ansell SM, Elliott MA, Tefferi A, Porrata LF, Gastineau DA, Lacy MQ, **Litzow MR**. A phase I/II trial of reduced intensity allogeneic hematopoietic cell transplant for hematologic malignancies using cladribine, thiotepea and rabbit antithymocyte globulin. *Leuk Lymphoma*. 2013 Aug; 54 (8):1713-8 Epub 2012 Dec 31 PMID: 23189958 DOI: 10.3109/10428194.2012.753444
 214. Singla A, Hogan WJ, Ansell SM, Buadi FK, Dingli D, Dispenzieri A, Gastineau DA, Gertz MA, Hayman SR, Inwards DJ, Johnston PB, Lacy MQ, **Litzow MR**, Micallef IN, Porrata LF, Kumar SK. Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation. *Biol Blood Marrow Transplant*. 2013 Aug; 19(8):1233-7. Epub 2013 Jun 06. PMID: 23747600 PMCID: 3752294 DOI: 10.1016/j.bbmt.2013.05.019
 215. Dispenzieri A, Seenithamby K, Lacy MQ, Kumar SK, Buadi FK, Hayman SR, Dingli D, **Litzow MR**, Gastineau DA, Inwards DJ, Micallef IN, Ansell SM, Johnston PB, Porrata LF, Patnaik MM, Hogan WJ, Gertz MA. Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center. *Bone Marrow Transplant*. 2013 Oct; 48(10):1302-7. Epub 2013 Apr 22. PMID: 23604010 DOI: 10.1038/bmt.2013.53
 216. Lee SJ, Storer B, Wang H, Lazarus HM, Waller EK, Isola LM, Klumpp TR, Umejiego JB, Savani BN, Loren AW, Cairo MS, Camitta BM, Cutler CS, George B, Jean Khoury H, Marks DI, Rizzieri DA, Copelan EA, Gupta V, Liesveld JL, **Litzow MR**, Miller AM, Schouten HC, Gale RP, Cahn JY, Weisdorf DJ. Providing personalized prognostic information for adult leukemia survivors. *Biol Blood Marrow Transplant*. 2013 Nov; 19(11):1600-7. Epub 2013 Sep 06. PMID: 24018394 PMCID: 3832127 DOI: 10.1016/j.bbmt.2013.08.013
 217. Copelan EA, Hamilton BK, Avalos B, Ahn KW, Bolwell BJ, Zhu X, Aljurf M, van Besien K, Bredeson C, Cahn JY, Costa LJ, de Lima M, Gale RP, Hale GA, Halter J, Hamadani M, Inamoto Y, Kamble RT, **Litzow MR**, Loren AW, Marks DI, Olavarria E, Roy V, Sabloff M, Savani BN, Seftel M, Schouten HC, Ustun C, Waller EK, Weisdorf DJ, Wirk B, Horowitz MM, Arora M, Szer J, Cortes J, Kalaycio ME, Maziarz RT, Saber W. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. *Blood*. 2013 Dec 5; 122(24):3863-70. Epub 2013 Sep 24. PMID: 24065243 PMCID: 3854108 DOI: 10.1182/blood-2013-07-514448
 218. **Litzow MR**. Acute lymphoblastic leukemia. *Hematol*. 2014; 19(4):246-7.
 219. **Litzow MR**. Antigen-based immunotherapy for the treatment of acute lymphoblastic leukemia: the emerging role of blinatumomab. *Immunotargets Ther*. 2014; 3:79-89 Epub 2014 Apr 09 PMID: 27471701 PMCID: 4918236 DOI: 10.2147/ITT.S37292
 220. Thoma MD, Glej J, Jacob E, Huneke TJ, DeCook LJ, Johnson ND, Patnaik MM, **Litzow MR**, Hogan WJ, Newell LF, Chandran R, Porrata LF, Holtan SG. Impact of clinical factors and allograft leukocyte content on post-transplant lymphopenia, monocytopenia, and survival in patients undergoing allogeneic peripheral blood haematopoietic cell transplant. *BMC Hematol*. 2014; 14 (1):14 Epub 2014 Sept 01 PMID: 25221674 PMCID: 4161916 DOI: 10.1186/2052-1839-14-14
 221. Kaufman GP, Aksamit AJ, Klein CJ, Yi ES, Delone DR, **Litzow MR**. Progressive multifocal leukoencephalopathy: a rare infectious complication following allogeneic hematopoietic cell transplantation (HCT). *Eur J Haematol*. 2014 Jan; 92(1):83-7. Epub 2013 Oct 25. PMID: 24118404 DOI: 10.1111/ejh.12208

222. Gupta V, Malone AK, Hari PN, Ahn KW, Hu ZH, Gale RP, Ballen KK, Hamadani M, Olavarria E, Gerds AT, Waller EK, Costa LJ, Antin JH, Kamble RT, van Besien KM, Savani BN, Schouten HC, Szer J, Cahn JY, de Lima MJ, Wirk B, Aljurf MD, Popat U, Bejanyan N, **Litzow MR**, Norkin M, Lewis ID, Hale GA, Woolfrey AE, Miller AM, Ustun C, Jagasia MH, Lill M, Maziarz RT, Cortes J, Kalaycio ME, Saber W. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. *Biol Blood Marrow Transplant*. 2014 Jan; 20 (1):89-97 Epub 2013 Oct 23 PMID: 24161923 PMCID: 3886623 DOI: 10.1016/j.bbmt.2013.10.018
223. Fielding AK, Rowe JM, Buck G, Foroni L, Gerrard G, **Litzow MR**, Lazarus H, Luger SM, Marks DI, McMillan AK, Moorman AV, Patel B, Paietta E, Tallman MS, Goldstone AH. UKALLXII/ECOG2993: Addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. *Blood*. 2014; 123(6):843-50. PMID: 24277073 PMCID: 3916877
224. Warlick ED, Paulson K, Brazauskas R, Zhong X, Miller AM, Camitta BM, George B, Savani BN, Ustun C, Marks DI, Waller EK, Baron F, Freytes CO, Socie G, Akpek G, Schouten HC, Lazarus HM, Horwitz EM, Koreth J, Cahn JY, Bornhauser M, Seftel M, Cairo MS, Laughlin MJ, Sabloff M, Ringden O, Gale RP, Kamble RT, Vij R, Gergis U, Mathews V, Saber W, Chen YB, Liesveld JL, Cutler CS, Ghobadi A, Uy GL, Eapen M, Weisdorf DJ, **Litzow MR**. Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission. *Biol Blood Marrow Transplant*. 2014 Feb; 20 (2):202-8 Epub 2013 Nov 01 PMID: 24184335 PMCID: 3924751 DOI: 10.1016/j.bbmt.2013.10.023
225. Bachanova V, Marks DI, Zhang MJ, Wang H, de Lima M, Aljurf MD, Arellano M, Artz AS, Bacher U, Cahn JY, Chen YB, Copelan EA, Drobyski WR, Gale RP, Greer JP, Gupta V, Hale GA, Kebriaei P, Lazarus HM, Lewis ID, Lewis VA, Liesveld JL, **Litzow MR**, Loren AW, Miller AM, Norkin M, Oran B, Pidala J, Rowe JM, Savani BN, Saber W, Vij R, Waller EK, Wiernik PH, Weisdorf DJ. Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease. *Leukemia*. 2014 Mar; 28 (3):658-65 Epub 2013 Aug 30 PMID: 23989431 PMCID: 3951192 DOI: 10.1038/leu.2013.253
226. Prebet T, Sun Z, Figueroa ME, Ketterling R, Melnick A, Greenberg PL, Herman J, Juckett M, Smith MR, Malick L, Paietta E, Czader M, **Litzow M**, Gabrilove J, Erba HP, Gore SD, Tallman MS. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. *J Clin Oncol*. 2014 Apr 20; 32 (12):1242-8 Epub 2014 Mar 24 PMID: 24663049 PMCID: 3986386 DOI: 10.1200/JCO.2013.50.3102
227. Burns LJ, Gajewski JL, Majhail NS, Navarro W, Perales MA, Shereck E, Selby GB, Snyder EL, Woolfrey AE, **Litzow MR**. Challenges and potential solutions for recruitment and retention of hematopoietic cell transplantation physicians: the National Marrow Donor Program's System Capacity Initiative Physician Workforce Group report. *Biol Blood Marrow Transplant*. 2014 May; 20(5):617-21. Epub 2014 Feb 05. PMID: 24508838 DOI: 10.1016/j.bbmt.2014.01.028
228. Gleason MK, Ross JA, Warlick ED, Lund TC, Verneris MR, Wiernik A, Spellman S, Haagenson MD, Lenvik AJ, **Litzow MR**, Epling-Burnette PK, Blazar BR, Weiner LM, Weisdorf DJ, Vallera DA, Miller JS. Cd16xcd33 bispecific killer cell engager (bike) activates nk cells against primary mds and mdsc cd33(+) targets. *Blood*. 2014 May 8; 123(19):3016-26. PMID: 24652987 PMCID: 4014844
229. Malik MI, **Litzow M**, Hogan W, Patnaik M, Murad MH, Prokop LJ, Winters JL, Hashmi S. Extracorporeal photopheresis for chronic graft-versus-host disease: a systematic review and meta-analysis. *Blood Res*. 2014 Jun; 49 (2):100-6 Epub 2014 June 25 PMID: 25025011 PMCID: 4090330 DOI: 10.5045/br.2014.49.2.100
230. Kochuparambil ST, **Litzow MR**. Novel antibody therapy in acute lymphoblastic leukemia. *Curr Hematol Malig Rep*. 2014 Jun; 9 (2):165-73 PMID: 24623281 DOI: 10.1007/s11899-014-0202-9
231. Shen N, Yan F, Pang J, Wu LC, Al-Kali A, **Litzow MR**, Liu S. A nucleolin-DNMT1 regulatory axis in acute myeloid leukemogenesis. *Oncotarget*. 2014 Jul 30; 5 (14):5494-509 PMID: 25015109 PMCID: 4170608 DOI: 10.18632/oncotarget.2131
232. Watts JM, Wang XV, **Litzow MR**, Luger SM, Lazarus HM, Cassileth PA, Fernandez HF, Douer D, Zickl L, Paietta E, Rowe JM, Tallman MS. Younger adults with acute myeloid leukemia in remission for >= 3 years have a high likelihood of cure: The ECOG experience in over 1200 patients. *Leuk Res*. 2014 Aug; 38 (8):901-6 Epub 2014 June 02 PMID: 24986381 PMCID: 4326112 DOI: 10.1016/j.leukres.2014.05.018
233. Levine JE, Hogan WJ, Harris AC, **Litzow MR**, Efebera YA, Devine SM, Reshef R, Ferrara JL. Improved accuracy of acute graft-versus-host disease staging among multiple centers. *Best Pract Res Clin Haematol*. 2014 Sep-Dec; 27 (3-4):283-7 Epub 2014 Oct 15 PMID: 25455279 PMCID: 4381784 DOI: 10.1016/j.beha.2014.10.011
234. Duong HK, Savani BN, Copelan E, Devine S, Costa LJ, Wingard JR, Shaughnessy P, Majhail N, Perales MA, Cutler CS, Bensinger W, **Litzow MR**, Mohty M, Champlin RE, Leather H, Giral S, Carpenter PA. Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2014 Sep; 20 (9):1262-73 Epub 2014 May 09 PMID: 24816581 DOI: 10.1016/j.bbmt.2014.05.003

235. Werner B, Gallagher RE, Paietta EM, **Litzow MR**, Tallman MS, Wiernik PH, Slack JL, Willman CL, Sun Z, Traulsen A, Dingli D. Dynamics of leukemia stem-like cell extinction in acute promyelocytic leukemia. *Cancer Res*. 2014 Oct 1; 74 (19):5386-96 Epub 2014 July 31 PMID: 25082816 PMCID: 4184925 DOI: 10.1158/0008-5472.CAN-14-1210
236. Parikh SA, **Litzow MR**. Philadelphia chromosome-negative acute lymphoblastic leukemia: therapies under development. *Future Oncol*. 2014 Nov; 10(14):2201-12. PMID: 25471034 DOI: 10.2217/fo.14.81
237. Abidi MZ, Sohail MR, Cummins N, Wilhelm M, Wengenack N, Brumble L, Shah H, Jane Hata D, McCullough A, Wendel A, Vikram HR, Kusne S, **Litzow M**, Letendre L, Lahr BD, Poeschla E, Walker RC. Stability in the cumulative incidence, severity and mortality of 101 cases of invasive mucormycosis in high-risk patients from 1995 to 2011: a comparison of eras immediately before and after the availability of voriconazole and echinocandin-amphotericin combination therapies. *Mycoses*. 2014 Nov; 57 (11):687-98 Epub 2014 July 18 PMID: 25040241 PMCID: 4192082 DOI: 10.1111/myc.12222
238. Topp MS, Gokbuget N, Stein AS, Zugmaier G, O'Brien S, Bargou RC, Dombret H, Fielding AK, Heffner L, Larson RA, Neumann S, Foa R, **Litzow M**, Ribera JM, Rambaldi A, Schiller G, Bruggemann M, Horst HA, Holland C, Jia C, Maniar T, Huber B, Nagorsen D, Forman SJ, Kantarjian HM. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. *Lancet Oncol*. 2015 Jan; 16 (1):57-66 Epub 2014 Dec 16 PMID: 25524800 DOI: 10.1016/S1470-2045(14)71170-2
239. Alsahlawi A, Alkhateeb H, Patnaik M, Begna K, Elliott M, Hogan WJ, **Litzow M**, Al-Kali A. Monosomal karyotype predicts adverse prognosis in patients diagnosed with chronic myelomonocytic leukemia: a single-institution experience. *Clin Lymphoma Myeloma Leuk*. 2015 Feb; 15(2):e39-41. Epub 2014 Jun 10. PMID: 25027568 DOI: 10.1016/j.clml.2014.06.007
240. Copelan EA, Avalos BR, Ahn KW, Zhu X, Gale RP, Grunwald MR, Hamadani M, Hamilton BK, Hale GA, Marks DI, Waller EK, Savani BN, Costa LJ, Ramanathan M, Cahn JY, Khoury HJ, Weisdorf DJ, Inamoto Y, Kamble RT, Schouten HC, Wirk B, **Litzow MR**, Aljurf MD, van Besien KW, Ustun C, Bolwell BJ, Bredeson CN, Fasan O, Ghosh N, Horowitz MM, Arora M, Szer J, Loren AW, Alyea EP, Cortes J, Maziarz RT, Kalaycio ME, Saber W. Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation. *Biol Blood Marrow Transplant*. 2015 Mar; 21 (3):552-8 Epub 2014 Dec 17 PMID: 25528388 PMCID: 4329042 DOI: 10.1016/j.bbmt.2014.12.010
241. Moyer AM, Walker DL, Avula R, Lapid MI, Kung S, Bryant SC, Edwards KK, Black JL, Karpyak VM, Shinozaki G, Jowsey-Gregoire SG, Ehlers SL, Romanowicz M, **Litzow MR**, Hogan WJ, Rundell JR, Hooten WM, Baudhuin LM. Relationship of genetic variation in the serotonin transporter gene (SLC6A4) and congenital and acquired cardiovascular diseases. *Genet Test Mol Biomarkers*. 2015 Mar; 19(3):115-23. Epub 2015 Feb 11. PMID: 25671637 DOI: 10.1089/gtmb.2014.0250
242. Loughran TP Jr, Zickl L, Olson TL, Wang V, Zhang D, Rajala HL, Hasanali Z, Bennett JM, Lazarus HM, **Litzow MR**, Evens AM, Mustjoki S, Tallman MS. Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). *Leukemia*. 2015 Apr; 29 (4):886-94 Epub 2014 Sept 13 PMID: 25306898 PMCID: 4377298 DOI: 10.1038/leu.2014.298
243. Abdelrahman RA, Begna KH, Al-Kali A, Hogan WJ, **Litzow MR**, Pardanani A, Tefferi A. Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis. *Br J Haematol*. 2015 Apr; 169 (1):77-80 Epub 2014 Dec 15 PMID: 25511866 DOI: 10.1111/bjh.13262
244. Wojenski DJ, Bartoo GT, Merten JA, Dierkhising RA, Barajas MR, El-Azhary RA, Wilson JW, Plevak MF, Hogan WJ, **Litzow MR**, Patnaik MM, Wolf RC, Hashmi SK. Voriconazole exposure and the risk of cutaneous squamous cell carcinoma in allogeneic hematopoietic stem cell transplant patients. *Transpl Infect Dis*. 2015 Apr; 17: (2)250-8. PMID: 25661996 DOI: 10.1111/tid.12367
245. He R, Wiktor AE, Hanson CA, Ketterling RP, Kurtin PJ, Van Dyke DL, **Litzow MR**, Howard MT, Reichard KK. Conventional karyotyping and fluorescence in situ hybridization: an effective utilization strategy in diagnostic adult acute myeloid leukemia. *Am J Clin Pathol*. 2015 Jun; 143 (6):873-8 PMID: 25972330 DOI: 10.1309/AJCPP6LVMQGG4LNCK
246. Russell A, Malik S, **Litzow M**, Gastineau D, Roy V, Zubair AC. Dual roles of autologous CD8+ T cells in hematopoietic progenitor cell mobilization and engraftment. *Transfusion*. 2015 Jul; 55(7):1758-65; quiz 1757. Epub 2015 Mar 11. PMID: 25757596 DOI: 10.1111/trf.13073
247. Chakraborty R, Savani BN, **Litzow M**, Mohty M, Hashmi S. A perspective on complementary/alternative medicine use among survivors of hematopoietic stem cell transplant: Benefits and uncertainties. *Cancer*. 2015 Jul 15; 121 (14):2303-13 Epub 2015 Apr 14 PMID: 25872879 DOI: 10.1002/cncr.29382
248. **Litzow MR**, Ferrando AA. How I treat T-cell acute lymphoblastic leukemia in adults. *Blood*. 2015 Aug 13; 126 (7):833-41 Epub 2015 May 12 PMID: 25966987 DOI: 10.1182/blood-2014-10-551895

249. Subari S, Patnaik M, Alfakara D, Gangat N, Elliott M, Hogan W, **Litzow M**, Al-Kali A. Patients With Therapy-Related CMML Have Shorter Median Overall Survival Than Those With De Novo CMML: Mayo Clinic Long-Term Follow-Up Experience. *Clin Lymphoma Myeloma Leuk*. 2015 Sep; 15: (9)546-9. PMID: 26189785 DOI: 10.1016/j.clml.2015.06.002
250. Zeidner JF, Foster MC, Blackford AL, **Litzow MR**, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. *Haematologica*. 2015 Sep; 100 (9):1172-9 Epub 2015 May 28 PMID: 26022709 PMCID: 4800702 DOI: 10.3324/haematol.2015.125849
251. Hefazi M, Hefazi M, Siddiqui M, Patnaik M, Wolanskyj A, Wolanskyj A, Alkhateeb H, Zblewski D, Elliott M, Hogan W, **Litzow M**, Al-Kali A. Prognostic impact of combined NPM1+/FLT3- genotype in patients with acute myeloid leukemia with intermediate risk cytogenetics stratified by age and treatment modalities. *Leuk Res*. 2015 Sep 3 Epub 2015 Sept 03 PMID: 26410460 DOI: 10.1016/j.leukres.2015.09.001
252. Alvarnas JC, Brown PA, Aoun P, Ballen KK, Barta SK, Borate U, Boyer MW, Burke PW, Cassaday R, Castro JE, Coccia PF, Coutre SE, Damon LE, DeAngelo DJ, Douer D, Frankfurt O, Greer JP, Johnson RA, Kantarjian HM, Klisovic RB, Kupfer G, **Litzow M**, Liu A, Rao AV, Shah B, Uy GL, Wang ES, Zelenetz AD, Gregory K, Smith C. Acute Lymphoblastic Leukemia, Version 2.2015. *J Natl Compr Canc Netw*. 2015 Oct; 13 (10):1240-79 PMID: 26483064
253. Damlaj M, Sulai NH, Oliveira JL, Ketterling RP, Hashmi S, Witzig T, Nowakowski G, Call TG, Shanafelt TD, Ding W, Hogan WJ, **Litzow MR**, Patnaik MM. Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience. *Clin Lymphoma Myeloma Leuk*. 2015 Nov; 15 (11):699-704 Epub 2015 Aug 05 PMID: 26422251 DOI: 10.1016/j.clml.2015.07.643
254. Lee EJ, Smith BD, Merrey JW, Lee AI, Podoltsev NA, Barbarotta L, **Litzow MR**, Prebet T, Luger SM, Gore S, Streiff MB, Zeidan AM. Patterns of Venous Thromboembolism Prophylaxis During Treatment of Acute Leukemia: Results of a North American Web-Based Survey. *Clin Lymphoma Myeloma Leuk*. 2015 Dec; 15 (12):766-770 Epub 2015 Aug 06 PMID: 26363982 PMCID: 4663156 DOI: 10.1016/j.clml.2015.07.637
255. Gangat N, Patnaik MM, Begna K, Kourelis T, Al-Kali A, Elliott MA, Hogan WJ, Letendre L, **Litzow MR**, Knudson RA, Ketterling RP, Hodnefield JM, Hanson CA, Pardani AD, Tefferi A. Primary Myelodysplastic Syndromes: The Mayo Clinic Experience With 1000 Patients. *Mayo Clin Proc*. 2015 Dec; 90 (12):1623-38 Epub 2015 Nov 03 PMID: 26546107 DOI: 10.1016/j.mayocp.2015.08.022
256. Kasi PM, **Litzow MR**, Patnaik MM, Hashmi SK, Gangat N. Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets. *Leuk Res Rep*. 2016; 5:7-10 Epub 2016 Jan 12 PMID: 26904404 PMCID: 4726703 DOI: 10.1016/j.lrr.2016.01.002
257. Kumar AJ, Gimotty PA, Gelfand J, Buck G, Rowe JM, Goldstone AH, Fielding A, Marks DI, **Litzow M**, Paietta E, Lazarus HM, Tallman MS, Luger SM, Loren AW. Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII *American Journal of Hematology*. 2016; 91: (11)1107-12.
258. Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, Chanswangphuwana C, Efebera YA, Holler E, **Litzow M**, Ordemann R, Qayed M, Renteria AS, Reshef R, Wolf M, Chen YB, Goldstein S, Jagasia M, Locatelli F, Mielke S, Porter D, Schechter T, Shekhovtsova Z, Ferrara JL, Levine JE. International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. *Biol Blood Marrow Transplant*. 2016 Jan; 22 (1):4-10 Epub 2015 Sept 16 PMID: 26386318 PMCID: 4706482 DOI: 10.1016/j.bbmt.2015.09.001
259. Hashmi S, Ahmed M, Murad MH, **Litzow MR**, Adams RH, Ball LM, Prasad VK, Kebriaei P, Ringden O. Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis. *Lancet Haematol*. 2016 Jan; 3 (1):e45-52 Epub 2015 Nov 27 PMID: 26765648 DOI: 10.1016/S2352-3026(15)00224-0
260. Baljevic M, Dumitriu B, Lee JW, Paietta EM, Wiernik PH, Racevskis J, Chen C, Stein EM, Gallagher RE, Rowe JM, Appelbaum FR, Powell BL, Larson RA, Coutre SE, Lancet J, **Litzow MR**, Luger SM, Young NS, Tallman MS. Telomere length recovery: a strong predictor of overall survival in acute promyelocytic leukemia *Acta Haematologica*. 2016; 136: (4)210-8.
261. Boyiadzis M, Bishop MR, Abonour R, Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Besien K, Bergsagel PL, Borrello I, Brody J, Brufsky J, Cairo M, Chari A, Cohen A, Cortes J, Forman SJ, Friedberg JW, Fuchs EJ, Gore SD, Jagannath S, Kahl BS, Kline J, Kochenderfer JN, Kwak LW, Levy R, Lima M, **Litzow MR**, Mahindra A, Miller J, Munshi NC, Orlovski RZ, Pagel JM, Porter DL, Russell SJ, Schwartz K, Shipp MA, Siegel D, Stone RM, Tallman MS, Timmerman JM, Rhee F, Waller EK, Welsh A, Werner M, Wiernik PH, Dhodapkar MV. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: Multiple myeloma, lymphoma, and acute leukemia *Journal for*

- ImmunoTherapy of Cancer. 2016; 4: (1)90.
262. Boyiadzis M#, Bishop MR#, Abonour R, Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Van Besien K, Bergsagel PL, Borrello I, Brody J, Brufsky J, Cairo M, Chari A, Cohen A, Cortes J, Forman SJ, Friedberg JW, Fuchs EJ, Gore SD, Jagannath S, Kahl BS, Kline J, Kochenderfer JN, Kwak LW, Levy R, de Lima M, **Litzow MR**, Mahindra A, Miller J, Munshi NC, Orlowski RZ, Pagel JM, Porter DL, Russell SJ, Schwartz K, Shipp MA, Siegel D, Stone RM, Tallman MS, Timmerman JM, Van Rhee F, Waller EK, Welsh A, Werner M, Wiernik PH, Dhodapkar MV. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. *J Immunother Cancer*. 2016; 4:90 Epub 2016 Dec 20 PMID: 28018601 PMCID: 5168808 DOI: 10.1186/s40425-016-0188-z
 263. Hefazi M, **Litzow M**, Hogan W, Gastineau D, Jacob E, Damlaj M, Hashmi S, Al-Kali A, Patnaik MM. ABO blood group incompatibility as an adverse risk factor for outcomes in patients with myelodysplastic syndromes and acute myeloid leukemia undergoing HLA-matched peripheral blood hematopoietic cell transplantation after reduced-intensity conditioning. *Transfusion*. 2016 Feb; 56: (2)518-27. PMID: 26446051 DOI: 10.1111/trf.13353
 264. Prebet T, Sun Z, Ketterling RP, Zeidan A, Greenberg P, Herman J, Juckett M, Smith MR, Malick L, Paietta E, Czader M, Figueroa M, Gabrielove J, Erba HP, Tallman MS, **Litzow M**, Gore SD, Eastern Cooperative Oncology Group and North American Leukemia intergroup. Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. *Br J Haematol*. 2016 Feb; 172 (3):384-91 Epub 2015 Nov 18 PMID: 26577691 PMCID: 4794257 DOI: 10.1111/bjh.13832
 265. Pasquini MC, Zhang MJ, Medeiros BC, Armand P, Hu ZH, Nishihori T, Aljurf MD, Akpek G, Cahn JY, Cairo MS, Cerny J, Copelan EA, Deol A, Freytes CO, Gale RP, Ganguly S, George B, Gupta V, Hale GA, Kamble RT, Klumpp TR, Lazarus HM, Luger SM, Liesveld JL, **Litzow MR**, Marks DI, Martino R, Norkin M, Olsson RF, Oran B, Pawarode A, Pulsipher MA, Ramanathan M, Reshef R, Saad AA, Saber W, Savani BN, Schouten HC, Ringden O, Tallman MS, Uy GL, Wood WA Jr, Wirk B, Perez WS, Batiwalla M, Weisdorf DJ. Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. *Biol Blood Marrow Transplant*. 2016 Feb; 22 (2):248-257 Epub 2015 Aug 29 PMID: 26327629 PMCID: 4716890 DOI: 10.1016/j.bbmt.2015.08.024
 266. Iacobucci I, Li Y, Roberts KG, Dobson SM, Kim JC, Payne-Turner D, Harvey RC, Valentine M, McCastlain K, Easton J, Yergeau D, Janke LJ, Shao Y, Chen IM, Rusch M, Zandi S, Kornblau SM, Konopleva M, Jabbour E, Paietta EM, Rowe JM, Pui CH, Gastier-Foster J, Gu Z, Reshmi S, Loh ML, Racevskis J, Tallman MS, Wiernik PH, **Litzow MR**, Willman CL, McPherson JD, Downing JR, Zhang J, Dick JE, Hunger SP, Mullighan CG. Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia. *Cancer Cell*. 2016 Feb 8; 29 (2):186-200 PMID: 26859458 PMCID: 4750652 DOI: 10.1016/j.ccell.2015.12.013
 267. Zent CS, Victoria Wang X, Ketterling RP, Hanson CA, Libby EN, Barrientos JC, Call TG, Chang JE, Liu JJ, Calvo AR, Lazarus HM, Rowe JM, Luger SM, **Litzow MR**, Tallman MS. A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908). *Am J Hematol*. 2016 Mar; 91 (3):308-12 Epub 2016 Feb 09 PMID: 26662208 PMCID: 4806550 DOI: 10.1002/ajh.24265
 268. Barajas MR, McCullough KB, Merten JA, Dierkhising RA, Bartoo GT, Hashmi SK, Hogan WJ, **Litzow MR**, Patnaik MM, Wilson JW, Wolf RC, Wermers RA. Correlation of Pain and Fluoride Concentration in Allogeneic Hematopoietic Stem Cell Transplant Recipients on Voriconazole. *Biol Blood Marrow Transplant*. 2016 Mar; 22: (3)579-83. PMID: 26524731 DOI: 10.1016/j.bbmt.2015.10.021
 269. Barba P, Burns LJ, **Litzow MR**, Juckett MB, Komanduri KV, Lee SJ, Devlin SM, Costa LJ, Khan S, King A, Klein A, Krishnan A, Malone A, Mir M, Moravec C, Selby G, Roy V, Cochran M, Stricherz MK, Westmoreland MD, Perales MA#, Wood WA#. Success of an International Learning Health Care System in Hematopoietic Cell Transplantation: The American Society of Blood and Marrow Transplantation Clinical Case Forum. *Biol Blood Marrow Transplant*. 2016 Mar; 22 (3):564-570 Epub 2015 Dec 21 PMID: 26718665 PMCID: 4965270 DOI: 10.1016/j.bbmt.2015.12.008
 270. Luskin MR, Lee JW, Fernandez HF, Abdel-Wahab O, Bennett JM, Ketterling RP, Lazarus HM, Levine RL, **Litzow MR**, Paietta EM, Patel JP, Racevskis J, Rowe JM, Tallman MS, Sun Z, Luger SM. Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. *Blood*. 2016 Mar 24; 127 (12):1551-8 Epub 2016 Jan 11 PMID: 26755712 PMCID: 4807422 DOI: 10.1182/blood-2015-07-657403
 271. Damlaj M, Bartoo G, Cartin-Ceba R, Gijima D, Alkhateeb HB, Merten J, Hashmi S, **Litzow M**, Gastineau D, Hogan W, Patnaik MM. Corticosteroid use as adjunct therapy for respiratory syncytial virus infection in adult allogeneic stem cell transplant recipients. *Transpl Infect Dis*. 2016 Apr; 18: (2)216-26. PMID: 26909896
 272. Subari S, Baidoun F, Hreh M, Patnaik M, Hashmi S, Elliott M, Hogan W, **Litzow M**, Al-Kali A. Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy. *Int J Hematol*. 2016 Apr; 103 (4):409-15 Epub 2016 Jan 18 PMID: 26781617 DOI: 10.1007/s12185-016-1935-0

273. Chaudhry HM, Bruce AJ, Wolf RC, **Litzow MR**, Hogan WJ, Patnaik MS, Kremers WK, Phillips GL, Hashmi SK. The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review. *Biol Blood Marrow Transplant*. 2016 Apr; 22 (4):605-616 Epub 2015 Sept 26 PMID: 26409924 DOI: 10.1016/j.bbmt.2015.09.014
274. Gangat N, Patnaik MM, Begna K, Al-Kali A, **Litzow MR**, Ketterling RP, Hanson CA, Pardanani AD, Tefferi A. Survival trends in primary myelodysplastic syndromes: a comparative analysis of 1000 patients by year of diagnosis and treatment. *Blood Cancer J* 2016 Apr 8; 6:e414 Epub 2016 Apr 08 PMID: 27058229 PMCID: 4855255 DOI: 10.1038/bcj.2016.23
275. Shaffer BC, Ahn KW, Hu ZH, Nishihori T, Malone AK, Valcarcel D, Grunwald MR, Bacher U, Hamilton B, Kharfan-Dabaja MA, Saad A, Cutler C, Warlick E, Reshef R, Wirk BM, Sabloff M, Fasan O, Gerds A, Marks D, Olsson R, Wood WA, Costa LJ, Miller AM, Cortes J, Daly A, Kindwall-Keller TL, Kamble R, Rizzieri DA, Cahn JY, Gale RP, William B, **Litzow M**, Wiernik PH, Liesveld J, Savani BN, Vij R, Ustun C, Copelan E, Popat U, Kalaycio M, Maziarz R, Alyea E, Sobecks R, Pavletic S, Tallman M, Saber W. Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. *J Clin Oncol*. 2016 Jun 1; 34 (16):1864-71 Epub 2016 Apr 04 PMID: 27044940 PMCID: 4966345 DOI: 10.1200/JCO.2015.65.0515
276. Yang X, Pang J, Shen N, Yan F, Wu LC, Al-Kali A, **Litzow MR**, Peng Y, Lee RJ, Liu S. Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis. *Oncotarget*. 2016 Jun 14; 7 (24):36382-36394 PMID: 27144331 PMCID: 5095007 DOI: 10.18632/oncotarget.8871
277. Luskin MR, Gimotty PA, Smith C, Loren AW, Figueroa ME, Harrison J, Sun Z, Tallman MS, Paietta EM, **Litzow MR**, Melnick AM, Levine RL, Fernandez HF, Luger SM, Carroll M, Master SR, Wertheim GB. A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemia. *JCI Insight*. 2016 Jun 16; 1 (9) PMID: 27446991 PMCID: 4951094 DOI: 10.1172/jci.insight.87323
278. Subari S, Patnaik M, Alfakara D, Zblewski D, Hook C, Hashmi S, Hogan W, **Litzow M**, Al-Kali A. Hypomethylating agents are effective in shrinking splenomegaly in patients with chronic myelomonocytic leukemia. *Leuk Lymphoma* 2016 Jul; 57 (7):1714-5 Epub 2016 Mar 14 PMID: 26462118 DOI: 10.3109/10428194.2015.1105371
279. Watts JM, Wang XV, Swords RT, Paietta E, Douer D, Luger SM, Fernandez HF, Rowe JM, Lazarus HM, Tallman MS, **Litzow MR**. Very late relapse of AML after allogeneic hematopoietic cell transplantation is often extramedullary. *Bone Marrow Transplant*. 2016 Jul; 51 (7):1013-5 Epub 2016 Mar 14 PMID: 26974275 PMCID: 5699708 DOI: 10.1038/bmt.2016.44
280. Ustun C, Gotlib J, Popat U, Artz A, **Litzow M**, Reiter A, Nakamura R, Kluin-Nelemans HC, Verstovsek S, Gajewski J, Perales MA, George T, Shore T, Sperr W, Saber W, Kota V, Yavuz AS, Pullarkat V, Rogosheske J, Hogan W, Van Besien K, Hagglund H, Damaj G, Arock M, Horny HP, Metcalfe DD, Deeg HJ, Devine S, Weisdorf D, Akin C, Valent P. Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. *Biol Blood Marrow Transplant*. 2016 Aug; 22 (8):1348-1356 Epub 2016 Apr 27 PMID: 27131865 DOI: 10.1016/j.bbmt.2016.04.018
281. Damlaj M, Alkhateeb HB, Hefazi M, Partain DK, Hashmi S, Gastineau DA, Al-Kali A, Wolf RC, Gangat N, **Litzow MR**, Hogan WJ, Patnaik MM. Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing. *Biol Blood Marrow Transplant*. 2016 Aug; 22 (8):1431-1439 Epub 2016 May 07 PMID: 27164061 DOI: 10.1016/j.bbmt.2016.04.026
282. Gao SJ, Wei W, Chen JT, Tan YH, Yu CB, **Litzow MR**, Liu QJ. Hypereosinophilic syndrome presenting with multiple organ infiltration and deep venous thrombosis: A case report and literature review. *Medicine (Baltimore)*. 2016 Aug; 95 (35):e4658 PMID: 27583887 PMCID: 5008571 DOI: 10.1097/MD.0000000000004658
283. Dias A, Kenderian SJ, Westin GF, **Litzow MR**. Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia. *Curr Hematol Malig Rep*. 2016 Aug; 11 (4):253-64 PMID: 27101015 DOI: 10.1007/s11899-016-0326-1
284. Zahid MF, Parnes A, Savani BN, **Litzow MR**, Hashmi SK. Therapy-related myeloid neoplasms - what have we learned so far? *World J Stem Cells*. 2016 Aug 26; 8 (8):231-42 PMID: 27621757 PMCID: 4999650 DOI: 10.4252/wjsc.v8.i8.231
285. Narayanan P, Wolanskyj A, Ehlers SL, **Litzow MR**, Patnaik MS, Hogan WJ, Hashmi SK. Medical students' knowledge, familiarity, and attitudes towards hematopoietic stem cell donation stem cell donation behaviors *Biology Of Blood And Marrow Transplantation*. 2016 Sep; 22: (9)1710-6.
286. Narayanan P, Wolanskyj A, Ehlers SL, **Litzow MR**, Patnaik MS, Hogan WJ, Hashmi SK. Medical Students' Knowledge, Familiarity, and Attitudes towards Hematopoietic Stem Cell Donation: Stem Cell Donation Behaviors. *Biol Blood Marrow Transplant*. 2016 Sep; 22 (9):1710-1716 Epub 2016 June 22 PMID: 27343721 DOI: 10.1016/j.bbmt.2016.06.014
287. Zahid MF, Murad MH, **Litzow MR**, Hogan WJ, Patnaik MS, Khorana A, Spyropoulos AC, Hashmi SK. Venous

thromboembolism following hematopoietic stem cell transplantation-a systematic review and meta-analysis.

288. Deol A, Sengsayadeth S, Ahn KW, Wang HL, Aljurf M, Antin JH, Battiwalla M, Bornhauser M, Cahn JY, Camitta B, Chen YB, Cutler CS, Gale RP, Ganguly S, Hamadani M, Inamoto Y, Jagasia M, Kamble R, Koreth J, Lazarus HM, Liesveld J, **Litzow MR**, Marks DI, Nishihori T, Olsson RF, Reshef R, Rowe JM, Saad AA, Sabloff M, Schouten HC, Shea TC, Soiffer RJ, Uy GL, Waller EK, Wiernik PH, Wirk B, Woolfrey AE, Bunjes D, Devine S, de Lima M, Sandmaier BM, Weisdorf D, Khoury HJ, Saber W. Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A center for international blood and marrow transplant research (cibmtr) analysis *Cancer*. 2016 Oct 1; 122: (19):3005-14.
289. Deol A#, Sengsayadeth S#, Ahn KW, Wang HL, Aljurf M, Antin JH, Battiwalla M, Bornhauser M, Cahn JY, Camitta B, Chen YB, Cutler CS, Gale RP, Ganguly S, Hamadani M, Inamoto Y, Jagasia M, Kamble R, Koreth J, Lazarus HM, Liesveld J, **Litzow MR**, Marks DI, Nishihori T, Olsson RF, Reshef R, Rowe JM, Saad AA, Sabloff M, Schouten HC, Shea TC, Soiffer RJ, Uy GL, Waller EK, Wiernik PH, Wirk B, Woolfrey AE, Bunjes D, Devine S, de Lima M, Sandmaier BM, Weisdorf D, Khoury HJ, Saber W. Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. *Cancer*. 2016 Oct; 122 (19):3005-3014 Epub 2016 June 17 PMID: 27315441 PMCID: 5030151 DOI: 10.1002/cncr.30140
290. Farhadfar N, **Litzow MR**. New monoclonal antibodies for the treatment of acute lymphoblastic leukemia. *Leuk Res*. 2016 Oct; 49:13-21 Epub 2016 July 26 PMID: 27521873 DOI: 10.1016/j.leukres.2016.07.009
291. Ganzel C, Manola J, Douer D, Rowe JM, Fernandez HF, Paietta EM, **Litzow MR**, Lee JW, Luger SM, Lazarus HM, Cripe LD, Wiernik PH, Tallman MS. Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008. *J Clin Oncol*. 2016 Oct 10; 34 (29):3544-3553 PMID: 27573652 PMCID: 5074349 DOI: 10.1200/JCO.2016.67.5892
292. Kumar AJ, Gimotty PA, Gelfand JM, Buck G, Rowe JM, Goldstone AH, Fielding A, Marks DI, **Litzow M**, Paietta E, Lazarus HM, Tallman MS, Luger SM, Loren AW. Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII. *Am J Hematol*. 2016 Nov; 91 (11):1107-1112 Epub 2016 Aug 22 PMID: 27468137 PMCID: 5073003 DOI: 10.1002/ajh.24497
293. Nanah R, Zblewski D, Patnaik MS, Begna K, Ketterling R, Iyer VN, Hogan WJ, **Litzow MR**, Al-Kali A. Deletion 5q is frequent in myelodysplastic syndrome (MDS) patients diagnosed with interstitial lung diseases (ILD): Mayo Clinic experience. *Leuk Res*. 2016 Nov; 50:112-115 Epub 2016 Oct 03 PMID: 27721163 DOI: 10.1016/j.leukres.2016.10.002
294. Artz AS, Logan B, Zhu X, Akpek G, Bufarull RM, Gupta V, Lazarus HM, **Litzow M**, Loren A, Majhail NS, Maziarz RT, McCarthy P, Popat U, Saber W, Spellman S, Ringden O, Wickrema A, Pasquini MC, Cooke KR, from the Center for International Blood and Marrow Transplantation Research. The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes. *Haematologica*. 2016 Nov; 101 (11):1426-1433 Epub 2016 Aug 04 PMID: 27662010 PMCID: 5394859 DOI: 10.3324/haematol.2016.145847
295. **Litzow MR**. Should anyone with Philadelphia chromosome-positive ALL who is negative for minimal residual disease receive a hematopoietic stem cell transplant in first remission? *Best Pract Res Clin Haematol*. 2016 Dec; 29 (4):345-350 Epub 2016 Oct 20 PMID: 27890258 DOI: 10.1016/j.beha.2016.10.009
296. Hefazi M, Damlaj M, Alkhateeb HB, Partain DK, Patel R, Razonable RR, Gastineau DA, Al-Kali A, Hashmi SK, Hogan WJ, **Litzow MR**, Patnaik MM. Vancomycin-resistant Enterococcus colonization and bloodstream infection: prevalence, risk factors, and the impact on early outcomes after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. *Transpl Infect Dis*. 2016 Dec; 18 (6):913-920 Epub 2016 Nov 11 PMID: 27642723 DOI: 10.1111/tid.12612
297. Switzer GE, Bruce J, Kiefer DM, Kobusingye H, Drexler R, Besser RM, Confer DL, Horowitz MM, King RJ, Shaw BE, Riches M, Hayes-Lattin B, Linenberger M, Bolwell B, Rowley SD, **Litzow MR**, Pulsipher MA. Health-related quality of life among older related hematopoietic stem cell donors (>60 years) is equivalent to that of younger related donors (18 to 60 years): a related donor safety study *Biology of Blood and Marrow Transplantation*. 2017; 23: (1):165-71.
298. Switzer GE, Bruce J, Kiefer DM, Kobusingye H, Drexler R, Besser RM, Confer DL, Horowitz MM, King RJ, Shaw BE, Riches M, Hayes-Lattin B, Linenberger M, Bolwell B, Rowley SD, **Litzow MR**, Pulsipher MA. Health-Related Quality of Life among Older Related Hematopoietic Stem Cell Donors (>60 Years) Is Equivalent to That of Younger Related Donors (18 to 60 Years): A Related Donor Safety Study. *Biol Blood Marrow Transplant*. 2017 Jan; 23 (1):165-171 Epub 2016 Oct 14 PMID: 27751935 PMCID: 5182103 DOI: 10.1016/j.bbmt.2016.10.008
299. Mangaonkar A, Khateeb HA, Duma N, St Louis EK, McKeon A, Patnaik M, Hogan W, **Litzow M**, Kourelis T. Immune-Mediated Autonomic Neuropathies following Allogeneic Stem Cell Transplantation in Acute Myeloid

Leukemia. Case Rep Hematol. 2017; 2017:6803804 Epub 2017 Aug 27 PMID: 28928996 PMCID: 5591963 DOI: 10.1155/2017/6803804

300. Pophali P, **Litzow M**. What Is the Best Daunorubicin Dose and Schedule for Acute Myeloid Leukemia Induction? *Curr Treat Options Oncol*. 2017 Jan; 18 (1):3 PMID: 28154969 DOI: 10.1007/s11864-017-0446-4
301. Roberts KG, Gu Z, Payne-Turner D, McCastlain K, Harvey RC, Chen IM, Pei D, Iacobucci I, Valentine M, Pounds SB, Shi L, Li Y, Zhang J, Cheng C, Rambaldi A, Tosi M, Spinelli O, Radich JP, Minden MD, Rowe JM, Luger S, **Litzow MR**, Tallman MS, Wiernik PH, Bhatia R, Aldoss I, Kohlschmidt J, Mrozek K, Marcucci G, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Paietta E, Willman CL, Mullighan CG. High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. *J Clin Oncol*. 2017 Feb; 35 (4):394-401 Epub 2016 Nov 21 PMID: 27870571 PMCID: 5455698 DOI: 10.1200/JCO.2016.69.0073
302. Pine AB, Lee EJ, Sekeres M, Steensma DP, Zelterman D, Prebet T, DeZern A, Komrokji R, **Litzow M**, Luger S, Stone R, Erba HP, Garcia-Manero G, Lee AI, Podoltsev NA, Barbarotta L, Kasberg S, Hendrickson JE, Gore SD, Zeidan AM. Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States. *Transfusion*. 2017 Feb; 57 (2):289-295 Epub 2016 Nov 22 PMID: 27878822 PMCID: 5309168 DOI: 10.1111/trf.13934
303. Hartwell MJ, Ozbek U, Holler E, Renteria AS, Major-Monfried H, Reddy P, Aziz M, Hogan WJ, Ayuk F, Efebera YA, Hexner EO, Bunworasate U, Qayed M, Ordemann R, Wolfi M, Mielke S, Pawarode A, Chen YB, Devine S, Harris AC, Jagasia M, Kitko CL, **Litzow MR**, Kroger N, Locatelli F, Morales G, Nakamura R, Reshef R, Rosler W, Weber D, Wudhikarn K, Yanik GA, Levine JE, Ferrara JL. An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. *JCI Insight*. 2017 Feb 9; 2 (3):e89798 Epub 2017 Feb 09 PMID: 28194439 PMCID: 5291735 DOI: 10.1172/jci.insight.89798
304. Pratz KW, Rudek MA, Gojo I, **Litzow MR**, McDevitt MA, Ji J, Karnitz LM, Herman JG, Kinders RJ, Smith BD, Gore SD, Carraway HE, Showel MM, Gladstone DE, Levis MJ, Tsai HL, Rosner G, Chen A, Kaufmann SH, Karp JE. A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia. *Clin Cancer Res*. 2017 Feb 15; 23 (4):899-907 Epub 2016 Aug 22 PMID: 27551000 PMCID: 5315611 DOI: 10.1158/1078-0432.CCR-16-1274
305. Mantha S, Goldman DA, Devlin SM, Lee JW, Zannino D, Collins M, Douer D, Iland HJ, **Litzow MR**, Stein EM, Appelbaum FR, Larson RA, Stone R, Powell BL, Geyer S, Laumann K, Rowe JM, Erba H, Coutre S, Othus M, Park JH, Wiernik PH, Tallman MS. Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. *Blood*. 2017 Mar 30; 129 (13):1763-1767 Epub 2017 Jan 12 PMID: 28082441 PMCID: 5374291 DOI: 10.1182/blood-2016-10-747170
306. Saeed L, Patnaik MM, Begna KH, Al-Kali A, **Litzow MR**, Hanson CA, Ketterling RP, Porrata LF, Pardanani A, Gangat N, Tefferi A. Prognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patients. *Blood Cancer J*. 2017 Mar 31; 7 (3):e550 PMID: 28362440 PMCID: 5380913 DOI: 10.1038/bcj.2017.30
307. Sharma P, Shinde SS, Damlaj M, Hefazi Rorghabeh M, Hashmi SK, **Litzow MR**, Hogan WJ, Gangat N, Elliott MA, Al-Kali A, Tefferi A, Patnaik MM. Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes. *Leuk Lymphoma*. 2017 Apr; 58 (4):872-881 Epub 2016 Aug 11 PMID: 27687869 DOI: 10.1080/10428194.2016.1217529
308. Farhadfar N, Cerquozzi S, Hessenauer MR, **Litzow MR**, Hogan WJ, Letendre L, Patnaik MM, Tefferi A, Gangat N. Acute leukemia in pregnancy: a single institution experience with 23 patients. *Leuk Lymphoma*. 2017 May; 58 (5):1052-1060 Epub 2016 Aug 26 PMID: 27562538 DOI: 10.1080/10428194.2016.1222379
309. Liu HD, Ahn KW, Hu ZH, Hamadani M, Nishihori T, Wirk B, Beitinjaneh A, Rizzieri D, Grunwald MR, Sabloff M, Olsson RF, Bajel A, Bredeson C, Daly A, Inamoto Y, Majhail N, Saad A, Gupta V, Gerds A, Malone A, Tallman M, Reshef R, Marks DI, Copelan E, Gergis U, Savoie ML, Ustun C, **Litzow MR**, Cahn JY, Kindwall-Keller T, Akpek G, Savani BN, Aljurf M, Rowe JM, Wiernik PH, Hsu JW, Cortes J, Kalaycio M, Maziarz R, Sobecks R, Popat U, Alyea E, Saber W. Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. *Biol Blood Marrow Transplant*. 2017 May; 23 (5):767-775 Epub 2017 Jan 20 PMID: 28115276 PMCID: 5590102 DOI: 10.1016/j.bbmt.2017.01.078
310. Khoury HJ, Wang T, Hemmer MT, Couriel D, Alousi A, Cutler C, Aljurf M, Antin JH, Ayas M, Battiwalla M, Cahn JY, Cairo M, Chen YB, Gale RP, Hashmi S, Hayashi RJ, Jagasia M, Juckett M, Kamble RT, Kharfani-Dabaja M, **Litzow M**, Majhail N, Miller A, Nishihori T, Qayed M, Schoemans H, Schouten HC, Socie G, Storek J, Verdonck L, Vij R, Wood WA, Yu L, Martino R, Carabasi M, Dandoy C, Gergis U, Hematti P, Solh M, Jamani K, Lehmann L, Savani B, Schultz KR, Wirk BM, Spellman S, Arora M, Pidala J. Improved survival after acute graft-versus-host disease diagnosis in the modern era. *Haematologica*. 2017 May; 102 (5):958-966 Epub 2017 Mar 16 PMID: 28302712 PMCID: 5477615 DOI: 10.3324/haematol.2016.156356
311. Yan F, Shen N, Pang JX, Zhang YW, Rao EY, Bode AM, Al-Kali A, Zhang DE, **Litzow MR**, Li B, Liu SJ. Fatty acid-binding protein FABP4 mechanistically links obesity with aggressive AML by enhancing aberrant DNA

- methylation in AML cells. *Leukemia*. 2017 Jun; 31 (6):1434-1442 Epub 2016 Nov 25 PMID: 27885273 PMCID: 5457
312. Kansagra A, **Litzow M**. Treatment of Young Adults with Acute Lymphoblastic Leukemia. *Curr Hematol Malig Rep*. 2017 Jun; 12 (3):187-196 PMID: 28353017 DOI: 10.1007/s11899-017-0377-y
 313. Gurney M, Patnaik MM, Hanson CA, **Litzow MR**, Al-Kali A, Ketterling RP, Tefferi A, Gangat N. The 2016 revised World Health Organization definition of 'myelodysplastic syndrome with isolated del(5q)'; prognostic implications of single versus double cytogenetic abnormalities. *Br J Haematol*. 2017 Jul; 178 (1):57-60 Epub 2017 Apr 17 PMID: 28419466 DOI: 10.1111/bjh.14636
 314. Strickland SA, Sun Z, Ketterling RP, Cherry AM, Cripe LD, Dewald G, Fernandez HF, Hicks GA, Higgins RR, Lazarus HM, **Litzow MR**, Luger SM, Paietta EM, Rowe JM, Vance GH, Wiernik P, Wiktor AE, Zhang Y, Tallman MS, ECOG-ACRIN Cancer Research Group. Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials. *Leuk Res*. 2017 Aug; 59:55-64 Epub 2017 May 12 PMID: 28551161 PMCID: 5573653 DOI: 10.1016/j.leukres.2017.05.010
 315. Perl AE, Altman JK, Cortes J, Smith C, **Litzow M**, Baer MR, Claxton D, Erba HP, Gill S, Goldberg S, Jurcic JG, Larson RA, Liu C, Ritchie E, Schiller G, Spira AI, Strickland SA, Tibes R, Ustun C, Wang ES, Stuart R, Rollig C, Neubauer A, Martinelli G, Bahceci E, Levis M. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. *Lancet Oncol*. 2017 Aug; 18 (8):1061-1075 Epub 2017 June 20 PMID: 28645776 PMCID: 5572576 DOI: 10.1016/S1470-2045(17)30416-3
 316. Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, **Litzow MR**, Buckstein R, Fang M, Roulston D, Bloomfield CD, Moseley A, Nazha A, Zhang Y, Velasco MR, Gaur R, Atallah E, Attar EC, Cook EK, Cull AH, Rauh MJ, Appelbaum FR, Erba HP. Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. *J Clin Oncol*. 2017 Aug 20; 35 (24):2745-2753 Epub 2017 May 09 PMID: 28486043 PMCID: 5562170 DOI: 10.1200/JCO.2015.66.2510
 317. Goyal G, Bartley AC, Patnaik MM, **Litzow MR**, Al-Kali A, Go RS. Clinical features and outcomes of extramedullary myeloid sarcoma in the United States: analysis using a national data set. *Blood Cancer J* 2017 Aug 25; 7 (8):e592 PMID: 28841208 PMCID: 5596389 DOI: 10.1038/bcj.2017.79
 318. Goyal G, Shah MV, Call TG, **Litzow MR**, Hogan WJ, Go RS. Clinical and Radiologic Responses to Cladribine for the Treatment of Erdheim-Chester Disease. *JAMA Oncol*. 2017 Sep 1; 3 (9):1253-1256 PMID: 28253394 PMCID: 5824289 DOI: 10.1001/jamaoncol.2017.0041
 319. Moyer AM, Hashmi SK, Kroning CM, Kremers WK, De Goey SR, Patnaik M, **Litzow M**, Gastineau DA, Hogan WJ, Jacob EK, Kreuter JD, Wakefield LL, Gandhi MJ. Clinical outcomes of HLA-DPB1 mismatches in 10/10 HLA-matched unrelated donor-recipient pairs undergoing allogeneic stem cell transplant. *Eur J Haematol*. 2017 Sep; 99 (3):275-282 Epub 2017 July 21 PMID: 28632323 DOI: 10.1111/ejh.12916
 320. Dias A, Al-Kali A, Van Dyke D, Niederwieser D, Vucinic V, Lemke J, Muller C, Schwind S, Teichmann AC, Bakken R, Burns LJ, **Litzow M**. Inversion 3 Cytogenetic Abnormality in an Allogeneic Hematopoietic Cell Transplant Recipient Representative of a Donor-Derived Constitutional Abnormality. *Biol Blood Marrow Transplant*. 2017 Sep; 23 (9):1582-1587 Epub 2017 May 23 PMID: 28549770 DOI: 10.1016/j.bbmt.2017.05.019
 321. Brown PA, Shah B, Fathi A, Wieduwilt M, Advani A, Aoun P, Barta SK, Boyer MW, Bryan T, Burke PW, Cassaday R, Coccia PF, Coutre SE, Damon LE, DeAngelo DJ, Frankfurt O, Greer JP, Kantarjian HM, Klisovic RB, Kupfer G, **Litzow M**, Liu A, Mattison R, Park J, Rubnitz J, Saad A, Uy GL, Wang ES, Gregory KM, Ogba N. NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017. *J Natl Compr Canc Netw*. 2017 Sep; 15 (9):1091-1102 PMID: 28874594 DOI: 10.6004/jnccn.2017.0147
 322. Nanah R, McCullough K, Hogan W, Begna K, Patnaik M, Elliott M, **Litzow M**, Al-Kali A. Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: Single institution experience. *Am J Hematol*. 2017 Sep; 92 (9):866-871 Epub 2017 June 05 PMID: 28474744 DOI: 10.1002/ajh.24780
 323. Yalniz FF, Hefazi M, McCullough K, **Litzow MR**, Hogan WJ, Wolf R, Alkhateeb H, Kansagra A, Damlaj M, Patnaik MM. Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease. *Biol Blood Marrow Transplant*. 2017 Sep; 23 (9):1478-1484 Epub 2017 May 08 PMID: 28495641 DOI: 10.1016/j.bbmt.2017.05.001
 324. Haddox CL, Mangaonkar AA, Chen D, Shi M, He R, Oliveira JL, **Litzow MR**, Al-Kali A, Hogan WJ, Elliott MA. Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis. *Blood Cancer J* 2017 Sep 15; 7 (9):e607 Epub 2017 Sept 15 PMID: 29016570 PMCID: 5637108 DOI: 10.1038/bcj.2017.89
 325. Dispenzieri A, D'Souza A, Gertz MA, Laumann K, Wiseman G, Lacy MQ, LaPlant B, Buadi F, Hayman SR, Kumar SK, Dingli D, Hogan WJ, Ansell SM, Gastineau DA, Inwards DJ, Micallef IN, Porrata LF, Johnston PB,

- Litzow MR**, Witzig TE. A phase 1 trial of (90)Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma. *Bone Marrow Transplant*. 2017 Oct; 52 (10):1372-1377 Epub 2017 Sept 04 PMID: 28996647 DOI: 10.1093/bmt/oxz144
326. Chakraborty R, El-Jawahri AR, **Litzow MR**, Syrjala KL, Parnes AD, Hashmi SK. A systematic review of religious beliefs about major end-of-life issues in the five major world religions. *Palliat Support Care*. 2017 Oct; 15 (5):609-622 PMID: 28901283 PMCID: 5865598 DOI: 10.1017/S1478951516001061
 327. Webster JA, Tibes R, Morris L, Blackford AL, **Litzow M**, Patnaik M, Rosner GL, Gojo I, Kinders R, Wang L, Doyle LA, Huntoon CJ, Karnitz LM, Kaufmann SH, Karp JE, Smith BD. Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia. *Leuk Res*. 2017 Oct; 61:108-116 Epub 2017 Sept 20 PMID: 28957699 PMCID: 5639924 DOI: 10.1016/j.leukres.2017.09.005
 328. Shen N, Yan F, Pang J, Zhao N, Gangat N, Wu L, Bode AM, Al-Kali A, **Litzow MR**, Liu S. Inactivation of Receptor Tyrosine Kinases Reverts Aberrant DNA Methylation in Acute Myeloid Leukemia. *Clin Cancer Res*. 2017 Oct 15; 23 (20):6254-6266 Epub 2017 July 18 PMID: 28720666 PMCID: 5641248 DOI: 10.1158/1078-0432.CCR-17-0235
 329. Cummins NW, Rizza S, **Litzow MR**, Hua S, Lee GQ, Einkauf K, Chun TW, Rhame F, Baker JV, Busch MP, Chomont N, Dean PG, Fromentin R, Haase AT, Hampton D, Keating SM, Lada SM, Lee TH, Natesampillai S, Richman DD, Schacker TW, Wietgreffe S, Yu XG, Yao JD, Zeuli J, Lichterfeld M, Badley AD. Extensive virologic and immunologic characterization in an HIV-infected individual following allogeneic stem cell transplant and analytic cessation of antiretroviral therapy: A case study. *PLoS Med*. 2017 Nov; 14 (11):e1002461 Epub 2017 Nov 28 PMID: 29182633 PMCID: 5705162 DOI: 10.1371/journal.pmed.1002461
 330. Hefazi M, Patnaik MM, Hogan WJ, **Litzow MR**, Pardi DS, Khanna S. Safety and Efficacy of Fecal Microbiota Transplant for Recurrent *Clostridium difficile* Infection in Patients With Cancer Treated With Cytotoxic Chemotherapy: A Single-Institution Retrospective Case Series. *Mayo Clin Proc*. 2017 Nov; 92 (11):1617-1624 Epub 2017 Nov 01 PMID: 29101931 DOI: 10.1016/j.mayocp.2017.08.016
 331. Barreto JN, McCullough KB, Peskey CS, Dierkhising RA, Mara KC, Elliott MA, Gastineau DA, Al-Kali A, Gangat N, Letendre L, Hogan WJ, **Litzow MR**, Patnaik MM. Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy<sup/>. *Leuk Lymphoma*. 2017 Nov; 58 (11):2588-2597 Epub 2017 May 09 PMID: 28482728 PMCID: 5546319 DOI: 10.1080/10428194.2017.1312384
 332. Sterner RM, Kremer KN, Al-Kali A, Patnaik MM, Gangat N, **Litzow MR**, Kaufmann SH, Westendorf JJ, van Wijnen AJ, Hedin KE. Histone deacetylase inhibitors reduce differentiating osteoblast-mediated protection of acute myeloid leukemia cells from cytarabine. *Oncotarget*. 2017 Nov 7; 8 (55):94569-94579 Epub 2017 Oct 10 PMID: 29212250 PMCID: 5706896 DOI: 10.18632/oncotarget.21809
 333. Lehman JS, Hashmi SK, Lazarus HM, El-Azhary RA, Gibson LE, Hogan WJ, **Litzow MR**, Patnaik MS, Buadi F, Lacy MQ, Dasari S, Vanderboom P, Meves A. Immunophenotypic and molecular comparison between allogeneic and autologous graft-vs-host disease of the skin: A retrospective study using immunohistochemical and proteomics methods. *J Cutan Pathol*. 2017 Dec; 44 (12):1087-1091 Epub 2017 Sept 14 PMID: 28906023 PMCID: 5942197 DOI: 10.1111/cup.13019
 334. **Litzow MR**, Fielding AK, Luger SM, Paietta E, Ofran Y, Rowe JM, Goldstone AH, Tallman MS, Lazarus HM. The evolving role of chemotherapy and hematopoietic cell transplants in Ph-positive acute lymphoblastic leukemia in adults. *Bone Marrow Transplant*. 2017 Dec; 52 (12):1592-1598 Epub 2017 June 05 PMID: 28581459 DOI: 10.1038/bmt.2017.110
 335. Larsen CM, Villarraga HR, Begna KH, **Litzow MR**, Al-Kali A, Herrmann J. Cardiovascular effects of the addition of nilotinib to standard therapy for acute myeloid leukemia. *Leuk Lymphoma* 2018 Jan; 59 (1):229-232 Epub 2017 June 08 PMID: 28592197 DOI: 10.1080/10428194.2017.1323268
 336. Alkharabsheh O, Patnaik MM, Gangat N, Begna KH, Alkhateeb HB, Shah MV, Hogan WJ, He R, Greipp P, Nguyen PL, **Litzow MR**. Marrow Blast Percentage Impact on High-Grade Myelodysplastic Syndrome by the Revised International Prognostic Scoring System Blood. 2018; 132:5510.
 337. Hefazi M, **Litzow MR**. Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia. *Blood Lymphat Cancer*. 2018; 8:47-61 Epub 2018 Sept 25 PMID: 31360093 PMCID: 6467350 DOI: 10.2147/BLCTT.S170351
 338. Anagnostou T, **Litzow MR**. Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives. *Blood Lymphat Cancer*. 2018; 8:1-9 Epub 2017 Dec 22 PMID: 31360088 PMCID: 6467344 DOI: 10.2147/BLCTT.S130197
 339. Topp MS, Stelljes M, Zugmaier G, Barnette P, Heffner LT Jr, Trippett T, Duell J, Bargou RC, Holland C, Benjamin JE, Klinger M, **Litzow MR**. Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia. *Leukemia* 2018 Feb; 32 (2):562-565 Epub 2017 Oct 09 PMID: 28990581 PMCID: 5808068 DOI: 10.1038/leu.2017.306

340. Kansagra A, Dahiya S, **Litzow M**. Continuing challenges and current issues in acute lymphoblastic leukemia. *Leuk Lymphoma*. 2018 Mar; 59 (3):526-541 Epub 2017 June 11 PMID: 28604239 DOI: 10.1080/10428194.2017.1335397
341. Saadeh SS, **Litzow MR**. Hematopoietic stem cell transplant in adults with acute lymphoblastic leukemia: the present state. *Expert Rev Hematol*. 2018 Mar; 11 (3):195-207 Epub 2018 Feb 07 PMID: 29376437 DOI: 10.1080/17474086.2018.1433030
342. Tefferi A, Barraco D, Lasho TL, Shah S, Begna KH, Al-Kali A, Hogan WJ, **Litzow MR**, Hanson CA, Ketterling RP, Gangat N, Pardanani A. Momelotinib therapy for myelofibrosis: a 7-year follow-up. *Blood Cancer J*. 2018 Mar 7; 8 (3):29 Epub 2018 Mar 07 PMID: 29515114 PMCID: 5841331 DOI: 10.1038/s41408-018-0067-6
343. Yan F, Shen N, Pang JX, Zhao N, Zhang YW, Bode AM, Al-Kali A, **Litzow MR**, Li B, Liu SJ. A vicious loop of fatty acid-binding protein 4 and DNA methyltransferase 1 promotes acute myeloid leukemia and acts as a therapeutic target. *Leukemia*. 2018 Apr; 32 (4):865-873 Epub 2017 Oct 10 PMID: 28993705 PMCID: 5871544 DOI: 10.1038/leu.2017.307
344. Kebriaei P, Anasetti C, Zhang MJ, Wang HL, Aldoss I, de Lima M, Khoury HJ, Sandmaier BM, Horowitz MM, Artz A, Bejanyan N, Ciurea S, Lazarus HM, Gale RP, **Litzow M**, Bredeson C, Seftel MD, Pulsipher MA, Boelens JJ, Alvarnas J, Champlin R, Forman S, Pullarkat V, Weisdorf D, Marks DI, Acute Leukemia Committee of the CIBMTR. Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. *Biol Blood Marrow Transplant*. 2018 Apr; 24 (4):726-733 Epub 2017 Dec 25 PMID: 29197676 PMCID: 5902420 DOI: 10.1016/j.bbmt.2017.11.025
345. Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard JD, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Fathi AT, Roboz GJ, Fenaux P, **Litzow MR**, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua JM, Serrano J, Gore SD, Zeidan AM. Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. *Blood Adv*. 2018 Apr 24; 2 (8):923-932 PMID: 29685952 PMCID: 5916007 DOI: 10.1182/bloodadvances.2018016121
346. Tefferi A, Partain DK, Palmer JM, Slack JL, Roy V, Hogan WJ, **Litzow ML**, Ketterling RP, Patnaik MM. Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis. *Am J Hematol*. 2018 May; 93 (5):649-654 Epub 2018 Feb 24 PMID: 29388258 DOI: 10.1002/ajh.25053
347. Shen N, Yan F, Pang J, Gao Z, Al-Kali A, Haynes CL, **Litzow MR**, Liu S. HDL-AuNPs-BMS Nanoparticle Conjugates as Molecularly Targeted Therapy for Leukemia. *ACS Appl Mater Interfaces*. 2018 May 2; 10 (17):14454-14462 Epub 2018 Apr 18 PMID: 29668254 DOI: 10.1021/acsami.8b01696
348. Moyer AM, Hashmi SK, Kroning C, De Goey SR, Patnaik M, **Litzow M**, Gastineau DA, Hogan WJ, Jacob EK, Kreuter JD, Wakefield LL, Gandhi MJ. Does matching for SNPs in the MHC gamma block in 10/10 HLA-matched unrelated donor-recipient pairs undergoing allogeneic stem cell transplant improve outcomes? *Hum Immunol*. 2018 Jul; 79 (7):532-536 Epub 2018 Apr 13 PMID: 29660451 DOI: 10.1016/j.humimm.2018.04.008
349. Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Majhail N, Barnard J, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, **Litzow M**, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Kobbe G, Bergua J, Serrano J, Gore SD, Zeidan AM. Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study. *Biol Blood Marrow Transplant*. 2018 Aug; 24 (8):1754-1758 Epub 2018 Apr 09 PMID: 29649620 DOI: 10.1016/j.bbmt.2018.03.025
350. Mangaonkar AA, Gangat N, Al-Kali A, Elliott MA, Begna KH, Hanson CA, Ketterling RP, Wolanskyj-Spinner AP, Hogan WJ, **Litzow MR**, Patnaik MM. Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblasts. *Leuk Res*. 2018 Aug; 71:60-62 Epub 2018 July 11 PMID: 30015104 DOI: 10.1016/j.leukres.2018.07.010
351. Hefazi M, **Litzow MR**. Recent Advances in the Biology and Treatment of T Cell Acute Lymphoblastic Leukemia. *Curr Hematol Malig Rep*. 2018 Aug; 13 (4):265-274 PMID: 29948644 DOI: 10.1007/s11899-018-0455-9
352. Ganzel C, Sun Z, Cripe LD, Fernandez HF, Douer D, Rowe JM, Paietta EM, Ketterling R, O'Connell MJ, Wiernik PH, Bennett JM, **Litzow MR**, Luger SM, Lazarus HM, Tallman MS. Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience. *Am J Hematol*. 2018 Aug; 93 (8):1074-1081 PMID: 29905379 PMCID: 6699929 DOI: 10.1002/ajh.25162
353. Ustun C, Morgan E, Moodie EEM, Pullarkat S, Yeung C, Broesby-Olsen S, Ohgami R, Kim Y, Sperr W, Vestergaard H, Chen D, Kluin PM, Dolan M, Mrozek K, Czuchlewski D, Horny HP, George TI, Kristensen TK, Ku NK, Yi CA, Moller MB, Marcucci G, Baughn L, Schiefer AI, Hilberink JR, Pullarkat V, Shanley R, Kohlschmidt J, Coulombe J, Salhotra A, Soma L, Cho C, Linden MA, Akin C, Gotlib J, Hoermann G, Hornick J, Nakamura R, Deeg J, Bloomfield CD, Weisdorf D, **Litzow MR**, Valent P, Huls G, Perales MA, Borthakur G. Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit).

Cancer Med. 2018 Sep; 7 (9):4447-4455 Epub 2018 Aug 16 PMID: 30117318 PMCID: 6144246 DOI: 10.1002/cam4.1733

354. Hefazi M, Langer KJ, Khera N, Adamski J, Roy V, Winters JL, Gastineau DA, Jacob EK, Kreuter JD, Gandhi MJ, Hogan WJ, **Litzow MR**, Hashmi SK, Yadav H, Iyer VN, Scott JP, Wylam ME, Cartin-Ceba R, Patnaik MM. Extracorporeal Photopheresis Improves Survival in Hematopoietic Cell Transplant Patients with Bronchiolitis Obliterans Syndrome without Significantly Impacting Measured Pulmonary Functions. *Biol Blood Marrow Transplant*. 2018 Sep; 24 (9):1906-1913 Epub 2018 Apr 18 PMID: 29679771 DOI: 10.1016/j.bbmt.2018.04.012
355. Tefferi A, Gangat N, Mudireddy M, Lasho TL, Finke C, Begna KH, Elliott MA, Al-Kali A, **Litzow MR**, Hook CC, Wolanskyj AP, Hogan WJ, Patnaik MM, Pardanani A, Zblewski DL, He R, Viswanatha D, Hanson CA, Ketterling RP, Tang JL, Chou WC, Lin CC, Tsai CH, Tien HF, Hou HA. Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information. *Mayo Clin Proc*. 2018 Oct; 93 (10):1363-1374 Epub 2018 June 14 PMID: 29866419 DOI: 10.1016/j.mayocp.2018.04.013
356. Yan F, Al-Kali A, Zhang Z, Liu J, Pang J, Zhao N, He C, **Litzow MR**, Liu S. A dynamic N(6)-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitors. *Cell Res*. 2018 Nov; 28 (11):1062-1076 Epub 2018 Oct 08 PMID: 30297871 PMCID: 6218444 DOI: 10.1038/s41422-018-0097-4
357. Stahl M, Pine A, Hendrickson JE, **Litzow MR**, Luger SM, Stone RM, Erba HP, Kim TK, Sekeres MA, Steensma DP, Komrokji RS, Gore SD, Zeidan AM. Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey(.) *Leuk Lymphoma* 2018 Nov; 59 (11):2723-2726 Epub 2018 Apr 18 PMID: 29667455 DOI: 10.1080/10428194.2018.1452219
358. Al-Kali A, Abou Hussein AK, Patnaik M, Zblewski D, Gangat N, Hashmi S, Elliott M, Hogan W, **Litzow M**. Hypomethylating agents (HMAs) effect on myelodysplastic/myeloproliferative neoplasm unclassifiable (MDS/MPN-U): single institution experience. *Leuk Lymphoma* 2018 Nov; 59 (11):2737-2739 Epub 2018 Feb 21 PMID: 29465270 DOI: 10.1080/10428194.2018.1436705
359. Radivoyevitch T, Dean RM, Shaw BE, Brazauskas R, Tecca HR, Molenaar RJ, Battiwalla M, Savani BN, Flowers MED, Cooke KR, Hamilton BK, Kalaycio M, Maciejewski JP, Ahmed I, Akpek G, Bajel A, Buchbinder D, Cahn JY, D'Souza A, Daly A, DeFilipp Z, Ganguly S, Hamadani M, Hayashi RJ, Hematti P, Inamoto Y, Khera N, Kindwall-Keller T, Landau H, Lazarus H, Majhail NS, Marks DI, Olsson RF, Seo S, Steinberg A, William BM, Wirk B, Yared JA, Aljurf M, Abidi MH, Allewelt H, Beitinjaneh A, Cook R, Cornell RF, Fay JW, Hale G, Chakrabarty JH, Jodele S, Kasow KA, Mahindra A, Malone AK, Popat U, Rizzo JD, Schouten HC, Warwick AB, Wood WA, Sekeres MA, **Litzow MR**, Gale RP, Hashmi SK. Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. *Leuk Res*. 2018 Nov; 74:130-136 Epub 2018 July 19 PMID: 30055822 PMCID: 6219911 DOI: 10.1016/j.leukres.2018.07.016
360. Alkharabsheh O, Al-Kali A, Saadeh S, He R, Viswanatha D, Greipp P, Reichard K, Shah M, Gangat N, Patnaik M, Hogan W, **Litzow M**, Alkhateeb H, Nguyen PL. The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDS. *Am J Hematol* 2018 Nov; 93 (11):E355-E357 Epub 2018 Oct 02 PMID: 30074268 DOI: 10.1002/ajh.25239
361. Chhabra S, Ahn KW, Hu ZH, Jain S, Assal A, Cerny J, Copelan EA, Daly A, DeFilipp Z, Gadalla SM, Gale RP, Ganguly S, Hamilton BK, Hildebrandt GC, Hsu JW, Inamoto Y, Kanate AS, Khoury HJ, Lazarus HM, **Litzow MR**, Nathan S, Olsson RF, Pawarode A, Ringden O, Rowe JM, Saad A, Savani BN, Schouten HC, Seo S, Shah NN, Solh M, Stuart RK, Ustun C, Woolfrey AE, Yared JA, Alyea EP, Kalaycio ME, Popat U, Sobecks RM, Saber W. Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. *Blood Adv*. 2018 Nov 13; 2 (21):2922-2936 PMID: 30396912 PMCID: 6234373 DOI: 10.1182/bloodadvances.2018024844
362. Jain T, **Litzow MR**. No free rides: management of toxicities of novel immunotherapies in ALL, including financial. *Blood Adv*. 2018 Nov 27; 2 (22):3393-3403 PMID: 30482769 PMCID: 6258912 DOI: 10.1182/bloodadvances.2018020198
363. Jain T, **Litzow MR**. No free rides: management of toxicities of novel immunotherapies in ALL, including financial. *Hematology Am Soc Hematol Educ Program*. 2018 Nov 30; 2018 (1):25-34 PMID: 30504288 PMCID: 6246022 DOI: 10.1182/asheducation-2018.1.25
364. Begna KH, Ali W, Gangat N, Elliott MA, Al-Kali A, **Litzow MR**, Hook CC, Wolanskyj AP, Hogan WJ, Patnaik MM, Pardanani A, Zblewski DL, Chen D, He R, Viswanatha D, Hanson CA, Ketterling RP, Tefferi A. A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3-ITD mutational status. *Am J Hematol* 2018 Dec; 93 (12):E401-E404 Epub 2018 Oct 17 PMID: 30230610 DOI: 10.1002/ajh.25290
365. **Litzow MR**. Allogeneic transplantation for patients with Philadelphia chromosome positive acute lymphoblastic leukemia: Is it imperative in the tyrosine kinase inhibitor era? *Best Pract Res Clin Haematol*. 2018 Dec; 31 (4):357-360 Epub 2018 Sept 20 PMID: 30466747 DOI: 10.1016/j.beha.2018.09.004
366. Alkharabsheh O, Saadeh SS, Patnaik MS, Alkhateeb H, Gangat N, Begna KH, Hogan WJ, Greipp PT, He R,

- Nguyen PL, **Litzow MR**, Al-Kali A. Impact of clone size with a single cytogenetic abnormality on the revised International Prognostic Scoring System in myelodysplastic syndromes. *Am J Hematol* 2018 Dec; 93
367. Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Coutre S, Hurria A, Brown JR, Lozanski G, Blachly JS, Ozer HG, Major-Elechi B, Fruth B, Nattam S, Larson RA, Erba H, **Litzow M**, Owen C, Kuzma C, Abramson JS, Little RF, Smith SE, Stone RM, Mandrekar SJ, Byrd JC. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. *N Engl J Med*. 2018 Dec 27; 379 (26):2517-2528 Epub 2018 Dec 01 PMID: 30501481 PMCID: 6325637 DOI: 10.1056/NEJMoa1812836
368. **Litzow MR**, Wang XV, Carroll MP, Karp JE, Ketterling RP, Zhang Y, Kaufmann SH, Lazarus HM, Luger SM, Paietta EM, Pratz KW, Tun HW, Altman JK, Broun ER, Rybka WB, Rowe JM, Tallman MS. A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease. *Am J Hematol*. 2019 Jan; 94 (1):111-117 Epub 2018 Nov 15 PMID: 30370956 PMCID: 6298814 DOI: 10.1002/ajh.25333
369. Chhabra S, Liu Y, Hemmer MT, Costa L, Pidala JA, Couriel DR, Alousi AM, Majhail NS, Stuart RK, Kim D, Ringden O, Urbano-Ispizua A, Saad A, Savani BN, Cooper B, Marks DI, Socie G, Schouten HC, Schoemans H, Abdel-Azim H, Yared J, Cahn JY, Wagner J, Antin JH, Verdonck LF, Lehmann L, Aljurf MD, MacMillan ML, **Litzow MR**, Solh MM, Qayed M, Hematti P, Kamble RT, Vij R, Hayashi RJ, Gale RP, Martino R, Seo S, Hashmi SK, Nishihori T, Teshima T, Gergis U, Inamoto Y, Spellman SR, Arora M, Hamilton BK. Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. *Biol Blood Marrow Transplant*. 2019 Jan; 25 (1):73-85 Epub 2018 Aug 25 PMID: 30153491 PMCID: 6355336 DOI: 10.1016/j.bbmt.2018.08.018
370. Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard J, Podoltsev NA, Brunner A, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, **Litzow M**, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua J, Serrano J, Gore SD, Zeidan AM. Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. *Leuk Lymphoma* 2019 Jan; 60 (1):246-249 Epub 2018 July 02 PMID: 29963936 DOI: 10.1080/10428194.2018.1468893
371. Alkharabsheh OA, Saadeh SS, Zblewski DL, Gangat N, Begna KH, Elliott MA, Alkhateeb HB, Patnaik MS, Hogan WJ, **Litzow MR**, Al-Kali A. Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy. *Ann Hematol*. 2019 Feb; 98 (2):331-337 Epub 2018 Oct 18 PMID: 30334068 DOI: 10.1007/s00277-018-3509-0
372. Gu Z, Churchman ML, Roberts KG, Moore I, Zhou X, Nakitandwe J, Hagiwara K, Pelletier S, Gingras S, Berns H, Payne-Turner D, Hill A, Iacobucci I, Shi L, Pounds S, Cheng C, Pei D, Qu C, Newman S, Devidas M, Dai Y, Reshmi SC, Gastier-Foster J, Raetz EA, Borowitz MJ, Wood BL, Carroll WL, Zweidler-McKay PA, Rabin KR, Mattano LA, Maloney KW, Rambaldi A, Spinelli O, Radich JP, Minden MD, Rowe JM, Luger S, **Litzow MR**, Tallman MS, Racevskis J, Zhang Y, Bhatia R, Kohlschmidt J, Mrozek K, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Evans WE, Jeha S, Pui CH, Yang J, Paietta E, Downing JR, Relling MV, Zhang J, Loh ML, Hunger SP, Mullighan CG. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. *Nat Genet*. 2019 Feb; 51 (2):296-307 Epub 2019 Jan 14 PMID: 30643249 PMCID: 6525306 DOI: 10.1038/s41588-018-0315-5
373. Alousi A, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Pidala J, Anderlini P, Boyiadzis M, Bredeson CN, Cahn JY, Cairo MS, Gadalla SM, Hashmi SK, Gale RP, Kanda J, Kamble RT, Kharfan-Dabaja MA, **Litzow MR**, Ringden O, Saad AA, Schultz KR, Verdonck LF, Waller EK, Yared JA, Holtan SG, Weisdorf DJ. Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival. *Biol Blood Marrow Transplant*. 2019 Feb; 25 (2):270-278 Epub 2018 Oct 03 PMID: 30292009 PMCID: 6339839 DOI: 10.1016/j.bbmt.2018.09.004
374. Wendorff AA, Quinn SA, Rashkovan M, Madubata CJ, Ambesi-Impiombato A, **Litzow MR**, Tallman MS, Paietta E, Paganin M, Basso G, Gastier-Foster JM, Loh ML, Rabadan R, Van Vlierberghe P, Ferrando AA. Phf6 Loss Enhances HSC Self-Renewal Driving Tumor Initiation and Leukemia Stem Cell Activity in T-ALL. *Cancer Discov*. 2019 Mar; 9 (3):436-451 Epub 2018 Dec 19 PMID: 30567843 PMCID: 6425751 DOI: 10.1158/2159-8290.CD-18-1005
375. Medeiros BC, Othus M, Tallman MS, Sun Z, Fernandez HF, Rowe JM, Lazarus HM, Appelbaum FR, Luger SM, **Litzow MR**, Erba HP. The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900). *Leuk Res*. 2019 Mar; 78:29-33 Epub 2019 Jan 17 PMID: 30673620 PMCID: 6615032 DOI: 10.1016/j.leukres.2019.01.007
376. Chen YB, Le-Rademacher J, Brazauskas R, Kiefer DM, Hamadani M, DiPersio JF, **Litzow MR**, Craig M, Horwitz ME, Artz AS, McClune BL, Fernandez HF, Duong HK, Kobusingye H, Proue M, Drexler RJ, Horowitz

- MM, Shaw BE, Miller JP, Hosoba S, Waller EK, Devine SM. Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells. *Blood Adv*. 2019 Mar 26; 3 (6):875-882 PMID: 30660544 PMCID: 6436647 DOI: 10.1182/bloodadvances.2018037500
377. Pulsipher MA, Logan BR, Chitphakdithai P, Kiefer DM, Riches ML, Rizzo JD, Anderlini P, Leitman SF, Varni JW, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Akard LP, Artz AS, Ball ED, Bayer RL, Bigelow C, Bolwell BJ, Broun ER, Bunin NJ, Delgado DC, Duckworth K, Dvorak CC, Hahn TE, Haight AE, Hari PN, Hayes-Lattin BM, Jacobsohn DA, Jakubowski AA, Kasow KA, Lazarus HM, Liesveld JL, Linenberger M, **Litzow MR**, Longo W, Magalhaes-Silverman M, McCarty JM, McGuirk JP, Mori S, Prasad VK, Rowley SD, Rybka WB, Sahdev I, Schriber JR, Selby GB, Shaughnessy PJ, Shenoy S, Spitzer T, Tse WT, Uberti JP, Vusirikala M, Waller EK, Weisdorf DJ, Yanik GA, Navarro WH, Horowitz MM, Switzer GE, Shaw BE, Confer DL. Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study. *Biol Blood Marrow Transplant*. 2019 Apr; 25 (4):699-711 Epub 2018 Nov 10 PMID: 30423480 PMCID: 6453753 DOI: 10.1016/j.bbmt.2018.11.004
378. Miller KC, Al-Kali A, Shah MV, Hogan WJ, Elliott MA, Begna KH, Gangat N, Patnaik MM, Viswanatha DS, He R, Greipp PT, Sproat LZ, Foran JM, **Litzow MR**, Alkhateeb HB. Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients. *Leuk Lymphoma*. 2019 Apr; 60 (4):990-999 Epub 2018 Oct 02 PMID: 30277111 DOI: 10.1080/10428194.2018.1509318
379. Fernandez HF, Sun Z, **Litzow MR**, Luger SM, Paietta E, Racevskis J, Levine RL, Patel JP, Abdel-Wahab O, Ketterling RP, Dewald GW, Bennett JM, Rowe JM, Lazarus HM, Tallman MS. Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900. *Haematologica* 2019 Apr; 104 (4):e147-e150 Epub 2018 Nov 22 PMID: 30467203 PMCID: 6442974 DOI: 10.3324/haematol.2018.197277
380. Pulsipher MA, Logan BR, Kiefer DM, Chitphakdithai P, Riches ML, Rizzo JD, Anderlini P, Leitman OF, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Akard LP, Artz AS, Ball ED, Bayer RL, Bigelow C, Bolwell BJ, Broun ER, Delgado DC, Duckworth K, Dvorak CC, Hahn TE, Haight AE, Hari PN, Hayes-Lattin BM, Jacobsohn DA, Jakubowski AA, Kasow KA, Lazarus HM, Liesveld JL, Linenberger M, **Litzow MR**, Longo W, Magalhaes-Silverman M, McCarty JM, McGuirk JP, Mori S, Parameswaran V, Prasad VK, Rowley SD, Rybka WB, Sahdev I, Schriber JR, Selby GB, Shaughnessy PJ, Shenoy S, Spitzer T, Tse WT, Uberti JP, Vusirikala M, Waller EK, Weisdorf DJ, Yanik GA, Navarro WH, Horowitz MM, Switzer GE, Confer DL, Shaw BE. Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors. *Haematologica*. 2019 Apr; 104 (4):844-854 Epub 2018 Oct 31 PMID: 30381298 PMCID: 6442962 DOI: 10.3324/haematol.2018.200121
381. Stock W, Luger SM, Advani AS, Yin J, Harvey RC, Mullighan CG, Willman CL, Fulton N, Laumann KM, Malnassy G, Paietta E, Parker E, Geyer S, Mrozek K, Bloomfield CD, Sanford B, Marcucci G, Liedtke M, Claxton DF, Foster MC, Bogart JA, Grecula JC, Appelbaum FR, Erba H, **Litzow MR**, Tallman MS, Stone RM, Larson RA. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. *Blood*. 2019 Apr 4; 133 (14):1548-1559 Epub 2019 Jan 18 PMID: 30658992 PMCID: 6450431 DOI: 10.1182/blood-2018-10-881961
382. Brown PA, Wieduwilt M, Logan A, DeAngelo DJ, Wang ES, Fathi A, Cassaday RD, **Litzow M**, Advani A, Aoun P, Bhatnagar B, Boyer MW, Bryan T, Burke PW, Coccia PF, Coutre SE, Jain N, Kirby S, Liu A, Massaro S, Mattison RJ, Oluwole O, Papadantonakis N, Park J, Rubnitz JE, Uy GL, Gregory KM, Ogba N, Shah B. Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019. *J Natl Compr Canc Netw*. 2019 May 1; 17 (5):414-423 PMID: 31085755 DOI: 10.6004/jnccn.2019.0024
383. Lehman JS, Dasari S, Damodaran SS, El-Azhary RA, Gibson LE, Hashmi SK, Hogan WJ, Kenderian SJ, Patnaik MS, **Litzow MR**, Lazarus HM, Meves A. Differential expression of interferon-induced genes and other tissue-based biomarkers in acute graft-versus-host disease vs. lupus erythematosus in skin. *Clin Exp Dermatol*. 2019 Jun; 44 (4):e81-e88 Epub 2018 Oct 02 PMID: 30280423 PMCID: 6445793 DOI: 10.1111/ced.13759
384. Higgins A, Khan Z, Coddington CC, Hashmi SK, Hefazi M, Alkhateeb H, **Litzow MR**, Hogan WJ, Cathcart-Rake E, Thompson CA, Patnaik MM. Utilization and Outcomes of Fertility Preservation Techniques in Women Undergoing Allogeneic Hematopoietic Cell Transplant. *Biol Blood Marrow Transplant*. 2019 Jun; 25 (6):1232-1239 Epub 2019 Feb 15 PMID: 30772513 PMCID: 6559870 DOI: 10.1016/j.bbmt.2019.02.013
385. Rashidi A, Hamadani M, Zhang MJ, Wang HL, Abdel-Azim H, Aljurf M, Assal A, Bajel A, Bashey A, Battiwalla M, Beitinjaneh AM, Bejanyan N, Bhatt VR, Bolanos-Meade J, Byrne M, Cahn JY, Cairo M, Ciurea S, Copelan E, Cutler C, Daly A, Diaz MA, Farhadfar N, Gale RP, Ganguly S, Grunwald MR, Hahn T, Hashmi S, Hildebrandt GC, Holland HK, Hossain N, Kanakry CG, Kharfan-Dabaja MA, Khera N, Koc Y, Lazarus HM, Lee JW, Maertens J, Martino R, McGuirk J, Munker R, Murthy HS, Nakamura R, Nathan S, Nishihori T, Palmisiano N, Patel S, Pidala J, Olin R, Olsson RF, Oran B, Ringden O, Rizzieri D, Rowe J, Savoie ML, Schultz KR, Seo S, Shaffer BC, Singh A, Solh M, Stockerl-Goldstein K, Verdonck LF, Wagner J, Waller EK, De Lima M, Sandmaier BM, **Litzow M**, Weisdorf D, Romee R, Saber W. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. *Blood Adv*. 2019 Jun 25; 3 (12):1826-1836 PMID: 31201170 PMCID: 6595262 DOI: 10.1182/bloodadvances.2019000050

386. Coston T, Pophali P, Vallapureddy R, Lasho TL, Finke CM, Ketterling RP, Carr R, Binder M, Mangaonkar AA, Gangat N, Al-Kali A, **Litzow M**, Zblewski D, Pardanani A, Tefferi A, Patnaik MM. Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. *Am J Hematol*. 2019 Jul; 94 (7):767-779 Epub 2019 May 03 PMID: 30964202 DOI: 10.1002/ajh.25488
387. Stein AS, Kantarjian H, Gokbuget N, Bargou R, **Litzow MR**, Rambaldi A, Ribera JM, Zhang A, Zimmerman Z, Zugmaier G, Topp MS. Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. *Biol Blood Marrow Transplant*. 2019 Aug; 25 (8):1498-1504 Epub 2019 Apr 17 PMID: 31002989 DOI: 10.1016/j.bbmt.2019.04.010
388. Hsieh RW, Ravindran A, Hook CC, Begna KH, Ashrani AA, Pruthi RK, Marshall AL, Hogan W, **Litzow M**, Hoyer J, Oliveira JL, Vishnu P, Call TG, Al-Kali A, Patnaik M, Gangat N, Pardanani A, Tefferi A, Go RS. Etiologies of Extreme Thrombocytosis: A Contemporary Series. *Mayo Clin Proc*. 2019 Aug; 94 (8):1542-1550 PMID: 31378229 DOI: 10.1016/j.mayocp.2019.01.041
389. Shanafelt TD, Wang XV, Kay NE, Hanson CA, O'Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba H, Stone RM, **Litzow M**, Tallman M. Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. *N Engl J Med*. 2019 Aug 1; 381 (5):432-443 PMID: 31365801 PMCID: 6908306 DOI: 10.1056/NEJMoa1817073
390. Al-Kali A, Zblewski D, Foran JM, Patnaik MS, Larrabee BR, Gangat N, Begna KH, Elliott MA, Hogan WJ, Tefferi A, **Litzow MR**, Go RS. Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013. *Mayo Clin Proc*. 2019 Aug; 94 (8):1467-1474 PMID: 31378228 DOI: 10.1016/j.mayocp.2019.02.029
391. Arslan S, **Litzow MR**, Cummins NW, Rizza SA, Badley AD, Navarro W, Hashmi SK. Risks and Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies in Patients with HIV Infection. *Biol Blood Marrow Transplant*. 2019 Aug; 25 (8):e260-e267 Epub 2019 Mar 26 PMID: 30926447 PMCID: 7144878 DOI: 10.1016/j.bbmt.2019.03.021
392. Mangaonkar AA, Ferrer A, Pinto E Vairo F, Cousin MA, Kuisle RJ, Gangat N, Hogan WJ, **Litzow MR**, McAllister TM, Klee EW, Lazaridis KN, Stewart AK, Patnaik MM. Clinical Applications and Utility of a Precision Medicine Approach for Patients With Unexplained Cytopenias. *Mayo Clin Proc*. 2019 Sep; 94 (9):1753-1768 Epub 2019 June 27 PMID: 31256854 PMCID: 6728219 DOI: 10.1016/j.mayocp.2019.04.007
393. Torres ME, Hashmi SK, Stevens MA, Tan AD, Callahan V, Sloan JA, Hogan WJ, **Litzow MR**, Roy V, Foran JM, Colon-Otero G. Impact of hospital hospitality house programs on quality of life and mood of patients and caregivers after hematopoietic stem cell transplant. *Hematol Oncol Stem Cell Ther*. 2019 Sep; 12 (3):155-160 Epub 2018 Dec 09 PMID: 30550729 DOI: 10.1016/j.hemonc.2018.11.004
394. Baidoun F, Chen D, Patnaik M, Gangat N, Begna K, Elliott M, Hogan W, **Litzow M**, Al-Kali A. Clinical outcome of patients diagnosed with myelodysplastic syndrome-unclassifiable (MDS-U): single center experience. *Leuk Lymphoma*. 2019 Oct; 60 (10):2483-2487 Epub 2019 Mar 07 PMID: 31609151 DOI: 10.1080/10428194.2019.1581930
395. Gokbuget N, Kantarjian HM, Bruggemann M, Stein AS, Bargou RC, Dombret H, Fielding AK, Heffner L, Rigal-Huguet F, **Litzow M**, O'Brien S, Zugmaier G, Gao S, Nagorsen D, Forman SJ, Topp MS. Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia. *Blood Adv*. 2019 Oct 22; 3 (20):3033-3037 PMID: 31648325 PMCID: 6849936 DOI: 10.1182/bloodadvances.2019000457
396. Ustun C, Le-Rademacher J, Wang HL, Othus M, Sun Z, Major B, Zhang MJ, Storrack E, Lafky JM, Chow S, Mrozek K, Attar EC, Nand S, Bloomfield CD, Cripe LD, Tallman MS, Appelbaum F, Larson RA, Marcucci G, Roboz GJ, Uy GL, Stone RM, Jatoi A, Shea TC, de Lima M, Foran JM, Sandmaier BM, **Litzow MR**, Erba HP, Hurria A, Weisdorf DJ, Artz AS. Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. *Leukemia*. 2019 Nov; 33 (11):2599-2609 Epub 2019 May 09 PMID: 31073153 PMCID: 6842042 DOI: 10.1038/s41375-019-0477-x
397. Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill JA, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, **Litzow MR**, Mohty M, Hashmi SK. Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). *Bone Marrow Transplant*. 2019 Nov; 54 (11):1868-1880 Epub 2019 May 15 PMID: 31092900 PMCID: 8268756 DOI: 10.1038/s41409-019-0451-2
398. Cascino GJ, Voss WB, Canaani J, Furiasse N, Rademaker A, Ky B, Luger S, Altman JK, Foran JM, **Litzow MR**, Tallman MS, Rigolin V, Akhter N. Two-dimensional speckle-tracking strain detects subclinical cardiotoxicity in older patients treated for acute myeloid leukemia. *Echocardiography*. 2019 Nov; 36 (11):2033-2040 Epub 2019 Nov 08 PMID: 31705570 PMCID: 6874906 DOI: 10.1111/echo.14518

399. Dou L, Yan F, Pang J, Zheng D, Li D, Gao L, Wang L, Xu Y, Shi J, Wang Q, Zhou L, Shen N, Singh P, Wang L, Li Y, Gao Y, Liu T, Chen C, Al-Kali A, **Litzow MR**, Chi YI, Bode AM, Liu C, Huang H, Liu D, Marcucci G, Liu S, Yu L. Protein lysine 43 methylation by EZH1 promotes AML1-ETO transcriptional repression in leukemia. *Nat Commun*. 2019 Nov 7; 10 (1):5051 Epub 2019 Nov 07 PMID: 31699991 PMCID: 6838331 DOI: 10.1038/s41467-019-12960-6
400. Nieborowska-Skorska M, Paietta EM, Levine RL, Fernandez HF, Tallman MS, **Litzow MR**, Skorski T. Inhibition of the mutated c-KIT kinase in AML1-ETO-positive leukemia cells restores sensitivity to PARP inhibitor. *Blood Adv*. 2019 Dec 10; 3 (23):4050-4054 PMID: 31816060 PMCID: 6963253 DOI: 10.1182/bloodadvances.2019000756
401. Jain T, **Litzow MR**. Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia. *Ther Adv Hematol*. 2020; 11:2040620719899897 Epub 2020 Jan 20 PMID: 32010436 PMCID: 6971963 DOI: 10.1177/2040620719899897
402. Anagnostou T, Knudson RA, Pearce KE, Meyer RG, Pitel BA, Peterson JF, Baughn LB, Reichard KK, Ketterling RP, Kloft-Nelson SM, Knutson DL, Khan SP, Gangat N, **Litzow MR**, Hogan WJ, Wolanskyj A, Al-Kali A, Begna KH, Elliott M, Pardanani A, Foran J, Shah M, Tefferi A, Alkhateeb H, Halling K, Rodriguez V, Greipp PT, Patnaik MM. Clinical utility of fluorescence in situ hybridization-based diagnosis of BCR-ABL1 like (Philadelphia chromosome like) B-acute lymphoblastic leukemia. *Am J Hematol* 2020 Mar; 95 (3):E68-E72 Epub 2020 Jan 26 PMID: 31919873 DOI: 10.1002/ajh.25729
403. Alkharabsheh O, Patnaik MM, Gangat N, Begna KH, Alkhateeb HB, Shah MV, Hogan WJ, He R, Greipp P, Nguyen PL, **Litzow MR**, Al-Kali A. Impact of marrow blasts percentage on high-grade myelodysplastic syndrome assessed using revised international prognostic scoring system. *Ann Hematol*. 2020 Mar; 99 (3):513-518 Epub 2020 Jan 23 PMID: 31974678 DOI: 10.1007/s00277-020-03917-7
404. Autry RJ, Paugh SW, Carter R, Shi L, Liu J, Ferguson DC, Lau CE, Bonten EJ, Yang W, McCorkle JR, Beard JA, Panetta JC, Diedrich JD, Crews KR, Pei D, Coke CJ, Natarajan S, Khatamian A, Karol SE, Lopez-Lopez E, Diouf B, Smith C, Gocho Y, Hagiwara K, Roberts KG, Pounds S, Kornblau SM, Stock W, Paietta EM, **Litzow MR**, Inaba H, Mullighan CG, Jeha S, Pui CH, Cheng C, Savic D, Yu J, Gawad C, Relling MV, Yang JJ, Evans WE. Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia. *Nat Cancer*. 2020 Mar; 1 (3):329-344 Epub 2020 Mar 09 PMID: 32885175 PMCID: 7467080 DOI: 10.1038/s43018-020-0037-3
405. DeFilipp Z, Ancheta R, Liu Y, Hu ZH, Gale RP, Snyder D, Schouten HC, Kalaycio M, Hildebrandt GC, Ustun C, Daly A, Ganguly S, Inamoto Y, **Litzow M**, Szer J, Savoie ML, Hossain N, Kharfan-Dabaja MA, Hamadani M, Reshef R, Bajel A, Schultz KR, Gadalla S, Gerds A, Liesveld J, Juckett MB, Kamble R, Hashmi S, Abdel-Azim H, Solh M, Bacher U, Lazarus H, Olsson R, Cahn JY, Grunwald MR, Savani BN, Yared J, Rowe JM, Cerny J, Chaudhri NA, Aljurf M, Beitinjaneh A, Seo S, Nishihori T, Hsu JW, Ramanathan M, Alyea E, Papat U, Sobecks R, Saber W. Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. *Biol Blood Marrow Transplant*. 2020 Mar; 26 (3):472-479 Epub 2019 Oct 25 PMID: 31669399 PMCID: 7358778 DOI: 10.1016/j.bbmt.2019.10.017
406. Lee CJ, Kim S, Tecca HR, Bo-Subait S, Phelan R, Brazauskas R, Buchbinder D, Hamilton BK, Battiwalla M, Majhail NS, Lazarus HM, Shaw PJ, Marks DI, **Litzow MR**, Chhabra S, Inamoto Y, DeFilipp Z, Hildebrandt GC, Olsson RF, Kasow KA, Liesveld JL, Rotz SJ, Badawy SM, Bhatt NS, Yared JA, Page KM, Arellano ML, Kent M, Farhadfar N, Seo S, Hematti P, Freytes CO, Rovo A, Ganguly S, Nathan S, Burns L, Shaw BE, Muffly LS. Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. *Blood Adv*. 2020 Mar 24; 4 (6):983-992 PMID: 32168378 PMCID: 7094022 DOI: 10.1182/bloodadvances.2019001126
407. Lancet JE, Moseley AB, Coutre SE, DeAngelo DJ, Othus M, Tallman MS, **Litzow MR**, Komrokji RS, Erba HP, Appelbaum FR. A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535). *Blood Adv*. 2020 Apr 28; 4 (8):1683-1689 PMID: 32330241 PMCID: 7189292 DOI: 10.1182/bloodadvances.2019001278
408. Lazaryan A, Dolan M, Zhang MJ, Wang HL, Kharfan-Dabaja MA, Marks DI, Bejanyan N, Copelan E, Majhail NS, Waller EK, Chao N, Prestidge T, Nishihori T, Kebriaei P, Inamoto Y, Hamilton B, Hashmi SK, Kamble RT, Bacher U, Hildebrandt GC, Stiff PJ, McGuirk J, Aldoss I, Beitinjaneh AM, Muffly L, Vij R, Olsson RF, Byrne M, Schultz KR, Aljurf M, Seftel M, Savoie ML, Savani BN, Verdonck LF, Cairo MS, Hossain N, Bhatt VR, Frangoul HA, Abdel-Azim H, Malki MA, Munker R, Rizzieri D, Khera N, Nakamura R, Ringden O, van der Poel M, Murthy HS, Liu H, Mori S, De Oliveira S, Bolanos-Meade J, Elsayy M, Barba P, Nathan S, George B, Pawarode A, Grunwald M, Agrawal V, Wang Y, Assal A, Caro PC, Kuwatsuka Y, Seo S, Ustun C, Politikos I, Lazarus HM, Saber W, Sandmaier BM, De Lima M, **Litzow M**, Bachanova V, Weisdorf D, Acute Leukemia Committee of the CIBMTR. Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research.

Haematologica. 2020 May; 105 (5):1329-1338 Epub 2019 Sept 26 PMID: 31558669 PMCID: 7193485 DOI:

409. Gowin K, Ballen K, Ahn KW, Hu ZH, Ali H, Arcasoy MO, Devlin R, Coakley M, Gerds AT, Green M, Gupta V, Hobbs G, Jain T, Kandarpa M, Komrokji R, Kuykendall AT, Luber K, Masarova L, Michaelis LC, Patches S, Pariser AC, Rampal R, Stein B, Talpaz M, Verstovsek S, Wadleigh M, Agrawal V, Aljurf M, Angel Diaz M, Avalos BR, Bacher U, Bashey A, Beitinjaneh AM, Cerny J, Chhabra S, Copelan E, Cutler CS, DeFilipp Z, Gadalla SM, Ganguly S, Grunwald MR, Hashmi SK, Kharfan-Dabaja MA, Kindwall-Keller T, Kroger N, Lazarus HM, Liesveld JL, **Litzow MR**, Marks DI, Nathan S, Nishihori T, Olsson RF, Pawarode A, Rowe JM, Savani BN, Savoie ML, Seo S, Solh M, Tamari R, Verdonck LF, Yared JA, Alyea E, Popat U, Sobecks R, Scott BL, Nakamura R, Mesa R, Saber W. Survival following allogeneic transplant in patients with myelofibrosis. *Blood Adv*. 2020 May 12; 4 (9):1965-1973 PMID: 32384540 PMCID: 7218417 DOI: 10.1182/bloodadvances.2019001084
410. Badar T, Szabo A, Advani A, Wadleigh M, Arslan S, Khan MA, Aldoss I, Siebenaller C, Schultz E, Hefazi M, Shallis RM, Yurkiewicz I, Podoltsev N, Patel AA, Curran E, Balasubramanian S, Yang J, Mattison RJ, Burkart M, Dinner S, Liedtke M, **Litzow MR**, Atallah E. Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. *Blood Adv*. 2020 May 26; 4 (10):2308-2316 PMID: 32453836 PMCID: 7252553 DOI: 10.1182/bloodadvances.2019001381
411. Epperla N#, Li A#, Logan B, Fretham C, Chhabra S, Aljurf M, Chee L, Copelan E, Freytes CO, Hematti P, Lazarus HM, **Litzow M**, Nishihori T, Olsson RF, Prestidge T, Saber W, Wirk B, Yared JA, Loren A, Pasquini M. Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic Microangiopathy. *Br J Haematol*. 2020 Jun; 189 (6):1171-1181 Epub 2020 Mar 02 PMID: 32124435 PMCID: 7726817 DOI: 10.1111/bjh.16457
412. Pagel JM, Othus M, Garcia-Manero G, Fang M, Radich JP, Rizzieri DA, Marcucci G, Strickland SA, **Litzow MR**, Savoie ML, Spellman SR, Confer DL, Chell JW, Brown M, Medeiros BC, Sekeres MA, Lin TL, Uy GL, Powell BL, Bayer RL, Larson RA, Stone RM, Claxton D, Essell J, Luger SM, Mohan SR, Moseley A, Erba HP, Appelbaum FR. Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia. *JCO Oncol Pract*. 2020 Jun; 16 (6):e464-e475 Epub 2020 Jan 27 PMID: 32048933 PMCID: 7291544 DOI: 10.1200/JOP.19.00133
413. Scott JF, Brough KR, Grigoryan KV, Muzic JG, Kim GY, Conic RRZ, Hill ST, Brewer JD, Baum CL, **Litzow MR**, Hogan WJ, Patnaik MS, Hashmi SK, Lazarus HM, Bordeaux JS, Thompson CL, Gerstenblith MR, Lehman JS. Risk Factors for Keratinocyte Carcinoma in Recipients of Allogeneic Hematopoietic Cell Transplants. *JAMA Dermatol*. 2020 Jun 1; 156 (6):631-639 PMID: 32267479 PMCID: 7142796 DOI: 10.1001/jamadermatol.2020.0559
414. Pine AB, Chokr N, Stahl M, Steensma DP, Sekeres MA, **Litzow MR**, Luger SM, Stone RM, Greenberg PL, Bejar R, Bewersdorf JP, Gore SD, Zeidan AM. Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey. *Leuk Lymphoma*. 2020 Jun; 61 (6):1455-1464 Epub 2020 Feb 06 PMID: 32026740 DOI: 10.1080/10428194.2020.1723013
415. Joshi M, Greipp P, Ball C, Vinod Shah M, Khurana A, Yogarajah M, Nguyen P, He R, Viswanatha D, Jevremovic D, Salama M, Alkhateeb HB, Gangat N, Patnaik M, Begna K, Hogan W, Zblewski D, **Litzow M**, Al-Kali A. Characteristics of patients with myelodysplastic syndrome with balanced translocations. *Br J Haematol*. 2020 Jul; 190 (2):244-248 Epub 2020 Mar 17 PMID: 32181489 DOI: 10.1111/bjh.16551
416. Bubik RJ, Barth DM, Hook C, Wolf RC, Muth JM, Mara K, Patnaik MS, Pruthi RK, Marshall AL, **Litzow MR**, Elliott MA, Hogan WJ, Shah MV, Begna KH, Alkhateeb H, Pardanani A, Ashrani AA, Call TG, Rivera CE, Camoriano JK, Go RS, Wolanskyj-Spinner AP, Parikh SA. Clinical outcomes of adults with hemophagocytic lymphohistiocytosis treated with the HLH-04 protocol: a retrospective analysis. *Leuk Lymphoma*. 2020 Jul; 61 (7):1592-1600 Epub 2020 Mar 11 PMID: 32157935 DOI: 10.1080/10428194.2020.1737684
417. Heybeli C, Sridharan M, Alkhateeb HB, Villasboas Bisneto JC, Buadi FK, Chen D, Dingli D, Dispenzieri A, Gertz MA, Go RS, Hashmi SK, Hayman SR, Hogan WJ, Inwards DJ, Kenderian SS, Kumar SK, **Litzow MR**, Porrata LF, Lacy MQ, Micallef IN, Patnaik MM, Shah MV, Leung N. Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. *Am J Hematol*. 2020 Jul 2 Epub 2020 July 02 PMID: 32618000 DOI: 10.1002/ajh.25922
418. Zhou Z, Nath R, Cerny J, Wang HL, Zhang MJ, Abdel-Azim H, Agrawal V, Ahmed G, Al-Homsi AS, Aljurf M, Alkhateeb HB, Assal A, Bacher U, Bajel A, Bashir Q, Battiwalla M, Bhatt VR, Byrne M, Cahn JY, Cairo M, Choe H, Copelan E, Cutler C, Damlaj MB, DeFilipp Z, De Lima M, Diaz MA, Farhadfar N, Foran J, Freytes CO, Gerds AT, Gergis U, Grunwald MR, Gul Z, Hamadani M, Hashmi S, Hertzberg M, Hildebrandt GC, Hossain N, Inamoto Y, Isola L, Jain T, Kamble RT, Khan MW, Kharfan-Dabaja MA, Kebriaei P, Kekre N, Khera N, Lazarus HM, Liesveld JL, **Litzow M**, Liu H, Marks DI, Martino R, Mathews V, Mishra A, Murthy HS, Nagler A, Nakamura R, Nathan S, Nishihori T, Olin R, Olsson RF, Palmisiano N, Patel SS, Patnaik MM, Pawarode A, Perales MA, Politikos I, Popat U, Rizzieri D, Sandmaier BM, Savani BN, Seo S, Shah NN, Uy GL, Valcarcel D, Verdonck LF, Waller EK, Wang Y, Weisdorf D, Wirk B, Wong E, Yared JA, Saber W. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. *Blood Adv*. 2020 Jul 14; 4 (13):3180-3190 PMID: 32663298 PMCID: 7362362 DOI: 10.1182/bloodadvances.2019001266

419. Cook J, **Litzow M**. Advances in Supportive Care for Acute Lymphoblastic Leukemia. *Curr Hematol Malig Rep*. 2020 Aug; 15 (4):276-293 PMID: 32607955 DOI: 10.1007/s11899-020-00585-2
420. Foss FM, Wang XV, Luger SM, Jegede O, Miller KB, Stadtmauer EA, Whiteside TL, Avigan DE, Gascoyne RD, Arber D, Wagner H, Strair RK, Hogan WJ, Sprague KA, Lazarus HM, **Litzow MR**, Tallman MS, Horning SJ. Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902. *Transfusion*. 2020 Aug; 60 (8):1867-1872 Epub 2020 July 12 PMID: 32654201 PMCID: 7606221 DOI: 10.1111/trf.15798
421. Badar T, Szabo A, Wadleigh M, Liedtke M, Arslan S, Siebenaller C, Aldoss I, Schultz E, Hefazi M, **Litzow MR**, Kuo E, Wang A, Curran E, Shallis RM, Podoltsev N, Balasubramanian S, Yang J, Mattison R, Burkart M, Dinner S, Advani A, Atallah E. Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin. *Clin Lymphoma Myeloma Leuk*. 2020 Aug; 20 (8):556-560.e2 Epub 2020 Mar 19 PMID: 32291234 DOI: 10.1016/j.clml.2020.03.004
422. Sekeres MA, Guyatt G, Abel G, Alibhai S, Altman JK, Buckstein R, Choe H, Desai P, Erba H, Hourigan CS, LeBlanc TW, **Litzow M**, MacEachern J, Michaelis LC, Mukherjee S, O'Dwyer K, Rosko A, Stone R, Agarwal A, Colunga-Lozano LE, Chang Y, Hao Q, Brignardello-Petersen R. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. *Blood Adv*. 2020 Aug 11; 4 (15):3528-3549 PMID: 32761235 PMCID: 7422124 DOI: 10.1182/bloodadvances.2020001920
423. Strickland SA, Wang XV, Cerny J, Rowe JM, Rybka W, Tallman MS, **Litzow M**, Lazarus HM. A novel PrECOG (PrE0901) dose-escalation trial using eltrombopag: enhanced platelet recovery during consolidation therapy in acute myeloid leukemia. *Leuk Lymphoma*. 2020 Sep; 61 (9):2191-2199 Epub 2020 May 30 PMID: 32476546 DOI: 10.1080/10428194.2020.1762878
424. Ice LL, Bartoo GT, McCullough KB, Wolf RC, Dierkhising RA, Mara KC, Jowsey-Gregoire SG, Damlaj M, **Litzow MR**, Merten JA. A Prospective Survey of Outpatient Medication Adherence in Adult Allogeneic Hematopoietic Stem Cell Transplantation Patients. *Biol Blood Marrow Transplant*. 2020 Sep; 26 (9):1627-1634 Epub 2020 June 04 PMID: 32505809 DOI: 10.1016/j.bbmt.2020.05.020
425. Ganzel C, Wang XV, Rowe JM, Richards SM, Buck G, Marks DI, **Litzow MR**, Paietta EM, Foroni L, Luger SM, Willman CL, Mullighan CG, Roberts KG, Wiernik PH, Douer D, Lazarus HM, Tallman MS, Goldstone AH. At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial. *Br J Haematol*. 2020 Oct; 191 (1):37-43 Epub 2020 Mar 27 PMID: 32220069 PMCID: 7687130 DOI: 10.1111/bjh.16616
426. James AJ, Smith CC, **Litzow M**, Perl AE, Altman JK, Shepard D, Kadokura T, Souda K, Patton M, Lu Z, Liu C, Moy S, Levis MJ, Bahceci E. Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor. *Clin Pharmacokinet*. 2020 Oct; 59 (10):1273-1290 PMID: 32304015 PMCID: 7550323 DOI: 10.1007/s40262-020-00888-w
427. Boyiadzis MM, Aksentijevich I, Arber DA, Barrett J, Brentjens RJ, Brufsky J, Cortes J, De Lima M, Forman SJ, Fuchs EJ, Fukas LJ, Gore SD, **Litzow MR**, Miller JS, Pagel JM, Waller EK, Tallman MS. The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia. *J Immunother Cancer*. 2020 Oct; 8 (2) PMID: 33077513 PMCID: 7574947 DOI: 10.1136/jitc-2020-000810
428. Le BV, Podszycwalow-Bartnicka P, Maifrede S, Sullivan-Reed K, Nieborowska-Skorska M, Golovine K, Yao JC, Nejati R, Cai KQ, Caruso LB, Swatler J, Dabrowski M, Lian Z, Valent P, Paietta EM, Levine RL, Fernandez HF, Tallman MS, **Litzow MR**, Huang J, Challen GA, Link D, Tempera I, Wasik MA, Piwocka K, Skorski T. TGFbetaR-SMAD3 Signaling Induces Resistance to PARP Inhibitors in the Bone Marrow Microenvironment. *Cell Rep*. 2020 Oct 6; 33 (1):108221 PMID: 33027668 PMCID: 7578922 DOI: 10.1016/j.celrep.2020.108221
429. Gupta V, Kim S, Hu ZH, Liu Y, Aljurf M, Bacher U, Beitinjaneh A, Cahn JY, Cerny J, Copelan E, Gadalla SM, Gale RP, Ganguly S, George B, Gerds AT, Gergis U, Hamilton BK, Hashmi S, Hildebrandt GC, Kamble RT, Kindwall-Keller T, Lazarus HM, Liesveld JL, **Litzow M**, Maziarz RT, Nishihori T, Olsson RF, Rizzieri D, Savani BN, Seo S, Solh M, Szer J, Verdonck LF, Wirk B, Woolfrey A, Yared JA, Alyea EP, Popat UR, Sobecks RM, Scott BL, Nakamura R, Saber W. Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS. *Blood Adv*. 2020 Oct 13; 4 (19):4748-4757 PMID: 33007075 PMCID: 7556156 DOI: 10.1182/bloodadvances.2020002621
430. Nazha A, Hu ZH, Wang T, Lindsley RC, Abdel-Azim H, Aljurf M, Bacher U, Bashey A, Cahn JY, Cerny J, Copelan E, DeFilipp Z, Diaz MA, Farhadfar N, Gadalla SM, Gale RP, George B, Gergis U, Grunwald MR, Hamilton B, Hashmi S, Hildebrandt GC, Inamoto Y, Kalaycio M, Kamble RT, Kharfan-Dabaja MA, Lazarus HM, Liesveld JL, **Litzow MR**, Majhail NS, Murthy HS, Nathan S, Nishihori T, Pawarode A, Rizzieri D, Sabloff M, Savani BN, Schachter L, Schouten HC, Seo S, Shah NN, Solh M, Valcarcel D, Vij R, Warlick E, Wirk B, Wood WA, Yared JA, Alyea E, Popat U, Sobecks RM, Scott BL, Nakamura R, Saber W. A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. *Biol Blood Marrow Transplant*. 2020 Nov; 26 (11):2139-2146 Epub 2020 Aug 08 PMID: 32781289 PMCID: 7609542 DOI: 10.1016/j.bbmt.2020.08.003

431. Oshima K#, Zhao J#, Perez-Duran P#, Brown JA#, Patino-Galindo JA, Chu T, Quinn A, Gunning T, Belver L, Ambesi-Impimbato A, Tosello V, Wang Z, Sulis ML, Kato M, Koh K, Paganin M, Basso G, Balbin M, Nicolas C, Gastier-Foster JM, Devidas M, Loh ML, Paietta E, Tallman MS, Rowe JM, **Litzow M**, Minden MD, Meijerink J, Rabadan R, Ferrando A. Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia. *Nat Cancer*. 2020 Nov; 1 (11):1113-1127 Epub 2020 Oct 19 PMID: 33796864 PMCID: 8011577 DOI: 10.1038/s43018-020-00124-1
432. Mangaonkar AA, Reichard KK, Binder M, Coltro G, Lasho TL, Carr RM, Chiu A, Negron V, Hefazi M, Anagnostou T, Timm MM, Hiebert JW, Villasboas JC, Gonsalves WI, Gangat N, Shah M, Alkhateeb HB, Al-Kali A, Elliott MA, Begna KH, Wolanskyj-Spinner AP, **Litzow MR**, Hogan WJ, Ansell SM, Pardanani A, Tefferi A, Patnaik MM. Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia. *Blood Adv*. 2020 Nov 10; 4(21):5425-5430. PMID: 33152058 PMCID: 7656937 DOI: 10.1182/bloodadvances.2020002415
433. Switzer GE, Bruce JG, Kiefer DM, Kobusingye H, Abebe KZ, Drexler R, Besser RM, Confer DL, Horowitz MM, King RJ, Shaw BE, Riches M, Hayes-Lattin B, Linenberger M, Bolwell B, Rowley SD, **Litzow MR**, Pulsipher MA. Health-Related Quality-of-Life Comparison of Adult Related and Unrelated HSC Donors: An RDSafe Study. *Biol Blood Marrow Transplant*. 2020 Dec; 26 (12):2365-2371 Epub 2020 Aug 21 PMID: 32829080 PMCID: 7686016 DOI: 10.1016/j.bbmt.2020.08.016
434. Burd A, Levine RL, Ruppert AS, Mims AS, Borate U, Stein EM, Patel P, Baer MR, Stock W, Deininger M, Blum W, Schiller G, Olin R, **Litzow M**, Foran J, Lin TL, Ball B, Boyiadzis M, Traer E, Odenike O, Arellano M, Walker A, Duong VH, Kovacovics T, Collins R, Shoben AB, Heerema NA, Foster MC, Vergilio JA, Brennan T, Vietz C, Severson E, Miller M, Rosenberg L, Marcus S, Yocum A, Chen T, Stefanos M, Druker B, Byrd JC. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. *Nat Med*. 2020 Dec; 26 (12):1852-1858 Epub 2020 Oct 26 PMID: 33106665 PMCID: 8530434 DOI: 10.1038/s41591-020-1089-8
435. Hu B, Lin X, Lee HC, Huang X, Tidwell RSS, Ahn KW, Hu ZH, Jabbour E, Verstovsek S, Ravandi F, Garcia-Manero G, Kharfan-Dabaja MA, Hossain NM, Marks DI, Kamble RT, Inamoto Y, Kindwall-Keller T, Saad A, **Litzow MR**, Savani BN, Hale GA, Bacher U, Gerds AT, Liesveld JL, Ustun C, Olsson RF, Daly A, Grunwald MR, Solh M, DeFilipp Z, Aljurf M, Wirk B, Akpek G, Nishihori T, Cerny J, Seo S, Hsu JW, Champlin R, de Lima M, Alyea E, Popat U, Sobecks R, Scott BL, Kantarjian H, Cortes J, Saber W. Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. *Leuk Lymphoma*. 2020 Dec; 61 (12):2811-2820 Epub 2020 July 14 PMID: 32662346 PMCID: 8424781 DOI: 10.1080/10428194.2020.1783444
436. Roboz GJ, Strickland SA, **Litzow MR**, Dalvisio A, Perl AE, Bonifacio G, Haines K, Barbera A, Purkayastha D, Sweet K. Updated safety of midostaurin plus chemotherapy in newly diagnosed FLT3 mutation-positive acute myeloid leukemia: the RADIUS-X expanded access program. *Leuk Lymphoma*. 2020 Dec; 61 (13):3146-3153 Epub 2020 Aug 19 PMID: 32812818 DOI: 10.1080/10428194.2020.1805109
437. Morsia E, McCullough K, Joshi M, Cook J, Alkhateeb HB, Al-Kali A, Begna K, Elliott M, Hogan W, **Litzow M**, Shah M, Pardanani A, Patnaik M, Tefferi A, Gangat N. Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. *Am J Hematol*. 2020 Dec; 95 (12):1511-1521 Epub 2020 Sept 16 PMID: 32833294 DOI: 10.1002/ajh.25978
438. Chang Y, Guyatt GH, Teich T, Dawdy JL, Shahid S, Altman JK, Stone RM, Sekeres MA, Mukherjee S, LeBlanc TW, Abel GA, Hourigan CS, **Litzow MR**, Michaelis LC, Alibhai SMH, Desai P, Buckstein R, MacEachern J, Brignardello-Petersen R. Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review. *PLoS One*. 2021; 16 (3):e0249087 Epub 2021 Mar 30 PMID: 33784346 PMCID: 8009379 DOI: 10.1371/journal.pone.0249087
439. Smith CJ, Kluck LA, Ruan GJ, Ashrani AA, Marshall AL, Pruthi RK, Shah MV, Wolanskyj-Spinner A, Gangat N, **Litzow MR**, Hogan WJ, Sridharan M, Go RS. Leukocytosis and Tobacco Use: An Observational Study of Asymptomatic Leukocytosis. *Am J Med*. 2021 Jan; 134 (1):e31-e35 Epub 2020 July 16 PMID: 32682870 DOI: 10.1016/j.amjmed.2020.06.014
440. Bejanyan N, Zhang M, Bo-Subait K, Brunstein C, Wang H, Warlick ED, Giralto S, Nishihori T, Martino R, Passweg J, Dias A, Copelan E, Hale G, Gale RP, Solh M, Kharfan-Dabaja MA, Diaz MA, Ganguly S, Gore S, Verdonck LF, Hossain NM, Kekre N, Savani B, Byrne M, Kanakry C, Cairo MS, Ciurea S, Schouten HC, Bredeson C, Munker R, Lazarus H, Cahn JY, van Der Poel M, Rizzieri D, Yared JA, Freytes C, Cerny J, Aljurf M, Palmisiano ND, Pawarode A, Bacher VU, Grunwald MR, Nathan S, Wirk B, Hildebrandt GC, Seo S, Olsson RF, George B, de Lima M, Hourigan CS, Sandmaier BM, **Litzow M**, Kebriaei P, Saber W, Weisdorf D. Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. *Transplant Cell Ther*. 2021 Jan; 27 (1):68.e1-68.e9 Epub 2020 Oct 01 PMID: 33010430 PMCID: 8015679 DOI: 10.1016/j.bbmt.2020.09.026
441. Liu Q, Major B, Le-Rademacher J, Al-Kali AA, Alkhateeb H, Begna K, Elliott MA, Gangat N, Hogan WJ, Hook

- CC, Kaufmann SH, Pardanani A, Patnaik MS, Tefferi A, Wolanskyj-Spinner AP, Wei W, **Litzow MR**. The Impact of Obesity on the Outcomes of Adult Patients with Acute Lymphoblastic Leukemia - A Single Center Retrospective Study. *Blood Lymphat Cancer*. 2021; 11:1-9 Epub 2021 Jan 22 PMID: 33519255 PMCID: 7837742 DOI: 10.2147/BLC.S260748
442. Ustun C, Morgan EA, Ritz EM, Vestergaard H, Pullarkat S, Kluin PM, Ohgami R, Baughn LB, Kim Y, Ku NK, Czuchlewski D, Boe Moller M, Schiefer AI, Mrozek K, Horny HP, George TI, Kielsingaard Kristensen T, Beck T, Nathan S, Arana Yi C, Yeung C, Pullarkat V, Gotlib J, Akin C, Kohlschmidt J, Salhotra A, Soma L, Chen D, Han SY, Cho C, Sperr W, Broesby-Olsen S, Linden MA, Dolan M, Hoermann G, Hornick JL, Bloomfield C, Nakamura R, Joachim Deeg H, **Litzow MR**, Borthakur G, Weisdorf D, Huls G, Perales MA, Valent P, Marcucci G. Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. *Int J Lab Hematol* 2021 Feb; 43 (1):e19-e25 Epub 2020 Sept 14 PMID: 32926565 PMCID: 8434847 DOI: 10.1111/ijlh.13338
443. Abdel Rahman ZH, Heckman MG, Miller K, Alkhateeb H, Patnaik MS, Sproat LZ, Jiang L, Roy V, Murthy HS, Ayala E, Hogan WJ, Greipp PT, Kharfan-Dabaja MA, **Litzow MR**, Foran JM. Impact of Novel Targeted Therapies and Cytogenetic Risk Groups on Outcome After Allogeneic Transplantation for Adult ALL. *Transplant Cell Ther*. 2021 Feb; 27 (2):165.e1-165.e11 Epub 2020 Dec 11 PMID: 33830026 DOI: 10.1016/j.jctc.2020.10.015
444. Gocho Y#, Liu J#, Hu J#, Yang W, Dharia NV, Zhang J, Shi H, Du G, John A, Lin TN, Hunt J, Huang X, Ju B, Rowland L, Shi L, Maxwell D, Smart B, Crews KR, Yang W, Hagiwara K, Zhang Y, Roberts K, Wang H, Jabbour E, Stock W, Eisfelder B, Paietta E, Newman S, Roti G, **Litzow M**, Easton J, Zhang J, Peng J, Chi H, Pounds S, Relling MV, Inaba H, Zhu X, Kornblau S, Pui CH, Konopleva M, Teachey D, Mullighan CG, Stegmaier K, Evans WE, Yu J, Yang JJ. Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. *Nat Cancer*. 2021 Mar; 2 (3):284-299 Epub 2021 Jan 21 PMID: 34151288 PMCID: 8208590 DOI: 10.1038/s43018-020-00167-4
445. Meleveedu KS, Chen D, Nadiminti K, Sidiqi H, Khan S, Alkhateeb H, Shah MV, Patnaik M, Hogan WJ, Begna K, **Litzow M**. PD-1/PD-L1 expression in extramedullary lesions of acute myeloid leukemia. *Leuk Lymphoma* 2021 Mar; 62 (3):764-767 Epub 2019 Oct 12 PMID: 31608729 DOI: 10.1080/10428194.2019.1675880
446. Xie Z, Nanaa A, Saliba AN, He R, Viswanatha D, Nguyen P, Jevremovic D, Greipp P, Salama ME, Gangat N, Alkhateeb HB, Tefferi A, **Litzow M**, Patnaik M, Shah M, Al-Kali A. Treatment outcome of clonal cytopenias of undetermined significance: a single-institution retrospective study. *Blood Cancer J* 2021 Mar 1; 11 (3):43 Epub 2021 Mar 01 PMID: 33649321 PMCID: 7921651 DOI: 10.1038/s41408-021-00439-x
447. Begna KH, Ali W, Naseema Gangat Gangat, Elliott MA, Al-Kali A, **Litzow MR**, Christopher Hook C, Wolanskyj-Spinner AP, Hogan WJ, Patnaik MM, Pardanani A, Zblewski DL, Chen D, He R, Viswanatha D, Hanson CA, Ketterling RP, Tefferi A. Mayo Clinic experience with 1123 adults with acute myeloid leukemia. *Blood Cancer J*. 2021 Mar 2; 11 (3):46 Epub 2021 Mar 02 PMID: 33654065 PMCID: 7925511 DOI: 10.1038/s41408-021-00435-1
448. Joshi M#, Cook J#, McCullough K, Nanaa A, Gangat N, Foran JM, Murthy HS, Kharfan-Dabaja MA, Sproat L, Palmer J, Pardanani A, Tefferi A, Begna K, Elliot M, Al-Kali A, Patnaik M, Shah MV, Hogan WJ, **Litzow MR**, Alkhateeb HB. Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation. *Blood Cancer J* 2021 Mar 4; 11 (3):49 Epub 2021 Mar 04 PMID: 33664234 PMCID: 7933161 DOI: 10.1038/s41408-021-00437-z
449. Nadiminti K, Sidiqi MH, Meleveedu K, Alkhateeb HB, Hogan WJ, **Litzow M**, Patnaik M, Kumar S, Gertz M, Chen D, Shah MV. Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma. *Blood Cancer J* 2021 Mar 19; 11 (3):63 PMID: 33741897 PMCID: 7979889 DOI: 10.1038/s41408-021-00454-y
450. List AF, Sun Z, Verma A, Bennett JM, Komrokji RS, McGraw K, Maciejewski J, Altman JK, Cheema PS, Claxton DF, Luger SM, Mattison RJ, Wassenaar TR, Artz AS, Schiffer CA, **Litzow MR**, Tallman MS. Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin. *J Clin Oncol*. 2021 Mar 20; 39 (9):1001-1009 Epub 2021 Jan 13 PMID: 33439748 PMCID: 8274743 DOI: 10.1200/JCO.20.01691
451. Schultz-Rogers L, Lach FP, Rickman KA, Ferrer A, Mangaonkar AA, Schwab TL, Schmitz CT, Clark KJ, Dsouza NR, Zimmermann MT, **Litzow M**, Jacobi N, Klee EW, Smogorzewska A, Patnaik MM. A homozygous missense variant in UBE2T is associated with a mild Fanconi anemia phenotype. *Haematologica* 2021 Apr 1; 106 (4):1188-1192 Epub 2021 Apr 01 PMID: 32646888 PMCID: 8018101 DOI: 10.3324/haematol.2020.259275
452. Kutzke JL, Merten JA, Taraba JL, Mara KC, Shah MV, Hashmi SK, Patnaik MM, **Litzow MR**, Hogan WJ, Alkhateeb HB. Risk of relapse in patients receiving azithromycin after allogeneic HSCT. *Bone Marrow Transplant*. 2021 Apr; 56 (4):960-962 Epub 2020 Oct 31 PMID: 33130820 DOI: 10.1038/s41409-020-01095-8
453. Badar T, Szabo A, Dinner S, Liedtke M, Burkart M, Shallis RM, Yurkiewicz IR, Kuo E, Khan MA, Balasubramanian S, Yang J, Hefazi M, Podoltsev N, Patel A, Curran E, Wang A, Arslan S, Aldoss I, Siebenaller C, Mattison RJ, **Litzow MR**, Wadleigh M, Advani AS, Atallah E. Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have

- comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. *Cancer*. 2021 Apr 1; 127 (7):1039-1048 Epub 2020 Dec 01 PMID: 33259056 DOI: 10.1002/cncr.33340
454. Seftel MD, Chitphakdithai P, Miller JP, Kobusingye H, Logan BR, Linenberger M, Artz AS, Haight AE, Jacobsohn DA, **Litzow MR**, Magalhaes-Silverman M, Selby GB, Vusirikala M, Horowitz MM, Switzer GE, Confer DL, Shaw BE, Pulsipher MA. Serious Adverse Events in Related Donors: A Report from the Related Donor Safe Study. *Transplant Cell Ther*. 2021 Apr; 27 (4):352.e1-352.e5 Epub 2021 Jan 15 PMID: 33836890 PMID: 8036235 DOI: 10.1016/j.jtct.2021.01.009
455. Li M, Binder M, Lasho T, Ferrer A, Gangat N, Al-Kali A, Mangaonkar A, Elliott M, **Litzow M**, Hogan W, Pardanani A, Wolanskyj-Spinner A, Howard M, King RL, Shah M, Alkhateeb H, Begna K, Tefferi A, Finke C, Oliveira J, Ketterling R, Olteanu H, Patnaik MM. Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients. *Blood Adv*. 2021 Apr 27; 5 (8):2272-2278 PMID: 33904893 PMID: 8095155 DOI: 10.1182/bloodadvances.2020003976
456. Han SY, Mrozek K, Voutsinas J, Wu Q, Morgan EA, Vestergaard H, Ohgami R, Kluin PM, Kristensen TK, Pullarkat S, Moller MB, Schiefer AI, Baughn LB, Kim Y, Czuchlewski D, Hilberink JR, Horny HP, George TI, Dolan M, Ku NK, Arana Yi C, Pullarkat V, Kohlschmidt J, Salhotra A, Soma L, Bloomfield CD, Chen D, Sperr WR, Marcucci G, Cho C, Akin C, Gottlib J, Broesby-Olsen S, Larson M, Linden MA, Deeg HJ, Hoermann G, Perales MA, Hornick JL, **Litzow MR**, Nakamura R, Weisdorf D, Borthakur G, Huls G, Valent P, Ustun C, Yeung CCS. Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). *Blood Adv*. 2021 May 25; 5 (10):2481-2489 PMID: 34003250 PMID: 8152510 DOI: 10.1182/bloodadvances.2020003605
457. Zhang Z, Wang C, Peters SG, Hogan WJ, Hashmi SK, **Litzow MR**, Patnaik MS, Niven AS, Yadav H. Epidemiology, Risk Factors, and Outcomes of Diffuse Alveolar Hemorrhage After Hematopoietic Stem Cell Transplantation. *Chest*. 2021 Jun; 159 (6):2325-2333 Epub 2021 Jan 09 PMID: 33434501 DOI: 10.1016/j.chest.2021.01.008
458. Nanaa A, Viswanatha D, Xie Z, Jevremovic D, Nguyen P, Salama ME, Greipp P, Bessonon K, Gangat N, Patnaik M, Pardanani A, Alkhateeb HB, Shah M, Hogan W, Tefferi A, **Litzow M**, He R#, Al-Kali A. Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience. *Blood Cancer J* 2021 Jun 30; 11 (6):122 Epub 2021 June 30 PMID: 34193836 PMID: 8245641 DOI: 10.1038/s41408-021-00517-0
459. Wieduwilt MJ, Stock W, Advani A, Luger S, Larson RA, Tallman M, Appelbaum F, Zhang MJ, Bo-Subait K, Wang HL, Bhatt VR, Dholaria B, Eapen M, Hamadani M, Jamy O, Prestidge T, Pulsipher M, Ritchie D, Rizzieri D, Sharma A, Barba P, Sandmaier BM, de Lima M, Kebriaei P, **Litzow M**, Saber W, Weisdorf D. Correction: Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. *Leukemia*. 2021 Jul; 35 (7):2140 PMID: 34088982 PMID: 8329698 DOI: 10.1038/s41375-021-01303-4
460. Moreira CL, Hasib Sidiqi M, Buadi FK, **Litzow MR**, Gertz MA, Dispenzieri A, Russell SJ, Ansell SM, Stegall MD, Prieto M, Dean PG, Nyberg SL, El Ters M, Hogan WJ, Amer H, Cosio FG, Leung N. Long-term Outcomes of Sequential Hematopoietic Stem Cell Transplantation and Kidney Transplantation: Single-center Experience. *Transplantation*. 2021 Jul 1; 105 (7):1615-1624 PMID: 33031227 DOI: 10.1097/TP.0000000000003477
461. Wiernik PH, Sun Z, Cripe LD, Rowe JM, Fernandez HF, Luger SM, Lazarus HM, Paietta EM, Tallman MS, **Litzow MR**. Prognostic effect of gender on outcome of treatment for adults with acute myeloid leukaemia. *Br J Haematol*. 2021 Jul; 194 (2):309-318 Epub 2021 June 17 PMID: 34145576 PMID: 8532194 DOI: 10.1111/bjh.17523
462. Wieduwilt MJ, Stock W, Advani A, Luger S, Larson RA, Tallman M, Appelbaum F, Zhang MJ, Bo-Subait K, Wang HL, Bhatt VR, Dholaria B, Eapen M, Hamadani M, Jamy O, Prestidge T, Pulsipher M, Ritchie D, Rizzieri D, Sharma A, Barba P, Sandmaier BM, de Lima M, Kebriaei P, **Litzow M**, Saber W, Weisdorf D. Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. *Leukemia*. 2021 Jul; 35 (7):2076-2085 Epub 2021 Mar 30 PMID: 33785862 PMID: 8257494 DOI: 10.1038/s41375-021-01213-5
463. Gangat N, Guglielmelli P, Szuber N, Begna KH, Patnaik MM, **Litzow MR**, Al-Kali A, Foran JM, Palmer JM, Alkhateeb H, Elliott MA, Hanson CA, Pardanani A, Mannelli F, Vannucchi AM, Tefferi A. Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases. *Am J Hematol*. 2021 Jul 1; 96 (7):781-789 Epub 2021 May 06 PMID: 33844862 PMID: 8251544 DOI: 10.1002/ajh.26186
464. Lazaryan A, Dolan M, Zhang MJ, Wang HL, Khafan-Dabaja MA, Marks DI, Bejanyan N, Copelan E, Majhail NS, Waller EK, Chao N, Prestidge T, Nishihori T, Kebriaei P, Inamoto Y, Hamilton B, Hashmi SK, Kamble RT, Bacher U, Hildebrandt GC, Stiff PJ, McGuirk J, Aldoss I, Beitinjaneh AM, Muffly L, Vij R, Olsson RF, Byrne M, Schultz KR, Aljurf M, Seftel M, Savoie ML, Savani BN, Verdonck LF, Cairo MS, Hossain N, Bhatt VR, Frangoul HA, Abdel-Azim H, Al Malki M, Munker R, Rizzieri D, Khera N, Nakamura R, Ringden O, Van der Poel M,

- Murthy HS, Liu H, Mori S, De Oliveira S, Bolanos-Meade J, Elsayy M, Barba P, Nathan S, George B, Pawarode A, Grunwald M, Agrawal V, Wang Y, Assal A, Caro PC, Kuwatsuka Y, Seo S, Ustun C, Politikos I, Lazarus HM, Saber W, Sandmaier BM, De Lima M, **Litzow M**, Bachanova V, Weisdorf D. Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. *Haematologica*. 2021 Aug 1; 106 (8):2295-
465. Badar T, Szabo A, **Litzow M**, Burkart M, Yurkiewicz I, Dinner S, Hefazi M, Shallis RM, Podoltsev N, Patel AA, Curran E, Wadleigh M, Balasubramanian S, Yang J, Arslan S, Aldoss I, Mattison R, Cenin D, Siebenaller C, Advani A, Liedtke M, Atallah E. Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data. *Bone Marrow Transplant*. 2021 Aug; 56 (8):1998-2004 Epub 2021 Apr 06 PMID: 33824440 DOI: 10.1038/s41409-021-01279-w
466. Percival ME, Wang HL, Zhang MJ, Saber W, de Lima M, **Litzow M**, Kebriaei P, Abdel-Azim H, Adekola K, Aljurf M, Bacher U, Badawy SM, Beitinjaneh A, Bejanyan N, Bhatt V, Byrne M, Cahn JY, Castillo P, Chao N, Chhabra S, Copelan E, Cutler C, DeFilipp Z, Dias A, Diaz MA, Estey E, Farhadfar N, Frangoul HA, Freytes CO, Gale RP, Ganguly S, Gowda L, Grunwald M, Hossain N, Kamble RT, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Krem M, Lazarus HM, Lee JW, Liesveld JL, Lin R, Liu H, McGuirk J, Munker R, Murthy HS, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Passweg JR, Prestidge T, Ringden O, Rizzieri DA, Rybka WB, Savoie ML, Schultz KR, Seo S, Sharma A, Solh M, Strair R, van der Poel M, Verdonck LF, Yared JA, Weisdorf D, Sandmaier BM. Correction to: Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant*. 2021 Sep; 56 (9):2319 PMID: 34017072 PMCID: 8450771 DOI: 10.1038/s41409-021-01353-3
467. James AJ, Smith CC, **Litzow M**, Perl AE, Altman JK, Shepard D, Kadokura T, Souda K, Patton M, Lu Z, Liu C, Moy S, Levis MJ, Bahceci E. Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor. *Clin Pharmacokinet*. 2021 Sep; 60 (9):1251 PMID: 34297319 PMCID: 8416867 DOI: 10.1007/s40262-021-01060-8
468. Percival ME, Wang HL, Zhang MJ, Saber W, de Lima M, **Litzow M**, Kebriaei P, Abdel-Azim H, Adekola K, Aljurf M, Bacher U, Badawy SM, Beitinjaneh A, Bejanyan N, Bhatt V, Byrne M, Cahn JY, Castillo P, Chao N, Chhabra S, Copelan E, Cutler C, DeFilipp Z, Dias A, Diaz MA, Estey E, Farhadfar N, Frangoul HA, Freytes CO, Gale RP, Ganguly S, Gowda L, Grunwald M, Hossain N, Kamble RT, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Krem M, Lazarus HM, Lee JW, Liesveld JL, Lin R, Liu H, McGuirk J, Munker R, Murthy HS, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Passweg JR, Prestidge T, Ringden O, Rizzieri DA, Rybka WB, Savoie ML, Schultz KR, Seo S, Sharma A, Solh M, Strair R, van der Poel M, Verdonck LF, Yared JA, Weisdorf D, Sandmaier BM. Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant*. 2021 Sep; 56 (9):2108-2117 Epub 2021 Apr 16 PMID: 33864019 PMCID: 8425595 DOI: 10.1038/s41409-021-01261-6
469. Venable ER, Chen D, Chen CP, Bessonon KR, Nguyen PL, Oliveira JL, Reichard KK, Hoyer JD, Althoff SD, Roh DJ, Miller MA, Begna K, Patnaik MM, **Litzow MR**, Al-Kali A, Viswanatha DS, He R. Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations. *Am J Clin Pathol*. 2021 Sep 8; 156 (4):679-690 PMID: 33978189 PMCID: 8427737 DOI: 10.1093/ajcp/qaqab010
470. Paietta E, Roberts KG, Wang V, Gu Z, Buck GAN, Pei D, Cheng C, Levine RL, Abdel-Wahab O, Cheng Z, Wu G, Qu C, Shi L, Pounds S, Willman CL, Harvey R, Racevskis J, Barinka J, Zhang Y, Dewald GW, Ketterling RP, Alejos D, Lazarus HM, Luger SM, Foroni L, Patel B, Fielding AK, Melnick A, Marks DI, Moorman AV, Wiernik PH, Rowe JM, Tallman MS, Goldstone AH, Mullighan CG, **Litzow MR**. Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL. *Blood*. 2021 Sep 16; 138 (11):948-958 PMID: 33895809 PMCID: 9069478 DOI: 10.1182/blood.2020010144
471. Brown PA, Shah B, Advani A, Aoun P, Boyer MW, Burke PW, DeAngelo DJ, Dinner S, Fathi AT, Gauthier J, Jain N, Kirby S, Liedtke M, **Litzow M**, Logan A, Luger S, Maness LJ, Massaro S, Mattison RJ, May W, Oluwole O, Park J, Przespolewski A, Rangaraju S, Rubnitz JE, Uy GL, Vusirikala M, Wieduwilt M, Lynn B, Berardi RA, Freedman-Cass DA, Campbell M. Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2021 Sep 20; 19 (9):1079-1109 Epub 2021 Sept 20 PMID: 34551384 DOI: 10.6004/jnccn.2021.0042
472. Abdel-Rahman ZH, Heckman MG, Anagnostou T, White LJ, Kloft-Nelson SM, Knudson RA, Alkhateeb HB, Sproat LZ, Khera N, Murthy HS, Ayala E, Hogan WJ, Roy V, Peterson JF, Kharfan-Dabaja MA, Ketterling RP, **Litzow MR**, Baughn LB, Patnaik M, Greipp PT#, Foran JM#. Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISH-based algorithm distinguishes prognostic groups and outcomes. *Blood Cancer J* 2021 Sep 21; 11 (9):156 Epub 2021 Sept 21 PMID: 34548472 PMCID: 8455651 DOI: 10.1038/s41408-021-00538-9
473. Ruppert AS, Booth AM, Ding W, Bartlett NL, Brander DM, Coutre S, Brown JR, Nattam S, Larson RA, Erba H,

- Litzow M**, Owen C, Kuzma CS, Abramson JS, Little RF, Smith SE, Stone RM, Byrd JC, Mandrekar SJ#, Woyach JA#. Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. *Leukemia*. 2021 Oct; 35 (10):2854-2861 Epub 2021 July 17 PMID:
474. Maifrede S, Le BV, Nieborowska-Skorska M, Golovine K, Sullivan-Reed K, Dunuville WMB, Nacson J, Hulse M, Keith K, Madzo J, Caruso LB, Gazze Z, Lian Z, Padella A, Chitralla KN, Bartholdy BA, Matlawska-Wasowska K, Di Marcantonio D, Simonetti G, Greiner G, Sykes SM, Valent P, Paietta EM, Tallman MS, Fernandez HF, **Litzow MR**, Minden MD, Huang J, Martinelli G, Vassiliou GS, Tempera I, Piwocka K, Johnson N, Challen GA, Skorski T. TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors. *Cancer Res*. 2021 Oct 1; 81 (19):5089-5101 Epub 2021 July 02 PMID: 34215619 PMCID: 8487956 DOI: 10.1158/0008-5472.CAN-20-3761
475. Mangaonkar AA#, Ferrer A#, Vairo FPE, Hammel CW, Prochnow C, Gangat N, Hogan WJ, **Litzow MR**, Peters SG, Scott JP, Utz JP, Baqir M, Carmona-Porquera EM, Kalra S, Sekiguchi H, Khan SP, Simonetto DA, Klee EW, Kamath PS, Roden AC, Joshi AY, Kennedy CC, Wylam ME, Patnaik MM. Clinical and molecular correlates from a predominantly adult cohort of patients with short telomere lengths. *Blood Cancer J* 2021 Oct 22; 11 (10):170 PMID: 34686653 PMCID: 8536738 DOI: 10.1038/s41408-021-00564-7
476. Metheny L, Callander NS, Hall AC, Zhang MJ, Bo-Subait K, Wang HL, Agrawal V, Al-Homsi AS, Assal A, Bacher U, Beitinjaneh A, Bejanyan N, Bhatt VR, Bredeson C, Byrne M, Cairo M, Cerny J, DeFilipp Z, Perez MAD, Freytes CO, Ganguly S, Grunwald MR, Hashmi S, Hildebrandt GC, Inamoto Y, Kanakry CG, Kharfan-Dabaja MA, Lazarus HM, Lee JW, Nathan S, Nishihori T, Olsson RF, Ringden O, Rizzieri D, Savani BN, Savoie ML, Seo S, van der Poel M, Verdonck LF, Wagner JL, Yared JA, Hourigan CS, Kebriaei P, **Litzow M**, Sandmaier BM, Saber W, Weisdorf D, de Lima M. Allogeneic transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults. *Transplant Cell Ther*. 2021 Nov; 27 (11):923.e1-923.e12 Epub 2021 Aug 21 PMID: 34428556 PMCID: 9064046 DOI: 10.1016/j.jtct.2021.08.010
477. Begna KH, Kittur J, Yui J, Gangat N, Patnaik MM, Al-Kali A, Elliott MA, Hogan WJ, **Litzow MR**, Hook CC, Wolanskyj AP, Howard MT, Hanson CA, Ketterling RP, Pardanani AD, Tefferi A. De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases. *Br J Haematol*. 2021 Nov; 195 (3):413-416 Epub 2021 Aug 03 PMID: 34346084 DOI: 10.1111/bjh.17742
478. Montefiori LE, Bendig S, Gu Z, Chen X, Polonen P, Ma X, Murison A, Zeng A, Garcia-Prat L, Dickerson K, Iacobucci I, Abdelhamed S, Hiltenbrand R, Mead PE, Mehr CM, Xu B, Cheng Z, Chang TC, Westover T, Ma J, Stengel A, Kimura S, Qu C, Valentine MB, Rashkovan M, Luger S, **Litzow MR**, Rowe JM, den Boer ML, Wang V, Yin J, Kornblau SM, Hunger SP, Loh ML, Pui CH, Yang W, Crews KR, Roberts KG, Yang JJ, Relling MV, Evans WE, Stock W, Paietta EM, Ferrando AA, Zhang J, Kern W, Haferlach T, Wu G, Dick JE, Klco JM, Haferlach C, Mullighan CG. Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage-Ambiguous Stem Cell Leukemia. *Cancer Discov*. 2021 Nov; 11 (11):2846-2867 Epub 2021 June 08 PMID: 34103329 PMCID: 8563395 DOI: 10.1158/2159-8290.CD-21-0145
479. Oran B, Ahn KW, Fretham C, Beitinjaneh A, Bashey A, Pawarode A, Wirk B, Scott BL, Savani BN, Bredeson C, Weisdorf D, Marks DI, Rizzieri D, Copelan E, Hildebrandt GC, Hale GA, Murthy HS, Lazarus HM, Cerny J, Liesveld JL, Yared JA, Yves-Cahn J, Szer J, Verdonck LF, Aljurf M, van der Poel M, **Litzow M**, Kalaycio M, Grunwald MR, Diaz MA, Sabloff M, Kharfan-Dabaja MA, Majhail NS, Farhadfar N, Reshef R, Olsson RF, Gale RP, Nakamura R, Seo S, Chhabra S, Hashmi S, Farhan S, Ganguly S, Nathan S, Nishihori T, Jain T, Agrawal V, Bacher U, Popat U, Saber W. Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. *Transplant Cell Ther*. 2021 Nov; 27 (11):921.e1-921.e10 Epub 2021 Aug 14 PMID: 34403791 PMCID: 9562611 DOI: 10.1016/j.jtct.2021.08.007
480. Santivasi WL, Childs DS, Wu KL, Partain DK, **Litzow MR**, LeBlanc TW, Strand JJ. Perceptions of Hematology Among Palliative Care Physicians: Results of a Nationwide Survey. *J Pain Symptom Manage*. 2021 Nov; 62 (5):949-959 Epub 2021 Apr 29 PMID: 33933620 DOI: 10.1016/j.jpainsymman.2021.04.021
481. Patel SA, **Litzow MR**, Cerny J. Targeted and cytotoxic therapies as maintenance treatment for non-transplant eligible patients with acute myeloid leukemia. *Blood Rev*. 2021 Nov; 50:100863 Epub 2021 June 21 PMID: 34210571 DOI: 10.1016/j.blre.2021.100863
482. Nadiminti K, Langer K, Shabbir E, Hefazi M, Dozeman L, Jethava Y, Loeffler B, AlKhateeb HB, **Litzow M**, Patnaik M, Shah M, Hogan W, Farooq U, Silverman M, Mott SL. A novel Iowa-Mayo validated composite risk assessment tool for allogeneic stem cell transplantation survival outcome prediction. *Blood Cancer J*. 2021 Nov 20; 11 (11):183 PMID: 34802042 PMCID: 8606004 DOI: 10.1038/s41408-021-00573-6
483. Ganzel C, Lee JW, Fernandez HF, Paietta EM, Luger SM, Lazarus HM, Cripe LD, Douer D, Wiernik PH, Rowe JM, Tallman MS, **Litzow MR**. CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trials. *Blood Adv*. 2021 Nov 23; 5 (22):4560-4568 PMID: 34597373 PMCID: 8759130 DOI: 10.1182/bloodadvances.2021004999
484. Jimenez Jimenez AM, De Lima M, Komanduri KV, Wang TP, Zhang MJ, Chen K, Abdel-Azim H, Abid MB,

- Aljurf M, Alkhateeb H, Assal A, Bacher U, Baron F, Battiwalla M, Beitinjaneh A, Bejanyan N, Bhatt VR, Byrne M, Cahn JY, Cairo M, Castillo P, Copelan E, DeFilipp Z, Perez MAD, Elsayy M, Gale RP, George B, Grunwald MR, Hildebrandt GC, Hogan WJ, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Khera N, Krem MM, Lazaryan A, Maakaron J, Martino R, McGuirk J, Michelis FV, Milone G, Mishra A, Murthy HS, Mussetti A, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Patel S, Saad A, Seo S, Sharma A, Solh M, Verdonck LF, Wirk B, Yared JA, **Litzow M**, Kebriaei P, Hourigan CS, Saber W, Weisdorf D. An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. *Bone Marrow Transplant*. 2021 Dec; 56 (12):3068-3077 PMID: 34773794
485. Luger SM, Wang VX, Rowe JM, **Litzow MR**, Paietta E, Ketterling RP, Lazarus H, Rybka WB, Craig MD, Karp J, Cooper BW, Makary AZ, Kaminer LS, Appelbaum FR, Larson RA, Tallman MS. Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial. *Leuk Res*. 2021 Dec; 111:106736 Epub 2021 Oct 28 PMID: 34773794 PMCID: 8643322 DOI: 10.1016/j.leukres.2021.106736
486. Chang Y, Min J, Jarusiewicz JA, Actis M, Yu-Chen Bradford S, Mayasundari A, Yang L, Chepyala D, Alcock LJ, Roberts KG, Nithianantham S, Maxwell D, Rowland L, Larsen R, Seth A, Goto H, Imamura T, Akahane K, Hansen BS, Pruet-Miller SM, Paietta EM, **Litzow MR**, Qu C, Yang JJ, Fischer M, Rankovic Z, Mullighan CG. Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia. *Blood*. 2021 Dec 9; 138 (23):2313-2326 PMID: 34110416 PMCID: 8662068 DOI: 10.1182/blood.202006846
487. Wang XV, Hanson CA, Tschumper RC, Lesnick CE, Braggio E, Paietta EM, O'Brien S, Barrientos JC, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Erba H, Stone R, **Litzow MR**, Tallman MS, Shanafelt TD, Kay NE. Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib. *Blood*. 2021 Dec 30; 138 (26):2810-2827 PMID: 34407545 PMCID: 8718628 DOI: 10.1182/blood.2020010146
488. Colunga-Lozano LE, Kenji Nampo F, Agarwal A, Desai P, **Litzow M**, Sekeres MA, Guyatt GH, Brignardello-Petersen R. Less intensive antileukemic therapies (monotherapy and/or combination) for older adults with acute myeloid leukemia who are not candidates for intensive antileukemic therapy: A systematic review and meta-analysis. *PLoS One*. 2022; 17 (2):e0263240 Epub 2022 Feb 02 PMID: 35108310 PMCID: 8809589 DOI: 10.1371/journal.pone.0263240
489. Menghrajani K, Gomez-Arteaga A, Madero-Marroquin R, Zhang MJ, Bo-Subait K, Sanchez J, Wang HL, Aljurf M, Assal A, Bacher VU, Badawy SM, Bejanyan N, Bhatt VR, Bredeson C, Byrne M, Castillo P, Cerny J, Chhabra S, Ciurea SO, DeFilipp Z, Farhadfar N, Gadalla S, Gale RP, Ganguly S, Gowda L, Grunwald MR, Hashmi S, Hildebrandt G, Kanakry CG, Kansagra A, Khimani F, Krem M, Lazarus H, Liu H, Martino R, Michelis FV, Nathan S, Nishihori T, Olsson R, Reshef R, Rizzieri D, Rowe JM, Savani BN, Seo S, Sharma A, Solh M, Ustun C, Verdonck LF, Hourigan C, Sandmaier B, **Litzow M**, Kebriaei P, Weisdorf D, Zhang Y, Tallman MS, Saber W. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. *Blood Adv*. 2022 Jan 8; 6 (3):828-847 PMID: 34551064 PMCID: 8945306 DOI: 10.1182/bloodadvances.2021004881
490. Wieduwilt MJ, Metheny L, Zhang MJ, Wang HL, Estrada-Merly N, Marks DI, Al-Homsi AS, Muffly L, Chao N, Rizzieri D, Gale RP, Gadalla SM, Cairo M, Mussetti A, Gore S, Bhatt VR, Patel SS, Michelis FV, Inamoto Y, Badawy SM, Copelan E, Palmisiano N, Kharfan-Dabaja MA, Lazarus HM, Ganguly S, Bredeson C, Diaz Perez MA, Cassaday R, Savani BN, Ballen K, Martino R, Wirk B, Bacher U, Aljurf M, Bashey A, Murthy HS, Yared JA, Aldoss I, Farhadfar N, Liu H, Abdel-Aziz H, Waller EK, Solh M, Seftel MD, van der Poel M, Grunwald MR, Liesveld JL, Kamble RT, McGuirk J, Munker R, Cahn JY, Lee JW, Freytes CO, Krem MM, Winestone LE, Gergis U, Nathan S, Olsson RF, Verdonck LF, Sharma A, Ringden O, Friend BD, Cerny J, Choe H, Chhabra S, Nishihori T, Seo S, George B, Baxter-Lowe LA, Hildebrandt GC, de Lima M, **Litzow M**, Kebriaei P, Hourigan CS, Abid MB, Weisdorf DJ, Saber W. Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. *Blood Adv*. 2022 Jan 11; 6 (1):339-357 PMID: 34547770 PMCID: 8753217 DOI: 10.1182/bloodadvances.2021004916
491. Begna KH, Kittur J, Gangat N, Alkhateeb H, Patnaik MS, Al-Kali A, Elliott MA, Hogan WJ, **Litzow MR**, Pardananani A, Hanson CA, Ketterling RP, Tefferi A. European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response. *Blood Cancer J*. 2022 Jan 17; 12 (1):7 PMID: 35039473 PMCID: 8764050 DOI: 10.1038/s41408-022-00606-8
492. Alkhateeb HB, Nanaa A, Viswanatha D, Foran JM, Badar T, Sproat L, He R, Nguyen P, Jevremovic D, Salama ME, Greipp P, Gangat N, Tefferi A, **Litzow MR**, Mangaonkar AA, Shah MV, Patnaik M, Al-Kali A. Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms. *Blood Adv*. 2022 Jan 25; 6 (2):528-532 PMID: 34644397 PMCID: 8791578 DOI: 10.1182/bloodadvances.2021005738
493. He R, Chiou J, Chiou A, Chen D, Chen CP, Spethman C, Bessonon KR, Oliveira JL, Nguyen PL, Reichard KK, Hoyer JD, Althoff SD, Roh DJ, Miller MA, Yuan J, Olteanu H, Begna K, Tefferi A, Alkhateeb H, Patnaik MM, **Litzow MR**, Al-Kali A, Viswanatha DS. Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patients. *Blood Cancer J* 2022 Jan 25; 12 (1):12 PMID:

494. He R, Chiou J, Chiou A, Chen D, Chen CP, Spethman C, Bessonon KR, Oliveira JL, Nguyen PL, Reichard KK, Hoyer JD, Althoff SD, Roh DJ, Miller MA, Yuan J, Olteanu H, Begna K, Tefferi A, Alkhateeb H, Patnaik MM, **Litzow MR**, Al-Kali A, Viswanatha DS. Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patients. *Blood Cancer J*. 2022 Jan 25; 12(1):12. PMID: 35078969 PMCID: 8789920 DOI: 10.1038/s41408-022-00612-w
495. Abdel Rahman ZH, Parrondo RD, Heckman MG, Wieczorek M, Miller KC, Alkhateeb H, Sproat LZ, Murthy H, Hogan WJ, Kharfan-Dabaja MA, Peterson JF, Baughn LB, Hoppman N, **Litzow MR**, Ketterling RP, Greipp PT, Foran JM. Comparative study of therapy-related and de novo adult b-cell acute lymphoblastic leukaemia. *Br J Haematol*. 2022 Feb; 196 (4):963-968 Epub 2021 Oct 25 PMID: 34697797 PMCID: 9034764 DOI: 10.1111/bjh.17906
496. Luznik L, Pasquini MC, Logan B, Soiffer RJ, Wu J, Devine SM, Geller N, Giralt S, Heslop HE, Horowitz MM, Jones RJ, **Litzow MR**, Mendizabal A, Muffly L, Nemecek ER, O'Donnell L, O'Reilly RJ, Palencia R, Schetelig J, Shune L, Solomon SR, Vasu S, Ho VT, Perales MA. Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. *J Clin Oncol*. 2022 Feb 1; 40 (4):356-368 Epub 2021 Dec 02 PMID: 34855460 PMCID: 8797487 DOI: 10.1200/JCO.21.02293
497. Numan Y, Abdel Rahman Z, Grenet J, Boisclair S, Bewersdorf JP, Collins C, Barth D, Fraga M, Bixby DL, Zeidan AM, Yilmaz M, Desai P, Mannis G, Deutsch YE, Abaza Y, Dinner S, Frankfurt O, **Litzow M**, Al-Kali A, Foran JM, Sproat LZ, Jovanovic B, Daver N, Perl AE, Altman JK. Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors. *Am J Hematol*. 2022 Mar 1; 97 (3):322-328 Epub 2022 Jan 07 PMID: 34981560 DOI: 10.1002/ajh.26447
498. Rashkovan M, Albero R, Gianni F, Perez-Duran P, Miller HI, Mackey AL, Paietta EM, Tallman MS, Rowe JM, **Litzow MR**, Wiernik PH, Luger S, Sulis ML, Soni RK, Ferrando AA. Intracellular Cholesterol Pools Regulate Oncogenic Signaling and Epigenetic Circuitries in Early T-cell Precursor Acute Lymphoblastic Leukemia. *Cancer Discov*. 2022 Mar 1; 12 (3):856-871 PMID: 34711640 PMCID: 8904296 DOI: 10.1158/2159-8290.CD-21-0551
499. Guru Murthy GS, Kim S, Hu ZH, Estrada-Merly N, Abid MB, Aljurf M, Bacher U, Badawy SM, Beitinjaneh A, Bredeson C, Cahn JY, Cerny J, Diaz Perez MA, Farhadfar N, Gale RP, Ganguly S, Gergis U, Hildebrandt GC, Grunwald MR, Hashmi S, Hossain NM, Kalaycio M, Kamble RT, Kharfan-Dabaja MA, Hamilton BK, Lazarus HM, Liesveld J, **Litzow M**, Marks DI, Murthy HS, Nathan S, Nazha A, Nishihori T, Patel SS, Pawarode A, Rizzieri D, Savani B, Seo S, Solh M, Ustun C, van der Poel M, Verdonck LF, Vij R, Wirk B, Oran B, Nakamura R, Scott B, Saber W. Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. *JAMA Oncol*. 2022 Mar 1; 8 (3):404-411 PMID: 35024768 PMCID: 8759031 DOI: 10.1001/jamaoncol.2021.6846
500. May HP, Bartoo GT, Wolf RC, Shah MV, **Litzow MR**, Hogan WJ, Alkhateeb H. Use of sublingual tacrolimus in adults undergoing hematopoietic cell transplant: A pilot study. *J Oncol Pharm Pract*. 2022 Mar; 28 (2):387-394 Epub 2021 Feb 16 PMID: 33593135 DOI: 10.1177/1078155221995230
501. Wang J, Bhakta N, Ayer Miller V, Revsine M, **Litzow MR**, Paietta E, Fedoriw Y, Roberts KG, Gu Z, Mullighan CG, Jones CD, Alexander TB. Acute Leukemia Classification Using Transcriptional Profiles From Low-Cost Nanopore mRNA Sequencing. *JCO Precis Oncol*. 2022 Apr; 6:e2100326 PMID: 35442720 PMCID: 9200386 DOI: 10.1200/PO.21.00326
502. Begna KH, Xu X, Gangat N, Alkhateeb H, Patnaik MM, Al-Kali A, Elliott MA, Hogan WJ, **Litzow MR**, Hook CC, Wolanskyj-Spinner AP, Mangaonkar A, He R, Pardanani A, Shah M, Ketterling RP, Tefferi A. Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with "7+3". *Blood Cancer J* 2022 Apr 7; 12 (4):55 Epub 2022 Apr 07 PMID: 35393398 PMCID: 8989998 DOI: 10.1038/s41408-022-00654-0
503. Jimenez Jimenez AM, De Lima M, Komanduri KV, Wang TP, Zhang MJ, Chen K, Abdel-Azim H, Abid MB, Aljurf M, Alkhateeb H, Assal A, Bacher U, Baron F, Battiwalla M, Beitinjaneh A, Bejanyan N, Bhatt VR, Byrne M, Cahn JY, Cairo M, Castillo P, Copelan E, DeFilipp Z, Perez MAD, Elsayy M, Gale RP, George B, Grunwald MR, Hildebrandt GC, Hogan WJ, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Khera N, Krem MM, Lazaryan A, Maakaron J, Martino R, McGuirk J, Michelis FV, Milone G, Mishra A, Murthy HS, Mussetti A, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Patel S, Saad A, Seo S, Sharma A, Solh M, Verdonck LF, Wirk B, Yared JA, **Litzow M**, Kebriaei P, Hourigan CS, Saber W, Weisdorf D. Correction to: An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. *Bone Marrow Transplant*. 2022 May; 57 (5):852 PMID: 35297406 DOI: 10.1038/s41409-022-01625-6
504. Singh A, Al-Kali A, Begna KH, **Litzow MR**, Larsen JT, Sher T, Abdelmagid MG, Farrukh F, Reichard KK, Gangat N, Pardanani A, Tefferi A. Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases. *Am J Hematol*. 2022 May; 97 (5):630-637 Epub 2022 Feb 22 PMID: 35156231 DOI: 10.1002/ajh.26498
505. Mangaonkar AA, Lasho TL, Finke C, Ketterling RP, Reichard KK, McCullough K, Gangat N, Al-Kali A, Begna

- KH, Hogan WH, **Litzow MR**, Alkhateeb H, Shah M, Pardanani A, Tefferi A, Al Ali NH, Talati C, Sallman D, Padron E, Komrokji R, Patnaik MM. SF3B1-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity. *Haematologica*. 2022 May 1; 107 (5):1189-1192 Epub 2022 May 01 PMID: 35142154 PMCID: 9052897 DOI: 10.3324/haematol.2021.280463
506. Advani AS, Moseley A, O'Dwyer KM, Wood BL, Fang M, Wieduwilt MJ, Aldoss I, Park JH, Klisovic RB, Baer MR, Stock W, Bhave RR, Othus M, Harvey RC, Willman CL, **Litzow MR**, Stone RM, Sharon E, Erba HP. SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. *J Clin Oncol*. 2022 May 10; 40 (14):1574-1582 Epub 2022 Feb 14 PMID: 35157496 PMCID: 9084435 DOI: 10.1200/JCO.21.01766
507. Hetzel S, Mattei AL, Kretzmer H, Qu C, Chen X, Fan Y, Wu G, Roberts KG, Luger S, **Litzow M**, Rowe J, Paietta E, Stock W, Mardis ER, Wilson RK, Downing JR, Mullighan CG, Meissner A. Acute lymphoblastic leukemia displays a distinct highly methylated genome. *Nat Cancer*. 2022 Jun; 3 (6):768-782 Epub 2022 May 19 PMID: 35590059 PMCID: 9236905 DOI: 10.1038/s43018-022-00370-5
508. Maakaron JE, Zhang MJ, Chen K, Abhyankar S, Bhatt VR, Chhabra S, El Jurdi N, Farag SS, He F, Juckett M, de Lima M, Majhail N, van der Poel M, Saad A, Savani B, Ustun C, Waller EK, **Litzow M**, Kebriaei P, Hourigan CS, Saber W, Weisdorf D. Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis. *Bone Marrow Transplant*. 2022 Jun; 57 (6):911-917 Epub 2022 Apr 02 PMID: 35368040 PMCID: 9232949 DOI: 10.1038/s41409-022-01650-5
509. Kimura S, Montefiori L, Iacobucci I, Zhao Y, Gao Q, Paietta EM, Haferlach C, Laird AD, Mead PE, Gu Z, Stock W, **Litzow M**, Rowe JM, Luger SM, Hunger SP, Ryland GL, Schmidt B, Ekert PG, Oshlack A, Grimmond SM, Rehn J, Breen J, Yeung D, White DL, Aldoss I, Jabbour EJ, Pui CH, Meggendorfer M, Walter W, Kern W, Haferlach T, Brady S, Zhang J, Roberts KG, Blombery P, Mullighan CG. Enhancer retargeting of CDX2 and UBTf::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia. *Blood*. 2022 Jun 16; 139 (24):3519-3531 PMID: 35192684 PMCID: 9203703 DOI: 10.1182/blood.2022015444
510. Ghorab A, Al-Kali A, Elliot M, Gangat N, Alkhateeb H, Shah M, Liu Y, Yi CA, Murthy H, Kharfan-Dabaja M, Tefferi A, Patnaik M, **Litzow M**, Badar T. Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs. *Blood Cancer J* 2022 Jun 24; 12 (6):93 Epub 2022 June 24 PMID: 35750664 PMCID: 9232594 DOI: 10.1038/s41408-022-00691-9
511. Shah MV, Mangaonkar AA, Begna KH, Alkhateeb HB, Greipp P, Nanaa A, Elliott MA, Hogan WJ, **Litzow MR**, McCullough K, Tefferi A, Gangat N, Patnaik MM, Al-Kali A, He R, Chen D. Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms. *Blood Cancer J*. 2022 Jul 8; 12 (7):106 Epub 2022 July 08 PMID: 35803921 PMCID: 9270475 DOI: 10.1038/s41408-022-00703-8
512. Kutzke JL, Merten JA, Pawlenty AG, Barreto EF, Bartoo GT, Mara KC, **Litzow MR**, Hogan WJ, Shah MV, Mangaonkar AA, Leung N, Alkhateeb HB. Relationship of iothalamate clearance and NRM in patients receiving fludarabine and melphalan reduced-intensity conditioning. *Blood Adv*. 2022 Jul 12; 6 (13):3844-3849 PMID: 35522968 PMCID: 9278281 DOI: 10.1182/bloodadvances.2021006395
513. Shanafelt TD, Wang XV, Hanson CA, Paietta EM, O'Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba H, Stone RM, **Litzow M**, Tallman M, Kay NE. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. *Blood*. 2022 Jul 14; 140 (2):112-120 PMID: 35427411 PMCID: 9283968 DOI: 10.1182/blood.2021014960
514. Muffy L, Yin J, Jacobson S, Wall A, Quiroz E, Advani AS, Luger SM, Tallman MS, **Litzow MR**, Foster MC, Erba HP, Appelbaum FR, Larson RA, Keegan THM, Stock W. Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia. *Blood Adv*. 2022 Jul 26; 6 (14):4085-4092 PMID: 35838753 PMCID: 9327550 DOI: 10.1182/bloodadvances.2022007197
515. Alkhateeb HB, Mohty R, Greipp P, Bansal R, Hathcock M, Rosenthal A, Murthy H, Kharfan-Dabaja M, Bisneto Villasboas JC, Bennani N, Ansell SM, Patnaik MM, **Litzow MR**, He R, Chen D, Al-Kali A, Kenderian SS, Lin Y, Shah MV. Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma. *Blood Cancer J* 2022 Jul 26; 12 (7):113 Epub 2022 July 26 PMID: 35882844 PMCID: 9325766 DOI: 10.1038/s41408-022-00707-4
516. Tefferi A, Gangat N, Al-Kali A, Alkhateeb H, Shah M, Patnaik MS, Elliott MA, Hogan WJ, **Litzow MR**, Hook CC, Mangaonkar A, Viswanatha D, Chen D, Pardanani A, Ketterling RP, DiNardo CD, Kadia TM, Ravandi F, Sasaki K, Begna KH. A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy. *Am J Hematol*. 2022 Sep; 97 (9):1127-1134 Epub 2022 June 30 PMID: 35702875 DOI: 10.1002/ajh.26630
517. Johnson IM, Bezerra ED, Farrukh F, McCullough K, Al-Kali A, Alkhateeb HB, Begna K, **Litzow MR**, Hogan WJ, Shah MV, Patnaik MM, Tefferi A, Gangat N. Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents. *Blood Adv*. 2022 Sep 13; 6 (17):5227-5231 PMID: 35358999 PMCID: 9631636 DOI: 10.1182/bloodadvances.2022007333

518. Nanaa A, He R, Viswanatha D, Nguyen P, Jevremovic D, Foran JM, Yi CA, Greipp PT, Gangat N, Patnaik M, Tefferi A, **Litzow MR**, Mangaonkar AA, Shah MV, Badar T, Alkhateeb HB, Al-Kali A. Comparison between GATA2 and DDX41-mutated myeloid neoplasms. *Leuk Res* 2022 Oct; 121:106931 Epub 2022 Aug 23 PMID: 36037623 DOI: 10.1016/j.leukres.2022.106931
519. Tefferi A, Gangat N, Shah M, Alkhateeb H, Patnaik MS, Al-Kali A, Elliott MA, Hogan WJ, **Litzow MR**, Hook CC, Mangaonkar A, Viswanatha D, Chen D, Pardanani A, Ketterling RP, Begna KH. Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience. *Haematologica*. 2022 Oct 1; 107 (10):2474-2479 Epub 2022 Oct 01 PMID: 35734931 PMCID: 9521235 DOI: 10.3324/haematol.2022.281045
520. Gangat N, Johnson I#, McCullough K, Farrukh F, Al-Kali A, Alkhateeb H, Begna K, Mangaonkar A, **Litzow M**, Hogan W, Shah M, Patnaik M, Pardanani A, Tefferi A. Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naive acute myeloid leukemia. *Haematologica*. 2022 Oct 1; 107 (10):2501-2505 Epub 2022 Oct 01 PMID: 35770533 PMCID: 9521222 DOI: 10.3324/haematol.2022.281214
521. Jevremovic D, Nanaa A, Geyer SM, Timm M, Azouz H, Hengel C, Reberg A, He R, Viswanatha D, Salama ME, Shi M, Olteanu H, Horna P, Otteson G, Greipp PT, Xie Z, Alkhateeb HB, Hogan W, **Litzow M**, Patnaik MM, Shah M, Al-Kali A, Nguyen PL. Abnormal CD13/HLA-DR Expression Pattern on Myeloblasts Predicts Development of Myeloid Neoplasia in Patients With Clonal Cytopenia of Undetermined Significance. *Am J Clin Pathol*. 2022 Oct 6; 158 (4):530-536 PMID: 35938646 PMCID: 9535519 DOI: 10.1093/ajcp/aaqc083
522. Baranwal A, Nanaa A, Viswanatha D, He R, Foran J, Badar T, Hogan WJ, **Litzow MR**, Shah MV, Patnaik MM, Al-Kali A, Alkhateeb HB. Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemia. *Bone Marrow Transplant* 2022 Nov; 57 (11):1716-1718 Epub 2022 Aug 20 PMID: 35987913 PMCID: 9392432 DOI: 10.1038/s41409-022-01776-6
523. Katamesh B, Nanaa A, He R, Viswanatha D, Nguyen P, Greipp P, Foran J, Begna K, Gangat N, Patnaik M, Tefferi A, **Litzow M**, Mangaonkar A, Shah MV, Badar T, Alkhateeb HB, Al-Kali A. Autoimmune manifestations in STAG2-mutated myeloid neoplasms. *Ann Hematol* 2022 Dec; 101 (12):2785-2787 Epub 2022 Oct 03 PMID: 36184685 DOI: 10.1007/s00277-022-04995-5
524. Fernandez-Gutierrez JA, Reyes-Cisneros OA, **Litzow MR**, Bojalil-Alvarez L, Garcia-Villasenor E, Gomez-Gomez ET, Murrieta-Alvarez I, Gomez-Almaguer D, Gutierrez-Aguirre CH, Karduss-Urueta AJ, Ruiz-Delgado GJ, Ruiz-Arguelles GJ. High dose melphalan is an adequate preparative regimen for autologous hematopoietic stem cell transplantation in relapsed/refractory lymphoma. *Hematology*. 2022 Dec; 27 (1):449-455 PMID: 35413225 DOI: 10.1080/16078454.2022.2059630
525. Ganzel C, Sun Z, Baslan T, Zhang Y, Gonen M, Abdel-Wahab OI, Racevskis J, Garrett-Bakelman F, Lowe SW, Fernandez HF, Ketterling R, Luger SM, **Litzow M**, Lazarus HM, Rowe JM, Tallman MS, Levine RL, Paietta E. Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling. *Leuk Res*. 2022 Dec; 123:106971 Epub 2022 Oct 21 PMID: 36332294 PMCID: 9789386 DOI: 10.1016/j.leukres.2022.106971
526. Daver N, Perl AE, Maly J, Levis M, Ritchie E, **Litzow M**, McCloskey J, Smith CC, Schiller G, Bradley T, Tiu RV, Naqvi K, Dail M, Brackman D, Siddani S, Wang J, Chyla B, Lee P, Altman JK. Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia. *J Clin Oncol*. 2022 Dec 10; 40 (35):4048-4059 Epub 2022 July 18 PMID: 35849791 PMCID: 9746764 DOI: 10.1200/JCO.22.00602
527. Li Y, Moriyama T, Yoshimura S, Zhao X, Li Z, Yang X, Paietta E, **Litzow MR**, Konopleva M, Yu J, Inaba H, Ribeiro RC, Pui CH, Yang JJ. PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemia. *Sci Adv*. 2022 Dec 14; 8 (50):eadd6403 PMID: 36516256 PMCID: 9750140 DOI: 10.1126/sciadv.add6403
528. Tefferi A, Singh A, Gangat N, Al-Kali A, Alkhateeb H, Shah M, Patnaik MS, Elliott MA, Hogan WJ, **Litzow MR**, Wolanskyj-Spinner A, Hook CC, Mangaonkar A, Viswanatha D, Chen D, Pardanani A, Begna KH, Ketterling RP. Adverse karyotype subcategories in acute myeloid leukemia display significant differences in mutation composition and transplant-augmented survival. *Haematologica* 2023 Jan 1; 108 (1):245-249 Epub 2023 Jan 01 PMID: 36073516 PMCID: 9827171 DOI: 10.3324/haematol.2022.281495
529. Katamesh B#, Nanaa A#, He R, Viswanatha D, Nguyen P, Greipp P, Foran J, Begna K, Gangat N, Patnaik M, Tefferi A, **Litzow M**, Mangaonkar A, Shah MV, Badar T, Alkhateeb HB, Al-Kali A. Co-mutational pattern of somatic GATA2-mutated myeloid neoplasms. *Ann Hematol* 2023 Jan; 102 (1):211-212 Epub 2022 Nov 04 PMID: 36331566 DOI: 10.1007/s00277-022-05016-1
530. Mei M, Pillai R, Kim S, Estrada-Merly N, Afkhami M, Yang L, Meng Z, Abid MB, Aljurf M, Bacher U, Beitinjaneh A, Bredeson C, Cahn JY, Cerny J, Copelan E, Cutler C, DeFilipp Z, Diaz Perez MA, Farhadfar N, Freytes CO, Gadalla SM, Ganguly S, Gale RP, Gergis U, Grunwald MR, Hamilton BK, Hashmi S, Hildebrandt GC, Lazarus HM, **Litzow M**, Munker R, Murthy HS, Nathan S, Nishihori T, Patel SS, Rizzieri D, Seo S, Shah MV, Solh M, Verdonck LF, Vij R, Sobeks RM, Oran B, Scott BL, Saber W, Nakamura R. The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a

- Center for Blood and Marrow Transplantation Research (CIBMTR) analysis. *Haematologica*. 2023 Jan 1; 108 (1):150-160 Epub 2023 Jan 01 PMID: 35443559 PMCID: 9827167 DOI: 10.3324/haematol.2021.280203
531. Gangat N, Begna KH, Al-Kali A, Hogan W, **Litzow M**, Pardanani A, Tefferi A. Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor. *Blood Cancer J*. 2023 Jan 4; 13 (1):3 Epub 2023 Jan 04 PMID: 36599841 PMCID: 9813003 DOI: 10.1038/s41408-022-00780-9
 532. Aldoss I, Yin J, Wall A, Mrozek K, Liedtke M, Claxton DF, Foster MC, Appelbaum FR, Erba HP, **Litzow MR**, Tallman MS, Stone RM, Larson RA, Advani AS, Stock W, Luger SM. The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study. *Blood Adv*. 2023 Jan 24; 7 (2):196-204 PMID: 36269846 PMCID: 9841239 DOI: 10.1182/bloodadvances.2022007791
 533. Gangat N, Begna KH, Al-Kali A, Hogan W, **Litzow M**, Pardanani A, Tefferi A. Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival. *Am J Hematol*. 2023 Feb; 98 (2):282-289 Epub 2022 Nov 15 PMID: 36349465 DOI: 10.1002/ajh.26778
 534. Abdelmagid MG, Al-Kali A, Begna KH, Hogan WJ, **Litzow MR**, Fleti F, Mangaonkar AA, Patnaik MS, Elliott MA, Alkhateeb H, Shi M, Howard MT, Reichard KK, Ketterling RP, Shah M, Pardanani A, Gangat N, Tefferi A. Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival. *Haematologica*. 2023 Feb 16 [Epub ahead of print] PMID: 36794509 DOI: 10.3324/haematol.2022.282627
 535. Al-Kali A, Tibes R, Atherton P, Palmer J, Alkhateeb HB, Patnaik M, Begna K, Gangat N, Hashmi S, He R, **Litzow M**. A phase II study of combination daunorubicin, cytarabine (Ara-c), and nilotinib (TAsigna) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expression. *Am J Hematol*. 2023 Mar; 98 (3):472-480 Epub 2023 Jan 22 PMID: 36625066 DOI: 10.1002/ajh.26831
 536. Singhal S, Saadeh SS, Durani U, Kansagra A, Alkhateeb HB, Shah MV, Mangaonkar A, Kenderian S, Hashmi S, Patnaik MV, **Litzow MR**, Hogan WJ. Allogeneic Hematopoietic Stem Cell Transplantation in the Outpatient Setting: The Mayo Clinic Experience. *Transplant Cell Ther*. 2023 Mar; 29 (3):183.e1-183.e6 Epub 2022 Dec 28 PMID: 36584940 DOI: 10.1016/j.jct.2022.12.016
 537. Moyer AM, Hashmi SK, Kroning CM, Patnaik M, **Litzow M**, Gastineau DA, Hogan WJ, Jacob EK, Kreuter JD, Wakefield LL, Gandhi MJ. Clinical impact of KIR haplotypes in 10/10 HLA-matched unrelated donor-recipient pairs undergoing allogeneic hematopoietic stem cell transplantation. *Leuk Lymphoma*. 2023 Mar; 64 (3):671-678 Epub 2022 Nov 30 PMID: 36448323 DOI: 10.1080/10428194.2022.2151838
 538. Gangat N, Ilyas R, Johnson IM, McCullough K, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar A, **Litzow MR**, Hogan W, Shah M, Patnaik MM, Pardanani A, Tefferi A. Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy. *Haematologica*. 2023 Mar 2 Epub 2023 Mar 02 PMID: 36861409 DOI: 10.3324/haematol.2022.282677
 539. Hiwase D, Hahn C, Tran ENH, Chhetri R, Baranwal A, Al-Kali A, Sharplin K, Ladon D, Hollins R, Greipp P, Kutyna M, Alkhateeb H, Badar T, Wang P, Ross DM, Singhal D, Shanmuganathan N, Bardy P, Beligaswatte A, Yeung D, **Litzow MR**, Mangaonkar A, Giri P, Lee C, Yong A, Horvath N, Singhal N, Gowda R, Hogan W, Gangat N, Patnaik M, Begna K, Tiong IS, Wei A, Kumar S, Brown A, Scott H, Thomas D, Kok CH, Tefferi A, Shah MV. TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype. *Blood*. 2023 Mar 2; 141 (9):1087-1091 PMID: 36574363 DOI: 10.1182/blood.2022018236
 540. Dillon LW, Gui G, Page KM, Ravindra N, Wong ZC, Andrew G, Mukherjee D, Zeger SL, El Chaer F, Spellman S, Howard A, Chen K, Auletta J, Devine SM, Jimenez Jimenez AM, De Lima MJG, **Litzow MR**, Kebriaei P, Saber W, Weisdorf DJ, Hourigan CS. DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant. *JAMA*. 2023 Mar 7; 329 (9):745-755 PMID: 36881031 PMCID: 9993183 DOI: 10.1001/jama.2023.1363
 541. Badar T, **Litzow MR**, Shallis RM, Patel A, Saliba AN, Burkart M, Bewersdorf JP, Stahl M, De Camargo Correia GS, Guru Murthy GS, Abaza Y, Duvall A, Bradshaw D, Kota V, Dinner S, Goldberg AD, Palmisiano N, Al Kali A, Atallah E. Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemia. *Cancer*. 2023 Mar 15; 129(6):934-945. Epub 2022 Dec 21. PMID: 36545710 DOI: 10.1002/cncr.34604
 542. Badar T, Atallah E, Shallis R, Saliba AN, Patel A, Bewersdorf JP, Grenet J, Stahl M, Duvall A, Burkart M, Palmisiano N, Bradshaw D, Kubiak M, Dinner S, Goldberg AD, Abaza Y, Murthy GSG, Kota V, **Litzow MR**. Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). *Leukemia*. 2023 Apr; 37 (4):799-806 Epub 2023 Feb 18 PMID: 36807649 DOI: 10.1038/s41375-023-01847-7
 543. Al-Kali A#, Nanaa A, Viswanatha D, He R, Nguyen P, Jevremovic D, Foran JM, Yi CA, Greipp PT, Gangat N, Patnaik M, Tefferi A, **Litzow MR**, Mangaonkar AA, Shah MV, Badar T, Alkhateeb HB. Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome. *Blood Cancer J* 2023

Apr 10; 13 (1):49 PMID: 37032414 PMCID: 10083167 DOI: 10.1038/s41408-023-00818-6

544. Advani AS, Moseley A, O'Dwyer KM, Wood BL, Park J, Wieduwilt M, Jeyakumar D, Yaghmour G, Atallah EL, Gerds AT, O'Brien SM, Liesveld JL, Othus M, **Litzow M**, Stone RM, Sharon E, Erba HP. Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia. *Blood Adv.* 2023 Apr 11; 7 (7):1279-1285 PMID: 36322825 PMCID: 10090098 DOI: 10.1182/bloodadvances.2022008216
545. Katamesh B, Nanaa A, He R, Viswanatha D, Nguyen P, Greipp P, Bessonon K, Gangat N, Begna K, Mangaonkar A, Patnaik M, Hogan WJ, Tefferi A, **Litzow M**, Shah MV, Yi CA, Foran J, Badar T, Alkhateeb HB, Al-Kali A. Clinical and prognostic impact of STAG2 mutations in myeloid neoplasms: the Mayo Clinic experience. *Blood Adv.* 2023 Apr 25; 7 (8):1351-1355 PMID: 36477202 PMCID: 10139934 DOI: 10.1182/bloodadvances.2022007937
546. Boyiadzis M, Zhang MJ, Chen K, Abdel-Azim H, Abid MB, Aljurf M, Bacher U, Badar T, Badawy SM, Battiwalla M, Bejanyan N, Bhatt VR, Brown VI, Castillo P, Cerny J, Copelan EA, Craddock C, Dholaria B, Perez MAD, Ebens CL, Gale RP, Ganguly S, Gowda L, Grunwald MR, Hashmi S, Hildebrandt GC, Iqbal M, Jamy O, Kharfan-Dabaja MA, Khera N, Lazarus HM, Lin R, Modi D, Nathan S, Nishihori T, Patel SS, Pawarode A, Saber W, Sharma A, Solh M, Wagner JL, Wang T, Williams KM, Winestone LE, Wirk B, Zeidan A, Hourigan CS, **Litzow M**, Kebriaei P, de Lima M, Page K, Weisdorf DJ. Correction to: Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113AML patients. *Leukemia.* 2023 May; 37 (5):1173 PMID: 36949156 DOI: 10.1038/s41375-023-01814-2
547. Boyiadzis M, Zhang MJ, Chen K, Abdel-Azim H, Abid MB, Aljurf M, Bacher U, Badar T, Badawy SM, Battiwalla M, Bejanyan N, Bhatt VR, Brown VI, Castillo P, Cerny J, Copelan EA, Craddock C, Dholaria B, Perez MAD, Ebens CL, Gale RP, Ganguly S, Gowda L, Grunwald MR, Hashmi S, Hildebrandt GC, Iqbal M, Jamy O, Kharfan-Dabaja MA, Khera N, Lazarus HM, Lin R, Modi D, Nathan S, Nishihori T, Patel SS, Pawarode A, Saber W, Sharma A, Solh M, Wagner JL, Wang T, Williams KM, Winestone LE, Wirk B, Zeidan A, Hourigan CS, **Litzow M**, Kebriaei P, de Lima M, Page K, Weisdorf DJ. Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients. *Leukemia.* 2023 May; 37 (5):1006-1017 Epub 2022 Oct 30 PMID: 36310182 PMCID: 10148918 DOI: 10.1038/s41375-022-01738-3
548. Matin A, Smith BH, Mangaonkar A, Duffy DJ, Wolf R, Alkhateeb H, Shah MV, Hogan WJ, **Litzow MR**. Pericardial Effusion as a Purported Manifestation of Graft-versus-Host Disease following Allogeneic Hematopoietic Cell Transplantation. *Transplant Cell Ther.* 2023 May; 29 (5):324.e1-324.e6 Epub 2023 Jan 20 PMID: 36682472 DOI: 10.1016/j.jtct.2023.01.019
549. Vekariya U, Toma M, Nieborowska-Skorska M, Le BV, Caron MC, Kukuyan AM, Sullivan-Reed K, Podszycalow-Bartnicka P, Chitralla KN, Atkins J, Drzewiecka M, Feng W, Chan J, Chatla S, Golovine K, Jelinek J, Sliwinski T, Ghosh J, Matlawska-Wasowska K, Chandramouly G, Nejati R, Wasik M, Sykes SM, Piwocka K, Hadzijušević E, Valent P, Pomerantz RT, Morton G, Childers W, Zhao H, Paietta EM, Levine RL, Tallman MS, Fernandez HF, **Litzow MR**, Gupta GP, Masson JY, Skorski T. DNA polymerase theta protects leukemia cells from metabolically induced DNA damage. *Blood.* 2023 May 11; 141 (19):2372-2389 PMID: 36580665 PMCID: 10273171 DOI: 10.1182/blood.2022018428
550. Badar T, Nanaa A, Foran JM, Viswanatha D, Al-Kali A, Lasho T, Finke C, Alkhateeb HB, He R, Gangat N, Shah M, Tefferi A, Mangaonkar AA, **Litzow MR**, Ongie LJ, Chlon T, Ferrer A, Patnaik MM. Clinical and molecular correlates of somatic and germline DDX41 variants in patients and families with myeloid neoplasms. *Haematologica.* 2023 May 18 [Epub ahead of print] PMID: 37199125 DOI: 10.3324/haematol.2023.282867
551. Acosta-Medina AA, Baranwal A, Johnson IM, Kharfan-Dabaja MA, Murthy H, Palmer JM, Sproat L, Mangaonkar A, Shah MV, Hogan WJ, **Litzow MR**, Tefferi A, Alkhateeb HB. Comparison of Pretransplantation Prediction Models for Nonrelapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation. *Transplant Cell Ther.* 2023 Jun; 29 (6):360.e1-360.e8 Epub 2023 Feb 09 PMID: 36773650 DOI: 10.1016/j.jtct.2023.02.002
552. Zarnegar-Lumley S, Alonzo T, Gerbing RB, Othus M, Sun Z, Ries RE, Wang J, Leonti AR, Kutny MA, Ostronoff F, Radich JP, Appelbaum FR, Pogossova-Agadjanyan EL, O'Dwyer KM, Tallman MS, **Litzow MR**, Atallah E, Cooper TM, Aplenc R, Abdel-Wahab OI, Gamis AS, Luger SM, Erba HP, Levine RL, Kolb EA, Stirewalt DL, Meshinchi S, Tarlock K. Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, ECOG analysis. *Blood Adv.* 2023 Jun 2 Epub 2023 June 02 PMID: 37267439 DOI: 10.1182/bloodadvances.2022008282
553. Saliba AN, Kaufmann SH, Stein EM, Patel PA, Baer MR, Stock W, Deininger M, Blum W, Schiller GJ, Olin RL, **Litzow MR**, Lin TL, Ball BJ, Boyiadzis MM, Traer E, Odenike O, Arellano ML, Walker A, Duong VH, Kovacsovics T, Collins RH, Shoben AB, Heerema NA, Foster MC, Peterson KL, Schneider PA, Martycz M, Gana TJ, Rosenberg L, Marcus S, Yocum AO, Chen T, Stefanos M, Mims AS, Borate U, Burd A, Druker BJ, Levine RL, Byrd JC, Foran JM. Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates. *Blood Adv.* 2023 Jun 13; 7 (11):2360-2363 PMID: 36315007 PMCID: 10230164 DOI: 10.1182/bloodadvances.2022008625

554. Gangat N, Kuykendall A, Al Ali N, Goel S, Abdelmagid M, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar A, **Litzow MR**, Hogan W, Shah M, Patnaik MM, Pardanani A, Komrokji R, Tefferi A. Black African-American patients with primary myelofibrosis: a comparative analysis of phenotype and survival. *Blood Adv*. 2023 Jun 27; 7 (12):2694-2698 PMID: 36780345 PMCID: 10333736 DOI: 10.1182/bloodadvances.2022009611
555. Murthy GSG, Kim S, Estrada-Merly N, Abid MB, Aljurf M, Assal A, Badar T, Badawy SM, Ballen K, Beitinjaneh A, Cerny J, Chhabra S, DeFilipp Z, Dholaria B, Perez MAD, Farhan S, Freytes CO, Gale RP, Ganguly S, Gupta V, Grunwald MR, Hamad N, Hildebrandt GC, Inamoto Y, Jain T, Jamy O, Juckett M, Kalaycio M, Krem MM, Lazarus HM, **Litzow M**, Munker R, Murthy HS, Nathan S, Nishihori T, Orti G, Patel SS, Van der Poel M, Rizzieri DA, Savani BN, Seo S, Solh M, Verdonck LF, Wirk B, Yared JA, Nakamura R, Oran B, Scott B, Saber W. Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis. *Haematologica*. 2023 Jul 1; 108 (7):1900-1908 Epub 2023 July 01 PMID: 36779595 PMCID: 10316233 DOI: 10.3324/haematol.2022.281958
556. Baranwal A, Chhetri R, Yeung D, Clark M, Shah S, **Litzow MR**, Hogan WJ, Mangaonkar A, Alkhateeb HB, Singhal D, Cibich A, Bardy P, Kok CH, Hiwase DK, Shah MV. Factors predicting survival following alloSCT in patients with therapy-related AML and MDS: a multicenter study. *Bone Marrow Transplant*. 2023 Jul; 58 (7):769-776 Epub 2023 Apr 03 PMID: 37012415 DOI: 10.1038/s41409-023-01970-0
557. Gurney M, Chekkaf I, Baranwal A, Basmaci R, Katamesh B, Greipp P, Foran JM, Badar T, Mangaonkar AA, Begna KH, Gangat N, Patnaik MM, **Litzow MR**, Shah MV, Viswanatha DS, He R, Alkhateeb HB, Al-Kali A. The clinical and molecular spectrum of ETV6 mutated myeloid neoplasms. *Br J Haematol*. 2023 Jul; 202 (2):279-283 Epub 2023 May 05 PMID: 37144345 DOI: 10.1111/bjh.18850
558. Abid MB, Estrada-Merly N, Zhang MJ, Chen K, Allan D, Bredeson C, Sabloff M, Guru Murthy GS, Badar T, Hashmi S, Aljurf M, **Litzow MR**, Kebriaei P, Hourigan CS, Saber W. Impact of Donor Age on Allogeneic Hematopoietic Cell Transplantation Outcomes in Older Adults with Acute Myeloid Leukemia. *Transplant Cell Ther*. 2023 Jul 3 Epub 2023 July 03 PMID: 37406882 DOI: 10.1016/j.jtct.2023.06.020
559. Borate U, Yang F, Press RD, Ruppert AS, Jones D, Caruthers S, Zhao W, Vergilio JA, Pavlick D, Juckett L, Norris BA, Bucy T, Burd A, Stein EM, Patel PA, Baer MR, Stock W, Schiller GJ, Blum W, Kovacsovics TJ, **Litzow MR**, Foran JM, Heerema NA, Rosenberg L, Marcus S, Yocum AO, Stefanos M, Druker BJ, Mims AS. AML Samples Show High Concordance in Detection of Mutations by NGS at Local Institutions versus Central Laboratories. *Blood Adv*. 2023 Jul 17 Epub 2023 July 17 PMID: 37459200 DOI: 10.1182/bloodadvances.2022009008
560. Abid MB, Estrada-Merly N, Zhang MJ, Chen K, Bredeson C, Allan D, Sabloff M, Marks DI, **Litzow M**, Hourigan C, Kebriaei P, Saber W. Younger Matched Unrelated Donors Confer Decreased Relapse Risk Compared to Older Sibling Donors in Older Patients with B Cell Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. *Transplant Cell Ther*. 2023 Jul 21 Epub 2023 July 21 PMID: 37481243 DOI: 10.1016/j.jtct.2023.07.015
561. Park CS, Yoshihara H, Gao Q, Qu C, Iacobucci I, Ghate PS, Connelly JP, Pruett-Miller SM, Wagner B, Robinson CG, Mishra A, Peng J, Yang L, Rankovic Z, Finkelstein D, Luger S, **Litzow M**, Paietta EM, Hebban N, Velasquez MP, Mullighan CG. Stromal-induced epithelial-mesenchymal transition induces targetable drug resistance in acute lymphoblastic leukemia. *Cell Rep*. 2023 Jul 25; 42 (7):112804 Epub 2023 July 14 PMID: 37453060 DOI: 10.1016/j.celrep.2023.112804
562. Khurana S, Heckman MG, Craig FE, Cochuyt JJ, Greipp P, Rahman ZA, Sproat LZ, **Litzow M**, Foran JM, Jiang LJ. Evaluation of Novel Targets, Including CC-Chemokine Receptor 4, in Adult T-Cell Acute Lymphoblastic Leukemia/Lymphoma. *Arch Pathol Lab Med*. 2023 Jul 27 Epub 2023 July 27 PMID: 37522711 DOI: 10.5858/arpa.2022-0482-OA
563. Duong VH, Ruppert AS, Mims AS, Borate U, Stein EM, Baer MR, Stock W, Kovacsovics T, Blum W, Arellano ML, Schiller GJ, Olin RL, Foran JM, **Litzow MR**, Lin TL, Patel PA, Foster MC, Redner RL, Al-Mansour Z, Cogle CR, Swords RT, Collins RH, Vergilio JA, Heerema NA, Rosenberg L, Yocum AO, Marcus S, Chen T, Druggan F, Stefanos M, Gana TJ, Shoben AB, Druker BJ, Burd A, Byrd JC, Levine RL, Boyiadzis MM. Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial. *Cancer*. 2023 Aug 1; 129 (15):2308-2320 Epub 2023 Apr 20 PMID: 37078412 DOI: 10.1002/cncr.34780
564. Tibes R, Kosiorek HE, Dueck AC, Palmer J, Sproat L, Bogenberger J, Hashmi S, Mesa R, Hogan W, **Litzow MR**, Al-Kali A. Phase 1/1b study of azacitidine and hedgehog pathway inhibitor sonidegib in patients with myeloid neoplasms. *Cancer*. 2023 Aug 1; 129 (15):2321-2330 Epub 2023 Apr 11 PMID: 37042080 DOI: 10.1002/cncr.34800
565. Harris LN, Blanke CD, Erba HP, Ford JM, Gray RJ, LeBlanc ML, Hu-Lieskovan S, **Litzow MR**, Luger SM, Meric-Bernstam F, O'Dwyer PJ, Othus MKD, Politi K, Shepherd LE, Allegra CJ, Chen HX, Ivy SP, Korde LA, Little RF, McShane LM, Moscow JA, Patton DR, Thurin M, Yee LM, Doroshow JH. The New NCI Precision Medicine Trials. *Clin Cancer Res*. 2023 Aug 2 Epub 2023 Aug 02 PMID: 37531248 DOI: 10.1158/1078-0432.CCR-23-0917

566. Gangat N, McCullough K, Abdelmagid M, Karrar O, Powell M, Al-Kali A, Alkhateeb H, Begna K, Mangaonkar A, Saliba A, Torghabeh MH, **Litzow M**, Hogan W, Shah M, Patnaik M, Pardanani A, Badar T, Foran J, Palmer J, Sproat L, Yi CA, Tefferi A. Molecular predictors of response and survival following IDH1/2 inhibitor monotherapy in acute myeloid leukemia. *Haematologica*. 2023 Aug 3 Epub 2023 Aug 03 PMID: 37534525 DOI: 10.3324/haematol.2023.283732
567. Tamari R, McLornan DP, Ahn KW, Estrada-Merly N, Hernandez-Boluda JC, Giralt S, Palmer J, Gale RP, DeFilipp Z, Marks D, van der Poel M, Verdonck LF, Battiwalla M, Diaz MA, Gupta V, Ali H, **Litzow MR**, Lazarus HM, Gergis U, Bashey A, Liesveld J, Hashmi S, Pu JJ, Beitinjaneh A, Bredeson C, Rizzieri D, Savani BN, Abid MB, Ganguly S, Agrawal V, Ulrike Bacher V, Wirk B, Jain T, Cutler C, Aljurf M, Kindwall-Keller T, Kharfan-Dabaja MA, Hildebrandt GC, Pawarode A, Solh MM, Yared JA, Grunwald MR, Nathan S, Nishihori T, Seo S, Scott BL, Nakamura R, Oran B, Czerw T, Yakoub-Agha I, Saber W. A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis. *Blood Adv*. 2023 Aug 8; 7 (15):3993-4002 PMID: 37134306 DOI: 10.1182/bloodadvances.2023009886
568. Foran JM, Sun Z, Lai C, Fernandez HF, Cripe LD, Ketterling RP, Racevskis J, Luger SM, Paietta E, Lazarus HM, Zhang Y, Bennett JM, Levine RL, Rowe JM, **Litzow MR**, Tallman MS. Obesity in adult acute myeloid leukemia is not associated with inferior response or survival even when dose capping anthracyclines: An ECOG-ACRIN analysis. *Cancer*. 2023 Aug 15; 129 (16):2479-2490 Epub 2023 Apr 25 PMID: 37185873 DOI: 10.1002/cncr.34807

Books

1. **Litzow MR**, Raetz EA. Clinical management of acute lymphoblastic leukemia: from bench to bedside. Springer Nature: 2022. 437 p..

Book Chapters

1. **Litzow MR**, Letendre L, Kaufmann SH. Acute leukemia in adults. In: Rakel RE, editor. Conn's Current Therapy 2000. Philadelphia: W. B. Saunders Company; 2000. p. 413-21.
2. **Litzow MR**. Acute leukemia. In: Tefferi A, editor. Primary Hematology. Totowa: Humana Press; 2001. p. 193-208.
3. **Litzow MR**. Blood and marrow transplantation. In: Tefferi A, editor. Primary Hematology. Totowa: Humana Press; 2001. p. 209-27.
4. **Litzow MR**. Blood and marrow transplantation. In: Hakim NS, Danovitch GM, editors. Transplantation Surgery. London: Springer; 2001. p. 295-341.
5. Dewald G, **Litzow M**. Cytogenetics of acute leukemia. In: Wiernik PH, Goldman JM, Dutcher JP, Kyle RA, editors. Neoplastic diseases of the blood. 4th Edition. Cambridge: Cambridge University Press; 2003. p. 232-48.
6. **Litzow MR**. BCR-ABL Mutations and Imatinib Resistance in Chronic Myeloid Leukemia Patients. In: Innocenti F. Cancer Drug Discovery and Development: Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response. 1st ed. Humana Press; 2008. p. 127-50.
7. **Litzow MR**. Late consequences of therapy of acute lymphoblastic leukemia. In: Advani AS; Lazarus HM editor. Adult acute lymphocytic leukemia: biology and treatment. New York: Humana Press; 2011. (Contemporary Hematology.). p. 331-49.
8. Hashmi S, **Litzow MR**. Late effects after allogeneic hematopoietic stem cell transplantation. In: Savani BN editor. Blood and marrow transplantation long-term management: prevention and complications. Chichester; Hoboken: Wiley Blackwell; 2013. p. 21-30.
9. **Litzow MR**, Shastri A. Leukemias and Other Myeloid Neoplasms. In: Levy, Benjamin P, editor(s). ASCO-SEP Medical Oncology Self-Evaluation Program. 7 ed. Chapter 19. 2020. p. 573.

Editorials

1. **Litzow MR.** PNAs for AML. *Blood*. 2003 Oct 1; 102(7):2315.
2. Tefferi A, **Litzow M.** Chronic phase chronic myeloid leukemia: More drugs, more lives saved, new challenges. *Oncology (Williston Park)* 2007 May; 21(6):664, 667-8.
3. **Litzow MR.** Adult Acute Lymphoblastic Leukemia. *Hematology Web Focus*. 2011 Oct.
4. Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill J, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, **Litzow MR**, Mohty M, Hashmi SK. Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2019 Mar; 25 (3):e76-e85 Epub 2018 Dec 18
5. **Litzow MR.** The increasing complexity of the management of core-binding factor acute myeloid leukemia. *Haematologica* 2020 Jun; 105 (6):1475-1477

Commentaries

1. **Litzow MR.** Is autologous progenitor cell mobilization getting any easier? *Leuk Lymphoma* 2007 Dec; 48 (12):2304-5 PMID:18067002 DOI:10.1080/10428190701671085
2. **Litzow MR.** TKIs and transplant for chronic myeloid leukemia. *Leuk Res*. 2010 Feb; 34(2):137-8. Epub 2009 Aug 03. PMID:19651441 DOI:10.1016/j.leukres.2009.07.018
3. Lazarus HM, **Litzow MR.** AML cytogenetics: the complex just got simpler. *Blood* 2012 Sep 20; 120 (12):2357-8 PMID:22996657 DOI:10.1182/blood-2012-08-448555
4. **Litzow MR**, Moynihan TJ. Hospice and where the doctor can be. *J Clin Oncol* 2013 Oct 10; 31 (29):3723 Epub 2013 Sept 09 PMID:24019542 DOI:10.1200/JCO.2013.51.6492
5. Lazarus HM, **Litzow MR**, Gale RP. Improving survival in acute myeloid leukemia: pick the best subjects? *J Clin Oncol*. 2013 Nov 1; 31(31):3854-6. Epub 2013 Sep 23. PMID:24062404 DOI:10.1200/JCO.2013.52.0296
6. **Litzow MR.** Finally moving forward in adult ALL. *Blood* 2015 Apr 16; 125 (16):2453-4 PMID:25883226 DOI:10.1182/blood-2015-02-623793
7. Vinod Shah M, **Litzow MR.** Emerging role of CEBP-alpha mutations in acute myeloid leukemia. *Eur J Haematol* 2015 Aug; 95 (2):99-100 PMID:26148898 DOI:10.1111/ejh.12489

Abstracts

1. **Litzow MR.** C1 esterase inhibitor deficiency and angioedema in a patient with non-Hodgkin's lymphoma and a paraprotein: a case report and review of the literature. (Abstract) Associates Program, Minnesota Chapter Meeting of the ACP. 1983 Oct.
2. **Litzow MR**, Solberg LA Jr, Oles KJ, Gertz MA. Deficiency of a plasma factor necessary for optimum megakaryocytic growth in vitro in a member of a kindred with autosomal dominant thrombocytopenia (T). (Abstract no. 1232). *Blood*. 1988 Nov; (Suppl):330A.
3. **Litzow MR**, Solberg LA Jr, Jenkins RB, Therneau T. In vitro culture and recombinant gamma interferon (r-IFN-gamma) increase the percentage of cytogenetically normal bone marrow (BM) cells in patients (PTS) with myelodysplastic syndromes (MDS). (Abstract no. 1487). *Blood*. 1988 Nov; 72(Suppl 1):394A.
4. **Litzow MR**, Petersen FB, Appelbaum FR, Buckner CD. Autologous versus allogeneic bone marrow transplantation (BMT) for Hodgkin's disease. (Abstract no. 2189). *Blood*. 1990 Nov 15; 76(Suppl 1):550A.
5. **Litzow MR**, Andrews RG, Bernstein ID. CD34+CD33-7B9-marrow cells have high proliferative potential and can be distinguished from CD34+CD33+7B9-marrow cells on the basis of their proliferative responses to IL-3 and G-CSF. (Abstract 403). *Blood*. 1990 Nov 15; 76(Suppl 1):103A.
6. Dhodapkar MV, Thibodeau SN, Lust JA, **Litzow MR.** Hypermethylation of the calcitonin gene as a marker for clonality in myelodysplastic syndromes. (Abstract no. 136). *Exp Hematol*. 1993 Aug; 21:1047.
7. Gertz MA, Pineda AA, Chen MG, Letendre L, Greipp PR, Solberg LA Jr, Witzig TE, Garton JP, Inwards DJ, **Litzow MR**, Tefferi A, Kyle RA, Noel P. High-dose melphalan cyclophosphamide and total body irradiation followed by peripheral blood stem cell rescue in refractory and relapsing multiple myeloma. *Clin Res*. 1993 Oct; 41:647A.
8. **Litzow MR.** Bone marrow transplantation for solid tumors: update. *Hematology/Oncology Update: Current Issues and Controversies*. 1994; 1-10.

9. **Litzow MR.** Management of acute myelogenous leukemia: treatment options. Hematology/Oncology Update: Current Issues and Controversies. 1994; 1-12.
10. **Litzow MR.** Management of acute non-lymphocytic leukemia: treatment options. Hematology/Oncology Update: Current Issues and Controversies. 1994; 1-8.
11. Gertz MA, Witzig TE, Pineda AA, Greipp PR, Kyle RA, **Litzow MR.** Monoclonal plasma cells in the peripheral blood stem cell harvest of patients with multiple myeloma is associated with shortened relapse-free survival following transplantation. Clin Res. 1995; 43(Suppl 3):482a.
12. Gertz MA, Witzig TE, Pineda AA, Greipp PR, Kyle RA, **Litzow MR.** Monoclonal plasma cells in the peripheral blood stem cell harvest of patients with multiple myeloma is associated with shortened relapse-free survival following transplantation. Journal of Investigative Medicine. 1995 Sep; 43(Suppl):482A.
13. Peethambaram PP, Okuno SH, Daniels TM, **Litzow MR,** Nichols WL. Acquired Glanzmann's thrombasthenia (GT) in a patient with chronic large granular lymphocytic leukemia (CLGLL). (Abstract 3389). Blood. 1995 Nov 15; 86(Suppl 1):850A.
14. Chen MG, **Litzow MR,** Tefferi A, Myers JL, Letendre L, Gastineau DA, Gertz MA, Inwards DJ, Huneke NE, Schroeder G, Skaar MR, Moore SB, Hoagland HC. Analysis of incidence, outcome, and risk factors for non-specific interstitial pneumonitis after allogeneic and autologous bone marrow transplantation (BMT) for hematologic malignancies. (Abstract no. 2259). Blood. 1995 Nov 15; 86(Suppl 1):568A.
15. Gertz MA, Witzig TE, Pineda AA, Greipp PR, Kyle RA, **Litzow MR.** Monotypic plasma cells in the peripheral blood stem cell harvest of patients with multiple myeloma is associated with shortened relapse-free survival following transplantation. (Abstract no. 817). Blood. 1995 Nov 15; 86(Suppl 1):207A.
16. **Litzow MR,** Repoussis P, Gertz MA, Rhodes KH, Gastineau DA, Inwards DJ, Lacy MQ, Tefferi A, Keating MR. Importance of streptococcal viridans bacteremia in morbidity and mortality post stem cell transplantation. (Abstract). ASH. 1996.
17. List A, Stiff P, Maziarz R, Jansen J, Liesveld J, Schuster M, Andrews DF, Karanes C, Wolff W, **Litzow M.** Lisofylline (LSF) reduces infection rate and improves survival in patients undergoing allogeneic bone marrow transplant (BMT): results of a randomized, placebo-controlled trial (Abstracts). Blood. 88:459a, 1996.
18. Kuffel D, Zinsmeister AR, Lindor N, **Litzow M,** Dewald G. A discriminant function using mitomycin C stress test to identify Fanconi anemia. (Abstract 108). Am J Hum Genet. 1996 Oct; 59(4 Suppl):A23.
19. **Litzow M,** Repoussis P, Gertz M, Rhodes K, Gastineau D, Inwards D, Lacy M, Tefferi A, Keating M. Importance of streptococcal viridans bacteremia in morbidity and mortality post stem cell transplantation (SCT). ASBMT/AACR Meeting, 1996 Oct.
20. Hanson CA, Hoyer JD, **Litzow MR,** Dewald GW. 12p11 abnormalities in hematologic diseases: a morphologic, cytogenetic, and clinical review (Abstract 736). Lab Invest. 1997; 76(1):126A.
21. Gertz MA, Lacy MQ, Inwards DJ, Pineda AA, Chen MG, Gastineau DA, Tefferi A, Kyle RA, **Litzow MR.** Factors influencing platelet recovery following blood cell transplantation in multiple myeloma. (Abstract 36). Program/Proc Am Soc Clin Oncol. 1997; 16:11a.
22. Rajkumar SV, Fonseca R, Lacy MQ, Witzig TE, Lust JA, Greipp PR, Kyle RA, **Litzow MR,** Gertz MA. Abnormal cytogenetics predict for poor survival after peripheral blood stem cell transplantation in relapsed multiple myeloma. (Abstract 2348 407-IV). Blood. 1997 Nov 15; 90(10 Suppl 1 part 1):527a.
23. Inwards DJ, Habermann TM, Chen MG, Gertz MA, Lacy MQ, Tefferi A, Gastineau DA, **Litzow MR.** Autologous transplantation for Hodgkin's disease: analysis of prognostic factors and patterns of treatment failure. (Abstract 4561). Blood. 1997 Nov 15; 90(10 Suppl 1 part 2):403b.
24. Palmas A, Tefferi A, Myers JL, Scott JP, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, **Litzow MR.** Late-onset, non-infectious pulmonary complications after allogeneic bone marrow transplantation (ALLO-BMT). (Abstract 1683 502-iii). Blood. 1997 Nov 15; 90(10 Suppl 1 part 1):378a.
25. **Litzow M,** Repoussis P, Schroeder G, Schembri-Wismayer D, Batts K, Anderson P, Arndt C, Gastineau D, Gertz M, Inwards D, Lacy M, Tefferi A, Noel P, Solberg L, Letendre L, Hoagland H. Venocclusive disease (VOD) of the liver following bone marrow transplantation (BMT): analysis of risk factors, and results of therapy with tissue plasminogen activator (TPA). (Abstract 968 430-II). Blood. 1997 Nov 15; 90(10 Suppl 1 part 1):220a.
26. Rajkumar SV, Fonseca R, Lacy MQ, Witzig TE, Lust JA, Greipp PR, Therneau TM, Kyle RA, **Litzow MR,** Gertz MA. Autologous stem cell transplantation overcomes chemotherapy resistance and is effective in patients with primary refractory myeloma. (Abstract A2735). Blood. 1998; 92(10 Suppl 1 Part 1-2):663a.
27. Lacy MQ, Rajkumar SV, Fonseca R, Witzig TE, Lust JA, Greipp PR, Kyle RA, **Litzow MR,** Gertz MA. Beta-2-microglobulin (beta-2M) and bone marrow plasma cell involvement identify complete responders among patients undergoing stem cell transplantation (SCT) for myeloma. (Abstract 133). Program/Proceedings of the

- American Society of Clinical Oncology. 1998; 17:34a.
28. Dietz AB, Bulur PA, **Litzow MR**, Vuk-Pavlovic S. CD83+ dendritic cells from CD14+ peripheral blood cells of chronic myelogenous leukemia patients. *J Leukoc Biol.* 1998; 64(Suppl 2):95.
 29. Gertz MA, Lacy MQ, Inwards DJ, Chen MG, Pineda AA, Gastineau DA, Greipp PR, Lust JA, Tefferi A, Witzig TE, Kyle RA, **Litzow MR**. Early harvest and late transplantation as a strategy to maximize survival in multiple myeloma. (Abstract 27). Program/Proceedings of the American Society of Clinical Oncology. 1998; 17:8a.
 30. Dietz AB, Bulur PA, **Litzow MR**, Valone FH, Peshwa MV, Vuk-Pavlovic S. Evaluation of dendritic cell preparations for immunotherapy in chronic myelogenous leukemia. *J Leukoc Biol.* 1998; 64(Suppl 2):89.
 31. Kaufmann S, Letendre L, **Litzow M**, Reed J, Hanson C, Sloan J. Phase I study of continuous infusion (CI) topotecan (TPT) and carboplatin (CBDCA) for relapsed or refractory acute leukemia (AL). (Abstract 107). Program/Proceedings of the American Society of Clinical Oncology. 1998; 17:28a.
 32. Ratanatharathorn V, Devine S, Nash R, Przepiorka D, Klein J, Weisdorf D, Fay J, Nademanee A, Antin J, Christiansen N, van der Ingt Herzig R, **Litzow M**, Wolff S, Longo W, Petersen F, Maher R, Buell D, Fitzsimmons W. Phase III study comparing Tacrolimus (Prograf, FK506) with Cyclosporine for graft-versus-host disease (GVHD) prophylaxis after HLA-identical sibling bone marrow transplantation (BMT) (Abstracts). *Blood.* 1998; 92(7):2303-14.
 33. **Litzow MR**, Bulur PA, Erickson MR, Vuk-Pavlovic S, Dietz AB. Phenotypic differences in dendritic cells derived from CD14+ peripheral blood cells of chronic myelogenous leukemia patients and normal donors. *Blood.* 1998; 92(10 Suppl 1 Part 1-2):256a.
 34. Rajkumar SV, Fonseca R, Lacy MQ, Witzig TE, Therneau TM, Kyle RA, **Litzow MR**, Gertz MA, Greipp PR. Plasmablastic morphology is an independent predictor of poor survival following autologous stem cell transplantation for relapsed or primary refractory myeloma. (Abstract A406). *Blood.* 1998; 92(10 Suppl 1 Part 1-2):99a.
 35. Kumar KRS, **Litzow M**, Chen M, Gastineau D, Gertz M, Inwards D, Lacy M, Tefferi A. Prophylaxis of graft-versus-host disease (GVHD) with cyclosporine-prednisone (CSP-PRED) is associated with an increased risk of chronic GVHD (CGVHD). *Blood.* 1998; 92(10 Suppl 1 Part 1-2):347b.
 36. Letendre L, Noel P, Tefferi A, **Litzow M**, White WL, Gastineau D, Li CY, Schroeder G. Treatment of unfavorable myelodysplastic syndrome with low dose cytosine arabinoside (LD-ARA-C) and trans-retinoic acid (TRA). (Abstract 115). Program/Proceedings of the American Society of Clinical Oncology. 1998; 17:30a.
 37. Gertz MA, Lacy MQ, Gastineau DA, Inwards DJ, Kyle RA, **Litzow MR**. Blood stem cell transplantation as initial therapy for primary systemic amyloidosis (AL). (Abstract 70). Program/Proc Am Soc Clin Oncol. 1999; 18:20a.
 38. Chao N, **Litzow MR**, Geller RB, Korbling M, Doroshow JH, Fay J, Beveridge RA, Carol D, Lebsack ME. Randomized phase II study of FLT3 ligand (Mobist) in combination with GM-CSF or G-CSF for mobilization of peripheral blood progenitor cells in patients with breast cancer (Abstract). *Blood.* 1999; 94(10 Suppl 1):6661.
 39. Charles A, Tefferi A, Capizzi SA, Huneke NE, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Hanson CA, Chen MG, Limper AH, Prakash UBS, **Litzow MR**. Acute respiratory distress syndrome (ARDS) in the first 100 days of autologous hematopoietic stem cell transplantation. *Journal of Investigative Medicine.* 1999 Aug; 47(7):234A.
 40. Gertz MA, Lacy MQ, Gastineau DA, Inwards DJ, Tefferi A, Chen M, **Litzow MR**. Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma. *Blood.* 1999 Nov 15; 94(10 Suppl 1 Part 1):577a.
 41. Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Witzig TE, Lust JA, Therneau TM, Kyle RA, **Litzow MR**, Greipp PR, Gertz MA. Effect of complete response on outcome following autologous stem cell transplantation for myeloma: implications for high risk patients. *Blood.* 1999 Nov 15; 94(10 Suppl 1 Part 1):576a.
 42. Hogan WJ, Letendre L, **Litzow MR**, Tefferi A, Hoagland HC, Pruthi RK, Kaufmann SH, Hook CC, Elliott MA. Gastrointestinal toxicity of idarubicin in the treatment of leukemia. *Blood.* 1999 Nov 15; 94(10 Suppl 1 Part 1):300a.
 43. Cripe LD, Neuberger D, Tallman MS, **Litzow MR**, O'Brien TE, Bedrosian C, Paietta E, Bennett J, Rowe J. A phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocytemacrophage colony stimulating factor in patients with acute myeloid leukemia receiving high-dose cytarabine during induction: ECOG 3997. (Abstract) *Blood.* 2000; 96(11):323a.
 44. Weisdorf D, Cairo M, Dharan B, Keating A, Lazarus H, **Litzow M**, Loberiza F, Marks D, Miller C, Milone G, Prentice H, Russell J, Trigg M, Wiernik P, Horowitz M, ABMTR/NMDP Writing Co.. Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia (Abstracts). *Blood.* 2000; 96(11):413a.
 45. Porrata LF, Gertz MA, Inwards DJ, **Litzow MR**, Lacy MQ, Tefferi A, Gastineau DA, Dispenzieri A, Ansell SM,

- Micallef INM, Geyer SM, Markovic SN. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin's lymphoma. *Blood*. 2000; 96(11):550a.
46. Inwards DJ, Ansell SM, Gertz MA, Lacy MQ, Gastineau DA, Tefferi A, White WL, Witzig TE, Colgan JP, Habermann TM, **Litzow MR**. High dose therapy with stem cell transplant is effective for non-Hodgkin's lymphoma patients age 65 and over. (Abstract 196). *Program/Proc Am Soc Clin Oncol*. 2000; 19:51a.
 47. Dietz AB, **Litzow MR**, Bulur PA, Vuk-Pavlovic S. Interleukin 2 gene transfer into and expression of functional IL-2 by BCR-ABI positive dendritic cells. *J Invest Dermatol*. 2000 Jan; 114(1):237.
 48. Dispenzieri A, Wiseman GA, Lacy MQ, **Litzow MR**, Tefferi A, Inwards DJ, Gastineau DA, Ansell S, Micallef I, Rajkumar SV, Fonseca R, Witzig TE, Lust JA, Kyle RA, Greipp PR, Gertz MA. A phase I study of a conditioning regimen for peripheral stem cell transplantation (PBSCT) for multiple myeloma (MM): 153Samarium ethylenediaminetetramethylenephosphonate (153Sm-EDMTP) and melphalan. *Blood*. 2000 Nov 16; 96(11 Part 1):558a.
 49. Dietz AB, Padley DJ, Bundy KL, Bulur PA, **Litzow MR**, Gastineau DA, Vuk-Pavlovic S. cGMP dendritic cells for immunotherapy of chronic myeloid leukemia. *Blood*. 2000 Nov 16; 96(11 Part 2):254b.
 50. Johnston PB, **Litzow MR**, Elliott MA, Ansell SM, Dispenzieri A, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Micallef IN, Tefferi A, Patel R, Thompson RL. Colonization with vancomycin-resistant enterococcus correlates with poor outcome in patients undergoing allogeneic blood and marrow transplants. *Blood*. 2000 Nov 16; 96(11 Part 1):786a.
 51. **Litzow MR**, Bolwell BJ, Camitta BM, Copelan EA, Gale RP, Giralt SA, Keating A, Klein JP, Lazarus HM, Marks DJ, McCarthy PL, Miller CB, Milone GA, Perez WS, Prentice HG, Russell JA, Schultz KR, Trigg ME, Weisdorf DJ, Horowitz MM. Comparison of allogeneic bone marrow transplantation (BMT) with cyclophosphamide-total body irradiation (CyTBI) versus busulfan- cyclophosphamide (BuCy) conditioning regimens for acute myelogenous leukemia (AML) in first remission (CR1). *Blood*. 2000 Nov 16; 96(11 Part 1):480a.
 52. Gertz MA, Lacy MQ, Dispenzieri A, Gastineau DA, Inwards DJ, Tefferi A, Chen M, **Litzow MR**. Declining early mortality in stem cell transplantation for multiple myeloma. *Blood*. 2000 Nov 16; 96(11 Part 2):369b.
 53. Kumar S, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, **Litzow MR**. Early prediction of relapse after allogeneic transplant for acute myelogenous leukemia. *Blood*. 2000 Nov 16; 96(11 Part 1):197a.
 54. Kumar S, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, **Litzow MR**. Omission of day +11 methotrexate for graft-versus-host disease prophylaxis after allogeneic BMT increases the risk of severe acute graft- versus- host disease. *Blood*. 2000 Nov 16; 96(11 Part 1):398a.
 55. Wiseman GA, Dispenzieri A, Anderson PM, Lacy MQ, **Litzow MR**, Gertz MA. Residual whole body 153-Samarium activity predicts for successful autologous peripheral blood progenitor cell (PBPC) engraftment following high dose 153-Samarium ethylene diamine tetramethylene phosphonate (153Sm-EDTMP) targeted radiotherapy. *Blood*. 2000 Nov 16; 96(11 Part 1):421a.
 56. Hogan WJ, Lacy MQ, Schroeter AL, **Litzow MR**, Gertz MA. Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantation. *Blood*. 2000 Nov 16; 96(11 Part 2):370b.
 57. **Litzow MR**, Bolwell B, Camitta B, Copelan E, Gale R, Giralt S, Keating A, Klein J, Lazarus H, et al. Comparison of outcome following allogeneic BMT with cyclophosphamide-total body irradiation versus busulfan-cyclophosphamide conditioning regimens for AML in first remission (Abstracts). *Biology of Blood and Marrow Transplantation*. 7(2):99, 2001
 58. Kumar S, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, **Litzow MR**. Omission of day +11 methotrexate for graft-versus-host disease prophylaxis after allogeneic BMT increases the risk of severe acute graft- versus- host Disease. (Abstract 11). *Biol Blood Marrow Transplant*. 2001; 7(2):101.
 59. Kumar S, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, **Litzow MR**. Predicting relapse after allogeneic transplant for acute myelogenous leukemia. (Abstract 57). *Biol Blood Marrow Transplant*. 2001; 7(2):79.
 60. Johnston PB, Micallef IN, Inwards DJ, Ansell SM, Geyer SM, Iturria NL, Gastineau DA, **Litzow MR**. Predictive factors for unsuccessful mobilization of peripheral blood stem Cells (PBSC) in patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HD). (Abstract 51). *Biol Blood Marrow Transplant*. 2001; 7(2):77.
 61. Porrata LF, Ingle JN, **Litzow MR**, Geyer SM, Markovic SN. Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. *Proc Am Soc Clin Oncol*. 2001; 20(1 of 2):9a. Abstract no. 33.
 62. Dispenzieri A, Wiseman G, Lacy MQ, **Litzow MR**, Tefferi A, Inwards DJ, Micallef IN, Gastineau DA, Ansell S, Rajkumar SV, Fonseca R, Porrata L, Witzig TE, Lust JA, Kyle RA, Greipp PR, Gertz MA. A phase I/II dose escalation study of 153-Samarium EDTMP (153-Sm-EDTMP) with fixed dose melphalan peripheral stem cell

- transplantation (PBSCT) for multiple myeloma (MM). *Blood*. 2001 Nov 16; 98(11 Part 1):682a-683a.
63. Kumar S, Lacy M, Inwards D, **Litzow M**, Tefferi A. Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantation. *Blood*. 2001 Nov 16; 98(11 Part 1):192a.
 64. Vuk-Pavlovic S, Dietz AB, Bulur P, Tefferi A, Dewald GW, **Litzow MR**. Dendritic cells from Gleevec(R)-treated CML patients: Implications for immunotherapy. *Blood*. 2001 Nov 16; 98(11 Part 2):268b.
 65. Porrata LF, **Litzow MR**, Tefferi A, Letendre L, Kumar S, Geyer SM, Markovic SN. Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. *Blood*. 2001 Nov 16; 98(11 Part 2):397b.
 66. Micallef INM, Ansell SM, Inwards DJ, Gastineau DA, Gertz MA, Dispenziera A, Lacy MQ, Porrata LF, Tefferi A, **Litzow MR**. Incidence and outcome of central venous catheter-related venous thromboembolism in autologous stem cell transplantation. *Blood*. 2001 Nov 16; 98(11 Part 1):270a.
 67. Dispenziera A, Lacy MQ, **Litzow MR**, Tefferi A, Inwards DJ, Micallef IN, Gastineau DA, Ansell S, Rajkumar SV, Fonseca R, Witzig TE, Lust JA, Kyle RA, Greipp PR, Gertz MA. Peripheral blood stem cell transplant (PBSCT) in patients with POEMS syndrome. *Blood*. 2001 Nov 16; 98(11 Part 2):391b.
 68. Elliott MA, Nichols WL, Plumhoff EA, Ansell SM, Dispenziera A, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Micallef IN, Tefferi A, **Litzow MR**. Post-transplant thrombotic thrombocytopenic purpura (TTP), a complication of high risk myeloablative and non-myeloablative transplantation, is not associated with von Willebrand factor-cleaving protease (vWF-CP) deficiency. *Blood*. 2001 Nov 16; 98(11 Part 1):193a-194a.
 69. Howe R, Micallef INM, Inwards DJ, Hanson CA, Ansell SM, Dispenziera A, Gastineau DA, Gertz MA, Lacy MQ, Tefferi A, **Litzow MR**. Secondary Myelodysplastic Syndrome and Acute Myelogenous Leukemia are significant complications of autologous stem cell transplantation. *Blood*. 2001 Nov 16; 98(11 Part 2):366b.
 70. Kumar S, Lacy MQ, Inwards DJ, Tefferi A, Gastineau DA, Gertz MA, **Litzow MR**. Slow lymphocyte recovery predicts increased risk for relapse after allogeneic bone marrow transplantation for acute lymphocytic leukemia. *Blood*. 2001 Nov 16; 98(11 Part 2):368b.
 71. Gertz MA, Lacy MQ, Dispenziera A, Gastineau DA, Chen MG, Ansell SM, Inwards DJ, Micallef IN, Tefferi A, **Litzow MR**. Stem cell transplantation for management of primary amyloidosis. *Blood*. 2001 Nov 16; 98(11 Part 1):816a.
 72. Gertz MA, Lacy MQ, Dispenziera A, Gastineau DA, Ansell SA, Inwards DJ, Micallef IN, Tefferi A, **Litzow MR**. Stem cell transplantation for management of systemic primary amyloidosis (AL). (Abstract 4.1.7.). *Amyloid*. 2001 Dec; 8(Suppl. 2):61.
 73. Porrata LF, Gertz MA, Inwards DJ, **Litzow MR**, Lacy MQ, Tefferi A, Dispenziera A, Ansell SM, Micallef IN, Markovic SN. Early lymphocyte recovery correlates with superior survival after autologous hematopoietic stem cell transplantation. (Abstract 10). *Biol Blood Marrow Transplant*. 2002; 8(2):64.
 74. Dietz AB, Bulur PA, Knutson GJ, **Litzow MR**, Vuk-Pavlovic S. Imatinib mesylate inhibits dendritic cell maturation and T cell proliferation (Abstract 2665). *Blood*. 2002; 100(11).
 75. Porrata LF, **Litzow MR**, Gastineau DA, Moore SB, Pineda AA, Bundy KL, Padley DJ, Persky D, Micallef INM, Markovic SN. Infused autograft absolute lymphocyte count correlates with lymphocyte recovery and clinical outcome after autologous peripheral hematopoietic stem cell transplantation (Abstract 3410). *Blood*. 2002; 100(11).
 76. Afessa B, Tefferi A, **Litzow MR**, Dunn WF, Peters SG. Noninvasive positive pressure ventilation in hematopoietic stem cell transplant recipients. *Am J Resp Crit Care Med*. 165:A388, 2002.
 77. Dispenziera A, Wiseman GA, Lacy MQ, **Litzow MR**, Tefferi A, Inwards DJ, Micallef IN, Gastineau DA, Ansell S, Gertz MA. Preliminary results from a phase I/II study of 153-Samarium EDTMP (153-Sm-EDTMP) with fixed dose Melphalan peripheral stem cell transplantation (PBSCT) for multiple myeloma (MM). (Abstract 32). *Biol Blood Marrow Transplant*. 2002; 8(2):70.
 78. Ghobrial I, Dispenziera A, Bundy K, Gastineau DA, Lacy M, Rajkumar S, Witzig T, **Litzow M**, Tefferi A, Inwards D, Ansell SM, Fonseca R, Greipp PR, Lust J, Gertz MA. Pretransplant induction with thalidomide-dexamethasone does not adversely affect stem cell collection or engraftment in patients with multiple myeloma (Abstract 1670). *Program/Proc Am Soc Clin Oncol*. 2002; 21(1):418a.
 79. Kumar S, Lacy MQ, Inwards DJ, Tefferi A, Gastineau DA, Gertz MA, **Litzow MR**. Slow lymphocyte recovery predicts increased risk for relapse after allogeneic bone marrow (i.e. marrow) transplantation for acute lymphocytic leukemia. (Abstract 114). *Biol Blood Marrow Transplant*. 2002; 8(2):93.
 80. Gertz MA, Lacy MQ, Dispenziera A, Gastineau DA, Chen MG, Ansell SM, Inwards DJ, Micallef IN, Tefferi A, Porrata LF, **Litzow MR**. Stem cell transplant for amyloidosis (Abstract 1115). *Program/Proc Am Soc Clin Oncol*. 2002; 21(1):279a.
 81. Caplice NM, Bunch TJ, Stalboerger PS, Wang S, Simper D, Miller D, Russell S, **Litzow M**, Edwards W. Bone-

- marrow derived smooth muscle cells are present in human coronary atherosclerosis. *Circulation*. 2002 Nov 5; 106(19 Suppl):II-151.
82. Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S, Iturria N, Allmer C, Lust JA, Witzig TE, Greipp PR, Kyle RA, **Litzow MR**, Gertz MA. Autologous peripheral blood stem cell transplantation for primary refractory multiple myeloma (Abstract 1674). *Blood*. 2002 Nov 16; 100(11):432a-433a.
 83. Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S, Allmer C, Iturria N, Witzig TE, Lust JA, Greipp PR, Kyle RA, **Litzow MR**, Gertz MA. Single agent dexamethasone for induction in patients with multiple myeloma undergoing autologous stem cell transplants (Abstract 1673). *Blood*. 2002 Nov 16; 100(11):432a.
 84. Ghobrial IM, Kumar S, Porrata LF, Gertz MA, Gastineau DA, Ansell SM, Lacy MQ, Rajkumar VS, Micallef IN, Tefferi A, Dispenzieri A, Inwards D, **Litzow MR**, Markovic SN. Thalidomide does not affect immune reconstitution post-autologous bone marrow transplantation in multiple myeloma (Abstract 1679). *Blood*. 2002 Nov 16; 100(11).
 85. Peethambaram P, **Litzow M**, Safgren S, Hartmann L, Barrette B, Long H, Suman V, Reid J, Ames M, Kaufmann S. A phase I trial of topotecan combined with cyclophosphamide and carboplatin with autologous blood stem cell transplant for the treatment of relapsed or persistent ovarian and primary peritoneal carcinoma. *Proceedings of ASCO*. 2003; 22:473(1902) Abstract.
 86. **Litzow M**, Goloubeva O, Rowe J, Cripe L, Tallman M, Gore S. A randomized phase II trial of gemtuzumab ozogamicin vs liposomal daunorubicin vs cyclophosphamide plus topotecan, each combined with intermediate dose Ara-C for the treatment of patients with relapsed or refractory acute myelogenous leukemia *Proc Am Soc Clin Oncol*. 2003; 22:587. Abstract no. 2359.
 87. Bulur PA, Dietz AB, Gastineau DA, **Litzow MR**, Vuk-Pavlovic S. Dendritic cell immunotherapy of chronic myeloid leukemia patients treated with imatinib mesylate. *Cellular Therapy*. 2003: Second International Symposium on the Clinical Use of Cellular Products, 2003; Book of Abstracts. 2003:B10.
 88. Sharma S, Tefferi A, **Litzow MR**, Peters SG, Afessa B. Pulmonary findings at autopsy of hematopoietic stem cell transplant recipients admitted to the intensive care unit. *Am J Respir Crit Care Med*. 2003;167(7):A241.
 89. Gertz MA, Lacy MQ, Dispenzieri A, Ansell SM, Elliott MA, Gastineau DA, Inwards DJ, Micallef INM, Porrata L, **Litzow MR**. Reducing the Dose of Melphalan Used for Stem Cell Transplantation in Amyloidosis is Associated with a Lower Response Rate. (Abstract 2346). *Proc Am Soc Clin Oncol*. 2003;22:583.
 90. Kumar S, **Litzow MR**, Rajkumar S. Effect of allogeneic stem cell transplantation on bone marrow (BM) angiogenesis in chronic myelogenous leukemia (Abstract 80). *Biol Blood Marrow Transplant*. 2003 Feb; 9(2):88.
 91. Kumar S, Micallef IN, Porrata LF, Elliot MA, Ansell SM, Dispenzieri A, Lacy MQ, Inwards DJ, Tefferi A, Gastineau DA, Gertz MA, **Litzow MR**. Lymphocyte recovery after allogeneic stem cell transplantation: comparison of bone marrow and peripheral blood stem cell transplantation (Abstract 138). *Biol Blood Marrow Transplant*. 2003 Feb; 9(2):106.
 92. Razonable RR, Brown RA, **Litzow MR**, Schwartz L, Wilson JA, Mitchell PS, Rutledge B, Patel R, Paya CV. Prospective surveillance of cytomegalovirus (CMV), human herpesvirus (HHV)-6 and HHV-7 infection in allogeneic bone marrow transplant (BMT) recipients. Program and abstracts of the 9th International CMV Workshop and 1st International ²-herpesvirus Conference (Maastricht, The Netherlands) 2003 May 20-25.
 93. Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S, Iturria N, Allmer C, Witzig TE, Lust JA, Greipp PR, Kyle RA, **Litzow MR**, Gertz MA. Autologous peripheral blood stem cell transplantation for primary refractory multiple myeloma (Abstract 265). Multiple Myeloma 9th International Workshop, 23-27 2003 May, Salamanca, Spain. *Hematol J* 2003 may;4(Suppl 1):S205.
 94. Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Witzig TE, Lust J, Greipp PR, Kyle RA, **Litzow MR**, Gertz MA. Comparison of three different induction regimens in patients with multiple myeloma undergoing autologous stem cell transplantation (Abstract 2343). *Am Soc Clin Oncol 39th Annual Meeting*, May 31-June 3, 2003, Chicago IL 2003;22:583.
 95. **Litzow MR**, Hogan WJ, Micallef IN, Dispenzieri A, Gertz MA, Inwards DJ, Tun HW, Roy V, Geyer SM, Allred JB, Ansell SM, Elliott MA, Tefferi A, Porrata LF, Gastineau DA, Lacy MQ. A phase I/II trial of cladribine (2-CDA), thiotepa (TT) and rabbit antithymocyte globulin (rATG) as a reduced intensity conditioning (RIC) regimen for non-myeloablative allogeneic peripheral blood stem cell transplant (NMA-PBSCT) for hematologic malignancies. *Blood*. 2003 Nov 16; 102(11):402b.
 96. Dispenzieri A, Wiseman GA, Lacy MQ, Geyer S, **Litzow MR**, Tefferi A, Inwards DJ, Micallef IN, Ansell S, Gastineau DA, Porrata L, Elliott MA, Gertz MA. A Phase II study of high dose 153-samarium EDTMP (153-Sm EDTMP) and melphalan for peripheral stem cell transplantation (PBSCT) in multiple myeloma (MM). *Blood*. 2003 Nov 16; 102(11):982a.
 97. **Litzow MR**, Lee S, Bennett JM, Gallagher RE, Paietta EM, Rousey SR, Tallman MS. A phase II trial of arsenic

- trioxide (AT) for relapsed and refractory acute lymphoblastic leukemia (ALL). *Blood*. 2003 Nov 16; 102(11):260b.
98. Porrata LF, **Litzow MR**, Gertz MA, Inwards DJ, Gastineau DA, Micallef INM, Lacy MQ, Ansell SA, Dispenzieri A, Tefferi A, Elliott M, Snow DS, Hogan WJ, Markovic SN. Early natural killer cell engraftment improves progression-free-survival after autologous hematopoietic stem cell transplantation. *Blood*. 2003 Nov 16; 102(11):989a.
 99. Dietz AB, Knutson GJ, Bulur PA, Souan L, **Litzow MR**, Vuk-Pavlovic S. Imatinib mesylate (Gleevec(R)) inhibits proliferation and signal transduction of activated T cells in vitro and suppresses immunity in vivo. *Blood*. 2003 Nov 16; 102(11):654a.
 100. Dispenzieri A, Lacy MQ, Kyle RA, Jaffe A, Snow DF, **Litzow MR**, Gastineau D, Tefferi A, Inwards DJ, Micallef IN, Ansell S, Porrata L, Elliot M, Hogan W, Burritt MF, Gertz MA. Shortened survival in primary systemic amyloidosis patients with elevated cardiac troponins undergoing peripheral blood stem cell transplant. *Blood*. 2003 Nov 16; 102(11):117a.
 101. Porrata LF, Gertz MA, **Litzow MR**, Gastineau DA, Moore SB, Pineda AA, Bundy KL, Padley DJ, Persky D, Lacy MQ, Dispenzieri A, Snow DS, Markovic SN. The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma. *Blood*. 2003 Nov 16; 102(11):988a.
 102. Elliott MA, Wolf RC, Hook CC, Pruthi RK, Heit JA, Letendre LL, Tefferi A, Kaufmann SH, Mesa RA, **Litzow MR**. Thromboembolism in adults with acute lymphoblastic leukemia (ALL) during induction with L-asparaginase (ASP)-containing multi-agent regimens: Incidence, risk factors, and possible role of antithrombin (AT) in pathogenesis and prophylaxis. *Blood*. 2003 Nov 16; 102(11):878a.
 103. Griffin MD, Leung N, Dispenzieri A, Gloor JM, Schwab TR, Textor SC, Lacy MQ, **Litzow MR**, Larson TS, Gertz MA, Stegall MD. Sequential living donor kidney and autologous stem cell transplantation for AL ("primary") amyloidosis with predominant renal involvement (Abstract 1172). *Am J Transplant*. 2004; 4(Suppl 8):478.
 104. Afessa B, Dispenzieri A, Tefferi A, **Litzow MR**, Huneke NE, Warden TH, Peters SG. Risk factors for ICU admission after blood and bone marrow transplant (Abstract 091). *Intensive Care Med*. 2004 Sep; 30(Suppl 1):S28.
 105. **Litzow MR**, Dietz AB, Bulur PA, Butler GW, Fink SR, Letendre L, Paternoster SF, Tefferi A, Hoering A, Vuk-Pavlovic S. A phase I trial of autologous dendritic cell therapy for chronic myelogenous leukemia. *Blood*. 2004 Nov 16; 104(11 Part 1):801A.
 106. Pornvipavee R, Kremers WK, Pedersen RA, Elliott M, Hogan WJ, Tefferi A, **Litzow MR**. Allogeneic stem cell transplantation (SCT) in untreated first relapse or following re-induction chemotherapy for patients with acute myeloid leukemia (AML). *Blood*. 2004 Nov 16; 104(11 Part 1):369B-70B.
 107. Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, **Litzow MR**, Henderson KJ, Van Wier SA, Ahmann GJ, Fonseca R. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32) and - 17p13 (p53) deletions in myeloma patients treated with high dose therapy. *Blood*. 2004 Nov 16; 104(11 Part 1):99A.
 108. Kumar S, Lacy MQ, Dispenzieri A, Hayman SR, Rajkumar SV, Witzig TE, Lust JA, Greipp PR, Kyle R, **Litzow MR**, Gertz MA. Comparison of early and late autologous stem cell transplants for multiple myeloma: A single institution experience. *Blood*. 2004 Nov 16; 104(11 Part 1):266A.
 109. Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, **Litzow MR**, Henderson KJ, VanWier S, Ahmann G, Fonseca R. Deletion 13 by FISH provides prognostic information on overall survival and time to progression independent of serum beta 2 microglobulin and bone marrow plasma cell labeling index in myeloma patients undergoing stem cell transplantation. *Blood*. 2004 Nov 16; 104(11 Part 1):295B-6B.
 110. Porrata LF, Gastineau DA, Pineda A, Winters JL, Moore SB, Padley DJ, Bundy KL, **Litzow MR**, Micallef INM, Inwards DJ, Ansell SM, Gertz MA, Lacy MQ, Dispenzieri A, Tefferi A, Elliott M, Hogan WJ, Hayman SR, Markovic SN. Increasing the number of apheresis collections increases lymphocyte collection and affects survival after autologous stem cell transplantation for non-Hodgkin lymphoma. *Blood*. 2004 Nov 16; 104(11 Part 1):254A-5A.
 111. Holtan SG, Porrata LF, Inwards DJ, Ansell SA, Micallef INM, **Litzow MR**, Gertz MA, Lacy MQ, Dispenzieri A, Gastineau DA, Tefferi A, Elliott M, Hogan WJ, Hayman S, Markovic SN. Time interval from last chemotherapy to stem cell collection correlates with peripheral blood absolute lymphocyte count at Apheresis and survival post-autologous stem cell transplantation in non-Hodgkin's lymphoma. *Blood*. 2004 Nov 16; 104(11 Part 1):800A.
 112. Pornvipaveel R, Dierkhising RA, Elliott MA, Hogan WJ, Kremers WK, Letendre L, Pedersen RA, Tefferi A, **Litzow MR**. Autologous stem cell transplantation (ASCT) in untreated first relapse (REL1) or following re-induction chemotherapy (CT) for patients (PTS) with acute myelogenous leukemia (AML) (Abstract I82). *Biol Blood Marrow Transplant*. 2005 Feb; 11(2 Suppl 1):61.

113. Micallef IN, Markovic SN, Greyer S, Porrata LF, Ansell SM, Inwards DJ, Gastineau DA, Padley DJ, Armstrong AS, **Litzow MR**. Immunological autologous stem cell graft engineering using combination G-CSF and aldesleukin (IL-2) in patients with non-Hodgkin's lymphoma (Abstract 21). *Biol Blood Marrow Transplant*. 2005 Feb; 11(2 Suppl 1):8.
114. Mahmoud AA, **Litzow MR**, Peters SG, Dispenzieri A, Tefferi A, Afessa B. Early infectious pulmonary complications in autologous hematopoietic stem cell transplant (HSCT) recipients. *Chest*. 2005 Oct; 128(4 Suppl):184S.
115. Dispenzieri A, Lacy MQ, Katzmann JA, Rajkumar SV, Abraham RS, Hayman SR, Kumar SK, Clark R, Kyle RA, **Litzow MR**, Inwards DJ, Elliott MA, Micallef IV, Ansell SM, Porrata LF, Johnston P, Zeldenrust SR, Witzig TE, Greipp PR, Lust JA, Russell SR, Gertz MA. Absolute values of serum immunoglobulin free light chains predict for survival in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplant (Abstract 422). *Blood*. 2005 Nov; 106(11):127a.
116. Elliott MA, Tefferi A, Hogan WJ, Letendre L, Gastineau DA, Ansell SM, Dispenzieri A, Gertz MA, Inwards DJ, Lacy MQ, Micallef IN, Porrata LF, **Litzow MR**. Allogeneic stem cell transplantation (ASCT) and donor lymphocyte infusions (DLI) in the management of chronic myelomonocytic leukemia (CMML) (Abstract 5422). *Blood*. 2005 Nov; 106(11):441b-442b.
117. Kumar S, Lacy M, Dispenzieri A, Hayman S, Hogan W, Porrata L, Elliott M, Ansell S, Johnston P, Micallef I, Inwards D, Gastineau D, **Litzow M**, Gertz M. Autologous stem cell transplantation for multiple myeloma in patients over 70 years: a matched comparison with patients under 65 years (Abstract 1173). *Blood*. 2005 Nov; 106(11):342a-343a.
118. Gertz MA, Dispenzieri A, Hayman SR, Kumar SK, Ansell SM, Elliott MA, Gastineau DA, Inwards DJ, Johnston PB, Micallef IN, Porrata LF, **Litzow MR**. Clinical outcome of IgM amyloidosis (AL) following stem cell transplantation (Abstract 5470). *Blood*. 2005 Nov; 106(11):455b.
119. Dingli D, Nowakowski GS, Dispenzieri A, Lacy MQ, Hayman S, **Litzow MR**, Gastineau DA, Gertz MA. Cyclophosphamide mobilization does not improve outcome in patients transplanted for multiple myeloma (Abstract 1165). *Blood*. 2005 Nov; 106(11):340a.
120. Holtan SG, Porrata LF, Inwards DJ, Ansell SA, Padley DJ, Micallef IN, **Litzow MR**, Johnston PB, Hayman SR, Kumar SK, Gertz MA, Lacy MQ, Dispenzieri A, Gastineau DA, Teferi A, Elliot M, Hogan WJ, Markovic SN. Effect of AMD3100 on T lymphocyte subpopulations in apheresis products of patients undergoing autologous hematopoietic stem cell transplantation for non Hodgkin lymphoma (Abstract 2918). *Blood*. 2005 Nov; 106(11):819a.
121. Dingli D, Nowakowski GS, Dispenzieri A, Lacy MQ, Hayman SR, Rajkumar VS, Greipp PR, **Litzow MR**, Gastineau DA, Witzig TE, Gertz MA. Flow cytometric detection of circulating myeloma cells pretransplant in patients with multiple myeloma: a simple risk stratification system (Abstract 1164). *Blood*. 2005 Nov; 106(11):340a.
122. Moorman AV, Harrison CJ, Richards SM, Fielding A, Tallman MS, **Litzow MR**, Rowe JM, Goldstone AH, Dewald GW. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukaemia (ALL): analysis of cytogenetic data from 1,235 patients on the Medical Research Council (MRC) UKALLXII / Eastern Cooperative Oncology Group (ECOG) 2993 trial (Abstract 331). *Blood*. 2005 Nov; 106(11):100a.
123. Tefferi A, Mesa RA, Hogan WJ, Shaw TA, Reyes GE, Allred JB, Ma CX, Dy GK, Wolanskyj AP, **Litzow ML**, Steensma DP, Call TG, McClure RF. Lenalidomide (CC-5013) treatment for anemia associated with myelofibrosis with myeloid metaplasia (Abstract 2583). *Blood*. 2005 Nov; 106(11):726a.
124. Malhotra P, Hogan WJ, **Litzow MR**, Elliott MA, Dispenzieri A, Call T, Kay NE, Zent C, Gastineau DA, Ansell SM, Hayman S, Gertz MA, Lacy MQ, Porrata LF, Inwards DJ, Tefferi A. Long term follow up of allograft hematopoietic stem cell transplantation (ASCT) in chronic lymphocytic leukemia (CLL) (Abstract 5420). *Blood*. 2005 Nov; 106(11):441b.
125. Fonseca R, Van Wier S, Chng WJ, Ketterling R, Lacy M, Dispenzieri A, Bergsagel PL, Rajkumar SV, Greipp P, **Litzow M**, Kumar S, Gonzalez-Paz N, Henderson K, Ahmann G, Gertz M. Low level amplification (duplication) of 1q21 in myeloma and prognosis; the role of CKS1B (Abstract 624). *Blood*. 2005 Nov; 106(11):185a.
126. Dispenzieri A, Lacy MQ, Hayman SR, Kyle RA, Kumar SK, **Litzow MR**, Gastineau DA, Inwards DJ, Micallef IN, Elliott MA, Porrata LF, Hogan WJ, Johnston PB, Gertz MA. Powerful risk stratification in patients with AL using serum cardiac biomarkers (Abstract 1162). *Blood*. 2005 Nov; 106(11):339a.
127. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK, Ansell SM, Elliott MA, Gastineau DA, Inwards DJ, Johnston PB, Micallef IN, Porrata LF, **Litzow MR**. Role of second stem cell transplant in patients with amyloidosis who are refractory or relapsing (Abstract 5469). *Blood*. 2005 Nov; 106(11):455b.
128. Porrata LF, Hayman SR, Gertz MA, Lacy MQ, Dispenzieri A, Kumar SK, **Litzow MR**, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Gastineau DA, Tefferi A, Elliot M, Hogan WJ, Markovic SN. The role of stem cell

- mobilization regimen on lymphocyte collection yield and survival after autologous hematopoietic stem cell transplantation in multiple myeloma (Abstract 1171). Blood. 2005 Nov; 106(11):3425.
129. Kumar S, Lacy M, Dispenzieri A, Hayman S, Hogan W, Poratta L, Elliot M, Ansell S, Johnston P, Micallef I, Inwards D, Gastineau D, **Litzow M**, Gertz M. Autologous stem cell transplantation for multiple myeloma in patients over 70 years: a matched comparison with patients under 65 years (Abstract 326). Biol Blood Marrow Transplant. 2006 Feb; 12(2 Suppl 1):114.
 130. Zirakzadeh A, Montori V, Imran H, **Litzow M**, Kumar S. Ursodiol prophylaxis against hepatic veno-occlusive disease in hematopoietic stem cell transplant recipients: a systematic review and meta-analysis (Abstract 395). Biol Blood Marrow Transplant. 2006 Feb; 12(2 Suppl 1):137-8.
 131. Elliott MA, Schulte S, Plumhoff EA, Pruthi RK, Nichols WL, **Litzow MR**, Gastineau DA, Heit JA. Frequency of heparin-induced thrombocytopenia and heparin-dependent IgG antibodies in hematopoietic stem cell transplant recipients (Abstract 4-59). Blood. 2006 Nov; 108(11 part 2):93b-4b.
 132. Mesa RA, Pardanani A, Steensma DP, **Litzow M**, Hogan W, Geyer S, Wu W, Zeldis J, Tefferi A. Phase II study of the combination of low-dose thalidomide, prednisone, and oral cyclophosphamide (TPC regimen) in the treatment of anemia, splenomegaly, and constitutional symptoms associated with myelofibrosis with myeloid metaplasia (MMM) (Abstract 2689). Blood. 2006 Nov; 108(11 part 1):760a.
 133. Moorman AV, Harrison CJ, Buck GAN, Richards SM, Secker-Walker LM, Martineau M, Vance GH, Cherry AM, Higgins RR, Fielding AK, Foroni L, Paietta E, Tallman MS, Wernik PH, **Litzow MR**, Rowe JM, Goldstone AH, Dewald GW. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukaemia. Br J Haematol. 2007 Apr; 137(Suppl 1):1.
 134. Moorman A, Harrison CJ, Buck GAN, Richards SM, Secker-Walker LM, Martineau M, Vance GH, Cherry AM, Higgins RR, Fielding AK, Foroni L, Paietta E, Tallman MS, **Litzow MR**, Wiernik PH, Rowe JM, Goldstone AH, Dewald GW. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia. Haematologica. 2007 Jun; 92(Suppl 1):139.
 135. Simpson L, Verma R, Kumar S, Lacy MQ, Dispenzieri A, Hayman SR, Rajkumar SV, **Litzow MR**, Gertz MA. Outcome after second stem cell transplantation for relapsed multiple myeloma. Haematologica. 2007 Jun; 92(6 Suppl 2):188-9.
 136. Costa LJ, Micallef IN, Inwards DJ, Johnston PB, Porrata LF, **Litzow MR**, Ansell SM. A higher ratio of dose to actual weight of conditioning chemotherapy leads to more toxicity without improvement in outcome in autologous HSC transplant for DLBCL. Blood. 2007 Nov; 110(11):886A.
 137. Costa LJ, Kumar S, Dispenzieri A, Hayman SE, Buadi FK, **Litzow MR**, Gertz MA, Lacy MQ. Allogeneic HSC transplantation for multiple myeloma: A single institution experience. Blood. 2007 Nov; 110(11):892A.
 138. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, **Litzow MR**, Rajkumar SV, Gertz MA. Delayed platelet engraftment and outcome of stem cell transplant for multiple myeloma: Possible microenvironment effect (Abstract 939)? Blood. 2007 Nov; 110(11):285A-6A.
 139. Fielding AK, Richards SM, Lazarus HM, **Litzow MR**, Luger SM, Marks DI, McMillan AK, Rowe JM, Tallman MS, Goldstone AH. Does imatinib change the outcome in philadelphia chromosome positive acute lymphoblastic leukaemia in adults? Data from the UKALLXII/ECOG2993 study. Blood. 2007 Nov; 110(11):10A.
 140. Elliott MA, **Litzow MR**, Letendre L, Wolf RC, Hanson CA, Tefferi A, Tallman MS. Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia (AML) predicts superior relapse-free survival. Blood. 2007 Nov; 110(11):547A.
 141. Dispenzieri A, Lacy MQ, Hayman SR, Kumar SK, Buadi F, Dingli D, **Litzow MR**, Gastineau DA, Inwards DJ, Elliott MA, Micallef IN, Ansell SM, Hogan WJ, Porrata LF, Afessa B, Bryce A, Kyle RA, Gertz MA. Engraftment syndrome is common in patients with POEMS syndrome undergoing PBSCT. Blood. 2007 Nov; 110(11):879A.
 142. Costa LJ, Rodriguez V, Porrata LF, Lacy MQ, Elliott MA, Tefferi A, Lust JA, Letendre L, Colgan JP, Gertz MA, Gastineau DA, **Litzow MR**. Experience with autologous HSC transplant in therapy-related MDS/AML using cells harvested prior to the development of the secondary malignancy. Blood. 2007 Nov; 110(11):356B.
 143. Costa LJ, Feldman AL, Micallef IN, Inwards DJ, Johnston PB, Porrata LF, **Litzow MR**, Ansell SM. Germinal center B cell and non-germinal center B cell-like DLBCL have similar clinical features at the time of progression and comparable outcome following autologous HSC transplantation. Blood. 2007 Nov; 110(11):564A-5A.
 144. Kumar S, Dingli D, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Rajkumar SV, **Litzow MR**, Gertz MA. Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders (Abstract 945). Blood. 2007 Nov; 110(11):287A.
 145. Kumar S, Lacy MQ, Dispenzieri A, Hayman S, Buadi FK, Dingli D, **Litzow MR**, Gertz MA. Prognostic value of serum lactate dehydrogenase (LDH) in patients with primary, systemic amyloidosis undergoing stem cell transplantation (Abstract 2871). Blood. 2007 Nov; 110(11):844A-5A.

146. Hochhaus A, Giles FJ, le Coutre P, Baccarani M, Gattertnann N, Bhalla KN, Alimena G, Ossenkoppele G, Nicolini F, **Litzow MR**, Bbatia R, Cervantes F, Wang J, Woodman R, Cortes J, Kantarjian H. Safety, and efficacy of nilotinib dose escalation 600mg BID in patients (pts) with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP). *Blood*. 2007 Nov; 110(11):314A-5A.
147. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK, Buadi F, Leung N, **Litzow MR**. Should troponin level be an exclusion criterion for stem cell primary amyloidosis? *Blood*. 2007 Nov; 110(11):882A.
148. Fernandez HF, Sun Z, Bennett JM, Paietta EM, **Litzow MR**, Rowe JM, Tallman MS, Lazarus HM. A single dose of Gemtuzumab-Ozogamicin (Go) in consolidation prior to autologous transplant for younger patients with newly diagnosed acute myeloid (Aml) is safe but has no effect on disease free survival: interim results of Eastern Cooperative Oncology Group Study (E1900). *Biol Blood Marrow Transplant*. 2008 Feb; 14(2 Suppl 2):52.
149. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Rajkumar SV, **Litzow MR**, Gertz MA. Delayed platelet engraftment and outcome of stem cell transplant for multiple myeloma: possible microenvironment effect? *Biol Blood Marrow Transplant*. 2008 Feb; 14(2 Suppl 2):94.
150. Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Gastineau DA, **Litzow MR**, Markovic SN. Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study. *Biol Blood Marrow Transplant*. 2008 Feb; 14(2 Suppl 2):89.
151. Kumar S, Dingli D, Dispenzieri A, Lacy M, Hayman S, Buadi F, Rajkumar SV, **Litzow MR**, Gertz MA. Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders. *Biol Blood Marrow Transplant*. 2008 Feb; 14(2 Suppl 2):88.
152. Dispenzieri A, Lacy MQ, Hayman SR, Kumar SK, Buadi F, Dingli D, **Litzow MR**, Gastineau DA, Inwards DJ, Elliott MA, Micallef IN, Ansell SM, Hogan WJ, Porrata LF, Johnston PB, Afessa B, Bryce A, Kyle RA, Gertz MA. Peripheral blood stem cell transplant for Poems syndrome is associated with high rates of engraftment syndrome. *Biol Blood Marrow Transplant*. 2008 Feb; 14(2 Suppl 2):87.
153. Micallef IN, Ansell SM, Buadi F, Dispenzieri A, Elliott MA, Gertz MA, Hayman SR, Hogan WJ, Inwards DJ, Gastineau DA, Johnston PB, Kumar S, Lacy MQ, Porrata LF, Marzolf M, Shaw T, Winters JL, Calandra G, **Litzow MR**. Rescue mobilization of hematopoietic progenitor cells with Amd3100+G-CSf is successful in patients who previously failed mobilization. *Biol Blood Marrow Transplant*. 2008 Feb; 14(2 Suppl 2):255.
154. Ringden OTH, Pavletic S, Anasetti C, Barrett JA, Wang T, Antin JH, Di Bartolomeo P, Bolwell BJ, Bredeson C, Cairo MS, Gale RP, Giral S, Hahn T, Hale GA, Halter J, Jagasia M, **Litzow MR**, Locatelli F, McCarthy PL, Cowan MJ, Petersdorf EW, Russel JA, Schiller GJ, Schouten H, Tallman MS, Verdonck LF, Wiley JM, Wingard JR, Horowitz MM, Arora M. Similar graft-versus-leukemia effect using matched unrelated donors, compared to Hla-identical siblings for hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant*. 2008 Feb; 14(2 Suppl 2):33.
155. **Litzow MR**, Perez WS, Tarima S, Keating A, Sierra J, Tallman MS, Weisdorf DJ. The outcome of allogeneic stem cell transplantation (AlloSCT) for the treatment of therapy-related myelodysplastic syndrome (tMDS) and acute myeloid leukemia (tAML) varies considerably by risk factor: an observational study from the center for international blood and marrow transplant research (CIBMTR). *Biol Blood Marrow Transplant*. 2008 Feb; 14(2 Suppl 2):13.
156. Gertz MA, Ansell SM, Dingli D, Dispenzieri A, Buadi FK, Elliott MA, Gastineau DA, Hayman SR, Hogan WJ, Inwards DJ, Johnston PB, Kumar S, Lacy MQ, Leung N, Micallef IN, Porrata LF, Schafer BA, Wolf RC, **Litzow MR**. A Multidisciplinary Quality Initiative for Stem Cell Transplantation in Multiple Myeloma: Outpatient Transplant with Low Therapy Related Mortality. *Blood*. 2008 Nov; 112:4440.
157. Mesa RA, Schwager S, Radia D, Cheville A, Hussein K, Niblack J, Pardanani AD, Steensma DP, **Litzow MR**, Rivera CE, Camoriano J, Verstovsek S, Sloan J, Harrison C, Tefferi A. Assessment and monitoring of constitutional symptoms in patients with myelofibrosis: a proposed new instrument the myelofibrosis symptom assessment form (MFSAF). *Blood*. 2008 Nov; 112(11):619.
158. Dingli D, Kumar SK, Buadi FK, Dispenzieri A, Hayman SR, Lacy MQ, Gastineau DA, **Litzow MR**, Gertz MA. Autologous stem cell transplantation in patients with autonomic neuropathy due to AL amyloidosis. *Blood*. 2008 Nov; 112(11):1139-40.
159. Gertz MA, Kumar S, Lacy M, Dispenzieri A, Hayman S, Buadi F, Dingli D, Gastineau D, Winters J, **Litzow M**. Comparison of high-dose cyclophosphamide and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. *Blood*. 2008 Nov; 112(11):802-3.
160. Paietta E, Li XC, Richards S, Racevskis J, Dewald GW, Rowe JM, Tallman MS, Lazarus HM, **Litzow M**, Goldstone AH, Wiernik PH. Implications for the use of monoclonal antibodies in future adult ALL trials: analysis of antigen expression in 505 B-lineage (B-Lin) ALL patients (pts) on the MRC UKALLXII/ECOG2993 intergroup trial. *Blood*. 2008 Nov; 112(11):666-7.

161. Navarro WH, Agovi MA, Logan B, Bacigalupo A, Ballen KK, Bolwell BJ, Frangoul H, Gupta V, Hahn T, Juckett M, Lazarus HM, **Litzow MR**, Liesveld J, Moreb J, Marks D, McCarthy PL, Rizzo JD. Obesity does not preclude safe and effective myeloablative hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML) in adults. *Blood*. 2008 Nov; 112(11):26.
162. Paietta E, Li XC, Richards S, Racevskis J, Dewald GW, Rowe JM, Tallman MS, Lazarus HM, **Litzow MR**, Goldstone AH, Wiernik P. Outcome in Philadelphia chromosome positive (Ph plus) adult ALL patients (Pts) may be more determined by CD25 expression than by Ph status Per Se. *Blood*. 2008 Nov; 112(11):533-4.
163. Lacy MQ, Mandrekar S, Kabat B, Dispenzieri A, Hayman S, Kumar S, Buadi F, Dingli D, **Litzow M**, Wettstein P, Rajkumar SV, Gastineau D, Gertz MA. Post autologous transplantation consolidation of multiple myeloma with idiotype-pulsed antigen presenting (Dendritic) cells (APC8020) is associated with prolonged survival. *Blood*. 2008 Nov; 112(11):613.
164. Schriber JR, Agovi MA, Ballen KK, Bacigalupo A, Hale GA, Gupta V, Lazarus HM, **Litzow MR**, Marks DI, Giller RH, Maziarz RT, Bornhauser M, Isola LM, Bredeson C, Rizzo JD. Second unrelated donor (URD) transplant as a rescue strategy for 122 patients with primary non engraftment: results from the CIBMTR. *Blood*. 2008 Nov; 112(11):295.
165. Rowe JM, Buck G, Moorman AV, Tallman MS, Richards SM, Fielding AK, Burnett AK, Franklin IM, Wiernik PH, Lazarus HM, Paietta E, **Litzow MR**, Marks DI, Luger S, Dewald GW, Goldstone AH. Standard consolidation/maintenance chemotherapy is consistently superior to a single autologous transplant for adult patients with acute lymphoblastic leukemia: results of the International ALL Trial (MRC UKALL XII/ECOG E2993). *Blood*. 2008 Nov; 112(11):1138.
166. Kumar S, Lacy M, Dispenzieri A, Hayman S, Buadi F, Dingli D, Miceli T, **Litzow M**, Rajkumar SV, Gertz M. Stem cell mobilization following initial therapy with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma. *Blood*. 2008 Nov; 112(11):1189.
167. Rowe JM, Yao XP, Cassileth PA, Appelbaum FR, Wiernik PH, Schiffer C, **Litzow MR**, Luger S, Bennett JM, Lazarus HM, Tallman MS. The pitfalls of early publication of data in acute myeloid leukemia: a report from the Eastern Cooperative Oncology Group (ECOG). *Blood*. 2008 Nov; 112(11):681.
168. Rowe JM, Sun ZX, Cassileth PA, Appelbaum FR, Wiernik PH, Lazarus HM, Blume KG, Fernandez HF, **Litzow MR**, Tallman MS. Treatment-related mortality and relapse rate from time of initiation of post-remission therapy for patients receiving allogeneic transplantation, autologous transplantation or intensive chemotherapy: a report from the Eastern Cooperative Oncology Group (ECOG). *Blood*. 2008 Nov; 112(11):25.
169. Holtan SG, Hogan WJ, Elliott MA, Gastineau DA, Call TG, Ansell SA, Inwards DJ, Johnston PB, Lacy MQ, Micallef IN, Porrata LF, Tefferi A, **Litzow MR**. Cd34+cell dose and full donor chimerism at day+100 is associated with survival in patients who received reduced-intensity conditioning (Ric) with fludarabine/melphalan prior to allogeneic hematopoietic stem cell transplantation (Hsct) for hematologic malignancies. *Biol Blood Marrow Transplant*. 2009 Feb; 15(2 Suppl 2):285.
170. Howle EL, Wolf RC, Burzynski JA, Gastineau DA, Lacy MQ, Gertz MA, Dispenzieri A, Kumar S, Dingli D, Buadi F, Inwards DJ, Ansell SM, Micallef INM, Johnston PB, Porrata LF, Elliott MA, Hogan WJ, **Litzow MR**. Clinical outcomes with and without sargramostim (Gm-Csf) post autologous peripheral blood stem cell transplantation. *Biol Blood Marrow Transplant*. 2009 Feb; 15(2 Suppl 2):109.
171. Kumar S, Dispenzieri A, Lacy MQ, Hayman S, Buadi FK, Dingli D, Rajkumar SV, **Litzow MR**, Gertz MA. Continued M protein responses beyond day 100 after autologous transplantation for myeloma: implications for post transplant strategies. *Biol Blood Marrow Transplant*. 2009 Feb; 15(2 Suppl 2):191.
172. Burzynski JA, Craver LF, Geerdes PA, Perreault SK, **Litzow MR**, Hogan WJ, Elliot MA, Wolf RC. Impact of a pharmacist in the outpatient allogeneic stem cell transplant clinic. *Biol Blood Marrow Transplant*. 2009 Feb; 15(2 Suppl 2):83.
173. Micallef IN, Maurer M, Ansell SM, Buadi F, Dispenzieri A, Gastineau DA, Gertz MA, Hayman SR, Hogan WJ, Inwards DJ, Johnston PB, Kumar S, Lacy MQ, **Litzow MR**, Porrata LF, Winters JL, Marzolf M, Shaw T, Calandra G. Peripheral blood Cd34 count can predict successful progenitor cell mobilization in poor mobilizers treated with plerixafor and G-Csf. *Biol Blood Marrow Transplant*. 2009 Feb; 15(2 Suppl 2):188.
174. Kumar S, Lacy MQ, Dispenzieri A, Hayman SR, Dingli D, Miceli T, **Litzow MR**, Rajkumar SV, Gertz MA. Stem cell mobilization in patients with newly diagnosed multiple myeloma following therapy with lenalidomide and dexamethasone. *Biol Blood Marrow Transplant*. 2009 Feb; 15(2 Suppl 2):177.
175. Mesa RA, Pardanani A, Hussein K, Gale R, Schwager S, **Litzow MR**, Hogan W, Tefferi A. Pomalidomide in myelofibrosis: results of a phase-1 dose-seeking trial. *Haematologica-the Hematology Journal*. 2009 Jun; 94 (Suppl 2):0648.
176. Micallef I, Ansell SM, Buadi F, Dingli D, Dispenzieri A, Gastineau D, Gertz M, Hayman SR, Hogan W, Inwards DJ, Johnston PL, Kumar S, Lacy MQ, **Litzow MR**, Porrata L, Wolf R, Miceli T, Winters J. A risk adapted

- approach utilizing plerixafor in autologous peripheral blood stem cell mobilization. *Blood*. 2009 Nov 20; 114(22):1321-1324.
177. Fernandez HF, Sun ZX, **Litzow MR**, Luger SM, Paietta EM, Dewald GW, Ketterling RP, Bennett JM, Rowe JM, Lazarus HM, Tallman MS. Autologous hematopoietic cell transplantation as consolidation for younger patients with acute myeloid leukemia in first complete remission: follow-up of E1900. *Blood*. 2009 Nov 20; 114(22):1322.
 178. Mesa RA, Pardanani AD, Hussein K, Wu WT, Schwager S, **Litzow MR**, Hogan WJ, Tefferi A. Phase 1/2 dose finding study of pomalidomide in myelofibrosis. *Blood*. 2009 Nov 20; 114(22):1138.
 179. Sinha S, Gastineau DA, Hogan WJ, Micallef IN, Buadi FK, Dingli D, Dispenzieri A, Gertz MA, Greiner C, Hayman S, Inwards DJ, Johnston PB, Lacy MQ, **Litzow MR**, Porrata LF, Winters J, Kumar S. Predicting poor peripheral blood stem cell mobilization in multiple myeloma (MM) using initial peripheral CD34 counts: developing target-based cut-points for early intervention. *Blood*. 2009 Nov 20; 114(22):1252-3.
 180. Levis M, Ravandi F, Wang ES, Baer MR, Perl A, Coutre S, Erba H, Stuart RK, Baccarani M, Cripe LD, Tallman MS, Meloni G, Godley LA, Langston AA, Amadori S, Lewis ID, Nagler A, Stone R, Yee K, Advani A, Douer D, Jedrzejczak WW, Juliusson G, **Litzow MR**, Petersdorf S, Sanz M, Kantarjian HM, Sato T, Tremmel L, Bensen-Kennedy DM, Small D, Smith BD. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for FLT3 mutant aml patients in first relapse. *Blood*. 2009 Nov 20; 114(22):325-6.
 181. Begna K, Mesa RA, Pardanani A, Hogan WJ, **Litzow MR**, McClure RF, Terreri A. A phase-2 trial of low-dose pomalidomide in myelofibrosis with anemia. *Blood*. 2010; 116:4109.
 182. Pardanani A, George G, Lasho T, Hogan WJ, **Litzow MR**, Begna K, Hanson CA, Fida R, Burns C, Smith GD, Tefferi A. A phase I/II study of CYT387, an oral JAK 1/2 inhibitor, in myelofibrosis significant response rates in anemia, splenomegaly, and constitutional symptoms. *Blood*. 2010 Nov 19; 116(21):206.
 183. Rosen DB, Putta S, Gayko U, Cesano A, Cripe L, Sun ZX, **Litzow MR**, Uno H, Tallman MS, Paietta E. Characterization of FLT3 pathway deregulation by single cell network profiling (SCNP) stratifies aml patients beyond molecular profiling. *Blood*. 2010 Nov 19; 116(21):1129.
 184. Armand P, Perez W, Zhang MJ, Kim H, Klumpp TR, Dal Cin P, Waller EK, **Litzow MR**, Liesveld JL, Lazarus HM, Artz A, Gupta V, Savani BN, McCarthy PL, Cahn JY, Schouten H, Finke J, Ball ED, Aljurf M, Cutler C, Rowe JM, Antin JH, Isola LM, Di Bartolomeo P, Camitta B, Miller AM, Cairo MS, Stockerl-Goldstein KE, Sierra J, Savoie ML, Halter J, Stiff PJ, Nabhan C, Jakubowski AA, Bunjes D, Petersdorf EW, Devine SM, Maziarz R, Bomhauser M, Lewis VA, Marks DI, Bredeson CN, Soiffer R, Weisdorf DJ. Cytogenetics abnormalities predict the outcome of allogeneic transplantation In AML A CIBMTR study. *Blood*. 2010 Nov 19; 116(21):299.
 185. Paulsen A, Malik S, **Litzow MR**, Gastineau D, Roy V, Solberg LA, Zubair A. Dual roles of CD8+t cell in hematopoietic progenitor cell mobilization and engraftment. *Blood*. 2010 Nov 19; 116(21):157.
 186. Patel JP, Wahab OA, Gonen M, Figueroa ME, Fernandez HF, Sun ZX, Racevskis J, Van Vlierberghe P, Dolgalev I, Cheng J, Viale A, Socci N, Heguy A, Ketterling R, Gallagher RE, **Litzow MR**, Rowe JM, Ferrando A, Paietta E, Tallman MS, Melnick AM, Levine R. High throughput mutational profiling in aml mutational analysis of the ECOG E1900 Trial. *Blood*. 2010 Nov 19; 116(21):370-1.
 187. Fielding AK, Buck G, Lazarus HM, **Litzow MR**, Luger S, Marks DI, McMillan A, Moorman AV, Paietta E, Richards SM, Tallman MS, Rowe JM, Goldstone AH. Imatinib significantly enhances long term outcomes in philadelphia positive acute lymphoblastic leukaemia, final results of the UKALLXII/ECOG2993 trial. *Blood*. 2010 Nov 19; 116(21):77.
 188. Sive JI, Buck G, Fielding A, Lazarus HM, **Litzow MR**, Luger S, Marks DI, McMillan A, Richards SM, Rowe JM, Tallman MS, Goldstone AH. Inability to tolerate standard therapy is a major reason for poor outcome in older adults with acute lymphoblastic leukemia (ALL) results from the international MRC/ECOG trial. *Blood*. 2010 Nov 19; 116(21):218-9.
 189. Smith MR, Neuberg D, Flinn IW, Grever MR, Bennett JM, Dewald G, Paietta EM, **Litzow MR**, Rowe JM, Lucas D, Kitada S, Jelinek DF, Gribben JG, Byrd JC, Reed JC, Hussein MA, Appelbaum FR, Larson RA, Moore DF, Tallman MS. Increased incidence of therapy related myeloid neoplasia (T MN) after initial therapy for cll with fludarabine cyclophosphamide (FC) vs fludarabine (F) long term follow up of US intergroup study e2997. *Blood*. 2010 Nov 19; 116(21):408-9.
 190. Geng HM, Neuberg D, Paietta E, Deng XT, Li YS, Xin YA, Racevskis J, Ketterling R, Richards SM, Tallman MS, Rowe JM, **Litzow MR**, Elemento O, Melnick AM. Integrative genome wide DNA methylation and gene expression analysis reveals biological and clinical insights in adult acute lymphoblastic leukemia. *Blood*. 2010 Nov 19; 116(21):371.
 191. Strickland SA, Sun ZX, Ketterling RP, Cherry AM, Cripe LD, Dewald G, Higgins RR, Lazarus HM, **Litzow MR**, Luger SM, Paietta E, Rowe JM, Uno H, Vance GH, Tallman MS. Monosomal karyotype (MK) in older patients with acute myeloid leukemia (AML) on Eastern cooperative oncology group (ECOG) therapeutic trials poor prognostic impact of MK, but not of monosomy. *Blood*. 2010 Nov 19; 116(21):256.

192. **Litzow MR**, Buck G, Dewald G, Fielding A, Ketterling R, Lazarus HM, Luger S, Marks DI, McMillan A, Moorman AV, Paietta E, Richards SM, Rowe JM, Tallman MS, Goldstone AH. Outcome of 1,229 adult Philadelphia chromosome negative B acute lymphoblastic leukemia (B ALL) patients (pts) from the international UKALLXII/E2993 trial no difference in results between B cell immuno phenotypic subgroups. *Blood*. 2010 Nov 19; 116(21):232-3.
193. Karp JE, Pratz KW, **Litzow MR**, Ji JP, Chen A, Rudek M, Kaufmann SH. Phase I trial of the oral poly (ADP ribose) polymerase (PARP) inhibitor veliparib (ABT 888, V) combined with topoecan (T) and carboplatin (C) for adults with relapsed and refractory acute leukemias. *Blood*. 2010 Nov 19; 116(21):1342-3.
194. Loughran TP, Yao XP, Bennett JM, **Litzow MR**, Evens AM, Tallman MS. Results of a prospective multicenter phase II study of initial treatment with methotrexate in LGL Leukemia (ECOG Protocol E5998). *Blood*. 2010 Nov 19; 116(21):310.
195. Jagasia M, Arora M, Flowers M, Chao NJ, McCarthy PL, Antin JH, Bolwell BJ, Bredeson C, Cahn JY, Cairo MS, Cutler C, Gale RP, Gupta V, Haagenson MD, Horowitz MM, Lee SJ, **Litzow MR**, Pavletic SZ, Urbano A, Weisdorf DJ, Zhang MJ, Hahn T. Risk factors for acute graft versus host disease and survival after hematopoietic cell transplantation from siblings and unrelated donors - an analysis of the CIBMTR. *Blood*. 2010 Nov 19; 116(21):394.
196. Cesano A, Putta S, Gayko U, Hackett J, Rosen DB, Cripe L, Sun ZX, Uno H, **Litzow MR**, Tallman MS, Paietta E. Single cell network profiling (SCNP) signatures independently predict response to induction therapy in older patients with acute myeloid leukemia (AML). *Blood*. 2010 Nov 19; 116(21):1110-1.
197. Cesano A, Rosen DB, Putta S, Gayko U, Cripe L, Sun ZX, Uno H, **Litzow MR**, Tallman MS, Paietta E. Specimen source (BM or PB) does not affect proteomic signaling in patients with AML and circulating blasts. *Blood*. 2010 Nov 19; 116(21):1109-10.
198. Luger S, Yao XP, Paietta E, Ketterling R, Rybka W, **Litzow MR**, Rowe JM, Larson R, Tallman MS. Tipifarnib is well tolerated as maintenance therapy in acute myeloid leukemia (AML) significant, but non fatal, hematologic toxicity not ameliorated by dose reduction preliminary results of the phase III intergroup trial E2902. *Blood*. 2010 Nov 19; 116(21):1358-9.
199. Gertz MAA, Lacy M, Dispenzieri A, Kumar S, Buadi F, Dingli D, Ansell SM, Gastineau D, Inwards DJ, Johnston PB, **Litzow MR**, Micallef I, Porrata L, Leung N, Wolf R, Hogan WJ, Hayman SR. Transplantation for immunoglobulin light chain amyloidosis a statistical analysis of factors predicting outcome in over 400 patients. *Blood*. 2010 Nov 19; 116(21):1463-4.
200. Gandhi MJ, DeGoey SR, Kroning CM, Schneider B, Stubbs J, Hogan W, **Litzow M**, Gastineau D. A case of rejection in 10/10 allele matched transplant with "high titer low avidity" hla-dp donor specific antibodies. *Hum Immunol*. 2011; 72(1):S4.
201. Micallef IN, Sinha S, Gastineau DA, Wolf R, Inwards DJ, Gertz MA, Hayman SR, Hogan WJ, Johnston PB, Lacy MQ, Ansell SM, Buadi F, Dingli D, Dispenzieri A, **Litzow MR**, Porrata LF, Winters JL, Kumar S. A cost effective analysis of a risk-adapted algorithm for plerixafor use in autologous peripheral blood stem cell mobilization. *Biol Blood Marrow Transplant*. 2011 Feb; 17(Suppl 2):S159-60.
202. Jiang L, Malik S, **Litzow M**, Gastineau D, Micallef I, Roy V, Solberg L, Zubair AC. CD34+cells from poor mobilizers are qualitatively equivalent to CD34+cells from good mobilizers. *Biol Blood Marrow Transplant*. 2011 Feb; 17(Suppl 2):S204.
203. McCullough KB, Burzynski JA, Hogan WJ, **Litzow MR**, Wolf RC, Wermers RA. Decline in bone mineral density in allogeneic hematopoietic stem cell transplantation: impact of myeloablative versus reduced intensity conditioning regimens. *Biol Blood Marrow Transplant*. 2011 Feb; 17(Suppl 2):S353-4.
204. Mistry B, Jones MM, Kubiak P, Garcia-Manero G, **Litzow MR**, Mesa RA, Rifkin R, Tarassoff P, Cortes JE. A phase 1 study to assess the absolute bioavailability and safety of an oral solution of decitabine in subjects with myelodysplastic syndromes (MDS). *Blood*. 2011 Nov 18; 118(21):1624. Abstract no. 3801.
205. Dispenzieri A, Gertz MA, Lacy MQ, Laumann K, LaPlant BR, Kumar S, Buadi FK, Hayman SR, Dingli D, Hogan WJ, Ansell SM, Gastineau DA, Inwards DJ, Micallef IN, Porrata LF, Johnston PB, **Litzow MR**, Witzig TE. A phase I trial of zevalin radioimmunotherapy with high-dose melphalan (HDM) and autologous stem cell transplant (ASCT) for multiple myeloma (mm). *Blood*. 2011 Nov 18; 118(21):1337-8.
206. Ding W, Shanafelt TD, Rabe K, Call TG, Zent CS, Kay N, Inwards DJ, Bowen D, **Litzow MR**, Slager SL, Schwager S, Hogan WJ. Alemtuzumab use and survival after reduced intensity allogeneic stem cell transplantation in high-risk chronic lymphocytic leukemia (CLL). *Blood*. 2011 Nov 18; 118(21):1776.
207. Pardanani A, Gotlib J, Gupta V, Roberts AW, Wadleigh M, Sirhan S, **Litzow MR**, Hogan WJ, Begna K, Smith G, Bavisotto LM, Kowalski M, Tefferi A. An expanded multicenter phase I/II Study of CYT387, a JAK-1/2 inhibitor for the treatment of myelofibrosis. *Blood*. 2011 Nov 18; 118(21):1645.

208. Battiwalla M, Ellis K, Pavletic SZ, Akpek G, Hematti P, Klumpp TR, Maziarz RT, Savani BN, Aljurf M, Cairo MS, Drobyski WR, George B, Hahn T, Khera N, **Litzow MR**, Loren AW, Saber W, Arora M, Urbano-Ispizua A, Cutler CS, Flowers MED, Spellman S. HLA DR15 antigen status does not impact graft-versus-host disease or disease-free survival in HLA-matched sibling transplantation for hematologic malignancies. *Blood*. 2011 Nov 18; 118(21):1337.
209. DeCook L, Thoma M, Huneke T, Johnson N, Wiegand R, **Litzow MR**, Hogan WJ, Porrata LF, Holtan SG. Impact of rapid lymphocyte and monocyte recovery on overall survival post-allogeneic hematopoietic stem cell transplantation (HSCT) with fludarabine/melphalan conditioning. *Blood*. 2011 Nov 18; 118(21):1310-1.
210. Tefferi A, Begna K, Hogan WJ, **Litzow MR**, Hanson CA, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. *Blood*. 2011 Nov 18; 118(21):764.
211. Pratz KW, Kaufmann SH, **Litzow MR**, Ji JP, Chen A, Rudek MA, Karp JE. Phase I trial of the oral poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888, V) combined with topoecan (T) and carboplatin (C) for adults with relapsed and refractory acute leukemias. *Blood*. 2011 Nov 18; 118(21):1552.
212. Begna K, Pardanani A, Mesa RA, Hogan WJ, **Litzow MR**, Tefferi A. Pomalidomide therapy for myelofibrosis: analysis of results from three consecutive clinical trials. *Blood*. 2011 Nov 18; 118(21):767. Abstract no. 1759.
213. Foran JM, Sun ZX, Fernandez HF, Cripe LD, Ketterling RP, Racevskis J, Luger SM, Paietta E, Lazarus HM, **Litzow MR**, Tallman MS. The impact of obesity on the presentation & outcome of adult acute myeloid leukemia (AML) - ECOG studies E1900 & E3999. *Blood*. 2011 Nov 18; 118(21):1101-2.
214. Fernandez HF, Sun ZX, **Litzow MR**, Luger SM, Paietta E, Racevskis J, Dewald GW, Ketterling RP, Bennett JM, Rowe JM, Lazarus HM, Tallman MS. Young adults presenting with extramedullary acute myeloid leukemia have a unique sensitivity to high doses of anthracyclines: subset analysis of ECOG 1900. *Blood*. 2011 Nov 18; 118(21):1546.
215. Gandhi MJ, Voit L, DeGoey SR, Kroning C, **Litzow MA**, Gastineau D, Hogan W, Patnaik M. History of hla-dp antibodies in a potential bone marrow recipient after granulocyte transfusion: clinical conundrum to transplant. *Hum Immunol*. 2012; 73:23.
216. Osagie NE, Ehlers SL, Merten JA, Hogan WJ, **Litzow MR**, Wolf RC. Correlation of medication burden and quality of life in allogeneic hematopoietic stem cell transplant patients. *Biol Blood Marrow Transplant*. 2012 Feb; 18(2):S240-1.
217. Singla A, Hogan WH, Ansell SM, Buadi FK, Dingli D, Dispenzieri A, Gastineau DA, Gertz MA, Hayman SR, Inwards DJ, Johnston PB, Lacy MQ, **Litzow MR**, Micallef IN, Porrata LF, Kumar SK. Incidence of cardiac arrhythmias during autologous peripheral blood stem cell transplantation. *Biol Blood Marrow Transplant*. 2012 Feb; 18(2):S207.
218. Gandhi MJ, Schneider BA, Jenkins S, Hogan WJ, **Litzow MR**, Gastineau DA, Stubbs JR, Patnaik MS. Platelet refractoriness is associated with delayed platelet engraftment and increased graft versus host disease following peripheral blood or bone marrow derived stem cell transplantation. *Biol Blood Marrow Transplant*. 2012 Feb; 18(2):S350-1.
219. Barker CA, Hong S, Klein JP, Shaw P, Bredeson C, Angelina A, Rowlings P, Cahn JY, Kharfan-Dabaja M, Aljurf M, Szer J, Wood WA, Ahmed I, Almaguer DG, Atsuta Y, Sanz M, Hale G, **Litzow M**, Pasquini MC. Radiotherapeutic techniques in allogeneic hematopoietic cell transplant (HCT). *Biol Blood Marrow Transplant*. 2012 Feb; 18(2):S351.
220. Fauble VDS, Slack JL, Hogan W, Roy V, Leis J, Dueck AC, **Litzow MR**, Patnaik MM, Animesh P, Rivera CE, Tibes R, Camoriano J, Adams RH, Noel P, Khera N, Sproat L, Mesa RA. Allogeneic stem cell transplantation for primary and post et/pv myelofibrosis at Mayo Clinic: a retrospective review across a geographically diverse 3 site cancer center. *Blood*. 2012 Nov 16; 120(21).
221. Swedeh A, Patnaik M, Alfakara D, Ashrani AA, Pruthi R, Elliott M, **Litzow M**, Al-Kali A. Autoimmunity in patients (pts) with chronic myelomonocytic leukemia (cmml): a frequent finding. *Blood*. 2012 Nov 16; 120(21).
222. Sirop SJ, Al-Kali A, Begna K, Gangat N, Letendre L, Porrata LF, Hogan WJ, **Litzow MR**, Patnaik MM. Lack of prognostic significance of monosomal karyotype and absolute lymphocyte count at diagnosis in Philadelphia chromosome negative acute lymphoblastic leukemia. *Blood*. 2012 Nov 16; 120(21).
223. Abdelfatah M, Al-Alwan A, Kanaan Z, **Litzow MR**, Wolanskyj A, Begna K, Hogan W, Van Dyke DL, Al-Kali A. Loss of the y chromosome predicts lower complete cytogenetic remission rate in patients (pts) with chronic myeloid leukemia (cml). *Blood*. 2012 Nov 16; 120(21).
224. Watts JM, Zickl L, **Litzow MR**, Luger SM, Lazarus HM, Cassileth PA, Fernandez HF, Douer D, Paietta E, Rowe JM, Tallman MS. Practically all patients with acute myeloid leukemia (aml) in continuous complete remission for 3 years or more are cured of their disease: the ecog experience. *Blood*. 2012 Nov 16; 120(21).
225. Zeidner JF, Gerber JM, Blackford A, **Litzow M**, Foster MC, Morris LE, Gojo I, Lancet JE, Bose P, Tibes R,

- Strickland SA, Greer JM, Drye M, Meads K, Doyle A, Little RF, Wright JJ, Karp JE. Randomized phase ii trial of timed-sequential therapy (tst) with flavopiridol (alvocidib), ara-c and mitoxantrone (flam) versus "7+3" for adults ages 70 years and under with newly diagnosed acute myeloid leukemia (aml). *Blood*. 2012 Nov 16; 120(21):3611-3617.
226. Roeker LE, Wolanskyj A, Elliott M, Hogan W, **Litzow M**, Al-Kali A. Treatment-related aml patients previously treated with taxanes for breast cancer have similar outcomes as de novo aml. *Blood*. 2012 Nov 16; 120(21):3618-3624.
 227. Elkhanany A, Hanson CA, Patnaik M, Elliott M, **Litzow M**, Al-Kali A. Y incidence of autoimmunity in patients (pts) with low-risk (lr) myelodysplastic syndrome (mds): 10 years follow-up. *Blood*. 2012 Nov 16; 120(21):3625-3631.
 228. Thoma M, Gleif J, Jacob EK, Huneke T, DeCook L, Johnson N, Patnaik M, **Litzow M**, Hogan W, Porrata L, Holtan S. Allograft leukocyte content and post-allogeneic hematopoietic cell transplant lymphopenia and monocytopenia. *Biol Blood Marrow Transplant*. 2013 Feb; 19(2):S309.
 229. Ostrem M, Merten J, Hogan W, **Litzow MR**, Patnaik M, Hashmi S, Bartoo G, Wolf R, Wermers R. Incidence of fluoride toxicity in allogeneic hematopoietic stem cell transplant (hsct) patients taking voriconazole. *Biol Blood Marrow Transplant*. 2013 Feb; 19(2):S377-8.
 230. Warlick E, Paulson K, Brazauskas R, Zhong XB, Eapen M, Weisdorf DJ, **Litzow MR**. Pre-transplant consolidation chemotherapy does not improve outcomes following reduced intensity conditioning (ric) hematopoietic cell transplant (hct) for acute myeloid leukemia (aml) in cr1. *Biol Blood Marrow Transplant*. 2013 Feb; 19(2):S231.
 231. Burnette BL, Gertz M, Kumar S, Lacy M, Buadi F, Hayman S, Dingli D, Inwards DJ, Johnston PB, Micallef IN, Porrata LE, Hogan W, **Litzow MR**, Patnaik M, Hashmi S, Leung N, Afessa B, Gastineau D, Ansell SM, Holtan S, Dispenzieri A. Redefining engraftment syndrome: the new Mayo Clinic criteria. *Biol Blood Marrow Transplant*. 2013 Feb; 19(2):S180-1.
 232. * McCullough KB, Barreto JN, Peskey CS, Gastineau DA, Elliott MA, Gangat N, Patnaik MS, **Litzow MR**, Hogan WJ. Cost-Effectiveness Of Antithrombin Repletion In Adult Patients With Acute Lymphoblastic Leukemia (ALL) Treated With Asparaginase-Containing Combination Chemotherapy; A Single Center Experience *Blood*.2013;122:(21)1732. Abstract no.59021.
 233. Barreto JN, McCullough KB, Peskey CS, Letendre L, Hogan WJ, Al-Kali A, **Litzow MR**, Patnaik MS. Hepatic and Metabolic Complications In Adult Patients With Acute Lymphoblastic Leukemia (ALL) Treated With Asparaginase-Containing Combination Chemotherapy: A Single Center Experience *Blood*.2013;122:(21)1405. Abstract no.64813.
 234. Barreto JN, McCullough KB, Peskey CS, Elliott MA, Gastineau DA, Al-kali A, Letendre L, Hogan WJ, **Litzow MR**, Patnaik MS. Thromboembolic and Hemorrhagic Complications In Adult Patients With Acute Lymphoblastic Leukemia (ALL) Treated With Asparaginase-Containing Combination Chemotherapy: A Single Center Experience *Blood*.2013;122:(21)3873. Abstract no.58763.
 235. Kelm D, **Litzow M**, Kennedy CC. Multiple bullae with recurrent pneumothoraces after allogeneic bone marrow transplantation. *Chest* 6.2014; *Chest* 2014 146:985A.
 236. Kochuparambil S, Jackson A, **Litzow MR**, Khan SP, Rodriguez V, Abraham R, Hogan W, Patnaik M. Allogeneic transplantation for mds/aml patients with germline gata2 mutations. *Biol Blood Marrow Transplant*. 2014 Feb; 20(2):S236-7.
 237. Mir M, Hashmi S, Patnaik M, Hogan W, **Litzow MR**. Diagnostic criteria for myositis as a facet of chronic gvhd. *Biol Blood Marrow Transplant*. 2014 Feb; 20(2):S275.
 238. Cordes S, Warad D, Gustafson M, Armstrong A, Butler G, Patnaik M, Hogan W, **Litzow MR**, Winters J, Gastineau D, Dietz A, Lin Y, Jacob EK. Immune profiling to predict treatment response from extracorporeal photopheresis in graft-versus-host disease. *Biol Blood Marrow Transplant*. 2014 Feb; 20(2):S263-4.
 239. Kochuparambil S, **Litzow MR**, Hogan W, Hashmi S, Gastineau D, Patnaik M. Post-transplant isoagglutinin induced pure red cell aplasia; incidence and clinic outcomes. *Biol Blood Marrow Transplant*. 2014 Feb; 20(2):S237.
 240. Gonsalves WI, Gangat N, Gupta V, Al-Kali A, Hogan W, Hashmi S, **Litzow MR**, Patnaik M. The role for induction chemotherapy and allogeneic stem cell transplant in patients with chronic myelomonocytic leukemia that have undergone leukemic transformation: a single center experience. *Biol Blood Marrow Transplant*. 2014 Feb; 20(2):S153-4.
 241. Hashmi S, Wojenski D, Merten J, Wolf R, Bartoo G, Wilson J, El-azhary R, Dierkhising R, Patnaik M, Hogan W, **Litzow MR**. Voriconazole exposure and the risk of cutaneous squamous cell carcinoma in allogeneic hematopoietic stem cell transplant patients. *Biol Blood Marrow Transplant*. 2014 Feb; 20(2):S227-8.
 242. Gijima D, Hogan WJ, **Litzow MR**, Gastineau DA, Hashmi SK, Patnaik MM. Clinical characteristics and outcomes of respiratory syncytial virus infection in recipients of allogeneic stem cell transplants. *Haematologica*. 2014 Jun 1; 99:194.

243. Al-Kali A, Hashmi S, Alsahlawi A, Patnaik M, Elliott M, Wolanskyj A, Hogan W, Siddiqui M, **Litzow M**. Decitabine as compared to azacitidine therapy may result in better overall survival but not quality of life in patients diagnosed with chronic myelomonocytic leukemia (cmml): a retrospective, single i. *Haematologica*. 2014 Jun 1; 99:612.
244. Alsahlawi A, **Litzow M**, Patnaik M, Alfakara D, Begna K, Michelle E, Hogan W, Al-Kali A. Heavy smokers have higher frequency of leukemic transformation than light smokers in patients diagnosed with chronic myelomonocytic leukemia (cmml). *Haematologica*. 2014 Jun 1; 99:617.
245. Begna K, Animesh P, **Litzow M**, Hanson C, Mesa R, Hogan W, Tefferi A. Pomalidomide in myelofibrosis: long term follow up and correlation with jak2v617f and calr mutations. *Haematologica*. 2014 Jun 1; 99:392.
246. Hegerova L, Patnaik M, Hogan W, **Litzow M**, Hashmi S. The clinical spectrum and outcomes of human herpesvirus 6-related infections after allogeneic hematopoietic stem cell transplantation. *Haematologica*. 2014 Jun 1; 99:194-5.
247. Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, **Litzow MR**, Buckstein R, Velasco MR, Gaur R, Atallah E, Attar E, Appelbaum FR, Erba HP. A randomized phase ii study of azacitidine combined with lenalidomide or with vorinostat vs. azacitidine monotherapy in higher-risk myelodysplastic syndromes (mds) and chronic myelomonocytic leukemia (cmml): North American intergroup study swog s1117. *Blood*. 2014 Dec 6; 124(21).
248. **Litzow MR**, Wang XV, Carroll MP, Karp JE, Ketterling R, Kaufmann SH, Lazarus HM, Luger SM, Paietta EM, Rowe JM, Altman JK, Pratz KW, Broun ER, Tallman MS. A randomized phase ii trial of three novel regimens for relapsed/refractory acute myeloid leukemia (aml) demonstrates encouraging results with a flavopiridol-based regimen: results of eastern cooperative oncology group (ecog) trial e1906. *Blood*. 2014 Dec 6; 124(21):3742.
249. Goekbuget N, Kantarjian H, Bruggemann M, Stein A, Bargou RC, Dombret H, Fielding AK, Heffner L, Rigal-Huguet F, **Litzow M**, O'Brien S, Zugmaier G, Jia C, Maniar T, Huber B, Nagorsen D, Forman SJ, Topp MS. An evaluation of molecular response in a phase 2 open-label, multicenter confirmatory study in patients (pts) with relapsed/refractory b-precursor acute lymphoblastic leukemia (r/r all) receiving treatment with the bite (r) antibody construct blinatumomab. *Blood*. 2014 Dec 6; 124(21).
250. Baidoun F, Chen D, Alkhateeb H, Zblewski D, Elliott M, Hogan WJ, **Litzow M**, Al-Kali A. Clinical outcome of patients diagnosed with myelodysplastic syndrome-unclassifiable (mds-u): single center experience. *Blood*. 2014 Dec 6; 124(21).
251. Mantha S, Goldman D, Devlin SM, Lee JW, Zannino D, Douer D, Iland HJ, **Litzow MR**, Stein EM, Appelbaum F, Larson RA, Rowe JM, Tallman MS. Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the atra era. *Blood*. 2014 Dec 6; 124(21):948.
252. Stock W, Luger SM, Advani AS, Geyer S, Harvey RC, Mullighan CG, Willman CL, Malnassy G, Parker E, Laumann KM, Sanford B, Marcucci G, Paietta EM, Liedtke M, Claxton DF, Foster MC, Appelbaum FR, Erba H, **Litzow MR**, Tallman MS, Stone RM, Larson RA. Favorable outcomes for older adolescents and young adults (aya) with acute lymphoblastic leukemia (all): early results of us intergroup trial c10403. *Blood*. 2014 Dec 6; 124(21):796.
253. Pardanani A, Abdelrahman RA, Finke C, Lasho TL, Begna K, Al-Kali A, Hogan WJ, **Litzow MR**, Hanson CA, Ketterling R, Tefferi A. Genetic determinants of response and survival in momelotinib treated myelofibrosis patients. *Blood*. 2014 Dec 6; 124(21):3162.
254. Thanarajasingam G, Foran JM, Roy V, Sproat L, Hogan WJ, **Litzow MR**, Al-Kali A, Gangat N, Patnaik MM. Hematopoietic stem cell transplantation as a successful salvage strategy for relapsed acute promyelocytic leukemia (apl): a Mayo Clinic series. *Blood*. 2014 Dec 6; 124(21).
255. Luskin MR, Lee JW, Fernandez HF, Lazarus HM, Rowe JM, Tallman MS, Paietta EM, **Litzow M**, Abdel-Wahab O, Patel JP, Levine RL, Sun ZX, Luger SM. High dose daunorubicin improves survival in aml up to age 60, across all cytogenetic risk groups including patients with unfavorable cytogenetic risk, and flt3-itd mutant aml: updated analyses from eastern cooperative oncology trial e1900. *Blood*. 2014 Dec 6; 124(21):373.
256. Abdelrahman RA, Begna K, Al-Kali A, Hogan WJ, **Litzow M**, Pardanani A, Tefferi A. Momelotinib treatment-associated neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis. *Blood*. 2014 Dec 6; 124(21):1837.
257. Hefazi Torghabeh M, Siddiqui MA, Patnaik MM, Wolanskyj A, Zblewski D, Elliott M, Hogan WJ, **Litzow MR**, Al-Kali A. Npm1+/flt3- patients with acute myeloid leukemia (aml) have excellent clinical outcome independent of age when treated with cytotoxic chemotherapy: Mayo Clinic experience. *Blood*. 2014 Dec 6; 124(21):5331.
258. Artz AS, Logan BR, Zhu XC, Akpek G, Martino R, Gupta V, Lazarus HM, **Litzow MR**, Loren AW, Majhail NS, Maziarz RT, McCarthy PL, Popat UR, Saber W, Spellman SR, Ringden O, Cooke KR, Pasquini MC. Pre-transplant c-reactive protein (crp), ferritin and albumin as biomarkers to predict transplant related mortality

- (Am) after allogeneic hematopoietic cell transplant (hct). Blood. 2014 Dec 6; 124(21):422.
259. Luskin MR, Lee JW, Fernandez HF, Lazarus HM, Rowe JM, Tallman MS, Paietta EM, **Litzow M**, Abdel-Wahab O, Patel JP, Levine RL, Sun ZX, Luger SM. Results of the ecog e1900 trial in younger adults with aml using an event free survival endpoint are concordant with results based on overall survival: potential for a surrogate endpoint to facilitate rapid approval of therapies in aml. Blood. 2014 Dec 6; 124(21).
 260. Kochuparambil ST, Jackson AE, **Litzow MR**, Khan S, Rodriguez V, Hogan WJ, Abraham R, Patnaik MM. Spectrum of phenotypic manifestations of a novel c1339a > c, ps447r germline gata2 mutation. Blood. 2014 Dec 6; 124(21).
 261. Hefazi M, **Litzow MR**, Hogan W, Gastineau DA, Jacob EK, Hashmi S, Al-kali A, Patnaik M. Abo blood group incompatibility has no impact on the outcomes in patients with myeloid neoplasms that underwent reduced intensity allogeneic hematopoietic stem cell transplantation - a single institution series of 148 patients. Biol Blood Marrow Transplant. 2015 Feb; 21(2):S288-9.
 262. Moyer AM, Hashmi S, Kroning CM, Kremers WK, De Goey SR, Patnaik M, **Litzow MR**, Gastineau DA, Hogan W, Kreuter JD, Voit LL, Gandhi M. Clinical outcomes of hla-dpb1 mismatches in 10/10 hla-matched donor-recipient pairs undergoing allogeneic stem cell transplant. Biol Blood Marrow Transplant. 2015 Feb; 21(2):S300.
 263. Eiten EC, Hashmi S, **Litzow MR**, Hogan W, Gastineau DA, Patriaik M. Etiology and spectrum of non-relapse mortality after reduced intensity allogeneic hematopoietic stem cell transplantation in adults with myeloid neoplasms. Biol Blood Marrow Transplant. 2015 Feb; 21(2):S355.
 264. Damlaj M, Hashmi S, Call T, Witzig TE, Nowakowski GS, Shanafelt T, Ding W, Oliveira J, Ketterling R, **Litzow MR**, Hogan W, Patnaik M. Feasibility of hematopoietic stem cell transplantation for t-prolymphocytic leukemia. experience of a large referral center. Biol Blood Marrow Transplant. 2015 Feb; 21(2):S185.
 265. Hashmi S, Taner T, Patnaik M, Leise M, Hathcock M, Kremers WK, Hogan W, **Litzow MR**. Liver transplantation for hepatic graft-versus-host-disease: a united network for organ sharing (unos) database study. Biol Blood Marrow Transplant. 2015 Feb; 21(2):S331.
 266. Damlaj M, Bartoo G, Gijima D, Hashmi S, **Litzow MR**, Hogan W, Patnaik M. Oral ribavirin for the treatment of respiratory syncytial virus infection in allogeneic stem cell transplant recipients-utility of the immunodeficiency scoring index for risk stratification. Biol Blood Marrow Transplant. 2015 Feb; 21(2):S173-4.
 267. Chaudhry HM, Bruce AJ, Wolf R, **Litzow MR**, Hogan W, Gastineau DA, Patnaik M, Prokop L, Hashmi S. The incidence and outcomes of oral mucositis among allogeneic stem cell transplantation patients: a systematic review and meta-analysis. Biol Blood Marrow Transplant. 2015 Feb; 21(2):S245-6.
 268. Ferzoco RM, Micallef IN, Winters J, Ansell S, Buadi F, Dingli D, Dispenziera A, Gastineau DA, Gertz M, Hashmi S, Hayman S, Hogan W, Inwards DJ, Johnston PB, Kapoor P, Lacy M, **Litzow MR**, Patnaik M, Porrata LF, Kumar S. Updated results of the mayo clinic risk adapted algorithm for peripheral blood stem cell mobilization utilizing g-csf and plerixafor. Biol Blood Marrow Transplant. 2015 Feb; 21(2):S50-1.
 269. Bartoo G, Damlaj M, Gijima D, Merten J, Hashmi S, **Litzow MR**, Gastineau DA, Hogan W, Patnaik M. Utility of corticosteroids as adjunct therapy for respiratory syncytial virus infection in allogeneic stem cell transplant recipients. Biol Blood Marrow Transplant. 2015 Feb; 21(2):S365.
 270. Hashmi S, Khorana A, Hogan W, Gastineau DA, Patnaik M, Prokop L, Zahid F, Spyropoulos A, **Litzow MR**. Venous thromboembolism is hematopoietic stem cell transplant patients-a meta-analysis and systemic review. Biol Blood Marrow Transplant. 2015 Feb; 21(2):S74-5.
 271. Abou Hussein AK, Patnaik MM, Zblewski D, Gangat N, Hashmi S, Elliott MA, Hogan WJ, **Litzow MR**, Al-Kali A. Case series of hypomethylating agents (hma) effect on myelodysplastic/myeloproliferative neoplasm unclassified (mds/mpn-u): Mayo Clinic experience. J Clin Oncol. 2015 May 20; 33(15).
 272. Cheema N, Baidoun F, Zblewski D, Hashmi S, Gangat N, Wolanskyj AP, Hogan WJ, **Litzow MR**, Chen D, Al-Kali A. Effect of grade (g) 3 fibrosis on clinical outcome of patients (pts) with myelodysplastic syndromes (mds): Mayo Clinic experience. J Clin Oncol. 2015 May 20; 33(15).
 273. Subari S, Baidoun F, Hreh M, Patnaik MM, Hashmi S, Elliott MA, Hogan WJ, **Litzow MR**, Al-Kali A. Effect of prior hypomethylating agent (hma) use on clinical outcome of patients (pts) with secondary acute myeloid leukemia (saml) arising from myelodysplastic syndrome (mds) when treated with standard induction chemotherapy (7+3). J Clin Oncol. 2015 May 20; 33(15).
 274. Topp MS, Stelljes M, Zugmaier G, Barnette P, Heffner LT, Trippett TM, Bargou RC, Holland C, Benjamin J, **Litzow MR**. Re-exposure to blinatumomab after cd19-positive relapse: experience from three trials in patients (pts) with relapsed/refractory b-precursor acute lymphoblastic leukemia (r/r all). J Clin Oncol. 2015 May 20; 33(15).
 275. Levis MJ, Perl AE, Altman JK, Cortes JE, Ritchie EK, Larson RA, Smith CC, Wang ES, Strickland SA, Baer MR, **Litzow MR**, Claxton D, Schiller GJ, Ustun C, Liu C, Gill S, Sargent B, Bahceci E. Results of a first-in-

- human, phase i/ii trial of asp2215, a selective, potent inhibitor of flt3/axl in patients with relapsed or refractory (r/r) acute myeloid leukemia (aml). *J Clin Oncol*. 2015 May 20; 33(15).
276. Lancet JE, Othus M, DeAngelo DJ, Coutre S, Komrokji RS, Tallman MS, **Litzow MR**, Appelbaum FR. Safety and tolerability of the combination of atra plus arsenic trioxide (ato) plus gemtuzumab ozogamicin (go) in high-risk acute promyelocytic leukemia (apl): initial report of the swog/alliance/ecog s0535 trial. *J Clin Oncol*. 2015 May 20; 33(15).
 277. Hefazi M, Siddiqui MA, Patnaik MM, Wolanskyj AP, Alkhateeb H, Zblewski D, Elliott MA, Hogan WJ, **Litzow MR**, Al-Kali A. The prognostic impact of combined npm1+/flt3-mutational status in newly diagnosed acute myeloid leukemia (aml) patients with intermediate risk cytogenetics according to age and treatment modality. *J Clin Oncol*. 2015 May 20; 33(15).
 278. Kochuparambil ST, Jackson AE, **Litzow MR**, Khan SP, Rodriguez V, Abraham RS, Hogan WJ, Patnaik MM. Allogeneic stem cell transplant in patients with germline gata2 mutation *Clinical Lymphoma Myeloma & Leukemia*. 2015 Jun; 15:S188-9.
 279. Alkhateeb H, Damraj M, Al-Kali A, Gangat N, Begna KH, **Litzow MR**, Hogan WJ, Elliott MA, Ketterling RP, Patnaik MS. Clinical impact of del (11q) in patients with de novo and secondary myelodysplastic syndromes-a single institution experience. *Haematologica*. 2015 Jun; 100:241.
 280. Kumar A, Gimotty P, Gelfand J, Buck G, Rowe J, Goldstone A, Fielding A, Marks D, **Litzow M**, Paietta E, Lazarus H, Tallman M, Luger S, Loren A. Delays in intensification are common in adults with acute lymphoblastic leukemia (all), are associated with decreased survival in allogeneic hematopoietic cell transplant (hct) patients *Clinical Lymphoma Myeloma & Leukemia*. 2015 Jun; 15:S176-7.
 281. Subari S, Patnaik M, Alfakara D, Zblewski D, Hook C, Hashmi S, Hogan W, **Litzow M**, Al-Kali A. Hypomethylating agents are effective in shrinking splenomegaly in patients with chronic myelomonocytic leukemia (cmml): mayo clinic experience. *Haematologica*. 2015 Jun; 100:489.
 282. Sharma P, Shinde S, Gangat N, Al-Kali A, Hashami S, **Litzow M**, Hogan W, Khan S, Rodriguez V, Patnaik M. Outcomes of allogeneic hematopoietic stem cell transplant in patients with mds/mpn overlap syndromes-a single institutional experience. *Haematologica*. 2015 Jun; 100:283.
 283. Subari S, Patnaik M, Alfakara D, Gangat N, Elliott M, Hogan W, **Litzow M**, Al-Kali A. Patients with therapy-related chronic myelomonocytic leukemia (tr-cmml) have shorter median overall survival than de novo cmml (dn-cmml): Mayo Clinic experience. *Haematologica*. 2015 Jun; 100:488.
 284. Perl A, Altman J, Cortes J, Levis M, Smith C, **Litzow M**, Baer MR, Claxton D, Erba H, Gill S, Goldberg S, Jurcic J, Larson RA, Liu C, Ritchie E, Sargent B, Schiller G, Spira A, Strickland S, Tibes R, Ustun C, Wang ES, Stuart R, Bahceci E. Results of a first-in-human, phase 1/2 trial of asp2215, a selective, potent oral inhibitor of flt3/axl, in patients with relapsed or refractory acute myeloid leukemia. *Haematologica*. 2015 Jun; 100:317-8.
 285. Topp MS, Stelljes M, Zugmaier G, Barnette P, Heffner LT, Trippett T, Bargou R, Jia C, Benjamin J, **Litzow MR**. Retreatment with blinatumomab after cd19-positive relapse: experience from 3 trials in patients with relapsed/refractory b-precursor acute lymphoblastic leukemia (r/r all). *Haematologica*. 2015 Jun; 100:31-2.
 286. Ferzoco R, Micallef I, Winters J, Ansell S, Buadi F, Dingli D, Dispenzieri A, Gastineau D, Gertz M, Hashmi S, Hayman S, Hogan W, Inwards D, Johnston P, Kapoor P, Lacy M, **Litzow M**, Patnaik M, Porrata L, Kumar S. Updated results of the Mayo Clinic risk adapted algorithm for peripheral blood stem cell mobilization utilizing g-csf and plerixafor. *Haematologica*. 2015 Jun; 100:116-7.
 287. Hefazi M, Al-Kali A, Hashmi S, Begna K, Hogan W, Gangat N, **Litzow M**, Viswanatha D, Patnaik M. Utility of chimerism analysis in detection of post-transplant disease relapse in patients with myeloid neoplasms undergoing reduced intensity conditioning allogeneic hematopoietic cell transplantation. *Haematologica*. 2015 Jun; 100:611.
 288. Shen N, Yan F, Pang JX, Gangat N, **Litzow MR**, Al-Kali A, Liu SJ. Nilotinib abrogates dnmt1-dependent dna methylation: a novel mechanism for induction of aml leukemia regression *Cancer Research*. 2015 Aug 1; 75: (Suppl 15).
 289. Barnes S, Tauscher C, Bendix B, Stubbs JR, Bryant SC, Patnaik M, **Litzow M**, Hashmi S, Hogan WJ, Gastineau D, Jacob EK. Abo compatibility in allogeneic hematopoietic progenitor cell transplantation affects survival *Transfusion*. 2015 Sep; 55: 12A-3A.
 290. Luskin MR, Gimotty P, Smith C, Loren A, Figueroa M, Harrison J, Sun ZX, Tallman MS, Paietta E, **Litzow MR**, Levine RL, Fernandez HF, Luger S, Carroll M, Master S, Wertheim G. A clinical measure of dna methylation predicts outcome in de novo aml *Blood*. 2015 Dec 3; 126: (23)2591.
 291. Al-Kali A, Tibes R, Palmer J, Alkhateeb HB, Atherton P, Yan F, Liu S, He R, Hashmi SK, **Litzow MR**. A phase ii of combination d aunorubicin and cytarabine (a ra-c) and nilotinib (ta signa) (data) in patients newly diagnosed with acute myeloid leukemia and kit expression: Interim results *Blood*. 2015 Dec 3; 126: (23)3808.
 292. Chen YB, Le-Rademacher J, Kiefer DM, Hamadani M, DiPersio JF, **Litzow MR**, Craig M, Horwitz ME, Artz A,

- McClune B, Waller EK, Fernandez HF, Duong HK, Kobusingye H, Proue M, Drexler RJ, Horowitz MM, Miller JP, Devine SM. A phase ii study evaluating the safety and efficacy of subcutaneous plerixafor for the mobilization and transplantation of hla-matched sibling donor hematopoietic stem cells in recipients with hematological malignancies Blood. 2015 Dec 3; 126: (23)389.
293. Gupta E, Hoffman R, Colleen T, Hogan WJ, **Litzow MR**, Sproat L, Foran JM, Finn LE, Roy V. A single institution study of allogeneic hematopoietic stem cell transplant for mds and aml in patients 60 years of age and older: impact of disease risk index and secondary disease Blood. 2015 Dec 3; 126: (23)5532.
294. Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, **Litzow MR**, Buckstein R, Fang M, Roulston D, Bloomfield CD, Zhang YM, Velasco MR, Gaur R, Atallah E, Attar EC, Appelbaum FR, Erba HP. Additional analyses of a randomized phase ii study of azacitidine combined with lenalidomide or with vorinostat vs. azacitidine monotherapy in higher-risk myelodysplastic syndromes (mds) and chronic myelomonocytic leukemia (cmml): North American intergroup study swog s1117 Blood. 2015 Dec 3; 126: (23)908.
295. Altman JK, Perl AE, Cortes JE, Levis MJ, Smith CC, **Litzow MR**, Baer MR, Claxton DF, Erba HP, Gill SC, Goldberg SL, Jurcic JG, Larson RA, Lui C, Ritchie EK, Sargent B, Schiller GJ, Spira AI, Strickland SA, Tibes R, Ustun C, Wang ES, Stuart RK, Baldus CD, Rollig C, Neubauer A, Martinelli G, Bahceci E. Antileukemic activity and tolerability of asp2215 80mg and greater in flt3 mutation-positive subjects with relapsed or refractory acute myeloid leukemia: results from a phase 1/2, open-label, dose-escalation/dose-response study Blood. 2015 Dec 3; 126: (23)321.
296. Gangat N, Lasho TL, Patnaik MM, Finke C, **Litzow MR**, Hanson CA, Ketterling RP, Pardanani A, Tefferi A. Asxl1 mutations in myelodysplastic syndromes with 1% or more ring sideroblasts: prevalence, clinical correlates and prognostic relevance Blood. 2015 Dec 3; 126: (23)2882.
297. Alkhateeb HB, Damlaj M, Al-Kali A, Gangat N, Hogan WJ, Elliott M, **Litzow MR**, Patnaik MM. Clinical characteristics and outcome of adult acute erythroleukemia; Mayo Clinic experience Blood. 2015 Dec 3; 126: (23)4980.
298. Cerquozzi S, Alkhateeb HB, Binder M, Zblewski D, Hashmi SK, Patnaik MM, Hogan WJ, **Litzow MR**, Al-Kali A. Clinical outcome of hypomethylating agents in hypocellular mds: Mayo Clinic experience Blood. 2015 Dec 3; 126: (23)5254.
299. Fossum C, Ketterling RP, Roeker LE, Dias AL, Elliott M, Hogan WJ, **Litzow MR**, Al-Kali A. Clinical outcome of therapy-related acute myeloid leukemia is strongly related to cytogenetic analysis Blood. 2015 Dec 3; 126: (23)1401.
300. Alkhateeb HB, Damlaj M, Lin T, Al-Kali A, Sproat L, Betcher JA, Barreto JN, Hashmi SK, Patnaik MM, Gangat N, Elliott M, **Litzow MR**, Hogan WJ. Clofarabine based chemotherapy in adult relapsed/refractory acute lymphoblastic leukemia/lymphoma-a single institution experience Blood. 2015 Dec 3; 126: (23)4910.
301. Al-Kali A, Tibes R, Foran JM, Patnaik MM, Gangat N, Bartley AC, Elliott M, **Litzow MR**, Go RS. Disparity in the overall survival improvement over time and the effect time-to-treatment on the outcome of acute promyelocytic leukemia: a us national cancer data base study from 1998-2011 Blood. 2015 Dec 3; 126: (23)3747.
302. Hefazi Torghabeh M, Damlaj M, Alkhateeb HB, Razonable R, Al-Kali A, Hashmi SK, Hogan WJ, **Litzow MR**, Patnaik MM. Early cmv infection detected by quantitative nucleic acid testing (qnat) is associated with lower risk of relapse after reduced intensity, but not myeloablative, hematopoietic cell transplantation in acute myeloid leukemia Blood. 2015 Dec 3; 126(23):1913. Epub 1900 Jan 01.
303. Farhadfar N, Moussab D, Dias AL, Alkhateeb HB, **Litzow MR**, Hashmi SK, Patnaik MM, Hogan WJ. Early t-lymphocyte chimerism kinetics is influenced by conditioning regimen in reduced intensity allogeneic stem cell transplantation Blood. 2015 Dec 3; 126: (23)1923.
304. Damlaj M, Alkhateeb HB, Partain DK, Almasri J, Hefazi M, Hashmi SK, Gastineau DA, Al-Kali A, Wolf RC, Gangat N, **Litzow MR**, Hogan WJ, Patnaik MM. Fludarabine busulfan compared to fludarabine melphalan is associated with increased relapse risk in reduced intensity conditioning transplant despite pharmacokinetic dosing Blood. 2015 Dec 3; 126: (23)736.
305. Harris AC, Young R, Devine SM, Hogan WJ, Ayuk F, Bunworasate U, Chanswangphuwana C, Efebera YA, Holler E, **Litzow MR**, Ordemann R, Qayed M, Renteria AS, Reshef R, Woelfi M, Chen YB, Goldstein S, Jagasia MH, Locatelli F, Mielke S, Porter DL, Schechter T, Shekhovtsova Z, Ferrara JLM, Levine JE. Guidelines for the standardization of acute graft-versus-host disease clinical data collection: an international consensus report Blood. 2015 Dec 3; 126: (23)3154.
306. Ganzel C, Victoria WX, Fielding AK, Rowe JM, Richards SM, Buck G, Chopra R, Durrant IJ, Marks D, Franklin IM, McMilan AK, **Litzow MR**, Paietta E, Luger S, Wiernik PH, Douer D, Lazarus HM, Tallman MS, Goldstone AH. In Philadelphia-chromosome-negative acute lymphoblastic leukemia, late relapses are not uncommon, occur mostly in patients at standard risk and have a relatively favorable outcome. results of the international all trial: mrc ukallxii/ecog e2993 Blood. 2015 Dec 3; 126: (23)795.

307. Vijayvargiya P, Gangat N, **Litzow MR**, Go RS, Vijayvargiya P, Murray JA, Patnaik MM. Incidence and outcomes of neutropenia in patients with celiac disease- a consecutive analysis of 1729 patients Blood. 2015 Dec 3; 126: (23)1013.
308. Rapaport F, Patel J, He J, Brennan TA, Nahas M, Balassubramanian S, Otto G, Lipson D, Stephens P, Miller VA, Racevskis J, **Litzow MR**, Wiernik PH, Goldstone AH, Luger S, van den Brink M, Viale A, Rowe JM, Tallman MS, Melnick A, Paietta E, Gonen M, Levine RL. Integrated dna/rna profiling for somatic alterations in adult b-cell all Blood. 2015 Dec 3; 126: (23)1422.
309. Tefferi A, Abdelrahman R, Finke C, Lasho TL, Begna KH, Al -Kali A, Hogan WJ, **Litzow MR**, Hanson CA, Ketterling RP, Gangat N, Pardanani A. Momelotinib therapy for myelofibrosis: impact on long-term survival and genotype correlations Blood. 2015 Dec 3; 126: (23)4062.
310. Pine AB, Lee EJ, Sekeres MA, Steensma DP, Prebet T, DeZern AE, Komrokji RS, **Litzow MR**, Luger S, Stone RM, Erba HP, Garcia-Manero G, Lee AI, Podoltsev NA, Barbarotta L, Hendrickson JE, Gore SD, Zeidan AM. North American cooperative group members' patterns of blood products transfusion for patients with acute leukemia Blood. 2015 Dec 3; 126: (23)1138.
311. Foran JM, Sun ZX, Claxton DF, Lazarus HM, Thomas ML, Melnick A, Levine RL, Paietta E, Arber D, Zhang YM, Rowe JM, Godwin JE, Altman JK, Luger S, Al-Kali A, Zheng H, Pratz K, Broun ER, Powell BL, O'Dwyer K, **Litzow MR**, Tallman MS. North American leukemia, intergroup phase iii randomized trial of single agent clofarabine as induction and post-remission therapy, and decitabine as maintenance therapy in newly-diagnosed acute myeloid leukemia in older adults (age >= 60 years): a trial of the ecog-acrin cancer research group (e2906) Blood. 2015 Dec 3; 126: (23)217.
312. Hreh M, Zblewski D, Patnaik MM, Baidoun F, Gangat N, Chen D, Hook C, Hogan WJ, **Litzow MR**, Al-Kali A. Patients with therapy-related myelodysplastic syndromes (t-mds) have shorter median overall survival than de novo mds: Mayo Clinic experience Blood. 2015 Dec 3; 126: (23)5234.
313. Lee EJ, Smith BD, Merrey JW, Lee AI, Podoltsev NA, Barbarotta L, **Litzow MR**, Prebet T, Luger S, Gore SD, Streiff MB, Zeidan AM. Patterns of venous thromboembolism prophylaxis during inpatient treatment of acute leukemia: results of a North American web-based survey Blood. 2015 Dec 3; 126: (23)4455.
314. Smith CC, Levis MJ, **Litzow MR**, Perl AE, Altman JK, Gill SC, Kadokura T, Yuen GJ, Fisniku O, Liu C, Nagase I, Sargent B, Welter N, Bahceci E. Pharmacokinetic profile and pharmacodynamic effects of asp2215, a selective, potent inhibitor of flt3/axl, in patients with relapsed or refractory acute myeloid leukemia: results from a first-in-human phase 1/2 study Blood. 2015 Dec 3; 126: (23)4836.
315. Lin T, Alkhateeb HB, Al-Kali A, Elliott MA, Gangat N, Hogan WJ, Nowakowski GS, Thompson CA, Witzig TE, Ansell SM, **Litzow MR**, Patnaik MM. Prognostic correlates and outcomes of relapsed t-cell acute lymphoblastic leukemia/lymphoma: an analysis of 41 consecutive patients Blood. 2015 Dec 3; 126: (23)3730.
316. Damlaj M, Alkhateeb HB, Hefazi M, Partain DK, Al-Kali A, Hashmi SK, Gangat N, **Litzow MR**, Hogan WJ, Patnaik MM. Prognostic impact of peripheral blood count recovery and cytogenetic remission prior to reduced intensity allogeneic transplantation in patients with acute myelogenous leukemia and myelodysplastic syndromes Blood. 2015 Dec 3; 126: (23)3210.
317. Webster JA, Tibes R, Blackford A, Morris L, Patnaik MM, Wang LH, Rebechi M, Greer J, **Litzow MR**, Karnitz L, Rosner GL, Doyle A, Kaufmann SH, Karp JE, Smith BD. Randomized phase ii trial of timed sequential cytosine arabinoside with and without the chk1 inhibitor mk-8876 in adults with relapsed and refractory acute myelogenous leukemia Blood. 2015 Dec 3; 126: (23)2563.
318. Alkhateeb HB, Hreh M, Damlaj M, Elliott M, Hogan WJ, Patnaik MM, **Litzow MR**, Al-Kali A. Response to hypomethylating agents in myelodysplastic syndromes based on who 2008 subtypes and ipss-r stratification and impact on survival Blood. 2015 Dec 3; 126: (23)5260.
319. Alkhateeb HB, Lin T, Damlaj M, Al-Kali A, Gangat N, Hogan WJ, Elliott M, Nowakowski GS, Thompson C, Witzig TE, Ansell SM, **Litzow MR**, Patnaik MM. Survival trends in adult t-acute lymphoblastic leukemia / lymphoma (all), a comparative analysis of 92 patients by year of diagnosis Blood. 2015 Dec 3; 126: (23)2490.
320. Gangat N, Patnaik MM, Begna KH, Al-Kali A, **Litzow MR**, Hanson CA, Ketterling RP, Pardanani A, Tefferi A. Survival trends in primary myelodysplastic syndromes: a comparative analysis of 1000 patients by year of diagnosis and treatment Blood. 2015 Dec 3; 126: (23)2875.
321. Alkhateeb HB, Damlaj M, Lin T, Hefazi M, Al-Kali A, Gangat N, Hogan WJ, Elliott M, Nowakowski GS, Thompson C, Witzig TE, Ansell SM, **Litzow MR**, Patnaik MM. The adverse impact of age and central nervous system involvement on survival in adult t-all, an analysis of 92 consecutive patients Blood. 2015 Dec 3; 126: (23)4993.
322. Partain DK, Damlaj M, Al -Kali A, Gangat N, **Litzow MR**, Hogan WJ, Hashmi SK, Gonsalves WI, Foran JM, Roy V, Mesa RA, Palmer J, Slack JL, Patnaik MM. The role of spleen directed therapy and predictors of outcomes with reduced intensity conditioning allogeneic hematopoietic stem cell transplantation for patients

- with primary myelofibrosis and splenomegaly Blood. 2015 Dec 3; 126: (23)1370.
323. Luger S, Wang VX, Paietta E, Ketterling RP, Rybka W, Lazarus HM, **Litzow MR**, Rowe JM, Larson RA, Appelbaum FR, Tallman MS. Tipifarnib as maintenance therapy in acute myeloid leukemia (aml) improves survival in a subgroup of patients with high risk disease. results of the phase iii intergroup trial e2902 Blood. 2015 Dec 3; 126: (23)1308.
 324. Stein AS, Topp MS, Kantarjian HM, Goekbuget N, Bargou RC, **Litzow MR**, Rambaldi A, Ribera J, Zhang A, Zimmerman Z, Forman SJ. Treatment with anti-cd19 bite (r) blinatumomab in adult patients with relapsed/refractory b-precursor acute lymphoblastic leukemia (r/r all) post-allogeneic hematopoietic stem cell transplantation Blood. 2015 Dec 3; 126: (23)861.
 325. Ganzel C, Cripe LD, Sun ZX, Fernandez HF, Cassileth PA, Douer D, Rowe JM, Paietta E, O'Connell M, Wiernik PH, Bennett JM, **Litzow MR**, Luger S, Lazarus HM, Tallman MS. Very poor long-term survival, also in contemporary studies, of patients with aml who relapse after achieving a first complete remission: the ecog-acrin cancer research group experience Blood. 2015 Dec 3; 126: (23)1315.
 326. Wertheim G, Luskin M, Gimotty PA, Smith C, Loren AW, Figueroa M, Harrison J, Sun Z, Tallman MS, Paietta EM, **Litzow MR**, Levine R, Melnick AM, Fernandez HF, Luger SM, Carroll M, Master SR. Integration of multi-locus dna methylation and genetic alterations outperforms genetic assessment alone for outcome prediction in adult patients with acute myeloid leukemia Laboratory Investigation. 2016 Feb; 96:384A.
 327. Wertheim G, Luskin M, Gimotty PA, Smith C, Loren AW, Figueroa M, Harrison J, Sun Z, Tallman MS, Paietta EM, **Litzow MR**, Levine R, Melnick AM, Fernandez HF, Luger SM, Carroll M, Master SR. Integration of multi-locus dna methylation and genetic alterations outperforms genetic assessment alone for outcome prediction in adult patients with acute myeloid leukemia Modern Pathology. 2016 Feb; 29:384A.
 328. Alkhateeb HB, Damlaj M, Hefazi M, Dias A, Hashmi SK, Hogan WJ, **Litzow MR**, Patnaik MS. Allogeneic hematopoietic stem cell transplant outcomes in patients with acute erythroleukemia Biology Of Blood And Marrow Transplantation. 2016 Mar; 22: (3)S195-6.
 329. Stein AS, Topp M, Kantarjian H, Goekbuget N, Bargou R, **Litzow M**, Rambaldi A, Ribera JM, Zhang A, Zimmerman Z, Forman S. Anti-cd19 bite blinatumomab treatment in adults with relapsed/refractory b precursor acute lymphoblastic leukemia (r/r all) post-allogeneic hematopoietic stem cell transplantation Bone Marrow Transplantation. 2016 Mar; 51:S9-S10.
 330. Moyer AM, Hashmi SK, Kroning CM, Kremers WK, De Goey SR, Patnaik MS, **Litzow MR**, Gastineau DA, Hogan WJ, Kreuter JD, Wakefield LL, Gandhi M. Clinical outcomes of hla-dpb1 mismatches in 10/10 hla-matched unrelated donor-recipient pairs undergoing allogeneic stem cell transplant Biology Of Blood And Marrow Transplantation. 2016 Mar; 22(3):S340. Epub 1900 Jan 01.
 331. Dias A, Alkhateeb HB, Farhadfar N, Westin G, Hashmi SK, **Litzow MR**, Patnaik MS, Razonable R, Hogan WJ. Cytomegalovirus reactivation after umbilical cord transplantation and its impact on outcomes- a Mayo Clinic experience Biology Of Blood And Marrow Transplantation. 2016 Mar; 22: (3)S314-5.
 332. Gupta E, Hoffman R, Thomas C, Hogan WJ, **Litzow MR**, Sproat LO, Foran J, Finn L, Roy V. Hematopoietic allogeneic stem cell transplant (hsct) with an older sibling donor > 50 years (osd) versus younger unrelated donor < 50 (yud) results in similar outcomes: results of a matched pair analysis Biology Of Blood And Marrow Transplantation. 2016 Mar; 22: (3)S320-1.
 333. Partain DK, Damlaj M, **Litzow MR**, Al-kali A, Hogan WJ, Hashmi SK, Gangat N, Foran J, Slack JL, Palmer J, Mesa RA, Patnaik MS. Incidence and outcomes of primary engraftment failure in patients undergoing reduced intensity conditioning allogeneic hematopoietic stem cell transplantation for primary myelofibrosis Biology Of Blood And Marrow Transplantation. 2016 Mar; 22: (3)S345.
 334. Farhadfar N, Sauter JL, Dias A, **Litzow MR**, Hogan WJ, Patnaik MS, Stan MN, Hashmi SK. Incidence of thyroid cancer after hematopoietic stem cell transplantation Biology Of Blood And Marrow Transplantation. 2016 Mar; 22: (3)S185.
 335. Dias A, Alkhateeb HB, Farhadfar N, Hashmi SK, Al-Kali A, Hogan WJ, Patnaik MS, Burns LJ, Van Dyke D, Niederwieser D, **Litzow MR**. Inversion (3) in an allogeneic stem cell transplant recipient representative of a donor derived constitutional abnormality- a unique case report Biology Of Blood And Marrow Transplantation. 2016 Mar; 22: (3)S314.
 336. Bartoo G, Merten J, Wolf R, Dierkhising R, Dingli D, Hashmi SK, Hogan WJ, **Litzow MR**, Patnaik MS. Safety and efficacy of amiloride in reducing the need for magnesium supplementation in allogeneic hematopoietic stem cell transplant recipients on calcineurin inhibitors Biology Of Blood And Marrow Transplantation. 2016 Mar; 22: (3)S116-7.
 337. Barba P, Burns LJ, Juckett MB, Komanduri KV, **Litzow MR**, Lee SJ, Devlin SM, Costa LJ, Khan SP, Klein AK, Krishnan A, Malone AK, Moravec CG, Mir M, Selby GB, Vivek R, Cochran M, Stricherz M, Westmoreland M, Tierney DK, Wood WA, Perales MA. Success of an international learning healthcare system in hematopoietic cell transplantation: the American society of blood and marrow transplantation clinical case forum Biology Of

- Blood And Marrow Transplantation. 2016 Mar; 22: (3)S266-7.
338. Hefazi M, Alkhateeb HB, Patel R, Razonable R, Gastineau DA, Al-kali A, Hashmi SK, Hogan WJ, **Litzow MR**, Patnaik MS. Vancomycin-resistant enterococcus (vre) colonization and blood stream infection (bsi): prevalence, risk factors, and impact on early clinical outcomes after allogeneic hematopoietic cell transplantation *Biology Of Blood And Marrow Transplantation*. 2016 Mar; 22: (3)S322-3.
 339. Zahid MF, Patnaik M, **Litzow M**, Hashmi S. Venous thromboembolism following hematopoietic stem cell transplantation - a systematic review and meta-analysis *Bone Marrow Transplantation*. 2016 Mar; 51:S427-8.
 340. Zimmerman CT, Shinde SS, Kasi PM, **Litzow MR**, Huddleston JM. Patterns of palliative care utilization and end-of-life care in adult patients with cancer who died as inpatients at Mayo Clinic. *Journal of Clinical Oncology*. October 2016; 34(26_suppl):60.
 341. Hefazi M, Patnaik M, Hogan WJ, **Litzow MR**, Pardi DS, Khanna. Safety and Efficacy of Fecal Microbiota Transplantation for Recurrent Clostridium Infection in Patients with Hematologic Malignancies *Blood*. 2016; 128(22):3599.
 342. Yalniz F, Mehrdad, Kristen, **Mark**, William, Robert, Hassan, Ankit, Moussab, Mrinal. Clinical outcomes related to the use of monoclonal antibody therapy for steroid refractory acute graft versus host disease after allogeneic hematopoietic cell transplantation. *Blood*. 2016; 128(22):4593.
 343. Tibes R, Kosiorek H, Dueck AC, Palmer JM, Slack JL, Knight EA, Hashmi S, Bogenberger JM, Zblewski DL, Hogan WJ, **Litzow MR**, Mesa RA, Foran JM, Sproat L, Al-Kali A. Phase I/IB Study of Azacitidine and Hedgehog Pathway Inhibition with Sonidegib (LDE225) in Myeloid Malignancies *Blood*. 2017; 130: Abstract no.2629.
 344. Yalniz FF, Hefazi M, McCullough KB, **Litzow MR**, Hogan WJ, Wolf RC, Alkhateeb H, Kansagra AJ, Damlaj M, Patnaik M. Infectious complications associated with infliximab therapy for allogeneic stem cell transplant patients with corticosteroid refractory acute graft-versus host disease. *Biology of Blood and Marrow Transplantation*. 2017; 3:S200-201.
 345. Hashmi S, Dean RM, Shaw B, Brazauskas R, Millard H, Battiwalla M, Savani B, Flowers ME, Cooke KR, Hamilton BK, Kalaycio M, Radivoyevitch T, **Litzow MR**, Gale RP. Dissectioning risk factors for myelodysplastic syndrome (mds) and acute myeloid leukemia (aml) after autotransplants for plasma cell myeloma and lymphomas *Leukemia Research*. 2017 Apr; 55:S41
 346. Miller K, Al-Kali A, Hogan W, Elliott M, Begna K, Gangat N, Patnaik M, **Litzow M**, Alkhateeb H. Clinical outcomes of elderly acute lymphoblastic leukemia/lymphoma - a single institution experience *Haematologica*. 2017 Jun 26; 102:32.
 347. Jessica A, Perl A, Cortes J, Smith C, **Litzow M**, Hill J, Larson R, Liu C, Ritchie E, Strickland S, Wang E, Neubauer A, Martinelli G, Bahceci E, Levis M. Deep molecular response to gilteritinib improves survival in flt3 mutation-positive relapsed/refractory acute myeloid leukemia *Haematologica*. 2017 Jun 26; 102:6.
 348. Levis M, Smith C, **Litzow M**, Perl A, Altman J, James A, Kadokura T, Sargent B, Yuen G, Lu Z, Liu C, Nagase I, Bahceci E. Drug-drug interaction potential of gilteritinib in healthy subjects and patients with relapsed/refractory acute myeloid leukemia *Haematologica*. 2017 Jun 26; 102:386.
 349. Levis M, Altman J, Perl A, Cortes J, Smith C, **Litzow M**, Hill J, Larson R, Liu C, Ritchie E, Strickland S, Wang E, Neubauer A, Martinelli G, Bahceci E. Evaluation of the impact of signal ratio on overall survival in flt3-mutation-positive relapsed/refractory acute myeloid leukemia following once-daily treatment with gilteritinib *Haematologica*. 2017 Jun 26; 102:216-7.
 350. Anagnostou T, Paludo J, Patnaik MM, **Litzow MR**, Gastineau DA, Duma N, Buadi FK, Porrata LF, Hogan WJ, Goyal G, Lehman JS, Hashmi SK, Kenderian SS. Risk factors, outcomes and characterization of 'autologous graft versus host disease': the Mayo Clinic experience *Haematologica*. 2017 Jun 26; 102:612.
 351. Anagnostou T, Shanafelt TD, Patnaik MS, Larson MC, Chaffee KG, Parikh SA, Gastineau DA, Ding W, Call TG, **Litzow MR**, Kay NE, Conte M, Bowen DA, Hogan WJ, Kenderian SJ. The prognostic significance of cll-ipi after reduced intensity conditioning allogeneic stem cell transplant in chronic lymphocytic leukemia: the Mayo Clinic experience *Haematologica*. 2017 Jun 26; 102:73. Epub 1900 Jan 01.
 352. Anagnostou T, Patnaik MS, Forsman J, Sakemura R, **Litzow MR**, Gastineau DA, Buadi FK, Porrata LF, Lehman JS, Hogan WJ, Hashmi SK, Kenderian SJ. Baseline immune dysregulation in autologous stem cell transplant recipients is associated with a 'graft versus host'-like syndrome and results in poor outcomes *Blood Conference: 59th Annual Meeting of the American Society of Hematology*. 2017.
 353. Ice LL, Merten J, Bartoo G, McCullough K, Wolf R, Dierkhising R, Jowsey-Gregoire SG, **Litzow MR**. A survey of outpatient medication adherence in adult allogeneic hematopoietic stem cell transplant recipients *Biology Of Blood And Marrow Transplantation*. 2018 Mar; 24(3 Suppl 1):S117
 354. Lehman JS, Dasari S, Damodaran S, El-Azhary R, Gibson LE, Hashmi SK, Hogan WJ, Kenderian SS, Lazarus

- HM, **Litzow MR**, Patnaik MM, Thanarajasingam U, Niewold T, Vanderboom P, Meves A. Differential expression of interferon-induced genes and other tissue-based acute gvhd biomarkers in acute gvhd compared
355. Hefazi M, Langer KJ, Khera N, Adamski J, Roy V, Winters J, Gastineau DA, Jacob EK, Kreuter JD, Gandhi MJ, Hogan WJ, **Litzow MR**, Hashmi SK, Yadav H, Iyer VN, Cartin-Ceba R, Patnaik MM. Extra-corporal photopheresis improves overall survival in patients with bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation: A multi site retrospective cohort study *Biology Of Blood And Marrow Transplantation*. 2018 Mar; 24(3 Suppl 1):S55-6. Epub 1900 Jan 01.
 356. Anagnostou T, Patnaik MM, Forsman CL, Sakemura R, **Litzow MR**, Gastineau DA, Buadi F, Porrata LF, Lehman JS, Hogan WJ, Hashmi SK, Kenderian SS. Immune dysregulation in autologous stem cell transplant recipients is associated with a "graft versus host"-like syndrome and results in poor outcomes *Biology Of Blood And Marrow Transplantation*. 2018 Mar; 24(3 Suppl 1):S121-2
 357. Sridharan M, Go RS, Shah MV, **Litzow MR**, Hogan WJ, Alkhateeb HB. Incidence and mortality outcomes in allogeneic transplant-associated thrombotic microangiopathy *Biology Of Blood And Marrow Transplantation*. 2018 Mar; 24(3 Suppl 1):S329-30
 358. El-Harasis M, Hefazi M, Hogan WJ, **Litzow MR**, Patnaik MM, Herrmann J. Incidence, risk factors, and outcomes of early adverse cardiac events (eace) after allogeneic hematopoietic stem cell transplantation stratified by conditioning regimen *Biology Of Blood And Marrow Transplantation*. 2018 Mar; 24(3 Suppl 1):S302-3
 359. Saadeh SS, Alkharabsheh O, Al-Kali A, Patnaik MM, Shah MV, **Litzow MR**, Hogan WJ, Alkhateeb HB. Outcome of patients with myelodysplastic syndrome and a monosomal karyotype following allogeneic stem cell transplant: Single institution experience *Biology Of Blood And Marrow Transplantation*. 2018 Mar; 24(3 Suppl 1):S239
 360. Arslan S, Cummins NW, Rizza SA, Badley AD, **Litzow MR**, Navarro WH, Hashmi SK. Outcomes and risks of allogeneic hematopoietic stem cell transplant for hematological malignancies in patients with hiv infection *Biology Of Blood And Marrow Transplantation*. 2018 Mar; 24(3 Suppl 1):S340-1
 361. Arslan S, Lee J, Shoukat S, Cummins NW, Badley AD, **Litzow MR**, Navarro WH, Hashmi SK. Outcomes and risks of autologous hematopoietic stem cell transplant for hematological malignancies in patients with hiv infection *Biology Of Blood And Marrow Transplantation*. 2018 Mar; 24(3 Suppl 1):S134
 362. Miller KC, Hefazi Torghabeh M, Hogan WJ, Kenderian SS, Shah MV, Patnaik MM, Sproat LZ, Foran J, **Litzow MR**, Alkhateeb HB. Outcomes of allogeneic hematopoietic stem cell transplantation in elderly patients with acute lymphoblastic leukemia/lymphoma: The Mayo Clinic experience. *Biology of Blood and Marrow Transplantation*. 2018 Mar; 24(3 Suppl 1):S237-8. Epub 1900 Jan 01.
 363. Malone AK, **Litzow MR**, Perales MA, Costa LJ, Wood WA, Komanduri KV, Selby GB, Khan SP, Roy V, Domm J, Burns LJ. Should bmt become a certified subspecialty? Results of the 2017 board certification survey *Biology Of Blood And Marrow Transplantation*. 2018 Mar; 24(3 suppl 1):S267-8
 364. Begna KH, Ali W, Gangat N, Elliott MA, Al-Kali A, **Litzow MR**, Hook CC, Wolanskyj A, Hogan WJ, Patnaik MM, Pardanani A, Zblewski D, Chen D, He R, Viswanatha DS, Hanson CA, Ketterling RP, Tefferi A. 1,123 consecutive adults with non-apl acute myeloid leukemia: the mayo clinic experience *Blood*. 2018 Nov 29; 132 (Suppl 1):2689
 365. Al-Kali A, Tibes R, Palmer J, Alkhateeb HB, Patnaik MM, Begna KH, Gangat N, Atherton P, Liu SJ, He R, Hashmi SK, **Litzow MR**. A phase ii of combination daunorubicin and cytarabine (ara-c) and nilotinib (tasigna) (data) in patients newly diagnosed with acute myeloid leukemia and kit expression: final results *Blood*. 2018 Nov 29; 132(Suppl 1):1443
 366. Shanafelt TD, Wang V, Kay NE, Hanson CA, O'Brien SM, Barrientos JC, Erba HP, Stone RM, **Litzow MR**, Tallman MS. A randomized phase iii study of ibrutinib (pci-32765)-based therapy vs. standard fludarabine, cyclophosphamide, and rituximab (fcr) chemoimmunotherapy in untreated younger patients with chronic lymphocytic leukemia (cll): a trial of the ecog-acrm cancer research group (e1912) *Blood*. 2018 Nov 29; 132 (Suppl 1):LBA-4
 367. Ustun C, Le-Rademacher J, Wang HL, Othus M, Sun ZX, Major B, Zhang MJ, Storrick E, Lafky JM, Chow S, Mrozek K, Attar EC, Bloomfield CD, Cripe LD, Larson RA, Marcucci G, Roboz GJ, Uy GL, Stone RM, Jatoi A, Shea TC, de Lima M, Foran JM, Sandmaier BM, **Litzow MR**, Erba HP, Hurria A, Weisdorf DJ, Artz AS. Allogeneic hematopoietic cell transplantation (hct) vs. non-hst consolidation therapies in acute myeloid leukemia (aml) patients 60-75 years of age in first complete remission (cr1): an alliance (a151509), swog, ecog-acrin and cibmtr study *Blood*. 2018 Nov 29; 132(Suppl 1):2170
 368. Lee JW, Kume K, Chen ZS, Xiao G, Cosgun KN, Chan LN, Chen CW, Pillai R, Chan WC, Forman SJ, Kwak LW, Zammarchi F, Van Berkel P, Weinstock DM, Melnick AM, Ngo VN, Geng HM, Luger S, **Litzow MR**, Belot A, Uzel G, McManus MT, Paietta EM, Meffre E, Muschen M. Cd25-dependent feedback control of the b-cell receptor and its oncogenic mimics in b-cell malignancies *Blood*. 2018 Nov 29; 132(Suppl 1):776

369. Foran JM, Sun ZX, Paietta E, Racevskis J, Claxton DF, Lazarus HM, Arber DA, Rowe JM, Godwin J, Zhang Y, Tallman MS, **Litzow MR**, Pratz KW, Luger S. Flt3-itd mutations are prevalent and significantly impact outcome after intensive therapy in elderly adults with acute myeloid leukemia (aml): analysis of the North American intergroup e2906 phase iii trial in patients age \geq 60 years Blood. 2018 Nov 29; 132(Suppl 1):3995
370. Woyach JA, Ruppert AS, Heerema NA, Zhao WQ, Booth AM, Ding W, Bartlett NL, Brander DM, Barr P, Rogers KA, Parikh SA, Coutre S, Hurria A, Lozanski G, Nattam S, Larson RA, Erba HP, **Litzow MR**, Owen C, Atkins J, Abramson JS, Little RF, Smith SE, Stone RM, Mandrekar SJ, Byrd JC. Ibrutinib alone or in combination with rituximab produces superior progression free survival (pfs) compared with bendamustine plus rituximab in untreated older patients with chronic lymphocytic leukemia (cll): results of alliance North American intergroup study a041202 Blood. 2018 Nov 29; 132:6
371. Mangaonkar AA, Reichard KK, Chiu A, Howard MT, King RL, Carr RM, Alver BM, Robertson KD, Cousin M, Villasboas JC, Fernandez-Zapico ME, Lasho TL, Gangat N, Al-Kali A, Elliott MA, Hogan WJ, **Litzow MR**, Pardanani A, Solary E, Tefferi A, Patnaik MM. Indoleamine 2,3-dioxygenase-1 expressing dendritic cell populations are associated with tumor-induced immune tolerance & aggressive disease biology in chronic myelomonocytic leukemia Blood. 2018 Nov 29; 132(Suppl 1):4344
372. Perl AE, Sweet KL, Roboz GJ, Strickland SA, **Litzow MR**, Bonifacio GJ, Haines K, Barbera A, Purkayastha D, Dalovisio A. Midostaurin in adults with newly diagnosed flt3-mutation-positive acute myeloid leukemia eligible for standard chemotherapy: update from the radius-x midostaurin expanded access program Blood. 2018 Nov 29; 132(Suppl 1):4038
373. Foran JM, Sun ZX, Paietta E, Racevskis J, Claxton DF, Lazarus HM, Arber DA, Rowe JM, Altman JK, Al-Kali A, Zheng H, Pratz KW, Broun ER, Powell BL, O'Dwyer KM, Godwin J, Zhang YM, Tallman MS, Luger S, **Litzow MR**. Minimal residual disease (mrd) at time of complete remission is commonly detected in acute myeloid leukemia (aml) patients age \geq 60 years and significantly impacts outcome based on post-remission treatment strategies: prospective analysis of ecog-acrin (e-a) e2906 phase iii trial Blood. 2018 Nov 29; 132 (Suppl 1):437
374. Lacy MQ, Peng KW, Russell SJ, Dueck AC, Patnaik MM, Witzig TE, Ginos BF, Buadi FK, Dispenzieri A, Gertz MA, Go RS, Hayman SR, Lust JA, Dingli D, Rajkumar SV, Leung N, Warsame R, Gonsalves WI, Kourelis T, Muchtar E, Broski S, Murphy RC, Kapoor P, Kyle RA, Zeldenrust S, Al-Kali A, **Litzow MR**, Naik S, Federspiel MJ, Kumar SK. Phase i trial of systemic administration of vesicular stomatitis virus genetically engineered to express nis and human interferon, in patients with relapsed or refractory multiple myeloma (mm), acute myeloid leukemia (aml), and t-cell neoplasms (tcl) Blood. 2018 Nov 29; 132(Suppl 1):3268
375. Nath R, Zhou Z, Cerny J, Wang HL, Bo-Subait K, Guth Z, Ahmed G, Khan MW, Hildebrandt GC, Alkhateeb HB, Damlaj M, Patnaik MM, Sandmaier BM, Weisdorf DJ, de Lima M, **Litzow MR**, Saber W. Reduced intensity conditioning (ric) regimens hematopoietic cell transplantation (hct) for acute myeloid leukemia (aml): a comparison of fludarabine/busulfan (fb) and fludarabine/melphalan (fm) based regimens from the cibmtr Blood. 2018 Nov 29; 132(Suppl 1):3456
376. Advani AS, Moseley A, O'Dwyer KM, Wood B, Fang M, Wieduwilt MJ, Aldoss I, Park JH, Klisovic R, Baer MR, Stock W, Bhave R, Othus M, **Litzow MR**, Stone RM, Erba HP. Results of swog 1318: a phase 2 trial of blinatumomab followed by pomp (prednisone, vincristine, methotrexate, 6-mercaptopurine) maintenance in elderly patients with newly diagnosed Philadelphia chromosome negative b-cell acute lymphoblastic leukemia Blood. 2018 Nov 29; 132(Suppl 1):33
377. Agura E, Gyurkocza B, Nath R, **Litzow MR**, Tomlinson BK, Abhyankar S, Seropian S, Stiff PJ, Choe HK, Kebriaei P, Foran JM, Chen G, Levy MY, Lazarus HM, Giralt S, Berger MS, Reddy V, Pagel JM. Targeted conditioning of iomab-b (i-131-anti-cd45) prior to allogeneic hematopoietic cell transplantation versus conventional care in relapsed or refractory acute myeloid leukemia (aml): preliminary feasibility and safety results from the prospective, randomized phase 3 sierra trial Blood. 2018 Nov 29; 132(Suppl 1):1017
378. Pine AB, Chokr NB, Stahl M, Steensma DP, Sekeres MA, **Litzow MR**, Luger S, Stone RM, Greenberg PL, Bejar R, Gore SD, Zeidan AM. Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes (mds): results of a large web-based survey Blood. 2018 Nov 29; 132(Suppl 1):1825
379. Santivasi WL, Wu KM, **Litzow MR**, LeBlanc TW, Strand JJ. Palliative Care Physicians' Views Toward Hematology and the Care of Patients with Hematologic Diseases: Results of a Nationwide Survey Blood. 2018; 132(s1):4783.
380. Santivasi WL, Wu KM, **Litzow MR**, LeBlanc TW, Strand JJ. Palliative Care Physicians' Views Toward Hematology and the Care of Patients with Hematologic Diseases: Results of a Nationwide Survey Journal of Clinical Oncology. 2018; 36(34s):95.
381. Zblewski D, Gangat N, Elliott MA, Al-Kali A, **Litzow MR**, Hook CC, Mielke T, Wolanskyj-Spinner A, Hogan W, Pardanani A, Shah MV, Alkhateeb HB, Kluck LA, Nedved A, McCullough K, Smith M, McAllister T, Lazaridis K,

- Stewart AK, Patnaik MM. The Clinical Utility of Pharmacogenomics Testing in Assessing Tyrosine Kinase Inhibitor Therapy, Intolerance and Responses in Patients with Chronic Myelogenous Leukemia Blood. 2018; 122:5440
382. Kay NE, Hanson CA, **Litzow MR**. LBA-4 A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN C Blood - ASH Abstracts. December 3, 2018.
 383. Santivasi WL, Wu K, **Litzow MR**, LeBlanc TW, Strand JJ. Palliative Care Physician Comfort (and Discomfort) with Discussing Prognosis in Hematologic Diseases: Results of a Nationwide Survey Journal of Pain and Symptom Management. 2019; 57(2):454. Abstract no. SA528B.
 384. Kutzke J, Taraba JL, Merten JA, Shah MV, Hashmi SK, Patnaik MM, **Litzow MR**, Hogan WJ. Relapse Rates in Patients Receiving Azithromycin for the Treatment of Bronchiolitis Obliterans after Allogeneic Hematopoietic Stem Cell Transplant Biol Blood Marrow Transplant. 2019; 25:S100-S289. Abstract no. 418.
 385. Lehman JS, Dasari S, Damodaran SS, Li M, Hashmi SK, el-Azhary RA, Gibson LE, Lazarus H, Hogan WJ, Kenderian S, Patnaik MM, **Litzow MR**, Meves A. Differentiation of acute graft-versus-host disease from drug reaction in skin by a novel tissue-based biomarker assay Journal Of Investigative Dermatology. 2019 May; 139(5 Suppl):S4
 386. Yogarajah M, Nguyen PL, He R, Alkhateeb H, Shah MV, Patnaik MM, Gangat N, Hogan WJ, Tefferi A, **Litzow MR**, Al-Kali A. Discrepancy of blast percentage between the bone marrow aspirate and biopsy and its impact on survival outcomes in patients with myelodysplastic syndromes excess blast (mds-eb) Journal Of Clinical Oncology. 2019 May 20; 37(15):7053
 387. Zblewski D, Nguyen PL, He R, Greipp PT, Begna K, Patnaik MM, Gangat N, Shah MV, Alkhateeb H, **Litzow MR**, Al-Kali A. Pyridoxine impact on patients with myelodysplastic syndromes with ring sideroblasts: single institution retrospective study Journal Of Clinical Oncology. 2019 May 20; 37(15):e18549
 388. Ferrer A, Schultz-Rogers L, Mangaonkar AA, Jacobi N, **Litzow MR**, Klee EW, Patnaik MM. New case of Fanconi Anemia complementation group T caused by a pathogenic missense variant in UBE2T 2019 ASHG Annual Meeting. 10/16/2019; Abstract no. PgmNr 2478.
 389. Mangaonkar AA, Ferrer A, Pinto e Vairo J, F, Cousin M, Kuisle R, Kennedy CC, Coltro G, Gangat N, Hogan WJ, **Litzow M**, Peters S, Klee EW, Scott JP, Utz JP, Baqir M, Porquera EC, Sekiguchi H, Khan SP, Rodriguez V, Simonetto DA, Kamath PS, Joshi AY, Wylam ME, Patnaik MM. Clinical Utility of Telomere Length-Directed Genomic Assessment in Patients with Short Telomere Syndromes Blood. 2019; 134(Supplement 1):1222.
 390. Shanafelt TD, Wang V, Kay NE, Hanson CA, O'Brien SM, Barrientos JC, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre S, Barr PM, Cashen AF, Mato AR, Singh A, Mullane MP, Little RF, Erba HP, Stone RM, **Litzow M**, Tallman MS. Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial. Blood. 2019 Nov 13; 134(Supplement_1):33. Epub 1900 Jan 01.
 391. Badar T, Advani AS, Liedtke M, Arslan S, Khan MA, Aldoss I, Sienbenaller C, Schultz E, Hefazi M, Shallis RM, Yurkiewicz I, Podoltsev N, Patel A, Curran E, Kuo E, Wang A, Balasubramanian S, Yang J, Mattison R, Burkart M, Dinner S, **Litzow MR**, Wadleigh M, Atallah E. Clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab or inotuzumab ozogamicin in patients with b-cell acute lymphoblastic leukemia: real world experience Biology Of Blood And Marrow Transplantation. 2020 Mar; 26(3):S101-2
 392. Mangaonkar A, Nadiminti K, Langer KJ, Buradkar A, Matin A, Hefazi M, Alkhateeb HB, Shah MV, Khan SP, Rodriguez V, Hogan WJ, **Litzow MR**, Patnaik MM. Low-dose total body irradiation (tbi) use as part of pre-transplant conditioning regimen is associated with worse outcomes in patients with severe aplastic anemia (saa) treated with allogeneic hematopoietic stem cell transplantation (hct) Biology Of Blood And Marrow Transplantation. 2020 Mar; 26(3):S251-2
 393. Menghrajani K, Zhang MJ, Bo-Subait K, Wang HL, Devlin SM, Madero-Marroquin R, Arteaga AG, Sandmaier BM, **Litzow MR**, Kebriaei P, Weisdorf DJ, Zhang YM, Tallman M, Saber W. Mll-rearranged aml is associated with poor outcomes as compared to patients with intermediate- and adverse-risk disease: a cibmtr study of 3779 adult patients Biology Of Blood And Marrow Transplantation. 2020 Mar; 26(3):S10-1
 394. Gyurkocza B, Nath R, Stiff PJ, Agura E, **Litzow MR**, Tomlinson B, Choe H, Abhyankar S, Seropian SE, Chen GL, Hari P, Al-Kadhimi Z, Foran J, Orozco JJ, van Besien K, Sabloff M, Kebriaei P, Abboud C, Levy MY, Lazarus HM, Giral SA, Berger MS, Reddy V, Pagel JM. Targeted conditioning with anti-cd45 iodine (i-131) apamistamab [iomab-b] leads to high rates of allogeneic transplantation and successful engraftment in older patients with active, relapsed or refractory (rel/ref) aml after failure of chemotherapy and targeted agents: preliminary midpoint results from the prospective, randomized phase 3 Sierra trial Biology Of Blood And Marrow Transplantation. 2020 Mar; 26(3):S32-3
 395. May HP, Wolf R, Bartoo G, **Litzow MR**, Hogan WJ, Shah MV, Alkhateeb HB. Use of sublingual tacrolimus in

adults undergoing hematopoietic cell transplant: a pilot study *Biology Of Blood And Marrow Transplantation*. 2020 May; 26(5):e2000-00

396. Ruan G, Smith C, Day CN, Harmsen WS, Zblewski D, Alkhateeb H, Al-Kali A, **Litzow MR**, Hogan WJ, Szuber N, Gangat N, Patnaik M, Pardanani AD, Elliott MA, Tefferi A, Go RS, Shah MV. A population-based study of chronic neutrophilic leukemia in the united states: 2004 to 2015 *Journal of Clinical Oncology*. 2020 May 20; 38(15 Suppl):e19538. Epub 1900 Jan 01.
397. Benkhadra R, Nayfeh T, Bakalov V, Hilton C, Khan C, Prokop L, Shah MV, Alkhateeb H, **Litzow MR**, Murad MH, Al-Kali A. Intensive chemotherapy in patients with high grade myelodysplastic syndromes (MDS): A systematic review and meta-analysis *Journal of Clinical Oncology*. 2020.
398. Ruppert AS, Mandrekar SJ, Booth AM, Ding W, Bartlett NL, Brander DM, Coutre SE, Brown JR, Nattam SR, Larson RA, Erba HP, **Litzow MR**, Owen C, Kuzma CS, Abramson JS, Little RF, Smith SE, Stone RM, Byrd JC, Woyach JA. Toxicity burden in older patients with chronic lymphocytic leukemia (cll) receiving bendamustine with rituximab (br) or ibrutinib (ib) regimens: alliance a041202 *Journal of Clinical Oncology*. 2020 May 20; 38(15 Suppl):e20004
399. Marissa Li, Terra Lasho, Alejandro Ferrer, Naseema Gangat, Aref Al-Kali, Abhishek Mangaonkar, Michelle Elliott, **Mark Litzow**, William Hogan, Animesh Pardanani, Alexandra Wolanskyj, Kaaren Reichard, Matthew Howard, Rebecca King, Mithun Shah, Hassan Alkhateeb, Kebede Begna, Ayalew Tefferi, Christy Finke, Moritz Binder, Horatiu Olteanu, Mrinal Patnaik. Clinical, Molecular, and Prognostic Comparisons between Clonal Cytopenias of Undetermined Significance and Lower-risk Myelodysplastic Syndromes - A Study of 184 Molecularly Annotated Patients 62nd ASH Annual Meeting. 2020.
400. Emma DiFilippo, Alejandro Ferrer, Laura Schultz-Rogers, Shakila Khan, Naseema Gangat, Aref Al-Kali, Abhishek Mangaonkar, Animesh Pardanani, Michelle Elliott, **Mark Litzow**, William Hogan, Alexandra Wolanskyj-Spinner, Phuong Nguyen, Kaaren Reichard, Matthew Howard, Rebecca King, Dong Chen, Rong He, David Viswanatha, Terra Lasho, Rajiv Pruthi, Pavel Pichurin, Teresa Krusselbrink, Brendan Lanpher, Mark Wylam, Jennifer Oliveira, Dusica Babovic-Vuksanovic, Horatiu Olteanu, Mrinal Patnaik. Spectrum of Hematological Malignancies in 130 Patients with Germline Predisposition Syndromes- Mayo Clinic Germline Predisposition Study 62nd ASH Annual Meeting Abstract#: 139050. 2020.
401. Johnson I, Al-Kali A, Gangat N, Patnaik M, Hefazi Torghabeh M, Shah M, Mangaonkar A, **Litzow MR**, Hogan WJ, Alkhateeb HB. Pre-transplant ferritin predicts non-relapse mortality in patients with myelodysplastic syndromes undergoing hematopoietic stem cell transplantation *Bone Marrow Transplantation*. 2021 Jun; 56(Suppl 1):290-1
402. Montefiori LE, Bendig S, Gu ZH, Chen XL, Polonen P, Ma XT, Murison A, Zeng A, Garcia-Prat L, Dickerson K, Iacobucci I, Abdelhamed S, Hiltenbrand R, Mead PE, Mehr CM, Xu BS, Cheng ZS, Chang TC, Westover T, Ma J, Stengel A, Kimura S, Qu CX, Valentine MB, Rashkovan M, Luger S, **Litzow MR**, Rowe JM, den Boer ML, Wang V, Yin J, Kornblau SM, Hunger SP, Loh ML, Pui CH, Yang WJ, Crews KR, Roberts KG, Yang JJ, Relling MV, Evans WE, Stock W, Paietta EM, Ferrando AA, Zhang JH, Kern W, Haferlach T, Wu G, Dick JE, Kico JM, Haferlach C, Mullighan CG. Oncogenic deregulation of bcl11b in lineage ambiguous leukemia *Clinical Lymphoma Myeloma & Leukemia*. 2021 Sep; 21:S269-70
403. Begna KH, Shah M, Gangat N, Alkhateeb H, Patnaik M, Al-Kali A, Elliott M, Hogan WJ, **Litzow MR**, Hook C, Mangaonkar A, He R, Chen D, Pardanani AD, Ketterling RP, Tefferi A. Acute Myeloid Leukemia in the Context of Previous History of Cancer with or without Exposure to Chemotherapy or Radiotherapy *Blood*. 2021; 138(Supplement 1):3368. Epub 2021 Nov 05.
404. Begna KH, Gangat N, Shah M, Alkhateeb H, Patnaik M, Al-Kali A, Elliott M, Hogan WJ, **Litzow MR**, Hook C, Mangaonkar A, Viswanatha DS, Chen D, Pardanani AD, Ketterling RP, Tefferi A. Anthracycline Choices for Induction Chemotherapy Among 797 Consecutive Adult Patients with Acute Myeloid Leukemia: Daunorubicin-60 Vs Idarubicin-12 Vs Daunorubicin-90 *Blood*. 2021; 138(Supplement 1):1267. Epub 2021 Nov 05.
405. Nanaa A, Al-Kali A, Viswanatha DS, Foran JM, Badar T, Sproat L, He R, Nguyen PL, Jevremovic D, Salama M, Greipp PT, Gangat N, Tefferi A, **Litzow MR**, Mangaonkar A, Shah M, Patnaik M, Alkhateeb H. Clinical Characteristics and Prognosis of Thirty-Three Patients with Myeloid Neoplasms and DDX41 Mutation: Mayo Clinic Experience. *Blood*. 2021; 138(Supplement 1):3691. Epub 2021 Nov 05.
406. Ghorab AN, Al-Kali A, Elliott M, Shah M, Palmer JM, Murthy H, Kharfan Dabaja M, **Litzow MR**, Foran JM, Badar T. Improved Clinical Outcome of Patients with Myelodysplastic Syndrome (MDS) Progressing after Hypomethylating Agent: In the Era of Novel Therapies *Blood*. 2021; 138(Supplement 1):3688. Epub 2021 Nov 05.
407. Shah M, Mangaonkar A, Begna KH, Alkhateeb H, Greipp PT, Chen D, Viswanatha DS, He R, Elliott M, Hogan WJ, **Litzow MR**, McCullough KB, Tefferi A, Gangat N, Patnaik M, Al-Kali A. Therapy-Related Cytopenia of Undetermined Significance (t-CCUS) As a Precursor to Therapy-Related Myeloid Neoplasms (t-MN) *Blood*. 2021; 138(Supplemental 1):1096. Epub 2021 Nov 05.
408. Shah M, Durani U, Alkhateeb H, **Litzow MR**, Hogan WJ, Tefferi A, Begna KH, Chhetri R, Kutyna M, Singhal D,

- Nayar S, Hiwase D. T-MDS Is a Distinct Clinical and Pathological Entity Characterized By Better Survival Compared to t-AML Blood. 2021; 138(Supplement 1):3377. Epub 2021 Nov 05.
409. Priyanka A Pophali, Xin Victoria Wang, Fengmin Zhao, Kay Neil E, Hanson Curtis A, Mary L Thomas, Susan M O'Brien, Jacqueline Barrientos, Elisabeth M Paietta, Leis Jose F, Cong Christine Zhang, Steven Coutre, Paul M Barr, Amanda Cashen, Mato Anthony R, Avina Singh, Richard F Little, Harry P Erba, Richard M Stone, **Litzow Mark R**, Martin S Tallman, Tait Shanafelt, Lynne I Wagner. Quality of Life in Patients <=70 Years of Age with Chronic Lymphocytic Leukemia Treated Frontline with Ibrutinib-Rituximab Versus Fludarabine Cyclophosphamide Rituximab: Analysis from ECOG-ACRIN E1912 Blood (2021) 138 (Supplement 1): 1562.. December 11, 2021.
 410. Baranwal A, Al-Kali A, Viswanatha DS, Patnaik MM, Shah MV, Hogan WJ, Foran J, He R, Mangaonkar A, **Litzow MR**, Alkhateeb HB. Allogeneic Stem Cell Transplant Outcomes in Patients with DDX41 Mutated Myeloid Malignancies Tandem Meetings - Transplant & Cellular Therapy Meetings. 2022.
 411. Acosta Medina AA, McKerrow Johnson I, Andrade-Gonzalez X, Smith BH, Shah MV, **Litzow MR**, Alkhateeb HB, Shah RA, Johnson BK, Tefferi A, Mangaonkar A, Hogan WJ. Clinical Outcomes of Pretransplant Mortality Prediction Models in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplant Tandem Meetings - Transplantation & Cellular Therapy Meetings. 2022.
 412. Baranwal A, Chhetri R, Alkhateeb HB, Johnson BK, Cibich A, Hogan WJ, Hiwase D, Kok C, Mangaonkar A, Clark MH, Bardy P, **Litzow MR**, Shah MV. Factors Predicting Survival Following Allogeneic Stem Cell Transplant in Patients with Therapy-Related Myeloid Neoplasms Tandem Meetings - Transplantation & Cellular Therapy Meetings (Poster). 2022.
 413. Nanaa A, Alkhateeb HB, Badar T, Foran JM, Sproat LO, Arana Yi CY, Nguyen PL, Jevremovic D, Greipp PT, Gangat N, Tefferi A, **Litzow MR**, Shah MV, Mangaonkar AA, Patnaik M, Viswanatha D, He R, Al-Kali A. Characteristics and prognosis of ddx41- and gata2-mutated myeloid neoplasms. Journal of Clinical Oncology. 2022 Jun 1; 40(16):E19010
 414. Katamesh B, Nanaa A, He R, Viswanatha D, Nguyen PL, Greipp PT, Gangat N, Begna K, Mangaonkar AA, Patnaik M, Hogan WJ, **Litzow MR**, Shah MV, Arana Yi CY, Foran JM, Badar T, Alkhateeb HB, Al-Kali A. Characteristics and prognosis of mutated stag2 myeloid neoplasms. Journal of Clinical Oncology. 2022 Jun 1; 40(16):E19014
 415. Mangaonkar A, Arana Yi C, Murthy H, Badar T, Foran JM, Geyer S, McCullough KB, Baba Lola ES, Hanson J, Al-Kali A, Alkhateeb H, Shah M, Begna KH, Elliott M, Gangat N, **Litzow MR**, Wolanskyj-Spinner A, Hogan W, Tefferi A, Patnaik M. Phase II trial of luspatercept with or without hydroxyurea for the treatment of patients with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis or unclassifiable with ring sideroblasts Journal of Clinical Oncology. 2022. Epub 2022 Jun 02.
 416. Hourigan CS, Dillon LW, Gui G, Ravindra N, Wong Z, Andrew G, Mukherjee D, El Chaer F, Yoon C, Spellman S, Howard A, Auletta J, Devine SM, Jimenez AMJ, De Lima MJG, **Litzow MR**, Kebriaei P, Saber W, Weisdorf DJ, Page K. Pre-measure: multicenter evaluation of the prognostic significance of measurable residual disease testing prior to allogeneic transplantation for adult patients with aml in first remission. Journal of Clinical Oncology. 2022 Jun 1; 40(16):7006
 417. Ghorab A, Al-Kali A, Elliot M, Gangat N, Alkhateeb H, Shah M, Yi CA, Murthy H, Dabaja MK, Tefferi A, Patnaik M, **Litzow M**, Badar T. MDS-353 Clinical Outcome of Myelodysplastic Syndrome Progressing on Hypomethylating Agents With Evolving Frontline Therapies: Continued Challenges and Unmet Needs. Clin Lymphoma Myeloma Leuk. 2022 Oct; 22 Suppl 2:S310. Epub 1900 Jan 01.
 418. Gangat N, Ilyas R, McCullough K, Begna KH, Al-Kali A, Patnaik, **Litzow MR**, Hogan WJ, Mangaonkar AA, Alkhateeb HB, Shah MV, Elliott MA, Foran JM, Badar T, Palmer JM, Hanson CA, Pardanani A, Tefferi A. Predictors of Response to Venetoclax Plus Hypomethylating Agent Therapy and Survival in Blast-Phase Myeloproliferative Neoplasm. Blood. 2022; 140(Supplement 1):9675-9676.
 419. Lee J, Kume K, Robinson ME, Sun R, Ma N, Chen Z, Xiao G, Cosgun KN, Chan LN, Leveille E, Klemm L, Vykunta V, Shy B, Geng H, Luger SM, **Litzow MR**, Marson A, Paietta E, Vaidehi N, Meffre E, Muschen M. A phosphatase membrane-shuttle enables feedback control of b-cell signaling. Blood. 2022 Nov 15; 140(Suppl 1):1698-9
 420. Stein E, Cai SF, Huang Y, Dunbar A, Baer MR, Stock W, Kovacsovic T, Blum WG, Schiller GJ, Olin RL, Foran JM, **Litzow MR**, Lin TL, Patel PA, Foster MC, Boyiadzis MM, Collins RH, Chervin J, Shoben AB, Vergilio JA, Heerema NA, Rosenberg L, Chen T, Yocum AO, Druggan F, Marcus S, Stefanos M, Martycz M, Druker BJ, Mims AS, Borate U, Burd A, Byrd JC, Levine RL. A risk-adapted study to assess the efficacy of enasidenib and subsequent response-driven addition of azacitidine for newly diagnosed idh2-mutant aml patients: 3-year follow-up. Blood. 2022 Nov 15; 140:2016-9
 421. Jillella AP, Lee SJ, Altman JK, Luger SM, Tallman MS, Foran JM, Law LY, Bryan LJ, Abou Zahr A, Begna K, Perl A, Vadakara J, Sanchez F, Bergan RC, Fisch MJ, Carlos RC, Wagner LI, **Litzow MR**, Kota VK. A

- simplified patient care strategy to decrease early deaths in acute promyelocytic leukemia (apl): results of the ECOG-ACRIN 2014 trial. *Blood*. 2022 Nov 15; 140(Suppl 1):1011-2
422. Little RF, Othus M, Assouline S, Ansher S, Atallah EL, Lindsley RC, Freidlin B, Gore SD, Harris L, Hourigan CS, Ivy SP, Jiwani S, Langan E, Luger SM, Michaelis LC, Odenike O, Patton D, Perales MA, Radich JP, Ramineni B, Salk JJ, Stiff P, Stock W, Stone RM, Uy GL, Williams PM, Wood BL, Worthington KH, Yee LM, Zeidan AM, Zhang J, **Litzow MR**, Erba HP. Acute myeloid leukemias: investigational therapies, excluding transplantation and cellular immunotherapies. *Blood*. 2022 Nov 15; 140(Suppl 1):9057-60
 423. Baranwal A, Shah MV, Barua A, Yikilmaz AS, He R, Viswanatha DS, Badar T, Katamesh B, Mangaonkar AA, Gangat N, Patnaik MM, **Litzow MR**, Hogan WJ, Begna K, Tefferi A, Al-Kali A, Alkhateeb HB. Characteristics and outcomes of patients with bcor mutated myeloid neoplasms. *Blood*. 2022 Nov 15; 140(Suppl 1):3235-6
 424. Torabi A, Alonzo TA, Othus M, Gerbing RB, Wang YC, Ries RE, Radich JP, Appelbaum FR, O'Dwyer K, Erba HP, Tallman MS, **Litzow MR**, Atallah EL, Luger SM, Kolb AE, Abdel-Wahab O, Stirewalt D, Levine RL, Paietta E, Meshinchi S. Characteristics and prognostic effects of dnmt3a co-mutations. *Blood*. 2022 Nov 15; 140:745-7
 425. Badar T, Atallah EL, Saliba AN, Shallis RM, Stahl MF, Bewersdorf JP, Correia GSD, Patel AA, Abaza Y, Murthy GSG, Duvall AS, Burkart M, Palmisiano N, Bradshaw D, Kota VK, Dinner S, Goldberg AD, **Litzow MR**. Clinical outcomes of patients with tp53-mutated aml after first relapse or with primary refractory disease: results from consortium on myeloid malignancies and neoplastic diseases (command). *Blood*. 2022 Nov 15; 140(Suppl 1):6058-60
 426. Abid MB, Estrada-Merly N, Zhang MJ, Chen K, Allan DS, Bredeson C, Sabloff M, **Litzow MR**, Kebriaei P, Saber W. Comparison of allogeneic hematopoietic cell transplantation outcomes from younger matched unrelated donor versus older sibling donor for acute myeloid leukemia. *Blood*. 2022 Nov 15; 140(Suppl 1):909-10
 427. Gangat N, Begna KH, Al-Kali A, Hogan WJ, **Litzow MR**, Pardanani A, Tefferi A. Determinants of survival and retrospective comparisons in 183 clinical trial patients with myelofibrosis treated with ruxolitinib, fedratinib, momelotinib, or bms-911543 jak2 inhibitor between 2007 and 2013. *Blood*. 2022 Nov 15; 140(Suppl 1):3945-6
 428. Moreno Vanegas Y, Nanaa A, Al-Kali A, He R, Alkhateeb HB, Patnaik MM, Gangat N, Shah MV, **Litzow MR**, Tefferi A, Badar T. Differential impact on survival in myeloid neoplasm patients with u2af1 mutations. *Blood*. 2022 Nov 15; 140:9602-3
 429. Shallis RM, Weiss J, Winer ES, Badar T, Swaroop A, Doukas P, Geramita E, Le H, Agarwal S, Merl MY, Im A, Abaza Y, **Litzow MR**, Podoltsev NA. Feasibility and safety of outpatient hypomethylating agent (hma) plus venetoclax (ven) initiation plus +/- ramp-up for patients (pts) with newly-diagnosed acute myeloid leukemia (aml). *Blood*. 2022 Nov 15; 140:8921-2
 430. Shah MV, Hahn CN, Chhetri R, Tran ENH, Singhal D, Hogan WJ, Kutyna MM, Alkhateeb HB, Al-Kali A, Gangat N, **Litzow MR**, Kebede B, Mangaonkar AA, Patnaik MM, Tefferi A, Baranwal A, Shanmuganathan N, Kumar S, Thomas D, Kok CH, Hiwase D. Integrated personalized prediction model identifies a subgroup of wild-type tp53therapy-related myeloid neoplasm patients with poor outcome. *Blood*. 2022 Nov 15; 140:6964-5
 431. Winer ES, Flamand Y, Shallis RM, Stempel JM, Goldberg AD, Stahl MF, Patel AA, Duvall AS, Abaza Y, Oh TS, Ma K, Badar T, **Litzow MR**, Kota V, Bradshaw D, Raman HS, Luskin MR, Stone RM, DeAngelo DJ. Intensive therapy for npm1 mutant aml patients: negative impact of flt3-itd(high)but not flt3-itdlow and flt3tkd and role of transplant in patients over 60 years of age. *Blood*. 2022 Nov 15; 140:6285-7
 432. Johnson IM, Ilyas R, McCullough K, Al-Kali A, Alkhateeb HB, Begna K, Mangaonkar AA, **Litzow MR**, Hogan WJ, Shah MV, Patnaik MM, Pardanani A, Tefferi A, Gangat N. Molecular predictors of response and survival in patients with relapsed/refractory acute myeloid leukemia following venetoclax plus hypomethylating agent therapy. *Blood*. 2022 Nov 15; 140(Suppl 1):3233-4
 433. Ilyas R, Johnson IM, McCullough K, Al-Kali A, Alkhateeb HB, Begna K, Mangaonkar AA, **Litzow MR**, Hogan WJ, Shah MV, Patnaik MM, Pardanani A, Tefferi A, Gangat N. Outcome of Patients with Acute Myeloid Leukemia Following Failure of Front-Line Venetoclax Plus Hypomethylating Agent Therapy *Blood*. 2022; 140 (Supplement 1):1286-7.
 434. Geramita E, Wang H, Bastacky M, Cohen J, Shallis RM, Badar T, **Litzow MR**, Im A. Outcomes of adults treated with a hypomethylating agent plus venetoclax for relapsed/refractory acute myeloid leukemia: a multicenter retrospective study. *Blood*. 2022 Nov 15; 140(Suppl 1):6187-8
 435. Kok CH, Tran ENH, Ladon D, Chhetri R, Baranwal A, Sharplin KM, Alkhateeb HB, Singhal D, Al-Kali A, Gangat N, Yeung DT, **Litzow MR**, Ross DM, Hogan WJ, Kebede AB, Mangaonkar AA, Patnaik MM, Tefferi A, Shanmuganathan N, Kumar S, Thomas D, Shah MV, Hiwase D. Personalized prediction model to risk stratify patients with therapy-related myeloid neoplasms. *Blood*. 2022 Nov 15; 140(Suppl 1):6962-3
 436. Lazarus HM, McGuirk JP, Zuckerman T, Metheny L, Pineiro L, **Litzow MR**, Rowley SD, Avni B, Tamari R, Sheleg M, Rothenstein D, Halevy N, Rowe JM. Plx-r18 (avoplace), a placental expanded mesenchymal-like

- stromal cell therapy shows favorable safety and appears to improve incomplete hematopoietic recovery after hematopoietic cell transplantation (hct). *Blood*. 2022 Nov 15; 140(Suppl 1):10447-8
437. Badar T, Atallah EL, Shallis RM, Saliba AN, Stahl MF, Bewersdorf JP, Grenet J, Patel AA, Abaza Y, Murthy GSG, Duvall AS, Burkart M, Palmisiano N, Kubiak MJ, Kota VK, Dinner S, Goldberg AD, **Litzow MR**. Predictors of long-term outcome in tp53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplant after first- or second-line therapy: results from the consortium on myeloid malignancies and neoplastic diseases (command). *Blood*. 2022 Nov 15; 140(Suppl 1):1435-7
438. Shah MV, Hahn CN, Tran ENH, Sharplin KM, Chhetri R, Baranwal A, Kutyna MM, Wang P, Ladon D, Al-Kali A, Alkhateeb HB, Ross DM, Yeung DT, Shanmuganathan N, **Litzow MR**, Mangaonkar AA, Hogan WJ, Gangat N, Patnaik MMM, Kebede B, Kumar S, Singhal D, Brown AL, Scott HS, Thomas D, Kok CH, Tefferi A, Hiwase D. Tp53 mutation status defines a distinct clinicopathological entity of therapy-related myeloid neoplasm, characterized by genomic instability and extremely poor outcome. *Blood*. 2022 Nov 15; 140:9798-9
439. Abid MB, Estrada-Merly N, Zhang MJ, Chen K, Bredeson C, Allan DS, Sabloff M, **Litzow MR**, Kebriaei P, Saber W. Younger matched unrelated donors confer a decreased relapse risk as compared to older sibling donors for adult b-cell all patients undergoing allogeneic hematopoietic cell transplantation. *Blood*. 2022 Nov 15; 140:10540-1
440. **Litzow MR**, Sun Z, Paietta E, Mattison RJ, Lazarus HM, Rowe JM, Arber DA, Mullighan CG, Willman CL, Zhang Y, Wieduwilt M, Liedtke M, Bergeron J, Pratz KW, Dinner S, Frey NV, Gore SD, Bhatnagar B, Atallah EL, Uy GL, Jeyakumar D, Lin TL, Little RF, Luger SM, Tallman MS. Consolidation therapy with blinatumomab improves overall survival in newly diagnosed adult patients with b-lineage acute lymphoblastic leukemia in measurable residual disease negative remission: results from the ECOG-ACRIN e1910 randomized phase iii National Cooperative Clinical Trials Network trial. *Blood*. 2022 Dec 6; 140(Suppl 2):LBA-1
441. Kristen McCullough, Abhishek A Mangaonkar, Ashya R. Burgess, Aref Al-Kali, Hassan B. Alkhateeb, Kebede Begna, Naseema Gangat, Susan Michelle Geyer, William J. Hogan, **Mark Robert Litzow**, Kaaren Reichard, Antoine N Saliba, Mithun Vinod Shah, Alexandra P. Wolanskyj-Spinner, Mrinal Mahesh Patnaik. Phase 1 study to determine the safety and efficacy of onvansertib, a novel, oral, PLK1 inhibitor in patients with proliferative chronic myelomonocytic leukemia relapsed/refractory or intolerant to available therapies. *J Clin Oncol*. 2023; 41(16). Abstract no. TPS7089.

Letters

1. Goldberg SL, Wilkowske MA, Daley JR, Seward JB, Gastineau DA, **Litzow MR**. Pericardial effusions after bone-marrow transplantation. *Lancet*. 1992 May 2; 339(8801):1117-8. PMID:1349136 DOI:
2. **Litzow MR**, Tefferi A. Bone marrow transplantation for chronic myelogenous leukemia. *Blood*. 1994 May 1; 83(9):2752-3. PMID:8167356 DOI:
3. Costa LJ, Rodriguez V, Porrata LF, Lacy MQ, Elliott MA, Gertz MA, Gastineau DA, **Litzow MR**. Autologous HSC transplant in t-MDS/AML using cells harvested prior to the development of the secondary malignancy. *Bone Marrow Transplant*. 2008 Oct; 42(7):497-8. Epub 2008 Jul 14. PMID:18622421 DOI:10.1038/bmt.2008.194
4. Steensma DP, Porcher JC, **Litzow MR**, Hogan WJ, Arora S, Van Laar ES. Assessment of ATRX expression in patients with myelodysplastic syndromes treated with decitabine. *Leuk Res*. 2009 Jul; 33(7):e81-2. Epub 2009 Jan 20. PMID:19157545 DOI:10.1016/j.leukres.2008.11.030
5. Pardanani A, Tefferi A, **Litzow MR**, Zent C, Hogan WJ, McClure RF, Viswanatha D. Chronic myeloid leukemia with p190BCR-ABL: prevalence, morphology, tyrosine kinase inhibitor response, and kinase domain mutation analysis. *Blood*. 2009 Oct 15; 114(16):3502-3. PMID:19833856 DOI:10.1182/blood-2009-07-234666
6. Mesa RA, Pardanani AD, Hussein K, Wu W, Schwager S, **Litzow MR**, Hogan WJ, Tefferi A. Phase 1/2 study of Pomalidomide in myelofibrosis. *Am J Hematol*. 2010 Feb; 85(2):129-30. PMID:20052748 DOI:10.1002/ajh.21598
7. Tefferi A, **Litzow MR**, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. *N Engl J Med*. 2011 Oct 13; 365(15):1455-7. PMID:21995409 DOI:10.1056/NEJMc1109555
8. Abdelrahman RA, Begna KH, Al-Kali A, Hogan WJ, **Litzow MR**, Tefferi A. Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib. *Leukemia* 2015 Feb; 29 (2):498-500 Epub 2014 Sept 25 PMID:25252872 DOI:10.1038/leu.2014.286
9. Pardanani A, Abdelrahman RA, Finke C, Lasho TT, Begna KH, Al-Kali A, Hogan WJ, **Litzow MR**, Hanson CA, Ketterling RP, Tefferi A. Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis. *Leukemia* 2015 Mar; 29 (3):741-4 Epub 2014 Nov 11 PMID:25322686 DOI:10.1038/leu.2014.306
10. He R, Reichard KK, Hanson CA, Kurtin PJ, Howard MT, **Litzow MR**, Van Dyke DL, Ketterling RP, Wiktor AE. Is it time for a new gold standard? FISH vs cytogenetics in aml diagnosis reply *American Journal Of Clinical Pathology* 2016 Mar; 145 (3):431-2
11. Ravindran A, Sankaran J, Jacob EK, Kreuter JD, Hook CC, Gertz MA, Call TG, Pruthi RK, **Litzow MR**,

- Wolanskyj AP, Hogan WJ, Ashrani AA, Begna KH, Marshall AL, Kyle RA, Kay NE, Go RS. High prevalence of monoclonal gammopathy among patients with warm autoimmune hemolytic anemia. *Am J Hematol* 2017 Aug; 92 (8):E164-E166 Epub 2017 June 01 PMID:28437873 DOI:10.1002/ajh.24765
12. Begna K, Al-Kali A, Elliott M, Foran J, Gangat N, Hogan W, Hook C, Leis J, **Litzow M**, Mesa R, Palmer J, Pardanani A, Patnaik M, Rivera C, Sproat L, Tibes R, Wolanskyj-Spinner A, Tefferi A. Current treatment preferences in chronic myeloid leukemia: The Mayo Clinic Physicians' survey. *Am J Hematol* 2017 Nov; 92 (11):E626-E627 Epub 2017 Aug 17 PMID:28730596 DOI:10.1002/ajh.24866
 13. Walter RB, Michaelis LC, Othus M, Uy GL, Radich JP, Little RF, Hita S, Saini L, Foran JM, Gerds AT, Klepin HD, Hay AE, Assouline S, Lancet JE, Couban S, **Litzow MR**, Stone RM, Erba HP. Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. *Am J Hematol* 2018 Feb; 93 (2):E49-E52 Epub 2017 Dec 04 PMID:29164656 DOI:10.1002/ajh.24980
 14. Mangaonkar AA, Lasho TL, Finke CM, Gangat N, Al-Kali A, Elliott MA, Begna KH, Alkhateeb H, Wolanskyj-Spinner AP, Hanson CA, Ketterling RP, Hogan WJ, Pardanani A, **Litzow MR**, Tefferi A, Patnaik MM. Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts. *Blood Cancer J* 2018 Feb 12; 8 (2):18 PMID:29434284 DOI:10.1038/s41408-018-0051-1
 15. Ogden J, Yui J, Ali W, Mudireddy M, Al-Kali A, Patnaik M, Gangat N, Elliott M, Hogan W, Hook C, Wolanskyj-Spinner A, Pardanani A, Villarraga H, **Litzow M**, Tefferi A, Begna K. Pre-anthracycline echocardiogram rarely changes treatment strategy in acute myeloid leukemia. *Am J Hematol* 2018 Jun; 93 (6):E144-E146 Epub 2018 Apr 11 PMID:29508441 DOI:10.1002/ajh.25083
 16. Zeidner JF, Foster MC, Blackford AL, **Litzow MR**, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Final results of a randomized multicenter phase II study of alvociclib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML). *Leuk Res* 2018 Sep; 72:92-95 Epub 2018 Aug 10 PMID:30118897 DOI:10.1016/j.leukres.2018.08.005
 17. Goyal G, Shah MV, Call TG, **Litzow MR**, Wolanskyj-Spinner AP, Koster MJ, Tobin WO, Vassallo R, Ryu JH, Hook CC, Hogan WJ, Go RS. Efficacy of biological agents in the treatment of Erdheim-Chester disease. *Br J Haematol* 2018 Nov; 183 (3):520-524 Epub 2017 Oct 30 PMID:29082516 DOI:10.1111/bjh.14997
 18. Truong H, Sierzchulski AG, Schram S, **Litzow M**, Hogan WJ. Systemic methotrexate absorption in a patient receiving intrathecal chemotherapy for acute lymphoblastic leukemia. *Leuk Lymphoma* 2020 Apr; 61 (4):993-995 Epub 2019 Dec 13 PMID:31833433 DOI:10.1080/10428194.2019.1702184
 19. Antelo G, Mangaonkar AA, Coltro G, Buradkar A, Lasho TL, Finke C, Carr R, Binder M, Gangat N, Al-Kali A, Elliott MA, King RL, Howard M, Melody ME, Hogan W, **Litzow MR**, Tefferi A, Fernandez-Zapico ME, Komrokji R, Patnaik MM. Response to erythropoiesis-stimulating agents in patients with WHO-defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). *Br J Haematol* 2020 May; 189 (3):e104-e108 Epub 2020 Mar 03 PMID:32128785 DOI:10.1111/bjh.16515
 20. Ruan GJ, Smith CJ, Day C, Harmsen WS, Zblewski DL, Alkhateeb H, Begna K, Al-Kali A, **Litzow MR**, Hogan W, Gangat N, Patnaik MS, Pardanani A, Tefferi A, Go RS, Shah MV. A population-based study of chronic eosinophilic leukemia-not otherwise specified in the United States. *Am J Hematol* 2020 Jun 13 Epub 2020 June 13 PMID:32533865 DOI:10.1002/ajh.25906
 21. Ruan GJ, Smith CJ, Day C, Harmsen WS, Zblewski DL, Alkhateeb H, Begna K, Al-Kali A, **Litzow MR**, Hogan W, Szuber N, Gangat N, Patnaik MS, Pardanani A, Elliott MA, Tefferi A, Go RS, Shah MV. A population-based study of chronic neutrophilic leukemia in the United States. *Blood Cancer J* 2020 Jun 15; 10 (6):68 Epub 2020 June 15 PMID:32541648 DOI:10.1038/s41408-020-0334-1
 22. Anagnostou T, Sakemura R, Forsman CL, Patnaik MS, Paludo J, Gastineau DA, Buadi FK, Porrata LF, Kumar SK, Gertz MA, Lacy MQ, Dispenzieri A, Gonsalves WI, Lehman JS, Hogan WJ, Hashmi SK, Alkhateeb H, Shah MV, **Litzow MR**, Kenderian SS. Baseline immune dysregulation in autologous stem cell transplant recipients is associated with a 'graft versus host'-like syndrome and poor outcomes. *Bone Marrow Transplant* 2020 Sep; 55 (9):1879-1881 Epub 2020 Mar 11 PMID:32161319 DOI:10.1038/s41409-020-0851-3
 23. Pophali P, Matin A, Mangaonkar AA, Carr R, Binder M, Al-Kali A, Begna KH, Reichard KK, Alkhateeb H, Shah MV, Tefferi A, Hogan WJ, **Litzow MR**, Patnaik MM. Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia. *Blood Cancer J* 2020 Nov 20; 10 (11):121 PMID:33219206 DOI:10.1038/s41408-020-00387-y
 24. El-Harasis MA, Hefazi M, Julakanti R, Hogan WJ, **Litzow MR**, Patnaik MM, Herrmann J. Cardiovascular outcomes in patients receiving myeloablative vs. reduced intensity conditioning prior to allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia. *Bone Marrow Transplant.* 2021 Feb; 56 (2):508-510. Epub 2020 Aug 08. PMID:32772045 DOI:10.1038/s41409-020-01021-y

25. Begna KH, Gangat N, Al-Kali A, **Litzow MR**, Hogan WJ, Patnaik MM, Pardanani A, Hook CC, Wolanskyj AP, Elliott MA, Hanson CA, Ketterling RP, Tefferi A. Acute myeloid leukemia after age 70 years: A retrospective comparison of survival following treatment with intensive versus HMA +/- venetoclax chemotherapy. *Am J Hematol* 2021 Apr 1; 96 (4):E108-E111 PMID:33527451 DOI:10.1002/ajh.26112
26. Zeidner JF, Lin TL, Vigil CE, Fine G, Yair Levy M, Nazha A, Esteve J, Lee DJ, Yee K, Dalovisio A, Wang ES, Bergua Burgues JM, Schriber J, **Litzow MR**, Frankfurt O, Castillo TBD, Bhatt VR, Bhatnagar B, Mehta P, Dillon R, Vicente MV, Anthony S, Bearss D, Montesinos P, Douglas Smith B. A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia. *Blood Cancer J.* 2021 Oct 30; 11 (10):175 PMID:34718324 DOI:10.1038/s41408-021-00568-3
27. Saliba AN, **Litzow MR**, Gangat N, Al-Kali A, Foran JM, Hogan WJ, Palmer JM, Mangaonkar AA, Tefferi A, Patnaik MM. Outcomes of venetoclax-based therapy in chronic phase and blast transformed chronic myelomonocytic leukemia. *Am J Hematol* 2021 Nov 1; 96 (11):E433-E436 Epub 2021 Sept 12 PMID:34428328 DOI:10.1002/ajh.26334
28. Farrukh F, Gangat N, Shah MV, **Litzow MR**, Elliott MA, Begna K, Hook CC, Tefferi A, Pardanani A. Midostaurin therapy for indolent and smoldering systemic mastocytosis: Retrospective review of Mayo Clinic experience. *Am J Hematol* 2022 Apr; 97 (4):E138-E140 Epub 2022 Jan 19 PMID:35015315 DOI:10.1002/ajh.26464
29. Xie Z, Campestri G, Lasho T, Finke C, Li M, Binder M, Fernandez J, Olteanu H, Reichard KK, Ketterling R, **Litzow M**, Tefferi A, Mangaonkar A, Gangat N, Al-Kali A, Patnaik MM. Clonal compositions involving epigenetic regulator and splicing mutations in CHIP, CCUS, MDS, and CMML. *Leuk Res* 2022 May; 116:106818 Epub 2022 Feb 22 PMID:35232597 DOI:10.1016/j.leukres.2022.106818
30. Gangat N, McCullough K, Johnson I, Al-Kali A, Begna KH, Patnaik MM, **Litzow MR**, Hogan W, Shah M, Alkhateeb H, Mangaonkar A, Foran JM, Badar T, Palmer JM, Sproat L, Arana Yi CY, Pardanani A, Tefferi A. Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts. *Am J Hematol* 2022 Jun 1; 97 (6):E214-E216 Epub 2022 Mar 24 PMID:35303376 DOI:10.1002/ajh.26539
31. Parrondo RD, Rahman ZA, Heckman MG, Wieczorek M, Jiang L, Alkhateeb HB, **Litzow MR**, Greipp P, Sher T, Bergsagel L, Fonseca R, Roy V, Dispenzieri A, Khafan-Dabaja MA, Murthy HS, Ailawadhi S, Foran JM. Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma. *Blood Cancer J* 2022 Jun 1; 12 (6):87 Epub 2022 June 01 PMID:35650175 DOI:10.1038/s41408-022-00680-y
32. Badar T, Atallah E, Shallis RM, Goldberg AD, Patel A, Abaza Y, Bewersdorf JP, Saliba AN, Correia GSC, Murthy G, Duvall A, Burkart M, Stahl M, Liu Y, Dinner S, Palmisiano N, **Litzow MR**, Foran JM. Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival. *Am J Hematol.* 2022 Jul; 97(7):E232-E235. Epub 2022 Mar 30. PMID:35338673 DOI:10.1002/ajh.26546
33. Abdelmagid MG, **Litzow MR**, McCullough KB, Gangat N, Pardanani A, Murthy HS, Foran JM, Ketterling RP, Viswanatha D, Begna KH, Tefferi A. Chronic phase CML with sole P190 (e1a2) BCR::ABL1: long-term outcome among ten consecutive cases. *Blood Cancer J* 2022 Jul 6; 12 (7):103 Epub 2022 July 06 PMID:35794090 DOI:10.1038/s41408-022-00696-4
34. Gangat N, McCullough K, Al-Kali A, Begna KH, Patnaik MM, **Litzow MR**, Hogan W, Shah M, Alkhateeb H, Mangaonkar A, Foran JM, Palmer JM, Pardanani A, Tefferi A. Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher: A real-world experience. *Br J Haematol* 2022 Aug; 198 (4):e54-e58 Epub 2022 May 25 PMID:35614565 DOI:10.1111/bjh.18284
35. Baranwal A, Mangaonkar A, Shah MV, **Litzow MR**, Hogan WJ, Patnaik MM, Alkhateeb HB. High EASIX score is an independent predictor of non-relapse mortality in patients with CMML undergoing allogeneic stem cell transplant. *Bone Marrow Transplant* 2022 Dec; 57 (12):1842-1844 Epub 2022 Sept 21 PMID:36131003 DOI:10.1038/s41409-022-01829-w
36. Gangat N, Chetram D, McCullough K, Al-Kali A, Begna K, Hogan W, **Litzow M**, Foran J, Badar T, Palmer J, Patnaik M, Pardanani A, Tefferi A. Limited activity of luspaterecept in myelofibrosis and myeloid neoplasms other than myelodysplastic syndromes with ring sideroblasts. *Am J Hematol.* 2022 Dec; 97(12):E474-E477. Epub 2022 Oct 17. PMID:36197043 DOI:10.1002/ajh.26749
37. Tefferi A, Pardanani A, Begna KH, Al-Kali A, Hogan WJ, **Litzow MR**, Hanson CA, Ketterling RP, Gangat N. Momelotinib for myelofibrosis: 12-year survival data and retrospective comparison to ruxolitinib. *Am J Hematol* 2022 Dec; 97 (12):E433-E435 Epub 2022 Sept 15 PMID:36057774 DOI:10.1002/ajh.26714
38. Mangaonkar AA#, Langer KJ#, Lasho TL, Finke C, **Litzow MR**, Hogan WJ, Shah MV, Go RS, Bartoo G, Kutzke J, McCullough KB, Koster M, Samec M, Warrington KJ, Reichard KK, Olteanu H, Riwes M, Patnaik MM, Alkhateeb HB. Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: Data from a prospective series of patients. *Am J Hematol* 2023 Feb; 98 (2):E28-E31 Epub 2022 Dec 01 PMID:36403135 DOI:10.1002/ajh.26786

39. Abdallah M, McCullough K, Ilyas R, Begna KH, Al-Kali A, **Litzow MR**, Hogan WJ, Mangaonkar A, Alkhateeb H, Shah MV, Elliott MA, Foran JM, Badar T, Palmer JM, Yi CA, Sproat L, Pardani A, Patnaik MM, Olteanu H, Ketterling RP, Tefferi A, Gangat N. Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). *Blood Cancer J* 2023 Mar 13; 13 (1):35 PMID:36907917 DOI:10.1038/s41408-023-00812-y
40. Gangat N, Ilyas R, McCullough K, Begna KH, Al-Kali A, Patnaik MM, **Litzow MR**, Hogan WJ, Mangaonkar A, Alkhateeb H, Shah MV, Elliott MA, Foran JM, Badar T, Palmer JM, Hanson CA, Pardani A, Tefferi A. Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blastphase myeloproliferative neoplasm. *Haematologica* 2023 May 1; 108 (5):1423-1428 Epub 2023 May 01 PMID:36519330 DOI:10.3324/haematol.2022.282019

* Indicates the primary author was a mentee of this author.

Indicates the authors contributed equally.

Ask Mayo Expert Model

1. Elliott, **Litzow MR**. Acute Myeloid Leukemia In: AskMayoExpert. 12-02-2015. Available from: <http://askmayoexpert.mayoclinic.org>
2. Hashmi SK, Hogan WJ, Thoma MD, Langer KJ, **Litzow MR**, Patnaik MS. Bone marrow transplant/hematopoietic cell transplant survivorship (adult) In: AskMayoExpert. 05-17-2016. Available from: <http://askmayoexpert.mayoclinic.org>
3. Elliott, **Litzow MR**, Al-Kali, Begna KH, Foran JM, Howard MT, Kaufmann SH, Mesa RA, Sproat, Thome SD, Tibes. Acute Promyelocytic Leukemia In: AskMayoExpert. 07-25-2016. Available from: <http://askmayoexpert.mayoclinic.org>
4. Elliott, **Litzow MR**, Al-Kali, Begna KH, Foran JM, Howard MT, Kaufmann SH, Sproat, Thome SD. Acute myeloid leukemia: induction chemotherapy (adult, age 18 to 60-65 years) In: AskMayoExpert. 08-16-2017. Available from: <http://askmayoexpert.mayoclinic.org>

Forthcoming

1. Mangaonkar A, Ferrer A, Pinto e Vairo F, Hammel Caleb W., Prochnow Shereen K. , R.N., Gangat N, Hogan WJ, **Litzow MR**, Peters SG, Scott JP, Utz JP, Baqir M, Carmona Porquera EM, Kalra S, Sekiguchi H, Khan S, Simonetto DA, Klee EW, Kamath PS, Roden AC, Joshi AY, Kennedy CC, Wylam M. Natural history and outcomes of patients with clinically relevant short telomere lengths: Clinical and molecular correlates from a predominantly adult cohort of patients Blood Cancer Journal 2021